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Abstract 
 
Aside from the typical retroviral gag, pol, and env genes, HIV-1 encodes a set of accessory 
proteins. Amongst those, Vpu modulates the expression of several cell surface receptors within 
the infected cell to promote HIV-1 replication. Particularly, Vpu enhances virus release by 
overcoming the antiviral action of tetherin.  
 HIV-1 is not the only virus to have evolved countermeasures to inactivate tetherin. Here we 
have investigated the strategy employed by Kaposi's sarcoma-associated herpesvirus (KSHV) 
to escape from tetherin-mediated restriction of virus particle release. We have found that KSHV 
encodes a ubiquitin ligase, K5, that ubiquitinates tetherin on its cytoplasmic tail to target it for 
endolysosomal degradation.  
 We then assessed the determinants in the Vpu transmembrane domain required to 
antagonize tetherin. Three amino acid residues that form one face of the transmembrane region 
of Vpu were found to be important for the interaction with tetherin. In contrast to Vpu from HIV-1 
Group M, those encoded by Group O have not acquired the capacity to counteract tetherin. The 
defects map to the transmembrane domain and the membrane-proximal hinge region of the first 
alpha helix of the cytoplasmic tail; both are respectively defective for tetherin binding and trans-
Golgi network-associated subcellular localization.  
 As the panel of Vpu's targets is increasing, we have collaborated with Paul Lehner’s group to 
identify new cellular substrates of Vpu. The glutamine transporter, SNAT-1, was identified by 
proteomic screening (SILAC). SNAT-1 is downregulated and degraded in HIV-1 infected CD4+ T 
cells. We are currently investigating the effects of Vpu-mediated SNAT-1 degradation and 
glutamine limitation on virus growth and cell proliferation/survival in primary CD4+ infected T 
cells. In parallel, we have investigated the molecular mechanism by which Vpu achieves SNAT-
1 depletion. 
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Chapter 1 Introduction 
1.1 Discovery and Origins of HIV 
Acquired Immune Deficiency Syndrome (AIDS) was the name given to a new disease that 
caused loss of CD4+ T lymphocytes in increasing numbers of young homosexual men in the 
early 1980's in the United States. These patients displayed a severely compromised immune 
system that led to unusual opportunistic infections such as Pneumocystis carinii pneumonia. At 
the time, the syndrome did not match with any of the diseases listed in the medical literature 
indicating that a new pathogenic agent was responsible. Epidemiologic analyses suggested that 
this new pathogen was sexually transmitted. 
 In 1983, Luc Montagnier and Françoise Barré-Sinoussi reported the detection of reverse 
transcriptase activity in a culture of lymph node cells taken from a patient with AIDS-related-
lymphadenopathy (1). They suggested that the etiologic agent was a retrovirus immunologically 
different from the only other known human retrovirus, HTLV. One year later, a research group 
led by Robert C. Gallo isolated and characterized a retrovirus from numerous AIDS patients (2, 
3). Later studies revealed that those two viruses were identical, and ultimately, human 
immunodeficiency virus type 1 (HIV-1) was chosen to designate the cause of AIDS. In 2008, 
Françoise Barré-Sinoussi and Luc Montagnier received the Nobel Prize in Physiology/Medicine 
for the discovery of HIV-1.  
 In 1986, a morphologically similar but antigenically distinct virus was found to cause AIDS in 
patients in western Africa (4). This new virus, termed human immunodeficiency virus type 2 
(HIV-2) was closely related to a simian virus that infected captive macaques (5, 6). From this 
observation came the idea that additional AIDS-causing viruses could exist in non-human 
primate hosts. Several simian immunodeficiency viruses (SIVs) were isolated from various 
different primates from sub-Saharan Africa, including African green monkeys, sooty 
mangabeys, mandrills, chimpanzees and many others. In contrast to HIV-1, these SIVs were 
found to be non-pathogenic in many of their natural hosts despite high plasma viral loads. 
Through comparison with sequences of SIVs, HIV-1 was proposed to result from the 
transmission of a sub-lineage of SIVcpz infecting chimpanzees from south-eastern Cameroon 
(SIVcpz Ptt-Pan troglodytes troglodytes) (7-10). The other SIVcpz lineage infecting 
chimpanzees from eastern Africa, SIVcpz Pts, displays a high degree of divergence from 
SIVcpz Ptt, and has not been transmitted to humans. Presumably, SIVcpz Ptt might have been 
better equipped to adapt to the human host than SIVcpz Pts, particularly in overcoming 
restriction factors such as tetherin (11). 
 Geographical and genetic evidence suggest that SIVcpz in chimpanzees is derived from two 
different lineages of infected monkeys, the red-capped mangabeys and various Cercopithecus 
species (greater spot-nosed, mustached and mona monkeys) (12). Since chimpanzees are 
known to hunt and kill other mammals, including monkeys, it is likely that they acquired SIVs in 
the context of predation. It is also presumably the same way that humans have acquired the 
     CELLULAR TARGETS OF HIV-1 VPU 
 
- 19 - 
ape precursor, through bushmeat hunting. But whatever the circumstances, it seems that 
human-ape encounters in west central Africa resulted in four independent cross-species 
transmission events giving rise to distinct lineages, termed groups M, N, O and P. Group M 
(Major) was the first to be discovered and it represents the most virulent form of HIV at the 
origin of the worldwide pandemic. Group O (Outlier) was discovered in 1990 and is much less 
prevalent than group M (13, 14). It represents less than 1% of global HIV-1 infections, and is 
largely restricted to Cameroon, Gabon, and neighbouring countries (15). Group N (non-M and 
non-O) was isolated in 1998 and is even more rare than group O with only 13 documented 
cases in total (16). Finally, group P was discovered in 2009 in a Cameroonian woman living in 
France (17).  
 The probable location of the early pandemic has been identified in the area around 
Kinshasa, then called Léopoldville (18). In that region, a human sample dating to 1959 and 
containing HIV-1 was found (19). Based on phylogenetic and statistical analyses, the last 
common ancestor of HIV-1 group M was extrapolated to around 1910-1930 (20). Léopoldville 
was the largest city in the region at that time and thus a likely destination for a newly emerging 
infection. Rivers, which served as major routes of travel and commerce, would have provided a 
link between the chimpanzee reservoir of HIV-1 group M in south-eastern Cameroon and 
Léopoldville on the banks of the Congo (21).  
 HIV-1 group M is classified into nine subtypes or clades (A-D, F-H, J, K) that result from 
transmission of the founder HIV-1 group M into different human populations (18). It is likely that 
HIV-1 group M has diversified in the Democratic Republic of the Congo and then has spread 
worldwide. For instance, subtype B, which accounts for the majority of HIV- infections in Europe 
and the Americas, arose from a single African strain that appears to have first spread to Haiti in 
the 1960s and then onward to the US and other western countries (22). Clades A and C 
account for the majority of infections worldwide. Clade C is mainly found in southern Africa and 
India, whereas clades A and D are frequent in central and eastern Africa. 
 While HIV-1 has infected millions of people worldwide, HIV-2 has remained largely restricted 
to West Africa, mainly in Guinea-Bissau and Senegal. HIV-2-infected patients tend to have 
lower viral loads than HIV-1, which may explain the lower transmission rate of HIV-2 and the 
near absence of mother-to-infant transmissions (23). In fact, most individuals infected with HIV-
2 do not progress to AIDS. HIV-2 originates from multiple cross-species transmissions of 
SIVsmm from sooty mangabeys (24-26). SIVsmm also gave rise to pathogenic SIVmac. 
SIVsmm was found to be non-pathogenic in its natural host but was accidentally transmitted to 
macaques in captivity through inoculation of various species of macaques with blood/tissues 
from naturally infected sooty mangabeys (27). 
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1.2 The AIDS Pandemic  
1.2.1 Report  
Since its identification almost thirty years ago, HIV-1 has infected approximately 60 million 
people and caused more than 30 million deaths (UNAIDS 2010, Global Report). The most 
recent report on the AIDS epidemic, based on data collected from 182 countries, was 
conducted by UNAIDS and published in 2010. In this study, it is reported that an estimated 
number of 33.3 million people were living with HIV at the end of 2009 compared with 26.2 
million in 1999 (27 % increase), despite a decrease of the annual number of new infections per 
year. In 2009, an estimated 2.6 million people became newly infected with HIV and 1.8 million 























Figure 1.1: HIV infections from 1990 to 2009.  
A: Number of people living with HIV-1 from 1990 to 2009. B: Number of people newly infected 
with HIV per year between 1990 and 2009. Source: The 2010 UNAIDS Report on the global 
AIDS epidemic. C: The red ribbon is the universal symbol of awareness and support for those 
living with HIV. The idea of the red ribbon comes from a New York arts organisation including 
photographers, painters, filmmakers and costume designers sat around in a gallery space in 
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 Although HIV/AIDS is found in all parts of the world, some areas are more afflicted than 
others. The worst affected region is sub-Saharan Africa, where in a few countries more than 

















Figure 1.2: Global view of HIV infection.  
This maps displays by geographical zones the number of people (adults and children) estimated 
to be living with HIV at the end of 2009 out of a total of 33.3 million HIV-infected individuals 
worldwide. Source: The 2010 UNAIDS Report on the global AIDS epidemic. 
 
1.2.2 HIV-1 Transmission and Pathogenesis 
The major mode of HIV transmission is through mucosal surfaces during sexual contact. HIV 
can also be transmitted by exposure to infected body fluids or tissues and from mother to child 
during delivery, and after delivery via breastfeeding, and in rare cases during pregnancy. Many 
HIV-1 infections also occur amongst intravenous drug users.  
 Dissemination of HIV through the body is believed to originate from a single infected cell. 
Initially, the founder virus preferentially infects CD4+ T cells present at sites of infection with high 
levels of CD4 and expressing the CCR5 co-receptor. Mucosal CD4+ memory T cells constitute 
the primary cells targeted by HIV-1. In approximately 50% of cases, at some point during 
infection, the virus evolves to infect a broader range of T cell subsets including naive CD4+ T 
cells by switching its co-receptor usage from CCR5 to CXCR4, and this is generally associated 
with a faster disease progression (28). 
 The time course of HIV infection can be divided into four different phases based on the 
measurement of two markers, the CD4+ T cell count in the blood and viremia (reviewed in (29)) 
(Figure 1.3). During the first phase, called eclipse, the founder virus starts replicating at the 
initial site of infection. As the virus multiplies, it gradually spreads to other tissues and organs. 
At that time, the viremia and immune responses directed against HIV are still low. It is believed 
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that it is during this short period of time, the first few weeks post-exposure, that the virus causes 
most of its irreversible damages to the host. This damage occurs predominantly in tissues other 
than the peripheral blood, particularly the gastrointestinal tract where massive depletion of CD4+ 
T cells is observed. The eclipse phase is then followed by a phase where high levels of viral 
load are detected in the blood accompanied by high levels of infected CD4+ T cells in the blood 
and in the lymph nodes. It is during this period that the viremia reaches its peak and that 
immune responses specifically directed against HIV start to be detected. This includes both the 
detection of HIV-1 Gagp24 antibodies defining seroconversion and CD8+ T cells specific to HIV 
viral antigens. As a result of theses responses, the peak of viremia then declines and from this 
point a longer phase of HIV infection establishes. This phase, called ''chronic'', is characterized 
by a gradual fall of CD4+ T cells while plasma viral loads persist slowly at increasing levels (30). 
Over the years, as CD4+ T cells decline, their number becomes so low that the immune system 
is too compromised to cope with other infectious agents. In that context, opportunistic infections 
begin to appear and ultimately lead to the patient death. 
 Therefore, the hallmark of HIV infection is the depletion of CD4+ T cells and subsequent loss 
of immune competence. However, the factors that cause this massive depletion are still debated 
(reviewed in (31, 32)). The first explanation is that HIV causes loss of CD4+ T lymphocytes by 
directly infecting and killing those cells. But this does not account for the death of bystander 
cells that are not productively infected. In many of these cells, particularly naive CD4+ T cells, 
HIV infection is aborted after viral entry as reverse transcription is initiated but fails to reach 
completion (33). As a result these cells accumulate reverse transcripts in their cytoplasm that 
activate a host defence program that elicits pro-apoptotic and pro-inflammatory response 
leading to cell death. Various factors have been proposed to account for the death of bystander 
cells including the action of host derived factors like TNF, Fas ligand and viral factors like Tat, 
Vpr and Nef released from productively infected cells. Finally, high level of immune activation is 
also a major cause of CD4+ T cells depletion. This constitutes a major outcome of pathogenic 
HIV infection whereas non-pathogenic SIV infections lack this exaggerated immune activation 
(reviewed in (34, 35)). 
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Figure 1.3: Time course of HIV infection.  
Evolution of CD4+ T lymphocytes count and levels of HIV RNA copies in the blood over the 
course of untreated HIV infection. Figure adapted from (30). 
 
1.2.3 Treatment and Prevention 
In the fight against the AIDS pandemic, research aiming to find preventive or curative medicines 
has been extensively studied. Measures for treatment of HIV-1 infections are represented by a 
panoply of twenty-four FDA-approved antiviral drugs that can suppress HIV-1 replication in vivo 
to undetectable levels when used in combination. A better understanding of the HIV-1 
replication cycle has been essential in the development of such antiviral drugs. These drugs can 
be classified into several groups based on which phase of the virus life cycle they target 
(reviewed in (36)): nucleoside-analogue reverse transcription inhibitors (NRTIs), non-nucleoside 
reverse transcriptase inhibitors (NNRTIs), integrase inhibitors, protease inhibitors, fusion 
inhibitors, and co-receptor antagonists. Combination anti-retroviral therapy, also known as 
HAART (Highly Active Anti-Retroviral Therapy) has been shown to dramatically suppress viral 
replication and reduce the plasma HIV viral load to below the limits of detection (< 50 RNA 
copies/ml). HIV-1-infected individuals on HAART display significant reconstitution of their 
immune system, an increase but not complete reconstitution of CD4+ T cells, and their life 
expectancy is increased (37, 38). However, even after several years of treatment, HAART fails 
to eradicate HIV-1 infection because viruses can persist as a reservoir of latent/inactive forms 
(reviewed in (39)). Latently infected cells are generated when activated CD4+ T cells, the major 
target cells for HIV-1, are infected and survive long enough to revert back to a resting memory 
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state. In this state, CD4+ T cells are not permissive for viral gene expression, and thus remain 
protected from immune recognition and drug therapy. The absence of Tat expression in these 
cells may contribute to maintain the reservoir. Once antiviral drugs are stopped these latent 
viruses are re-activated and can establish chronic infection again. 
 In many cases, long-term therapy with HAART induces toxicities, persisting inflammation 
and immune activation in treated-patients. The other reason for treatment failure is due to the 
ability of HIV-1 to develop drug-resistant escape mutants. Even though the Pol polyprotein is 
the most conserved across HIV strains, Pol enzymes targeted by antiviral drugs (protease, 
reverse transcriptase, integrase) display a high degree of inherent plasticity that confers the 
capacity to generate compensatory changes in response to drug pressure. 
 Given the limitations and the potential complications of HAART, there has been interest in 
novel approaches to control or preferably cure HIV infection. For instance, cell and gene 
therapies aiming to modify host cells to resist HIV infection have also provided promising 
perspective, especially with the case of the ''Berlin patient'' (40). This HIV-1 infected patient 
received a hematopoietic stem cell transplant from a donor carrying a homozygous CCR5Δ32 
mutation in the CCR5 gene. Three and half years post-transplant and in the absence of HAART, 
no traces of HIV were detected in this patient (41). Several gene therapy strategies are currently 
being investigated aiming to either reduce or disrupt CCR5 expression by zinc-finger nucleases 
(42). 
 In parallel to these studies, considerable efforts have been carried out to create a suitable 
HIV vaccine. The lack of a relevant animal model for HIV-1 infection has rendered difficult the 
development and screening of vaccines. Macaques infected with SIVmac or chimeric HIV/SIV 
viruses (SHIVs) have so far provided the best model of HIV infection. Experimental preventive 
HIV vaccines have been administered to more than 44,000 human volunteers in more than 187 
separate trials since 1987. Initially, studies were aimed at eliciting neutralizing antibodies. 
Based on that approach, two phase III gp120 vaccine trials were conducted each with a bivalent 
formulation of two strains of recombinant gp120 (AIDSVAX), but they showed no significant 
impact on acquisition of HIV-1 infection and had no effect on viremia or peripheral CD4+ T-cell 
counts. The error-prone nature of RT, the strain diversity, the low spike density on the virion 
surface, the highly glycosylated nature of the envelope protein and its conformational flexibility, 
all render difficult the induction of neutralizing antibodies. 
 Due to disappointing efforts to induce neutralizing antibodies, and based on the observation 
that CD8+ T cells play an important role in immune control of HIV-1 replication, several products 
were developed aiming to stimulate CD8+ T-cell responses. This strategy requires antigen 
expression within the host cell, and its processing/presentation on MHC class I molecules for 
CTL recognition. In the phase III human trial RV144, a canary pox-based vector (ALVAC) was 
used to deliver HIV genes to host cells in combination with a boost of recombinant glycoprotein 
gp120 (AIDSVAX). This study showed 31% efficacy in protection from infection amongst 
community-risk Thai participants, and was shown to elicit non-neutralizing envelope-specific 
antibodies associated with CD4+ T-cell but no CD8+ T-cell responses (43). 
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1.3 HIV-1 Structure and Genome 
HIV-1 is a retrovirus of the lentivirus subfamily. As such, it has an ssRNA genome that during 
the life cycle is reverse transcribed to a DNA form. The DNA is then incorporated into the host's 
genome, and acts as template to allow virus multiplication within the infected cell. Reverse 
transcription and integration are the two characteristics that distinguish retroviruses from others 
viruses.  
 The HIV-1 genome contains nine open reading frames (ORF) (Figure 1.4) (44). From the 5' 
to 3' ends of the genome are found the gag, pol and env genes. The gag (group-specific 
antigen) gene encodes a polyprotein precursor designated as Pr55Gag to refer to its molecular 
weight. Pr55Gag is cleaved by the viral protease (PR) into MA (matrix-p17), CA (capsid-p24), NC 
(nucleocapsid-p7) and p6. Two spacer peptides, sp1 and sp2, are also generated upon Gag 
processing. The pol-encoded enzymes including PR (protease), RT (reverse transcriptase) and 
IN (integrase) are initially synthesized as part of a large polyprotein precursor, Pr160GagPol, 
whose synthesis results from a frame-shifting event during Pr55Gag translation. The subunits of 
Pol are subsequently generated by PR cleavage. The env ORF also encodes for a polyprotein 
precursor. Unlike Gag and Pol precursors, which are cleaved by the viral PR, the Env precursor, 
known as gp160, is processed by cellular proteases of the furin family during its trafficking to the 
cell surface. This results in the generation of the surface (SU) Env glycoprotein gp120 and the 
transmembrane (TM) glycoprotein gp41. 
 The four Gag proteins and the two Env proteins are the structural components that make up 
the core of the virion and the outer membrane envelope (Figure 1.5). The external lipid 
membrane is taken from the infected cell when a newly formed virus particle buds out of the 
plasma membrane. Between 10-20 spikes composed of trimers of gp120/gp41 heterodimers 
stud the surface of each particle. The three Pol products provide essential enzymatic functions 
and are encapsulated within the viral particle. 
 While Gag, Pol and Env encode the major structural and non-structural proteins common to 
all replication-competent retroviruses, HIV-1 also encodes six additional proteins. Amongst 
these, Tat and Rev are regulatory proteins, essential to control viral gene expression. Finally, 
Vpu, Nef, Vif and Vpr, referred to as accessory proteins, are not packaged into the virion with 
the exception of Vpr, and perform essential functions at various steps to facilitate HIV-1 
replication in vivo (reviewed in (45)).  
 The retroviral genome is encoded by a ≈ 9.5kb RNA. Two copies of this positive sense 
single-stranded RNA are packaged within the virion core. The RNA genome contains several 
cis acting elements that are important at different stages of HIV-1 replication cycle. Beginning at 
the 5' end, the cis elements include the TAR (trans-activating response region) hairpin region 
that serves as binding site for Tat, a primer-binding site (pbs) that enables cellular tRNALys3 to 
anneal for initiation of reverse transcription, the packaging signal ψ for viral RNA incorporation 
into the virion through interaction with NC, a dimerization site, a major splice donor site for 
generating all subgenomic spliced mRNAs, a Gag-Pol frame-shifting region, the polypurine 
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tracts (PPT) for plus strand DNA synthesis, the Rev-response element (RRE) involved in 
nuclear export, and several splice acceptor sites.  
 Like cellular mRNAs, viral RNA molecules are capped at their 5' end with 7-methylguanosine 
and polyadenylated (polyA tail) at their 3' end. Once released into the target cell, the genomic 
RNA serves as a template for reverse transcription, whereby a dsDNA copy is produced, 
delivered into the nucleus and integrated into the host genome. This copy of integrated viral 
DNA is referred to as a provirus. The provirus is flanked by two long terminal repeat (LTR) 
regions, which are essential to mediate integration of viral DNA into the host genome. In 
addition to the TAR motif, the 5' LTR also contains a promoter region that regulates transcription 
initiation. Viral RNA transcripts are then generated by the host cellular machinery, exported into 
the cytoplasm for translation into proteins or for packaging into virions. 
 Thus, the HIV-1 genome represents a molecular entity consisting of only 15 proteins and one 
RNA, but despite this apparent simplicity HIV-1 possesses all the information needed to actively 















Figure 1.4: Landmarks of the HIV-1 genome. 
This figure displays the nine open frames gag, pol, env, vif, vpr, vpu, nef, tat and rev of HIV-1 
genome in its proviral form. The LTR regions are indicated at both extremities of the provirus. 
The LTR sequence contains the regions U3, R and U5. The ψ symbol indicates the position of 
the RNA packaging signal that binds to Gag-NC. The gag open reading frame consists of four 
domains MA, CA, NC and p6, which are generated from Pr55Gag by protease cleavage. The 
Gag spacer peptides sp1 and sp2 are also indicated. At the 3' end of p6, a slippery sequence 
allows the ribosome to skip gag's stop codon to generate the Gag-Pol polyprotein. The pol gene 
encodes three enzymes, PR, RT and IN. RT contains two subdomains, p66 and p51. The SU 
(surface-gp120) and TM (transmembrane-gp41) glycoproteins are encoded by the env gene. 
The Tat binding motif, TAR is also indicated. RRE, the motif recognized by Rev to mediate 
nuclear export, is located in the env region. 
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Figure 1.5: Structure of a mature HIV-1 virion. 
The size of a virion is approximately 0.1 micron (1 seventieth of the diameter of a human CD4+ 
T cell). HIV-1 produces 15 proteins that combine to make the infectious virion. The virion is 
spherical in shape. All the parts of the virion are made by the virus itself with the exception of 
the lipid membrane, which is taken from the infected cell during budding. Cellular components 




1.4 HIV-1 Replication Cycle 
Following the attachment of HIV-1 virions to the host cell, a succession of complex events 
occurs within the cell before newly fully competent viral particles are produced (Figure 1.6) 
(reviewed in (47)). Binding and fusion of HIV particles with the target cell constitute the first 
steps of HIV-1 replication. The virus, then, releases its RNA and other viral proteins into the 
cytoplasm to initiate reverse transcription from which the single-stranded HIV RNA will be 
converted into double-stranded DNA. The newly formed HIV DNA enters the nucleus and 
integrates into the host genome. This copy of viral DNA, called a provirus, is then transcribed to 
mRNA, which is exported out of the nucleus and translated by the cellular machinery into 
proteins. HIV-1 proteins and genomic RNA copies are then directed to the plasma membrane, 
assembled into an immature virion that buds out of the plasma membrane before being 
released into the extracellular milieu. Nascent virions then undergo protease cleavages leading 
to formation of mature virions able to establish another round of replication. This constitutes the 
last step of HIV-1 replication cycle. 
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Figure 1.6: HIV-1 replication cycle. 
This is an overview of HIV-1 life cycle showing the different processes that the incoming virus 
undergoes within the infected cell to ultimately lead to the production of a new HIV-1 virion. The 
host proteins involved in the replication cycle are also indicated. These proteins include 
essential proteins for virus replication designated as co-factors, and restriction factors (grey 
boxes), which act at various stages to interfere and limit virus production. Drugs inhibiting 
essential steps of the replication cycle are also indicated (white boxes). In this picture, the 
replication cycle begins with the recognition of the CD4 receptor on the surface of the target cell 
by the envelope glycoprotein of the incoming virion (step 1: attachment). This interaction 
induces a conformational change that allows the surface subunit gp120 of Env to bind the 
chemokine co-receptor CCR5 (CXCR4 can also be used as co-receptor depending the tropism 
of the viral strain). Spatial rearrangement of the transmembrane unit gp41 of Env allows the 
virus to fuse with the host cell membrane and to introduce its viral core into the cytoplasm of the 
target cell (step 2: fusion). Inside the cell, the viral core shaped by the capsid proteins, 
undergoes a poorly characterized process called uncoating (step 3: uncoating), which is then 
followed by the reverse transcription (step 4: reverse transcription). During this process, the viral 
RNA is converted into double-stranded DNA by the reverse transcriptase (RT). Associated 
within a pre-integration complex (PIC), the viral DNA shuttles from the cytoplasm to the nucleus 
by crossing nuclear pores (step 5: nuclear import). Insertion of viral DNA into the host genome 
is catalysed by the integrase (IN) and facilitated by the host protein LEDGF (step 6: integration). 
Cellular RNA polymerase II transcribes the integrated provirus but the success of this process 
depends on the ability of the viral protein Tat to recruit the P-TEFb complex to boost the 
elongation efficiency of RNA Pol II (step 7: transcription). Unspliced and partially spliced mRNA 
encoding the polyproteins Gag, Gag-Pol and Vif, Env, Vpr, Vpu, respectively, are exported out 
of the nucleus in a Rev and Crm1 dependent manner, while completely spliced mRNA encoding 
Rev, Tat and Nef are exported by the normal export pathway (step 8: nuclear export). 
Cytoplasmic viral mRNAs then serve as templates for protein production (step 9: translation) 
while genome full length RNA is incorporated into viral particle through its interaction with the 
Gag-NC domain. At the plasma membrane Gag multimerizes and orchestrates the assembly of 
the different viral components into an immature spherical virion (step 10: assembly). During this 
process, Gag recruits ESCRT-I and ALIX through its late domains in p6 (step 11: budding). In 
turn, this attracts ESCRT-III, the membrane fission machinery that cuts the thin membrane neck 
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between the cell and the immature virion (step 12: release). Thereby the immature virion 
separates from the producer cell and is released into the extracellular environment. After this, 
the viral particle undergoes a process called maturation driven by the protease (PR) (step 13: 
maturation). PR cleaves at several sites the Gag and Gag-Pol polyproteins and thus allows the 
viral components to reorganize in a way that ultimately forms a mature and infectious virion. 
Figure adapted from (47). 
 
1.4.1  Attachment and Entry 
The first step of the HIV-1 life cycle is mediated by the binding of virions to the target cells, a 
process depending on the interaction between the envelope glycoprotein (Env) on the virus and 
the CD4 receptor at the surface of the host cell. CD4 is a glycoprotein expressed on the surface 
of T helper lymphocytes, monocytes, macrophages and dendritic cells. In T cells, CD4 serves 
as a co-receptor that assists the T cell receptor to amplify the signal generated upon antigen 
recognition. Consistent with the observation that AIDS patients were reported to have a decline 
of CD4+ T cells, it was shown that HIV-1 preferentially infected CD4+ T cells (48, 49) and that 
infection was inhibited by CD4 antibody treatment (reviewed in (50)). However, CD4 expression 
in mouse cells could only restore binding of virus to the cell surface but not entry, suggesting 
that an additional component was required (51). Later, the chemokine receptors CCR5 and 
CXCR4 were isolated as secondary receptors (co-receptors) required for full entry of HIV-virion 
into host cell (52-57).  
 Env is a heavily glycosylated protein displayed at the surface of the virion as trimers of 
gp120 and gp41 heterodimers (''spikes''). A specific region within gp120 referred to as the CD4 
binding site (CD4bs) initiates the entry process by interacting with the CD4 receptor (Figure 1.7) 
(58, 59). CD4 constitutes the primary entry receptor of HIV and is absolutely required for further 
steps; Env binding to CD4 causes rearrangements of gp120 allowing it to bind the co-receptor. 
HIV-1 strains can be classified into two groups based on their co-receptor affinity either for 
CCR5 or CXCR4 (60). Originally, viruses using CCR5 were designated as macrophage-tropic 
viruses to differentiate them from viruses only able to infect CD4+ T cell lines. Later on, this 
classification was changed since primary CD4+ T cells can express either CXCR4, CCR5 or 
both receptors on their cell surface, depending on their activation state, whereas derived CD4+ 
T cell lines only express CXCR4. To alleviate this ambiguity, viruses that use CCR5 are called 
R5 and those using CXCR4 are termed X4. Some viruses have been found to be able to use 
both chemokine receptors to gain entry into the host cell and are called dual tropic of R5X4. X4 
viruses are found at later stage during disease progression and may be more virulent, but the 
mechanism by which the virus switches from one co-receptor to the other is unclear. Co-
receptor binding induces structural changes in gp41, which allow it to insert its fusion peptide 
into the host cell membrane (61, 62). The fusion peptide of each gp41 in the trimer fold, bringing 
the two terminal regions from each gp41 subunit together. This results in the formation of a six-
helix bundle between gp41 monomers, that brings the viral and host membranes into close 
proximity. In such configuration, a fusion pore is generated between the two membranes 
whereby the viral core can enter into the host cell cytoplasm. 
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Figure 1.7: Early contacts between HIV-1 and its target cell.  
Entry of HIV-1 into the target cell is an ordered multistep process mediated by HIV Env, which is 
composed of two subunits, gp120 and gp41 (step 1). Firstly, Env binds to the CD4 receptor 
(step 2: CD4 binding) expressed at the cell surface of CD4+ T cells, macrophages, and dendritic 
cells through interactions with the surface subunit gp120 of the viral envelope protein. This 
interaction triggers a conformational change in the structure of gp120 that allows the protein to 
interact with a secondary receptor or co-receptor (step 3: co-receptor binding). In turn, the 
transmembrane unit of Env gp41 undergoes a conformational change and inserts its fusion 
peptide into the cellular membrane. This results in the formation of a six-helix bundle, which 
brings into close proximity the viral and the cellular membranes, thereby allowing the two 
membranes to fuse with each other. Figure adapted from (63). 
 
1.4.2 From RNA to DNA: Reverse Transcription 
Following the fusion of HIV-1 with the host cell membrane, the core of the virion is then 
introduced into the cytoplasm of the cell. Shortly after, reverse transcription is initiated and 
ensures the conversion of single-stranded viral RNA into a linear double-stranded DNA. This 
viral DNA product then constitutes the substrate for the integration process. Although only 
reverse transcriptase (RT) and viral RNA are required for synthesis of ds DNA in vitro, this 
process in infected cells is much more complicated and occurs within an entity called the 
reverse transcription complex (RTC). In addition to RT and RNA, multiple viral proteins, 
including MA, CA, NC, IN, and Vpr have been reported to be associated with the RTC (64, 65).  
 The role of MA in the RTC is unclear. While some studies suggest that MA might direct the 
nuclear import of RTC and allows HIV-1 to infect non-dividing cells (66, 67), this conclusion was 
disproved by others (68, 69). CA most likely provides the overall structure of the RTC, whereas 
NC acts as a nucleic acid chaperone by assisting DNA elongation in regions where secondary 
structures form, and by facilitating strand transfer (70-72). Vpr is also present in the RTC but its 
contribution is still a matter of debate. In addition to these viral components, the RTC can also 
contain host restriction factors such as APOBEC3G, which have been incorporated into virions 
from the virus-producer cell, and cause mutations during DNA synthesis (cf. section 1.7.2).  
 The nature of the RTC is still unclear. One model predicts that the structure of the core 
evolves along with the on-going reverse transcription through a process called uncoating that 
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ultimately transforms the RTC into a pre-integration complex (PIC) (73, 74). The RTC is a target 
for TRIM5α and TRIMCyp because they can interact with hexameric CA protein and interfere 
with the uncoating process in a way that blocks reverse transcription (cf. section 1.7.4). Another 
model proposes that the RTC maintains the same structure as the viral core within which DNA 
synthesis occurs. Once reverse transcription is completed, this core-like structure is transported 
to the nuclear pores and converted into PICs before they enter the nucleus (75).  
 Whatever the composition of the RTC is, within this entity RT mediates two essential 
enzymatic activities during the reverse transcription reaction: a DNA polymerase that can copy 
either DNA or RNA templates into DNA, and a RNase H that degrades RNA from the RNA-DNA 
duplex (reviewed in (76)). RT is produced from a Gag-Pol polyprotein by cleavage with the viral 
protease PR, ensuring that the Pol portion of Gag-Pol including RT is assembled into virions. 
RT is a heterodimer composed of two subunits: the larger p66 and the smaller, p51. The p66 
subunit consists of two domains: polymerase and RNase H while the p51 subunit corresponds 
closely, but not exactly, to the polymerase domain of p66. The p66 domain has a catalytic role, 
whereas the p51 subunit plays a structural role. The high error frequency of RT, due to its lack 
of proofreading function, is one of the major factors responsible for the sequence variation of 
the HIV-1 genome even within an individual patient initially infected with a single virus. Through 
this mechanism, HIV-1 can rapidly adapt to avoid the adaptive immune response and escape 
antiviral drugs. Reverse transcription is an essential step in the HIV-1 life cycle and for this 
reason constitutes a primary target for anti-HIV drugs. The first approved anti-HIV drug, AZT, 
targets RT and of the 26 drugs currently approved to treat HIV-1 infections, 14 are RT inhibitors.  
 The process of reverse transcription starts with the host tRNA Lys3 incorporated from the 
virus producer cell that acts as a primer by annealing to a complementary sequence near the 5' 
end of the viral RNA (Figure 1.8) (reviewed in (76)). From this sequence, called the primer 
binding site (pbs), the synthesis of the minus-strand DNA is initiated. The RNA-DNA duplex is 
recognized by RT, which uses its RNase H domain to remove the 5' end of the viral RNA, 
exposing the newly synthesized minus-strand DNA. This minus-strand DNA is then transferred 
to the direct repeat sequence (R) at the 3' end of the viral RNA and serves as a primer for a 
second round of DNA synthesis. Since there are two copies of the viral RNA genome, this 
transfer or jump can also involve the R sequence at the 3' ends of the second copy of viral RNA. 
Then the corresponding minus-strand DNA of the rest of the viral genome is generated until the 
5' pbs sequence is reached. As DNA synthesis proceeds, RNase H degradation removes the 
RNA fragments from RNA-DNA complexes but leaves intact portions of RNA that are purine-
rich. These sequences are called polypurine tracts (ppt) and serve as primers for the initiation of 
the plus-strand DNA synthesis. The HIV-1 genome contains two ppt sequences, one near the 3' 
end of the RNA (ppt) and the other near the middle of the genome (cppt). The 3' ppt is essential 
for viral replication, while the central ppt probably increases the ability of the virus to complete 
plus-strand DNA synthesis but is not essential ((77)). When RT generates the plus-strand DNA 
that is initiated from the 3' ppt, it not only copies the minus-strand DNA, but also the nucleotides 
of the Lys3 tRNA which then become a new substrate for RNase H. Then RNase H does not 
cleave entirely the tRNA and leaves a single A ribonucleotide at the 5' end of the minus-strand 
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DNA. Removal of the tRNA primer allows the second transfer ('' jump '') of the plus-strand DNA 
from the 5' end to the 3' end of the minus-strand DNA where the pbs sequences from both DNA 
strands hybridize with each other. Both DNA strands are then extended to the ends of both 
templates, generating a complete double-stranded linear viral DNA. Thus, the reverse 
transcription creates a DNA product that is longer than the initial RNA template genome from 
which it is derived because both ends of the DNA contain sequences from each end of the 
RNA: U3 from the 3' end and U5 from the 5' end. Each end of the viral DNA has the same 
sequence, U3-R-U5 called the long terminal repeats (LTRs), which will be, after integration, the 
extremities of the provirus. At some point late in the reverse transcription process, the RTC 
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Figure 1.8: Conversion of viral RNA into DNA via the process of reverse transcription.  
Reverse transcription begins with the annealing of the cellular tRNA on the primer binding site 
(pbs) located at the 5' end of the positive sense single stranded viral RNA (+ ss RNA). From this 
point, RT through its DNA polymerase domain generates the minus-strand DNA while its RNase 
H domain degrades the RNA template (step: a). This newly synthesized minus-strand DNA is 
then transferred to the opposite end in 3' of the + ss RNA by complementarity between the 
repeated sequences (R) (step: b), and serves as primer to direct the elongation of the minus-
strand DNA (step: c). RNAse H removes the initial plus-strand RNA (step: d) with the exception 
of two regions, cppt and ppt, which then serve as primers for the synthesis of plus-strand DNA 
(step: e). Plus-strand DNA continues until the tRNA is copied, allowing RNAse H cleavage to 
remove the tRNA primer. This second round of DNA amplification is then followed by a second 
jump or strand transfer of the positive-strand DNA which hybridizes with the complementary pbs 
on the minus strand DNA (step: f). Both strands are extended leading to the synthesis of the 
complete double-stranded linear viral DNA (step: g). The ds DNA is longer than the initial + ss 
RNA template and contains two long terminal repeat sequences (LTR) at its both ends. 
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1.4.3 Nuclear Import and Integration 
As described above, reverse transcription generates a linear double-stranded DNA copy of the 
retroviral genome. This viral DNA is associated with integrase (IN) and other proteins to form 
the pre-integration complex (PIC). In contrast to oncoretroviruses, lentiviruses can replicate in 
non-dividing cells. The pre-integration complex of lentiviruses must therefore be transported 
through the nuclear pores via an active nuclear import mechanism in order to penetrate the 
nucleus. Oncoretroviruses, by contrast, cannot cross the nuclear pore and therefore require 
nuclear membrane breakdown to enter the nucleus.  
 The exact mechanism by which the PIC gains entry to the nucleus is still unclear. One of the 
reasons that render this field complicated is the difficulty of isolating large amounts of PICs 
functional for integration. The viral determinants for nuclear import have been subject to much 
controversy over the years (reviewed in (78)). In addition to proviral DNA, MA, CA, NC, IN and 
Vpr were also found associated with the PIC (reviewed in (79)). Their participation in nuclear 
import pathway was suggested since several of these proteins exhibit karyophilic properties and 
localize to the nucleus when expressed alone. However, none have specifically been shown to 
play a role in viral nuclear entry. Current evidence suggests that CA is the principal determinant 
of whether HIV-1 can infect non-dividing cells. Exchange of HIV-1 MA and CA with those from 
MLV abolish the ability of HIV-1 to infect non-dividing cells, however, addition of HIV-1 MA 
alone is not sufficient to restore viral infection (80). Furthermore, MLV, that cannot infect non-
dividing cells, contains capsid in its PICs (81), whereas CA is below the limit of detection in 
purified HIV-1 PICs (64). However, the labile nature of mature HIV-1 CA lattices may confound 
these observations. 
 Recent studies on the cellular factors involved in the early steps of HIV-1 infection have been 
more informative as to the mechanism of nuclear entry. Studies using an in vitro nuclear import 
assay reported the importance of importin-β/7, an import receptor for ribosomal proteins and 
histone H1, and the Ran GTPase for mediating nuclear import of purified PICs (82). Further 
studies by the same group indicated that damaged tRNAs with defective 3'CCA tails were 
associated with purified PICs and promoted nuclear transit (83). To identify HIV-1 cofactors, 
several genome-wide siRNA screens were performed (reviewed in (84)). Among the 
candidates, knockdown of the nuclear import receptor transportin 3 (TNPO3/transportin-SR2) 
and several nuclear pore proteins including Nup358/RanBP2 and Nup153, were found to inhibit 
HIV-1 infection and induced 2-LTR circle accumulation (85). 2-LTR circles are covalently closed 
circular forms of DNA that can form when HIV-1 cDNA enters the nucleus. Such a structure is 
unable to support integration. TNPO3 was initially identified in a yeast two-hybrid screen as a 
binding partner for integrase (86). TNPO3 and Nup358 also appeared in a second RNAi screen 
for HIV-1 co-factors (87). Furthermore, TNPO3 was also proposed to regulate nuclear export of 
tRNAs and capsid from the nucleus (88), suggesting a specific nuclear import/export pathway 
that regulates HIV-1 infection. Finally, screening of cDNA libraries for post-entry inhibitors of 
viral infection identified a fragment of Cleavage and Polyadenylation Factor 6, CPSF6 (89). 
When enriched in the cytoplasm, a CPSF6 fragment prevents HIV-1 nuclear entry by targeting 
CA. Importantly, HIV-1 viruses resistant to overexpression of this fragment CPSF6 were found 
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to contain a mutation in CA (N74D). This mutant is defective for CPSF6 binding, but was found 
to efficiently infect cycling cells in a manner dependent on Nup155 rather than Nup153, 
suggesting that HIV-1 PICs may be transported into the nucleus through several alternative 
import pathways. However, the N74D mutant was unable to infect macrophages, implying that 
this may not be true in primary HIV-1 target cells. In accordance with this notion, a recent study 
showed that interactions between CA and the cyclophilin domain of Nup358 could dictate the 
use of Nup358/Nup153 for HIV-1 nuclear entry (90). Importantly, failure to engage the Nup358 
pathway impairs HIV infection of non-dividing macrophages.  
 Once in the nucleus, IN catalyses the covalent attachment of proviral DNA to the host cells 
DNA (reviewed in (91)). The integration reaction starts in the cytoplasm with the removal of two 
nucleotides from each 3' end of the blunt-ended linear viral DNA, a process called 3' end-
processing, and then carries on into the nucleus. The 3' ends generated by 3' processing attack 
a pair of phosphodiester bonds in the target DNA. The sites of attack on the two target DNA 
strands are separated by five nucleotides. The 3' ends of the viral DNA are then joined to the 5' 
ends of the target DNA at the site of integration. Completion of integration requires removal of 
the two unpaired bases at the 5' ends of the viral DNA, the filling in the single-strand DNA gaps 
between viral and target DNA and then the ligation of the 5' ends of the viral DNA to target DNA. 
Among all these steps, IN catalyses the 3' processing and DNA-strand transfer to form the 
integration intermediate while the subsequent steps are catalysed by cellular DNA repair 
enzymes. 
 Integration can take place at many locations in the host genome, but preferentially in 
transcriptionally active regions (92). These sites are likely to promote efficient viral gene 
expression after integration. Some features characterize these regions such as high G/C 
content and high gene density. The selection for integration sites has been proposed to be 
linked to the ability of IN to interact with the cellular factor LEDGF/p75 (lens epithelium growth 
factor) which itself binds to regions within transcription units (''LEDGF islands'') (93-95). 
LEDGF/p75 was initially found by affinity-based screening performed to identify cellular proteins 
bound to IN (96, 97). LEDGF contains a PWWP chromatin-binding domain, an A/T hook domain 
likely involved in DNA binding, a nuclear localization signal and the domain that binds to IN. 
Depletion of LEDGF results in the loss of much of the targeting to transcription units and causes 
reduction of infectivity. An increase in formation of 2-LTR circles is also observed when LEDGF 
expression is silenced (98) or in the presence of IN inhibitors.  
 Overall, the data support a model in which LEDGF boosts the efficiency of integration by 
binding to IN and to chromatin at active transcription units and mediates integration at these 
locations. The cellular DNA condensing protein BAF is also required for efficient integration as it 
blocks 'suicidal' auto-integration events (99). 
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1.4.4 Transcription and Nuclear Export  
After integration into the host genome, the HIV-1 provirus acts as a host gene. Transcription is 
initiated at the 5' LTR, which contains several DNA regulatory elements that serve as binding 
sites for cellular transcription initiation factors and control the level of viral transcription (100). 
The core promoter consists of three tandem SP1 binding sites (101), an efficient TATA element 
(102) and a highly active initiator sequence (103) (Figure 1.9A). Together these elements 
participate in the binding of the initiation factors TFIID and its associated TAF co-factors to the 
TATA box and actively recruit RNA polymerase II (RNA Pol II). In addition to the core promoter, 
the 5'-LTR also contains an enhancer region that provides two binding motifs for NK-κB and 
NFAT (104-106). While the HIV-1 LTR appears to be an extremely potent promoter to initiate 
transcription, the efficiency of transcription is impaired by the low processivity of RNA Pol II. As 
a result, in the absence of the viral transcriptional activator Tat, most viral transcripts terminate 
prematurely at many positions throughout the 9.5 kilobase proviral genome. Tat does not 
enhance the frequency of transcriptional initiation but rather stimulates RNA polymerase II 
processivity causing an increase in the amount of transcripts generated that extend all the way 
to the 3' end of the provirus (reviewed in (107, 108)). Tat recognizes a hairpin loop structure, 
known as the TAR (transactivating responsive region), near the 5' end of the viral RNA in the 
LTR region (109, 110) and recruits components of the positive acting elongation factor complex 
P-TEFb (Figure 1.9B). In this complex Tat binds with high affinity to Cyclin T1 (CycT1) (111). 
Since the Cyclin T1-Tat complex binds the TAR with higher affinity than Tat alone, it contributes 
to enhance Tat binding to TAR. In turn, CycT1 recruits and activates the cyclin-dependent 
kinase 9 (CDk9), which phosphorylates the carboxy-terminal heptad-repeat domain (CTD) of 
the RNA polymerase II large subunit. CTD phosphorylation of RNA Pol II enhances its 
elongation capacity. In line with this model, CDk9 protein kinase inhibitors were shown to block 
HIV-1 transcription (112). Tat is inactive in murine cells because the murine Cyclin T1 sequence 
differs from the human sequence by a single amino acid difference. Replacement of Y261 into 
the human CycT1 blocked Tat-mediated HIV-1 transactivation in transfected cells whereas 
introduction of C261 into the murine CycT1 restored Tat's activity (113).  
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Figure 1.9: Tat-mediated HIV-1 transcriptional activation.  
A: Tat regulates HIV-1 transcriptional elongation by binding to the TAR RNA sequence in HIV-1 
RNA and recruits the P-TEFb complex. In this complex, Tat binds to cyclin T1 which itself is 
associated to the protein kinase CDk9. This association induces a conformational change in 
CDk9 that activates its enzymatic function. This leads to hyperphosphorylation of the CTD of 
RNA polymerase II and, thus, stimulates its elongation capacity to extend the full HIV-1 
genome. The LTR region acts as a promoter region of the HIV-1 provirus. It contains binding 
motifs for the transcription factors Sp1, TFIID that are required to initiate the transcription 
reaction. The HIV-LTR has also motifs for recognition by NF-KB and NFAT. Recognition of 
these motifs by NF-KB enhances transcription initiation and thus increases Tat expression 
levels, which in turn positively regulates HIV-1 gene expression. Therefore, NF-KB can also 
indirectly influences HIV-1 transcription efficiency. Low levels of Tat drive the HIV-1 provirus into 
latency. B: Recognition of TAR by Tat and Cyclin T1. Figure adapted from (108). 
 
 
 Once transcribed, nascent viral pre-mRNAs are processed by the spliceosome. This 
complex contains an array of small nuclear ribonucleoproteins (snRNPs) that remove introns 
and join the exons from pre-mRNA. This process is called splicing and in general only spliced 
mRNAs can be exported out of the nucleus into the cytoplasm for translation. RNA splicing 
constitutes an obstacle for HIV-1 because all HIV viral proteins with the exception of Tat, Rev 
and Nef are translated from incompletely spliced or unspliced transcripts (reviewed in (108)). 
For this reason, Tat and Rev are the first viral proteins to be expressed and their presence is 
essential for expression of the other viral proteins. While Tat, as described above, stimulates 
transcription elongation, Rev protects unspliced and incompletely spliced transcripts from 
degradation by mediating their export out of the nucleus. The completely spliced ≈ 1.8kb mRNA 
transcripts which encode Tat, Rev and Nef are exported to the cytoplasm by an endogenous 
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cellular pathway used by cellular mRNAs (Figure 1.10A), while the ≈ 9kb unspliced mRNA and 
the ≈ 4kb incompletely spliced mRNAs which encode the polyproteins Gag, Gag-Pol and the 





















Figure 1.10: Rev mediates the nuclear export of partially spliced and unspliced HIV-1 
mRNAs. 
A: At the early stages of HIV-1 transcription, only the completely spliced mRNAs (~ 1.8 kb) 
encoding the Tat, Rev and Nef proteins are exported to the cytoplasm while the other unspliced 
(~ 9 kb) and partially spliced (~ 4 kb) transcripts are restricted to the nucleus for subsequent 
splicing or degradation. Completely spliced transcripts are then exported to the cytoplasm by 
the normal nuclear export cellular pathway and then translated into Tat, Rev or Nef proteins. B: 
By virtue of its NLS, Rev can penetrate back into the nucleus to assist the nuclear export of 
larger unspliced mRNAs (~ 9 kb) and partially spliced (~ 4 kb) encoding the polyproteins Gag, 
Gag-Pol and Env, Vif, Vpr, Vpu, respectively. Therefore, Rev bypasses the default nuclear 
export pathway in which mRNAs are spliced prior to nuclear export, allowing the subsequent 
translation of the full-length HIV-1 genome. The Rev-response element (RRE) is shown as a red 
rectangle. Figure adapted from (114). 
 
 
 Rev facilitates the transport of intron-containing viral RNA out of the nucleus by interacting 
with a highly structured RNA segment in the env coding region of unspliced and partially spliced 
viral mRNAs (115, 116). This sequence is referred as the Rev-responsive element (RRE) and 
adopts an elongated stem-loop structure of 351 nucleotides. Multimers of Rev bound to the 
RRE interact with the karyopherin family member Crm1 (also referred to as exportin 1) through 
a 10 amino acid leucine-rich nuclear export signal (NES) near its carboxyl terminus (Figure 
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1.11) (117, 118). Crm1 interacts with a small guanine nucleotide binding protein, Ran which 
facilitates binding between Crm1 and Rev. In the nucleus, Ran is bound to GTP while in the 
cytoplasm it associates with GDP. The relative abundance between nuclear pools of GTP and 
cytoplasmic GDP generates a gradient that provides the driving force to direct transport into and 
out of the nucleus. Rev associated to this export machinery complex is then transported out of 
the nucleus via the nuclear pore complex (NPC). After export to the cytoplasm, the bound GTP 
is hydrolysed to GDP by the proteins RanGAP (Ran GTPase-activating protein) and RanBP1. 
This reaction destabilizes the Rev complex and releases factors from the RRE (119). Crm1 is 
then transported back into the nucleus and Rev gains entry back to the nucleus by binding to 
the nuclear import factor, importin-β, where it can oligomerize and mediate another cycle of 



















Figure 1.11: Rev-mediated HIV-1 nuclear export.  
Rev interacts with unspliced and partially spliced transcripts containing a RRE element. Rev 
associated to RRE binds Crm1 through the nuclear export sequence (NES) and together cross 
the nuclear membrane through interactions with the nuclear pore proteins. Once in the 
cytoplasm Ran-GTP is converted into Ran-GDP which leads to destabilization of the complex 
and ultimately releases Rev, HIV-1 RNA and Crm1. Crm1 is then imported back to the nucleus. 
Rev binds to importin-β through its NLS and with Ran-GDP to mediate import into the nucleus. 
In the nucleus, conversion of Ran-GDP into Ran-GTP, allows Rev to dissociate from the 
complex and bind HIV-1 pre-mRNA to mediate another cycle of nuclear export. Figure adapted 
from (114). 
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1.4.5 Translation and Assembly of viral proteins 
Once in the cytoplasm, HIV-1 mRNAs are scanned by ribosomes from the 5' cap until an 
initiation AUG with an appropriate Kozak consensus sequence is detected. In some cases the 
initiation of the translation can be rendered difficult. For example, the gag ORF contains multiple 
highly structured regions such as the TAR sequence, the primer binding site or the RNA 
packaging signal that potentially interfere with the ribosomal scanning. Moreover, some coding 
sequences can contain an AUG motif upstream of the authentic initiator start codon that can 
mislead the translation initiation at the authentic AUG. To circumvent these issues, it is thought 
that HIV-1 might include an internal ribosome binding site (IRES) to facilitate the recognition of 
the gag initiation codon, but this remains unclear (reviewed in (121)). Post-transcriptional 
elements (PCEs) along the HIV-1 RNA can bind to cellular RNA binding proteins to facilitate 
translation initiation. For instance, the binding of the cellular proteins SRp40 and SRp55 can 
enhance Gag translation (122). Since Vpu and Env are translated from the same bicistronic 
mRNA, additional components are also likely to be required to bypass the vpu open reading 
frame to start instead the translation at the env AUG (123). To add further complexity, HIV-1 
also contains cis-acting sequence elements (''slippery'' sequence: UUUUUUA) upstream of the 
gag termination codon required for frame shifting. When ribosomes encounter these elements 
the reading frame shifts from the gag reading frame to the pro and pol reading frame. This 
frame shift occurs ~ 5% of the time and allows the production of the Gag-Pro-Pol precursor 
polyprotein. Individually produced in the cytoplasm, Gag, Gag-Pro-Pol, Env, Vpr and the viral 
genomic RNAs are then directed to the plasma membrane for assembly. 
 Viral assembly is entirely orchestrated by the Gag polyprotein at the plasma membrane, and 
this allows the virus to assemble all of its components using a single targeting signal (Figure 
1.12) (124-127). Gag is the main constituent of the virion providing ~ 50% of the entire virion 
mass. All the Gag subunits have a specific role and altogether they assemble the viral 
components at the plasma membrane into a spherical immature particle. In this structure, the 
membrane-bound Gag molecules are oriented radially with their amino-terminal MA domains 
bound to the inner membrane leaflet and their carboxy-terminal p6 domain facing the interior of 
the virion.  
 Since the assembly occurs at the plasma membrane, the viral proteins need to traffic from 
their point of synthesis in the cytoplasm to sites of virus assembly (128). Gag has been reported 
to interact with various components of intracellular vesicle trafficking pathways but the 
mechanism by which Gag and Gag-Pro-Pol polyproteins reach the plasma membrane is still 
poorly understood. Gag membrane targeting requires myristoylation of the MA domain and the 
presence of the lipid phosphatidyl inositol (4,5) biphosphate (PI(4,5)P2) in the composition of the 
plasma membrane (129, 130). The interaction between MA domain and PI(4,5)P2 exposes the 
amino-terminal myristoyl group which then stabilizes the anchoring of Gag on the inner leaflet. 
En route to the PM, Gag-NC packages the dimeric genomic RNA via its two zinc fingers that 
can recognize the packaging signal sequence (Ψ) (131, 132). This sequence consists of four 
stable stem loop structures. The two RNA strands are non-covalently dimerized in their 5' UTR. 
In the cytoplasm Gag poorly polymerizes but when it arrives at the plasma membrane 
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associated with genomic RNA, it can form high-order multimers (133). At the PM, Gag and Gag-
Pol polyproteins are sorted into detergent-resistant membrane microdomains, also called lipid 
rafts (134). The capsid (CA) domain organizes the interaction between Gag monomers required 
for the formation of the Gag lattice in immature virions (135). The carboxy-terminal Gag p6 
subunit contains a binding site for Vpr and thereby packages it into immature virions (136). In 
addition to the viral proteins encoded by the HIV-1 genome, small cellular RNAs and most 
notably tRNAs required for priming the reverse transcription are also packaged into virions 
(137). 
 Env is inserted into ER membranes during its translation and then travels through the cellular 
secretory pathway where it is glycosylated, assembled into trimeric complexes, processed into 
the transmembrane (gp41-TM) and the surface (gp120-SU) subunits by the cellular protease 
furin and delivered to the PM via vesicular transport (reviewed in (138)). Env trafficking to the 
PM does not rely on Gag and requires its intracellular tail to be directed into raft-like domains. 
This tail is then thought to interact with MA at the plasma membrane to promote Env 
incorporation into assembling virions.  
 
Figure 1.12: Gag orchestrates assembly of viral components at the plasma membrane. 
The polyprotein Gag produced in the cytosol can only form low-order multimers. During its 
trafficking to the plasma membrane, Gag packages dimeric genomic RNA through recognition 
of the packaging signal ψ by its NC domain. At the plasma membrane MA domain interacts with 
PI(4,5)P2 which results in exposure of its myristoyl group. This allows Gag to remain embedded 
in the membrane. MA also recruits Env glycoproteins. At the plasma membrane Gag 
polymerizes at several nucleation sites. During the budding process, ESCRT-I is engaged 
through interactions between regions of Gag-p6 domain called the late domains with the 
subunits Tsg101 and ALIX. This leads to the recruitment of the CHMP proteins from ESCRT-III 
and VSP4, which together mediate the final membrane scission event that releases the budding 
virion from the producer cell. Later on, final maturation of the virion is driven by the viral 
protease PR that catalyses a series of proteolytic cleavages. Figure adapted from (139). 
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1.4.6 Budding and Release 
Although Gag mediates virion assembly, the budding event that allows the immature virion to be 
released from the producer cell is mediated by the host ESCRT machinery (endosomal sorting 
complex required for transport) (Figure 1.13). Gag recruits the ESCRT machinery through 
interactions between its p6 domain and ESCRT-I subunits. p6 contains two different late domain 
motifs that bind ESCRT. The Pro-Thr-Ala-Pro (PTAP) late domain binds the Tsg101 subunit of 
ESCRT-I complex (140, 141). Each of the four residues of this late domain makes specific 
contact within an extended groove on the amino-terminal E2 variant (UEV) domain of Tsg101. 
The second late domain called YPXL (Tyr-Pro-X-Leu with X being variable in sequence and 
length) binds the V domain of the ESCRT-associated factor ALIX (142). 
 CA interacts with NEDD4L, a member of the human NEDD4 ubiquitin E3 ligase protein 
family (143). However, this interaction does not appear to be absolutely required for HIV-1 
budding suggesting that NEDD4-mediated Gag ubiquitination might help the p6 late domains at 
recruiting the ESCRT machinery. Budding of PTAP or YPXL mutated HIV-1 can be rescued by 
overexpression of this ubiquitin ligase. 
 Thus, Gag acts an adaptor to link the future virion membrane with the ESCRT machinery. 
These interactions lead to the recruitment of ESCRT-III proteins of the CHMP1, CHMP2, 
CHMP4 families (CHromatin Modifying Protein) and the VPS4 ATPase. These ESCRT-III 
subunits are then believed to polymerize into a dome that promotes closure of the membrane 
neck (Figure 1.13B) (144). This mechanism is topologically equivalent to the membrane fission 
events occurring during the release of vesicles into endosomal multivesicular bodies (MVB) or 
during the abscission stage of cytokinesis (Figure 1.13A) (139, 145). CHMP4 subunits are 
thought to form spiralling filaments around the inside of the neck of the budding virus. As the 
filaments spiral inward, they may create closed domes that constrict the opposing membranes 
until they separate from each other. VPS4 is also required for membrane fission, possibly by 
helping the dome formation and in the final stage, VPS4 uses the energy of ATP hydrolysis to 
disassemble the filaments and release the ESCRT-III subunits back into the cytoplasm as 
soluble, auto-inhibited proteins (146). 
 The membrane fission event completes assembly and the immature virion is released into 
the extracellular environment. At this final stage, the interferon-inducible restriction factor 
tetherin can interfere and block virus release. Its role in restricting virus particle release will be 
extensively described later in this chapter.  
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Figure 1.13: Role of ESCRT machinery in HIV-1 budding and release. 
A: The membrane fission machinery mediated by ESCRT is required for three different cellular 
pathways. During cytokinesis ESCRT resolves the membrane neck at the midbody to separate 
the daughter cell. Fusion of late endosomes within multivesicular bodies (MVBs) also requires 
the ESCRT scission machinery. Finally, ESCRT mediates the budding of enveloped viruses at 
the plasma membrane. Figure adapted from (139). B: CHMP4 and CHMP2, components of 
ESCRT-III as well as the ATPase VPS4 are recruited by Gag-p6 at site of assembling virion. It 
is thought that ESCRT-III subunits assemble into filaments to form a dome-like structure, which 
ultimately constricts the junction between the cell membrane and the virion. This process is then 
accelerated and finalized by action of VPS4 through its ATPase activity to release the virion. 
Figure adapted from (147). C: Electron micrographs showing the effects of p6 PTAP mutation, 
depletion of Tsg101 and over-expression of the dominant negative Vps4 E228G on HIV-1 
budding. In those conditions, virus budding is arrested at late stage with immature particles 
remaining connected to the plasma membrane via membrane stalks or to other budding 
particles to form clusters of inter-connected particles. Figure adapted from (140). 
 
1.4.7 Maturation  
While the HIV-1 virion is budding through the plasma membrane, the process of maturation 
begins. Gag and Gag-Pol multimerization triggers the activation of the viral protease PR, which 
then processes Gag into its constituent subunits. Once cleaved, the Gag domains undergo a 
series of conformational rearrangements that ultimately lead to the formation of a mature 
infectious viral particle. The most visible characteristic of HIV-1 maturation is the morphology 
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Figure 1.14: HIV-1 virion maturation. 
A: Representation of the tertiary structure model of full-length HIV-1 Gag. Gag domains are 
displayed in different colours and the cleavage sites of PR are indicated by arrowheads. B: 
Representation of the organization of viral Gag proteins in an immature virion. C: Spatial 
arrangement of Gag proteins in a mature HIV-1 virion. D: Central section from a cryo-EM 
tomographic reconstruction of an immature HIV-1 virion. E: Same than E for a mature virion. 
Figure adapted from (148). 
 
 
 Maturation is driven by the viral protease PR. PR cleaves Gag at five different sites, 
ultimately producing the fully processed MA, CA, NC, and p6 proteins (Figure 1.15A). These 
cleavages occur in sequential order beginning with the cleavage between NC and sp1 followed 
by sp2/NC cleavage (149). Once released, NC stabilizes the genomic RNA as a dimer. MA/CA 
cleavage disassembles the immature lattice and releases CA-sp1. MA remains anchored with 
the inner leaflet of the viral membrane forming a discontinuous layer that covers the internal 
lipid envelope. The final stage of PR-mediated Gag processing is accomplished by cleavage 
between CA and sp1. This releases the CA proteins, which then assemble into hexamers to 
form the core structure. Occasionally, CA can associate into pentamers causing irregularities in 
the hexameric organisation. As a result, a cone structure is generated that closely resembles 
the fullerenes formed by elemental carbon (Figure 1.15B) (135, 150, 151). PR also cleaves at 
five different sites within the Gag-Pol polyprotein to generate IN, RT and PR proteins. Owing its 
crucial role in the HIV-1 replication cycle, several PR inhibitors have been designed and applied 
for the treatment of HIV-infected individuals. 
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Figure 1.15: PR-mediated processing of Gag polyprotein. 
A: Schematic representation of the proteolytic cleavages catalysed by PR during the HIV-1 
maturation process. Arrowheads indicate proteolytic sites before cleavage. The order of 
cleavage events shown is based on the rates of cleavage: rapid (sp1/NC), intermediate (sp2/p6, 
MA/CA), and slow (NC/sp2, CA/sp1). B: Model of the HIV-1 capsid. Stereo view of a backbone-
only fullerene cone model composed of 1,056 CA subunits. The hexamers, pentamers and 
dimers are coloured in orange, yellow and blue, respectively. This structure encloses the viral 
genome and facilitates its delivery into new host cells. Figure adapted from (152). 
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1.5 Immune Responses to HIV-1 Infection  
HIV-1 infection elicits strong immune responses in patients, especially during the acute phase. 
However, they fail to eradicate the virus. The immune system harbours two different lines of 
defences that intervene at different stage during infection and are complementary with each 
other. The first line of defence, called innate immunity, involves the non-specific, and thus rapid 
intervention of immune cells, molecules, cellular pathways, all unified to react against a broad 
range of infectious agents. In this section we will discuss how intrinsic immunity factors called 
restriction factors and cellular sensors can elicit innate immune responses during HIV-1 
infection. The second line of defence is represented by the adaptive immune system, which is 
antigen-specific and involves recognition and processing of antigens by the immune system. 
Once generated, adaptive immune responses are much more efficient at clearing traces of 
external agents than innate responses. The adaptive immunity can be classified into two types 
depending on the type of components that are involved, humoral or cellular mediated-immunity.  
 
1.5.1 The Antibody Response 
The adaptive (or acquired) humoral immune response involves B lymphocytes, which upon 
antigen-specific activation differentiate into plasma cells to secrete antibodies (reviewed in 
(153)). Neutralizing antibodies (NAbs) are able to directly bind to HIV-1 envelope glycoprotein 
and block the interaction of viral particles with CD4 and CCR5, or fusion by gp41. Non-
neutralizing antibodies may also inhibit infection through recruitment of effector cells such as NK 
cells or the complement system. 
 At early times post-HIV-1 infection, antigen-antibody interactions result in the secretion of 
anti-gp41 and anti-gp120 non-neutralizing antibodies that do not reduce circulating viral loads. 
Months later, autologous NAbs appear but their spectrum of action is limited; they generally only 
recognize the specific invading viral strain since they tend to target specific variable regions of 
the envelope glycoprotein (154-156). These autologous NAbs drive the evolution of the 
envelope protein to escape from neutralizing responses. Escape variants emerge through single 
amino acid substitutions, insertions, and deletions or through changes in the glycan shield in 
which shifting N-linked glycans prevents access of NAbs to their cognate epitopes (156). In 
some individuals, autologous NAbs develop the ability to recognize more conserved viral 
regions thus rendering them able to neutralize heterologous HIV-1 variants. The reasons why 
some individuals (≈ 30%) develop these broadly cross neutralizing (BCN) antibodies is unclear 
but these responses seem to be related to the duration of infection and viral levels suggesting 
that years of persistent viral stimulation are necessary for their generation (reviewed in (157)). 
 BCN antibodies target conserved envelope regions; IgG1b12 targets the CD4 binding site in 
gp120 (anti-CD4bs), the antibodies 4E10 and 2F5 bind to conserved epitopes within the 
membrane-proximal external region of gp41. The investigation of such antibodies and their 
targets is important to develop potential immunogens that could serve as candidates for 
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vaccines (158). HIV-1 might have more difficulty to develop mutants able to escape from such 
BCN antibodies. The CD4 binding site represents one of the most attractive targets because it 
is a highly conserved site present on all HIV-1 genetic subtypes, and mutations into this region 
are likely to impair virus fitness.  
 Despite the establishment of an antibody response against HIV-1 infection, the results 
generated so far seem to indicate that the role of NAbs in controlling established infection is 
limited due to viral escape (reviewed in (157)). Human vaccine trials that focused on envelope 
immunogens failed to elicit strong NAbs. But the considerable technical improvements might 
allow in the future to identify new sites of vulnerability in the HIV-1 envelope. 
 
1.5.2 The T-Cell Response 
Cellular immunity is mainly mediated by cytotoxic T lymphocytes (CTLs) that directly kill infected 
cells upon recognition of MHC Class I-peptide complexes presented on their surface. During the 
acute phase of HIV-1 infection, CD8+ T-cell responses are generated and play an important role 
in controlling initial viremia. CD8+ T cells that develop during this phase tend to react against a 
narrow range of epitopes mainly derived from Env and Nef, regions that are amongst the most 
variable in the virus (159-161). Following acute infection, CTLs evolve to extend their repertoire 
of epitopes. Most chronically infected individuals target more than a dozen CD8+ epitopes 
simultaneously and in some instances up to 19% of CD8+ T cells are specific for HIV, yet control 
of viremia is not achieved. Without ruling out the contribution of cytokine and chemokine 
production (interferon-γ, IL-2, TNFα, etc.), it is through their lytic ability that CTLs mainly 
modulate disease progression.  
 Some individuals control HIV better than others, and this was shown to be related to certain 
HLA-B alleles (162-164). Some protective HLA-B class I alleles have been identified such as 
B57, B58, B81, B14 and HLA-B27 that target conserved epitopes in Gag. In most cases, these 
protective HLA-B alleles are associated with a decrease of disease progression. The 
determinants of this influence on HIV control map to residues within the HLA binding groove 
that bind to the viral peptide (165). Presumably, certain amino acids are preferential to provide a 
stronger association with the viral peptide, and thus promote a better presentation to CTLs. 
Protective HLA alleles may also function in part through induction of fitness-impairing mutations. 
For instance, escape mutations within Gag that arise to avoid recognition by HLA B57 impair 
the capacity of the virus to replicate (166). This might explain the reason why CD8+ T-cell 
responses targeting conserved Gag epitopes are associated with lower viral loads, whereas 
CD8+ T-cell responses targeting Env that can readily be tolerated by the virus without affecting 
its fitness are associated with higher viral loads. Although CD8+ T cells from infected patients 
display robust responses to inhibit viral replication in vivo, the individuals can still progress to 
AIDS. CD4+ T-cell responses are much more attenuated since they are constantly damaged by 
viral replication and impaired considerably in their proliferative capacity.  
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1.5.3 Innate Immune Control of HIV-1 and Restriction factors  
The first line of defence of the immune system upon HIV-1 entry into the human host involves 
an array of cell subsets, intracellular antiviral proteins, inflammatory cytokines and the 
complement system, which altogether constitute the arsenal of the innate immune system. 
Innate immune cells include phagocytes (monocytes, macrophages, dendritic cells), cytolytic 
cells (NK cells and neutrophils) and professional antigen-presenting cells such as dendritic cells 
(DCs). Each of these cells express distinct innate immune receptors called pattern recognition 
receptors (PRRs) (reviewed in (167)). Unlike the antigen-specific receptors of the adaptive 
immune system, PRRs are able to directly detect small molecular motifs common to pathogens 
called PAMPs (pathogen associated molecular patterns). PRRs include the toll-like receptors 
(TLRs), C-type lectin receptors (CLRs) and the cytoplasmic PRRs (RIG-I like helicases, NOD-
like receptors, DNA sensors). The recognition of PAMPs is then followed by an intracellular 
signalling cascade that ultimately leads to the transcription of pro-inflammatory genes and 
generates an antiviral state. Two classes of transcription factors are mobilized upon PRR 
engagement: interferon regulatory factors (IRFs), which activate transcription of type I 
interferon, and NF-κB essential for expression of pro-inflammatory cytokines and chemokines. 
 HIV-1 particles can induce expression of IFNα from plasmacytoid dendritic cells (pDCs) 
through engagement with TLRs, particularly via the recognition of viral genomic single-stranded 
RNA by TLR7 and TLR9 from endocytosed virions (168-171). TLRs are transmembrane 
proteins, and the TLRs that recognize nucleic acids (TLR3, TLR7, TLR8 and TLR9) are located 
in endosomes of antigen-presenting cells. Whereas the endosomal TLRs detect nucleic acids 
after internalization, specialized cytosolic nucleic acid sensors detect RNA or DNA derived from 
infection. 
 In T cells and macrophages, HIV-1 infection does not induce a strong antiviral interferon 
response in vitro. A reason for this is the presence of a cytosolic exonuclease, TREX1, that 
hides HIV-1 from cytosolic nucleic acid sensors by degrading cytoplasmic HIV-1 ssDNA (172). 
In the absence of TREX1, HIV-1 infection leads to the accumulation of HIV-1 DNA in the 
cytosol, which triggers DNA sensors and interferon responses. The cytoplasmic DNA sensors 
involved in this pathway have not been identified yet. Triggering of this unknown sensor by HIV-
1 DNA activates STING, activating TBK1, which phosphorylates IRF3. Phosphorylated IRF3 
dimerizes and translocates into the nucleus, where it interacts with the promoters of interferon 
genes. 
 In quiescent CD4+ T cells, accumulation of incomplete reverse transcripts that fail to 
integrate elicit pro-apoptotic and pro-inflammatory responses leading to cell death (33). 
 Monocytic-derived DCs are relatively refractory to HIV-1 infection and produce low levels of 
IFN when encountering HIV-1. The reason for that has been attributed to the newly identified 
restriction factor SAMHD1 (173). But when resistance to infection with HIV-1 is circumvented, 
the virus induces DC maturation and type I IFN production (174). This process might rely on the 
interaction of newly synthesized viral capsid (CA) with cellular cyclophilin A. The protein sensor 
that triggers this IFN production has not yet been identified. 
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 Among the innate immune cells involved in the control of HIV, evidence indicates a central 
role for NK cells (175). NK cells are a subset of large granular lymphocytes that are able to 
sense viral infections bypassing the antigen presentation process. When NK cells bind to MHC 
class I molecules on the surface of uninfected cells, NK receptors called killer immunoglobulin-
like receptors (KIRs) provide a negative or inhibitory signal to the NK cells, preventing them 
from mediating killing. HIV-1 infection reduces the expression of certain MHC class I alleles at 
the surface of infected cells, thus allowing the activation of NK cells. But loss of MHC class I 
expression is not sufficient to trigger NK-cell destruction of an HIV-infected cell, and requires a 
second activating signal through recognition of a stress-ligand. For instance, HIV-1 infection 
often results in the upregulation of the stress-inducible ligands for the activating c-type lectin 
NK-cell receptor NKG2D. MIC-A, ULBP-1/2 are examples of those ligands and their expression 
may be downregulated by Nef in infected cells (176).  
 While in vitro HIV-1 infection does not trigger a strong IFN production, acutely infected 
patients present high levels of plasma type I interferon (177). Production of interferon released 
into the extracellular environment serves as a stimulatory signal to induce expression of more 
than a hundred IFN-stimulated genes (ISGs). Amongst the genes upregulated upon interferon 
production, those encoding for cellular factors called restriction factors provide direct resistance 
to HIV-1 and other viral infections. These factors possess intrinsic immune functions and can be 
seen as an extension of the innate immune system. To date four restrictions factors have been 
identified: APOBEC3G, Tetherin, SAMHD1 and TRIM5α (cf. Figure 1.6). They all directly 
interfere with the virus life cycle at a different stage through distinct mechanisms. The notion 
that specific cellular proteins could be entirely devoted to block retroviral replication emerged 
following the identification of Fv1 (Friend virus susceptibility 1). Fv1 was found to block the 
replication of MLV (murine leukaemia virus) in mice by targeting viral capsid proteins. For years 
the efforts were focused on identifying cellular molecules, called co-factors, recruited by the 
virus to perform its functions but this concept could not explain the cell-tropism of retroviruses. 
Importantly, restriction factors share common features. Firstly, they can be constitutively 
expressed in certain cell types and they are induced or upregulated by type I interferon. 
Sequence analyses reveal that restriction factors have undergone strong positive selection 
during mammalian evolution as a result of viral pressure. Viruses and host have co-evolved 
over millions of years. Evolution of a given restriction factor is followed by adaption of its viral 
countermeasure. Both sides rapidly evolve to gain an advantage (reviewed in (178)). HIV-1 has 
developed a countermeasure for all the restriction factors identified either through a specific 
protein dedicated to this function or by mutating its structural components.  
 In the next section we will provide an overview of the findings concerning tetherin and its 
antiviral function.  
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1.6 Tetherin 
1.6.1 Tetherin, the last block before virus escape 
The antiviral activity of tetherin was identified through the investigation of the HIV-1 accessory 
protein Vpu. Vpu was known to be required to enhance virus particle release from HIV-1 
infected cells in a cell-type dependent manner, but the reasons for this phenotype remained to 
be solved (179, 180). HeLa were an example of human cells that were not permissive (or 
restrictive) to HIV-1 release in the absence of Vpu (181). By contrast, other human cells such as 
293T, HT1080 or African green monkey cell lines COS-7 allowed viral egress independently of 
Vpu expression (182-184). Infection of non-permissive cells with HIV-1 lacking Vpu resulted in 
newly assembled virions that remained attached to the cell surface and accumulated in 
endosomal vesicles (CD63+ late endosomes), rather than being released into the supernatant 
(183). This phenotype could be induced in permissive COS-7 cells by fusing them with 
restrictive HeLa cells, suggesting the existence of a dominant inhibitor expressed by HeLa cells 
but not by COS-7 cells that was antagonized by Vpu (184). Importantly, permissive cells treated 
with type I interferon could also become restrictive to Vpu-defective HIV-1 release (185). 
 It was also known that, beyond its ability to enhance HIV-1 release, Vpu could also promote 
the release of other retroviruses such as Murine Leukaemia virus (MLV), or VLPs from Ebola 
virus, indicating that the unknown viral inhibitor could function in a non-specific way to block 
enveloped-virus particle release (181, 185). Additional experiments revealed that fully mature 
virions retained at the surface of cells infected with Vpu-deleted HIV-1 could be released by 
proteolysis, particularly when their endocytosis was blocked using a dominant negative form of 
Rab5 (183, 185). Therefore based on these data, the inhibitor candidate was predicted to be a 
cellular interferon-induced protein constitutively expressed in HeLa cells but not in 293T cells, 
that could block virus release and that was antagonized by HIV-1 Vpu. Then, in early 2008, two 
independent groups attributed the restriction of the release of HIV-1 virions to BST-2 (186, 187). 
Neil et al renamed BST-2 '' tetherin '' to refer to its potential mode of action consisting of 
tethering the nascent virions to the cell surface. In cells where HIV-1 virion release required Vpu 
expression, siRNA depletion of tetherin rescued Vpu-deficient HIV-1 particle release. Tetherin 
was identified by microarray analyses of messenger RNAs between cells that required Vpu for 
HIV-1 release and those that did not. In this screening, tetherin mRNA was 20-fold higher in 
HeLa than in HOS cells and upregulated with the same magnitude by IFN-α in 293T and 
HT1080 cells. At that time, tetherin was designated BST-2 (bone marrow stromal antigen 2 or 
CD317) and described as expressed on terminally differentiated B cells (188), bone marrow 
stromal cells (hence the name BST-2) (189), and plasmacytoid dendritic cells (190). Its 
expression on B cells supposed a potential role in B cell development. Tetherin was also 
previously identified as the most downregulated cell-surface protein by KSHV-K5 from a 
quantitative proteomics SILAC screening (191). 
 Since then, tetherin has become a novel component of the innate immune response against 
HIV-1 infection. Even if later studies revealed the broad range of tetherin against other 
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enveloped viruses, HIV-1 Vpu historically remains the prototype viral antagonist of tetherin. For 
the last four years tetherin has been extensively studied, and, beyond the restriction of virus 
particle release, additional studies suggest that tetherin might have a wider role in the antiviral 
immune response (reviewed in (192)). 
 
1.6.2 Tetherin: Features of a unique protein 
Tetherin is expressed in plasmacytoid dendritic cells, some cancer cells, terminally 
differentiated B cells, macrophages, T cells and in bone marrow stromal cells. However, it 
becomes generally expressed in many cell types and tissues after treatment with type I 
interferon underscoring its crucial role in the innate immune response to virus infections (190). 
 Tetherin is a glycosylated type II integral membrane protein whose the molecular weight can 
vary from 28 kDa to 36 kDa depending on its glycosylation profile (190, 193, 194). In the 
literature tetherin is often qualified as '' unusual '' due to its topology that so far is shared with 
only one variant of the prion protein (Figure 1.16A) (195). Tetherin is anchored in the plasma 
membrane via two types of membrane anchors at the N- and C-terminal regions (193). Tetherin 
is composed of a short N-terminal cytoplasmic tail linked to a transmembrane region that is 
predicted to be a single alpha-helix followed by a coiled-coil structure in the extracellular 
domain, and a C-terminal glycophosphatidyl-inositol (GPI) lipid anchor that links the protein 
back to the cellular membrane. The GPI anchor is added post-translationally by the ER-resident 
enzyme PIGL. In the absence of PIGL, proteins such as tetherin harbouring a GPI modification 
signal are inserted into the ER membrane but remain trapped and fail to enter the secretory 
pathway (196, 197). The ectodomain contains two N-linked glycosylation sites (N-65 and N-92) 
and three cysteine residues (C-53, C-63 and C-91) that mediate disulfide bond formation 
(Figure 1.16A) (197, 198). The extracellular core region forms a single long helix that associates 
as a parallel dimeric disulphide-linked coiled-coil domain (residues 47-152), and adopts a 17 nm 
long rod-like structure that displays flexibility at the N-terminus (Figure 1.17) (199-202). The N-
terminus of the extracellular domain can also form an anti-parallel four-helix bundle through 
association with another tetherin dimer, creating a global tetrameric structure. However, 
mutagenesis studies indicate that the tetrameric form of tetherin might not be essential for its 
antiviral activity and is likely to be an artefact resulting from production of tetherin in bacteria 
under reducing conditions. 
 Although tetherin glycosylation has been shown to positively contribute to its transport and 
folding, it seems to be dispensable for its antiviral function (197). Mutations of all three cysteine 
residues abolish tetherin antiviral function despite expression being maintained at the cell 
surface. Interactions within the coiled-coil region and at least one of out the three cysteine 
residues in the extracellular domain are required to allow disulphide bond formation, promote 
dimer stability and consequently support antiviral function.  
 Tetherin localizes to sites of HIV-1 assembly at the plasma membrane (186, 193, 203, 204). 
Super-resolution microscopy analysis showed the presence of tetherin clusters containing on 
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average 4 to 7 tetherin dimers at HIV-1 assembly sites (205). Interestingly, a tetherin mutant 
lacking the C-terminal GPI anchor (tetherin delGPI) but not tetherin delTM (deletion of the C-
transmembrane anchor) has been found associated with Gag-containing budding sites 
indicating that the tetherin transmembrane domain might drive tetherin localization to HIV-1 
budding sites. At the plasma membrane, tetherin is inserted into cholesterol-rich micro-domains 
(also called lipid rafts) via its GPI lipid anchor (193). In addition to its localization at the cell 
surface, tetherin is also expressed in intracellular compartments, particularly in the TGN and in 
early/recycling endosomes.  
 Unlike other known GPI-anchored proteins, tetherin is endocytosed from the cell surface in a 
clathrin-dependent manner. This internalization appears to rely on the interaction between the 
clathrin adaptor protein AP-2 subunit and a non-canonical, highly conserved dual tyrosine motif 
within the tetherin cytoplasmic tail (YxYxxϕ) (206, 207). Tetherin is then transported from the 
endosomes to the TGN through recognition of the cytoplasmic domain by the AP-1 complex. 
Therefore, the trafficking of tetherin from the plasma membrane to the TGN requires a 
sequential action of AP-2 and AP-1 adaptor proteins. Additionally, tetherin localizes at the apical 
surface of polarized epithelial cells where it interacts with the underlying actin cytoskeleton 
through association with RICH-2, EBP50 and ezrin, thus providing a physical link between lipid 
rafts and the apical actin network in these cells (203). The potential contribution of these 
properties for tetherin’s antiviral action has yet to be evaluated. 
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Figure 1.16: Topology and features of tetherin. 
A: Predicted secondary structure of tetherin monomer. The tyrosine-based endocytic motif 
(YxYxxϕ) and the potential ubiquitin-acceptor lysine residues (K18 and K21) are indicated on 
the cytoplasmic tail. Three cysteine residues at position 53, 63 and 91 involved in dimerization 
and the two N-glycosylation sites (N-65 and N-92) are indicated in the extracellular domain. The 
core region of the ectodomain forms a coiled-coil domain composed of two α-helical regions 
followed by a GPI anchor that links back the protein to the membrane. B: Primary structure of 
tetherin. On the sequence are displayed the features indicated in panel A. 
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Figure 1.17: Structure of tetherin ectodomain. 
A: Tertiary structure of reduced tetherin (residues 47-152) based on X-ray crystallographic 
studies. The structure forms a single long helix that associates as a parallel dimeric coiled coil 
over its C-terminal two-thirds (yellow/magenta and blue/ green dimers), while the N-terminal 
third forms an anti-parallel four-helix bundle with another dimer, creating a global tetramer. 
Figure adapted from (200). B: Model of the global rod-like structure adopted by the entire 
extracellular domain (residues 47-159). The parallel dimeric α-helical coiled-coil domain 
(residues 80-147) is indicated. Figure adapted from (199). 
 
1.6.3 Tetherin ties up a broad range of enveloped viruses: Antiviral activities 
The inhibitory mechanism is relatively non-specific, as tetherin can restrict the release of a 
broad range of viruses that all share a lipid envelope derived from host cells. Initially, tetherin 
was identified as the inhibitor of HIV-1 virus release, but further studies revealed the ability of 
tetherin to restrict many other retroviruses (alpha-retrovirus, beta-retrovirus, delta-retrovirus, 
lentivirus, spumaretrovirus), filoviruses (Ebola and Marburg viruses), arenaviruses (Lassa and 
Machupo viruses), paramyxovirus, gamma-herpesvirus (KSHV) and rhabdoviruses (vesicular 
stomatitis virus) (204, 208-211). Because tetherin restricts such a wide spectrum of viruses, it is 
unlikely that the mechanism requires specific interactions with viral proteins. Presumably, 
tetherin could trap any enveloped virus that buds from the cellular membrane by interacting with 
the virion lipid envelope, unless the virus buds from a region devoid of tetherin. This notion, 
however, was recently challenged by a study showing that influenza A virus was insensitive to 
tetherin expression (212). In contradiction to this, Mangeat et al. showed that expression of 
tetherin strongly inhibited fully replicative influenza virus with the same potency as other anti-
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influenza cellular factors such as MxA, ADAR1, ISG15 and viperin (213). These results 
combined with the fact that tetherin is largely expressed upon interferon stimulation, indicate 
that tetherin may be an effective component of innate immune defence against pathogens. 
	  
1.6.4 Tetherin, an aptly named protein: Mode of action  
In the absence of counteracting factors like Vpu, tetherin restricts retroviral particle release by 
trapping nascent virions at the cell surface. Aggregated virions at the plasma membrane are 
subsequently internalized into endosomes and directed to lysosomes for destruction. Dominant-
negative mutants of Rab5a, the early endocytic GTPase, can inhibit this process (186). So far, 
studies performed to elucidate the mechanism by which tetherin retains viral particles at the cell 
surface suggest that it, as implied by its name, directly tethers/cross-links the virions to the host-
cell membrane (Figure 1.18A). This model is supported by the observation that Vpu-defective 
particles can be released from the cell surface by protease treatment (186). Tetherin 
colocalization with the HIV-1 structural protein Gag along the plasma membrane has been 
observed in immunofluorescence assays. Consistent with a direct tethering mechanism, 
immunoelectron microscopy showed that tetherin was detected between virions and the plasma 
















Figure 1.18: Tetherin functions as a physical bridge between virions and the plasma 
membrane. 
A: Virions tethered to the plasma membrane. Ultrathin sections of HIV-1 delVpu infected Jurkat 
cells and processed for TEM. Tethered virions are indicated with arrows. Bar=100 nm. These 
Vpu-defective particles appear to be connected by a membrane stalk. Such a stalk could be 
lined with multiple tetherin molecules. Figure adapted from (216). B: Visual evidence of direct 
virion tethering and virion-incorporation of tetherin. HeLa cells were transfected to express a 
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Vpu-defective HIV-1 and stained for cell surface tetherin (antibody against tetherin ectodomain) 
and processed for electron microscopy. Figure adapted from (215). C: Immunoelectron 
micrographic of indinavir-treated Vpu-defective infected A3.01 cells. Detection of linear tetherin 
filament bridging virions demonstrating inter-virion connections. Bar=50 nm. Figure adapted 
from (214). D: immuno-electron micrographic analysis of Vpu-defective-infected A3.01 cells 
treated with indinavir. Immunogold labelling of tetherin localized to particle budding sites on the 
plasma membrane of IFN-α stimulated cells. Bar=50nm. Figure adapted from (214). 
 
 
 Beyond the visual evidence, biochemical studies also revealed that tetherin was physically 
incorporated into HIV-1 particles in the absence of Vpu (197). Importantly, tetherin's unusual 
configuration rather than its primary sequence seems to determine its antiviral function. Indeed, 
a complete artificial tetherin-like protein composed of unrelated protein subunits (TMD from the 
transferrin receptor, a coiled-coil domain from distrophia myotonica protein kinase, and a GPI 
anchor from urokinase plasminogen activator receptor), thus mimicking tetherin topology, 
inhibited the release of HIV-1 and Ebola virus particles almost as efficiently as the native protein 
(197). This result suggests that tetherin acts on its own as a cross-linker and does not require a 
cellular co-factor to achieve its function. Altogether these data support a model in which tetherin 
serves as physical bridge between nascent virions and host cell membrane, however the 
precise configuration adopted by tetherin molecules in this context is still unclear. The ability of 
tetherin molecules to form dimers is required for its restriction activity and this conformation 
implies the integrity of at least one of the three cysteine residues to mediate disulphide bonds 
(197, 198). Studies performed on the crystal structure of the extracellular core of tetherin 
reveals a parallel dimeric disulphide-linked α-helical coiled coil structure (199-201). Weak 
interactions exist between the coiled-coil domain of each monomer but because of irregularities 
in the sequence, the disulphide bonds are thought to provide dimer stability. Actually, the weak 
coiled-coil interactions through salt bridges together with the stabilizing disulphide bonds 
generate a dynamic structure, which confers a controlled-flexibility of the coiled-coil essential 
during dynamic processes such as virus particles budding from the plasma membrane. Indeed 
this dynamic feature would be essential to allow tetherin to maintain its links with both the 
cellular membrane and the newly forming virus membrane. This model might explain the fact 
that treatment of infected cells with a reducing agent such as DTT fails to release trapped 
virions from the cell surface indicating that interactions might subsist within the coiled-coil 
regions.  
 The dimerization state of tetherin is required for its antiviral activity but the precise 
configuration adopted by the dimers remains to be clarified. Indeed, several models of possible 
direct tethering mechanisms have been proposed. For instance, tetherin might be anchored in a 
single membrane either from the virus or the host cell, and virions would be retained through the 
interaction between the ectodomains (Figure 1.19A). Alternatively, both tetherin anchor regions 
might be incorporated into different membranes, one end in the cellular membrane and the 
other end in the viral membrane, and in that configuration, ectodomains interaction would 
consolidate virion trapping (Figure 1.19B). Based on the X-ray structure study of the coiled-coil 
domain, it is predicted that the two tetherin monomers face each other in a parallel orientation. 
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Finally, to add more complexity, the parallel dimers could be arranged either with the GPI 
anchors in the viral membrane or in the cellular membrane. The discrimination between the 
three models proposed has not been fully solved, disrupted by contradictory results. Elimination 
of either the N-terminal transmembrane region (TM) or the C-terminal GPI anchor abolishes the 
ability of the molecule to tether virions supporting the model in which tetherin is a parallel 
homodimer with one set of anchors in the host membrane while the other set is embedded in 
the virion membrane (197). But both inactive-tetherin mutants are efficiently incorporated into 
released virions. Virions recovered from restriction at the cell-surface by protease stripping 
contained N-terminal tetherin fragments suggesting that tetherin might insert its TM anchor into 
virus membranes (197). Paradoxically, treatment of retained virions with the GPI anchor 
cleavage enzyme, phosphatidyl inositol-specific phospholipase C (Pi-PLC) did not entirely 
released virions from the cell surface (215). Crystal structure analysis revealed that the 
complete extracellular domain of tetherin formed an extended 170Å long structure (199-201) 
inconsistent with EM studies detecting distances larger than that between cellular membranes 
and retained-virions (214, 215). Potentially, retention of virus particles involves the formation of 
more complex structures such as clusters of tetherin dimers similar to those observed by super 
resolution microscopy (205). Therefore, more studies will need to be done to fully understand 
the spatial arrangement of tetherin dimers required to capture and retain virus particles at the 



















Figure 1.19: Models of tetherin-mediated retention of virus particle. 
A: In this model, virions are retained through interactions of the ectodomains of each tetherin 
monomer. One monomer is anchored, via both ends, in the host cell membrane while the other 
monomer is inserted in the virion. B: Each monomer is inserted in both membranes. Monomers 
are arranged in a parallel orientation, and either the GPI anchors or the N-TM domains can 
span the cellular membrane. 
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1.6.5 Tetherin, a common enemy: Viral countermeasures 
By the nature of its mode of action, tetherin can restrict many enveloped viruses. Tetherin 
reflects the capacity of the host cellular machinery to react against invading pathogens and, 
thus, may constitute a mandatory target for enveloped viruses. As membranes of viruses are 
immutable, this has led several viruses to develop their own countermeasures to overcome 
tetherin’s function (reviewed in (217)). Specific proteins encoded by diverse viruses have been 
identified that share the ability to inactivate tetherin’s function. In addition to the prototype 
tetherin antagonist, Vpu, six other mammalian virus-encoded proteins have been characterized 





Table 1.1: Viral antagonists of tetherin. 
This table summarizes the mechanisms employed by viral countermeasures from primate 
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Tantalus monkey SIVtan 
 
Env Intracellular sequestration / No degradation 
Similar to HIV-2 Env 
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HIV-1 Vpu 
Vpu reduces tetherin expression on the cell-surface (187) and directs it towards a lysosomal 
compartment for degradation (Figure 1.20) (218-220). Vpu targets tetherin by interacting with its 
transmembrane domain. Some of the determinants required for this interaction have been 
mapped and form a single face of both proteins’ respective TM domains (221, 222). Vpu 
displays species-specificity governed by these TM domain interactions (223, 224). For this 
reason, HIV-1 Vpu can only counteract human, chimpanzee, and gorilla tetherins. The 
mechanism by which Vpu neutralizes tetherin has been extensively studied for the last four 
years. Several hypotheses have been proposed to explain how Vpu induces tetherin 
downregulation from the cell surface, and as a result inactivates its antiviral activity on HIV-1 
release. The molecular mechanism of Vpu-mediated tetherin antagonism will be discussed in 
depth later (cf. section 1.8.2.2). 
 
 
SIV Nef  
Most of the SIV strains that do not encode a Vpu gene have acquired anti-tetherin activities in 
their Nef proteins (225-227). Specifically, the SIVmac (macaque/rhesus), SIVagm (African 
green monkey), SIVsmm (sooty mangabey), SIVblu (blu monkey), SIVrcm (red capped monkey) 
Nef proteins can suppress tetherin activity in a species-specific manner. Indeed, all these Nefs 
only efficiently counteract the tetherin proteins from their natural host, but they fail to target 
human tetherin. This specificity is governed by the deletion of a motif in the human cytoplasmic 
tail of tetherin (-GDIWK-). The tryptophan residue of this motif has been under high selective 
pressure in primates potentially imposed by viruses, and this may have forced the protein to 
mutate into a resistant form. Interestingly, insertion of this motif into the human tetherin 
cytoplasmic domain confers sensitivity to SIV Nef proteins (227). For the same reason, HIV-1 
and HIV-2 Nef proteins are unable to antagonize human tetherin but retain some activity against 
rhesus and sooty mangabey tetherins but are less potent than SIV Nefs. In contrast to the SIV 
strains mentioned above, SIVcpz (chimpanzee) and SIVgor (gorilla), which do encode Vpu 
proteins, also use their Nef proteins to overcome tetherin’s function.  
 Like Vpu, SIVmac Nef downregulates rhesus tetherin from the cell surface (Figure 1.20). The 
myristoylation site and a putative cholesterol recognition motif within Nef sequence are required 
for tetherin downregulation, thus highlighting the importance of Nef membrane localization. This 
is consistent with recent findings suggesting that Nef increases the internalization of tetherin 
from the cell surface (228). Depletion of the clathrin adaptor AP-2 using RNA interference, and 
mutations in an AP-2 binding site in Nef impair its ability to antagonize tetherin, demonstrating 
that AP-2 recruitment is required for Nef proteins to counteract tetherin. This suggests that Nef 
uses the same mechanism to downregulate CD4 and tetherin: recruitment of AP-2 and 
stimulation of clathrin-mediated endocytosis.  
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HIV-2 and SIVtan Envelope glycoproteins 
It was long known that HIV-2 Env had a Vpu-like activity in that it could enhance the virus 
particle release from certain cell types and could substitute for Vpu in rescuing HIV-1 particle 
release from HeLa cells (229). HIV-2 Env was shown to act as a human tetherin antagonist 
(230). The envelope protein from the human CD4+ T cell-line passaged tantalus SIV (SIVtan) 
has a similar activity against tetherin (231). In addition to the ability to antagonize tetherin from 
their natural host, HIV-2 Env and SIVtan Env also display activity against rhesus tetherin.  
 Studies showed that, similar to Vpu, HIV-2 Env and SIVtan Env could interact and reduce 
tetherin expression at the cell surface (Figure 1.20). HIV-2 Env requires an intact GYxxθ 
endocytic sorting motif in the cytoplasmic domain of gp41 to mediate cell-surface tetherin 
downregulation (230, 232, 233). This motif binds to the clathrin adaptor complex AP-2, 
suggesting a mechanism in which Envs might promote tetherin internalization by recruiting the 
endocytic machinery. Importantly, only mature Env proteins, processed into gp105 and gp41 by 
furin digestion, are able to antagonize tetherin. The ability of Env to overcome tetherin may rely 
on mutual interactions through the ectodomains. This was illustrated by studies showing that 
substitution of a single amino acid (A100D), found in the porcine protein, in the extracellular 
domain of human tetherin could confer resistance to HIV-2 Env and SIVtan Env (231). 
Interestingly, this residue was found to be under positive selection in mammals. 
 Unlike Vpu, Env proteins do not reduce total tetherin cellular levels but rather induce 
accumulation of tetherin in intracellular compartments, preventing it from localizing to the cell 
surface and virus assembly sites. 
 Finally, Nef-deleted SIVmac viruses are attenuated in macaques and maintain persistent 
low-level replication without generally causing disease in their host (234). But, occasionally, 
Nef-deleted SIVmac reverts to pathogenicity inducing severe effects in vivo. Isolation of these 
pathogenic revertants revealed that activity against rhesus tetherin had been developed by the 
envelope protein (235). The genetic changes associated with pathogenic Nef-deleted SIVmac 
included five amino acid substitutions in the cytoplasmic tail of the gp41 subunit of Env. The 
resulting envelope protein was found to interact with rhesus tetherin and its activity relies on the 
presence of the membrane-proximal GYXXθ sorting signal in gp41 cytoplasmic tail in 
combination with the new five amino acids. Unlike HIV-2 and SIVtan Envs, the ectodomain of 
Nef-deleted SIVmac Env was dispensable for overcoming tetherin. Therefore, there are several 
ways for Env to evolve into a tetherin antagonist. 
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Figure 1.20: Mechanisms of tetherin antagonism in primate lentiviruses.  
Env, Vpu and Nef are all tetherin antagonists. The mechanisms by which they neutralize 





SIVmus (moustached monkey)/mon (Mona monkey)/gsn (greater spot-nosed monkey) and the 
SIVden (Dent’s mona) isolate are members of the SIVsyk lineage, and encode Nef and Vpu in 
their genome. But only Vpu has activity against macaque tetherin with their Nef proteins being 
limited to CD4 targeting (226). 
 Interestingly, Vpu from SIVgsn was found to also suppress human tetherin activity 
suggesting that the presence of Vpu in the ancestral SIVmus/mon/gsn virus has contributed to 
HIV-1 Vpu evolution/adaptation (237). SIVmon, SIVden and SIVmus Vpus could also counteract 
human tetherin when its transmembrane domain was replaced by the TMD from macaque 
tetherin indicating that similar to the situation with HIV-1 Vpu, the specificity of the interaction 




Ebola virus (EBOV) is a highly pathogenic negative-sense RNA virus first described in 1976 that 
causes severe haemorrhagic disease in humans and nonhuman primates. It belongs to the 
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family of Filoviridae, whose members, the Ebola and Marburg viruses, produce filamentous 
virions. Tetherin has been shown to restrict the release of Ebola virus-like particles, generated 
by the expression of the matrix protein VP40 (204). Because HIV-1 Vpu could efficiently 
circumvent tetherin-mediated restriction of Ebola VLPs, it was proposed that Ebola may encode 
a protein with a Vpu-like function in its genome (185). Within the Ebola genome, four proteins 
out of seven have been previously shown to influence virus release (GP, NP, VP24 and VP35), 
but only expression of GP correlates with restoration of VLP release in the presence of tetherin 
(208). GP is the glycoprotein spike in the viral envelope membrane used by the virus to promote 
entry in the target cells. The mechanism by which Ebola GP counteracts tetherin is unclear. Co-
immunoprecipitation studies show that Ebola GP interacts with tetherin (208). In contrast to 
Vpu, Nef and Env, GP mediated tetherin antagonism does not rely on specific determinants in 
tetherin sequence since GP can successfully overcome the restriction of a complete artificial 
tetherin protein (238). Ebola GP can also antagonize the murine tetherin that shares only ≈36% 
protein sequence analogy, but the main features with the human orthologue are conserved (N-
terminal TMD, C-terminal GPI anchor, and 3 cysteines in the extracellular domain). Although 
tetherin retains Ebola particles on the cell surface, studies so far show that Ebola GP inactivates 
tetherin without removing it from the plasma membrane (238). This is especially surprising since 
early reports showed that EBOV GP leads to a general downregulation of cell surface 
molecules (239, 240). The intracellular levels of tetherin are not reduced under GP expression 
indicating that it is unlikely that GP diverts tetherin toward a degradative pathway. Altogether 
these observations suggest a novel mechanism to circumvent tetherin restriction that implies 
neither downregulation from the cell surface nor specific molecular interactions. Hypothetically, 
Ebola GP might physically interfere with the retention mechanism of tetherin at the plasma 
membrane. Clearly, more studies are required to fully understand this unusual way of 




Kaposi’s sarcoma-associated herpesvirus (KSHV or HHV-8) release is blocked by tetherin in 
the absence of its K5 protein (209, 210). K5 is an E3-ubiquitin ligase described in the literature 
as a viral immune modulator due to its ability to downregulate a large panel of cell surface 
receptors involved in immune recognition (reviewed in (241)). MHC class I molecules are the 
best described targets of K5. K5 is derived from the cellular homologue MARCH proteins found 
in mammals. MARCH proteins represent a family of transmembrane ubiquitin ligases 
modulating intracellular trafficking and turnover of transmembrane protein targets. K5 induces 
tetherin ubiquitination on its cytoplasmic tail resulting in delivery to late endosomes and 
subsequent degradation in lysosomes in an ESCRT-dependent manner. The mechanistic 
details employed by K5 to abrogate tetherin-mediated restriction of HIV-1 and KSHV particle 
release will be addressed more extensively in the results section (cf. Chapter 4). 
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1.6.6 Tetherin-driven remodelling of primate lentiviruses: Adaptation of Vpu, Nef and Env 
Evolutionary data indicate that SIVcpz is a recombinant virus (12) that received its Vpu from the 
precursor of the SIVgsn/mus/mon lineage, whereas its Nef is derived from the SIVrcm lineage. 
Each protein is able to antagonize the tetherins from their corresponding host and other 
monkey-related tetherins (Figure 1.21) (226). Thus, initially the resulting SIVcpz virus issued 
from both lineages contained two candidates to counteract chimpanzee tetherin. It is likely, 
however, that they both had weak activity against cpz tetherin as Nef and Vpu have been 
shown to antagonize tetherin in a host-specific manner (223-225, 227). The acquisition of a 
competent cpz tetherin antagonist might have been a requirement for the cross-species 
transmission of monkey SIVs to chimpanzees. Ultimately, function against cpz tetherin emerged 
in the Nef protein rather than Vpu.  
 However, upon zoonotic transfer to humans, SIVcpz Nef became inefficient due to the 
deletion of its target motif in the cytoplasmic tail of tetherin (G/DIWKK). This deletion occured at 
least 800,000 years ago before the separation between Homo neanderthalensis, Homo sapiens 
and Homo denisovans. Since the cpz tetherin transmembrane (TM) domain displays high 
sequence homology with human tetherin TM domain, it might have been easier for SIVcpz to 
adapt against the tetherin TM domain rather than the cytoplasmic region. Vpu was presumably 
the best candidate to adapt to the human tetherin TM domain. 
 Transmission of SIVcpz to humans occurred at least four independent times, giving rise to 
HIV-1 group M, N, O and P. Only Vpus from group M and N successfully adapt to overcome 
human tetherin (226). Consistent with that notion, SIVcpz Vpu does not antagonize human 
tetherin unless its TM domain is replaced by that from HIV-1 M Vpu. HIV-1 Nef had completely 
lost its activity against human tetherin (226), but its function could be restored by inserting the 
ancestral five amino acids into human tetherin (225, 227). 
 Vpu from HIV-1 group M shows species specificity, in that HIV-1 Vpu can only counteract 
human and ape tetherins including chimpanzees, gorilla, but not the monkey tetherins or those 
from other mammals (mouse, rat or pig). The specificity of HIV-1 Vpu and other SIV Vpus maps 
to the transmembrane domain of tetherin. An exchange of the TM domain in human tetherin 
with that of monkey tetherin (agm or rh) renders it resistant to HIV-1 Vpus (224), but conferred 
sensitivity to SIV Vpus. A mutation of a single amino acid found in the TMD of monkey tetherins 
into human tetherin can confer resistance against HIV-1 Vpu (223). These findings suggest that 
the tetherin TMD has been under positive selection pressure during primate evolution from 
monkeys to chimpanzees and finally to humans, forcing it to modify its sequence. In turn, this 
has forced primate lentiviruses to adapt to these changes through acquisition of new functions 
either in their Nef or Vpu proteins, to constantly maintain tetherin antagonism. In other words, 
tetherin, because of its sequence variation, has driven the evolution and adaptation of primate 
lentiviruses, in particular Nef and Vpu proteins. Overall these adaptations have been successful 
since tetherin antagonism is conserved in many primate lentiviruses tested so far. This flexibility 
of lentiviruses to switch between Nef and Vpu to counteract tetherin might have been a key 
determinant for cross-species transmission events.  
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 Finally, Nef-deleted SIVmac and HIV-2 viruses are additional illustrations of the selective 
pressure that tetherin can exert on lentiviruses and the importance of maintaining tetherin 
antagonism. Nef-deleted SIVmac and HIV-2 derive from SIV strains lacking Vpu, hence the 
necessity to acquire a tetherin antagonist in another viral component. In the case of Nef-deleted 
SIVmac virus, the absence of Nef has forced the acquisition of an anti-tetherin activity in its 
envelope protein (235). Whether this adaptation to tetherin by Nef-deleted SIVmac contributed 
to the gain of pathogenicity is unknown. For HIV-2, anti-tetherin function in its envelope must 
have been the preferential option due to the inability of Nef to target the missing five amino 
acids in the human tetherin cytoplasmic tail. Whether this adaptation has impaired the primary 
function of the envelope protein is unknown, but we can speculate that this might be a reason 






























Figure 1.21: Co-evolution of tetherin and Vpu/Nef/Env proteins.  
Arrows represent cross-species transmission events, and the viral gene product that 
antagonizes tetherin from the corresponding host is displayed in color. The simian 
immunodeficiency virus of chimpanzees (SIVcpz) is believed to be the result of a recombination 
between viruses infecting red-capped mangabeys (SIVrcm) and those infecting Greater spot-
nosed (SIVgsn), mustached (SIVmus), and Mona monkeys (SIVmon). SIVrcm uses its Nef 
protein to overcome tetherin from its host while Vpus from SIVgsn, SIVmus and SIV mon 
possess the anti-tetherin activity. Presumably, chimpanzees in contact in the wild with these 
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monkeys became co-infected with both simian viruses. In SIVcpz, Nef rather than Vpu targets 
tetherin. SIVcpz was then transmitted to gorillas and to humans evolving to SIVgor and HIV-1 
respectively. Vpus from HIV-1 Group N and M are tetherin antagonists while Vpus from HIV-1 
Group O and P are not. At present it is unclear whether HIV-1 Group O derives from SIVgor or 
from SIVcpz (dashed lines). It is unknown whether HIV-1 Group O and P have acquired the 
capacity to neutralize tetherin in one of their others encoded viral proteins. HIV-2 and SIVmac 
reflect the cross-species transmission of SIVsmm from sooty mangabeys to humans and from 
sooty mangabey to macaques respectively. In HIV-2, the anti-tetherin function has been 
acquired in its envelope protein presumably because Nef failed to adapt due to deletion of a 
motif in tetherin cytoplasmic tail. This graph also highlights the fact that the tetherin antagonists 
vary from one species to another. 
 
1.6.7 Tetherin and HIV-1 transmission between cells 
HIV-1 can be transmitted between cells by two mechanisms (Figure 1.22). The first one involves 
the release of cell-free virions. In that scenario, nascent virions diffuse into the extracellular 
environment until they reach cells bearing the receptors they need for entry. In the second 
scenario, nascent virions are directly transferred from infected cells to uninfected cells. This 
second mode of transmission is called cell-to-cell transmission and is in general, more rapid and 
efficient than cell-free virus spread (reviewed in (242)). It is unclear whether the direct cell-cell 
spread also allows the virions to remain unseen and protected from patrolling immune cells 
(macrophages, dendritic cells) or from immune components such as neutralizing antibodies and 
complement molecules. While studies using matrix-GFP viral constructs have suggested that 
transfer of virions via the VS is less sensitive to antibodies (243, 244), there are concerns about 
the assembly of these viral constructs (139). Studies using the full-length virus have 
contradicted this and reconstruction of cryo-electron microscopy images reveals that the VS 
should be permeable to antibodies (245). This mode of transmission requires the same 
determinants for viral entry as cell-free virus transmission; both modes of HIV-1 transmission 
require the engagement of envelope protein with its receptors on the target cell and a fully 
assembled virion. The relative contribution of each of these modes of transmission in the 
context of in vivo HIV-1 infection is still unclear, but a recent study showing that HIV-infected T 
cells were migratory vehicles for viral dissemination strongly suggests that cell-to-cell transfer is 
likely to be the predominant mode of HIV-1 transmission between T cells (246). 
 Cell-to-cell transmission of HIV-1 is initiated at the interface between HIV-infected cells and 
target cells via the formation of virological synapses (VS) (247). The VS was first described for 
HTLV-1 (248). VSs are multi-molecular structures generated by binding of the HIV-1 envelope 
glycoprotein Env, expressed at the surface of infected cell, to its entry receptor (CD4 and either 
CXCR4 or CCR5) displayed on the target cell membrane (243, 247, 249). Additional 
components are required to maintain the cell-junction and VS stability such as adhesion 
molecules (interactions between LFA-1 and ICAM-1 and ICAM-3) (247, 250). This configuration 
allows a close intercellular contact whereby viral particles can be transferred.  But the cell-cell 
spread would not be functional in the absence of a dynamic cellular process that directs 
intracellular HIV-1 proteins towards the VS (251). Indeed, remodelling of the cytoskeleton from 
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the donor-infected cell, in particular actin and tubulin networks, regulates polarization of HIV-1 
components at the cell-cell interface, thus forcing HIV-1 assembly and egress to take place at 
the VS for subsequent passage into the engaged target cell. Viral particles are then transferred 
by budding into the synaptic cleft and virions attach to the target cell membrane to trigger entry. 
In this configuration, the VSs promote more rapid round of infections and ultimately contribute to 
increase HIV-1 pathogenesis. 
 Since tetherin traps nascent virions at the surface of the infected cell, thereby inhibiting cell-
free virus release, it was asked whether, in addition to blocking cell-free virus dissemination, 
tetherin could also influence cell-to-cell virus spread. These questions can be addressed by 




















Figure 1.22: Cell-free versus cell-to-cell transmission of HIV-1 in the presence of tetherin.  
In the top half of the figure, HIV-1 Wt virus particles are not restricted by tetherin and can be 
released from the infected cell (or donor cell) into the extracellular environment to infect a new 
target cell. Alternatively, HIV-1 Wt particles can also be transmitted by direct cell-cell 
dissemination. In contrast, Vpu-defective HIV-1 particles (bottom half of the figure) are retained 
by tetherin (red) at the plasma membrane and they can be transmitted to a donor cell via cell-to-
cell transfer. Whether these tethered particles are fusion competent and fully infectious is still a 
matter of debate (question mark).  
 
 
 The contribution of tetherin to HIV-1's mode of transmission remains unclear, as opposing 
results have been described (216, 252, 253). The studies are based on the quantification of 
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target cells that become Gag positive when co-cultured, for a short period of time, with HIV-1 Wt 
or delVpu infected cells. One study reported that tetherin inhibited productive cell-to-cell 
transmission of Vpu-defective virus to target cells (252). This result was tested using several 
types of donor cells expressing tetherin either endogenously (HeLa cells) or expressed by 
transient transfection in 293T cells, while primary lymphocytes and Jurkats served as target 
cells. Importantly, tetherin was found to colocalize with Gag at the contact zone between 
infected and target cells, but did not alter the formation of the VS. However, in the presence of 
tetherin in the donor cell, delVpu viruses form large patches on the target cell after transfer 
whereas small puncta are observed with Wt virus. This observation may be cofounded by the 
fact that Gag-GFP constructs, such as those used in this study, have assembly defects and as 
a result often induce artefacts. These viral aggregates were found to be defective for second 
round replication because they were impaired in their fusion capacities.  
 By contrast, a parallel study revealed that Vpu-defective HIV-1 disseminated more efficiently 
by cell-to-cell contact between Jurkat cells (donor cells) and primary CD4+ T cells (target cells) 
than Wt virus, under conditions where tetherin restricted cell-free virion release (216). In the 
same study the authors showed that small interfering RNA-mediated depletion of tetherin 
affected VS formation and cell-to-cell transmission of Vpu-defective HIV-1. Presumably, tetherin 
might promote more Env-CD4 interactions to occur by concentrating clusters of virions at the 
assembly site and as a consequence increase the formation of VS. In contrast to the previous 
study, virions produced from T cells expressing endogenous tetherin did not lose infectivity. This 
result raises the intriguing question of what are the benefits to the virus of inhibiting its most 
efficient mode of transmission. In line with this study, early reports indicate that Vpu-deficient 
HIV-1 could replicate at the same rate as wild-type virus even though less Vpu-deficient free 
virions were released into the supernatant (179, 180).  
 The contradictory results between the two studies might be explained by the variable tetherin 
expression levels between cell types. T cells and Jurkat express comparatively less tetherin 
than HeLa cells or transiently transfected-293T, and it is possible that the outcome of HIV-1 cell-
to-cell spread varies with tetherin expression levels. At high tetherin levels, cell-to cell transfer 
might be impaired whereas at low levels the opposite effect occurs. However, this hypothesis is 
in contradiction with data from Jolly et al. showing that cell-to-cell transmission of HIV-1 delVpu 
particles was not affected even after tetherin upregulation by IFN. Alternatively, the ultimate 
goal of Vpu might be to reduce tetherin expression on the cell surface to such levels where its 
most efficient mode of HIV-1 transmission, cell-to-cell transfer, is promoted. This might explain 
why HIV-1 bearing a Vpu S52-56A mutant, impaired in its capacity to degrade tetherin, 
replicates much less efficiently in macrophages than in primary CD4+ T cells (254). Importantly, 
macrophages express high levels of tetherin compared to T lymphocytes. 
 HIV-1 might also employ tetherin to switch between the cell-free and cell-cell transmission 
modes. Thus, tetherin offers an opportunity for the virus to orientate its mode of transmission 
and potentially control the propagation of the virus over the body. Cell-free virus transmission is 
likely to favour rapid dissemination of the virus throughout the host while cell-cell transmission 
favours localized virus spread within a tissue. 
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1.6.8 Tetherin, more than just an inhibitor of virus release?  
By virtue of its mode of action, tetherin labels the surface of infected cells with virions, and thus 
enhances the potential targets for antibody deposition. This might facilitate the recruitment of 
molecules from the complement system, which in turn mediate the destruction of the infected 
cell. Alternatively, recognition of antibodies bound to virions on the target cell activates patrolling 
NK cells via Fc receptors leading to the lysis of the infected cell. This last process is called 
antibody-dependent cell-mediated cytotoxicity (ADCC). Subsequent internalization of retained 
virus particles might induce several biological effects. In antigen presenting cells, such as 
macrophages or dendritic cells, internalized tetherin-trapped virions are processed into small 
peptides that can serve as antigens for presentation. This function would place tetherin at the 
interface of the innate and adaptive immune responses. Endocytosis of viral particles might also 
contribute to enhance the intracellular pool of PAMPs, such as viral nucleic acids, available to 
activate endosomal TLRs, cytoplasmic PRR, and DNA sensors. For this reason, tetherin might 
control a positive feedback loop of interferon response.  
 As described above, exposure of pDCs to HIV-1 products is sensed by endosomal TLR7 and 
TLR9, which in turn activate transcription of type I interferon (Figure 1.23) (170, 171). This leads 
to the expression of several IFN-stimulated genes, including tetherin. Studies showed that 
tetherin could act as a negative feedback regulator of interferon production by pDCs. Tetherin 
has been found to be the natural ligand for the receptor ILT7 that is expressed exclusively on 
pDCs (255). Interaction between tetherin and ILT7-FcεRIγ complex triggers a signalling pathway 
that ultimately leads to repression of TLR7 or TLR9-mediated type I interferon and pro-
inflammatory cytokine secretion.  
 Therefore, tetherin might be involved in the modulation of the interferon response following 
infection, either by downregulating the inflammatory response to avoid immune hyper-activation 
or by upregulating an inflammatory response if a more robust immune intervention is required. 
 Finally, tetherin might itself serve as a signalling receptor. In a large-scale study aiming to 
identify human genes that activate NF-κB and MAPK signalling pathways, tetherin was one of 
those (256).  
 Therefore, tetherin might have a wider role in the antiviral innate immune response, but 
whether these functions are just ''side effects'' of viral retention or whether they are real intrinsic 
functions of tetherin has yet to be determined (Figure 1.23). Tetherin might be versatile, 
harbouring different functions depending on the type of immune cell in which it is expressed. 
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Figure 1.23: Tetherin is at the center of the antiviral response. 
HIV-1 virions bind to CD4 on the surface of plasmacytoid dendritic cells. Virions are then 
endocytosed. In the endosomes, recognition of viral genomic RNA by TLR7/9 triggers the 
transcription of interferon type I gene. IFN-I interacts with their receptor on the surface of T cell. 
This signal is then transduced to the nucleus via the JAK-STAT pathway leading to the 
expression of several interferon-stimulated genes such as tetherin. At the cell surface of the 
infected T cell, tetherin bridges the nascent virions with the host plasma membrane. This results 
in the internalization and most likely lysosomal degradation of virions. Hypothetically, peptides 
derived from endocytosed-virions could be loaded on MHC class I complexes and then 
displayed on the cell surface for recognition by cytotoxic CD8+ T lymphocytes. Retention of 
virions by tetherin might also activate the NF-KB signaling pathway. Finally, tetherin can interact 
with ILT7 expressed on the surface of pDCs and induces a negative feedback of interferon 
production to prevent overproduction of pro-inflammatory cytokines.  
 
1.6.9 Evidence of tetherin's antiviral effect in mouse models 
 
The role of tetherin as a key antiviral determinant in vivo is best evidenced by infection of 
tetherin-deficient mice with MLV (257). In this study the authors showed that tetherin restricts 
Moloney Murine Leukemia virus (Mo-MLV) and a pathogenic MLV complex known as LP-BM5 
in vivo. Treatment of mice with IFN-α was required to reveal the anti-Mo-MLV activity of tetherin. 
Tetherin-deficient mice infected with the MLV strain LP-BM5 showed more pathologic effects 
than the control mice. The ability of tetherin to inhibit retroviral replication in vivo was also 
illustrated through the identification of a single nucleotide polymorphism (SNP) in the tetherin 
sequence of NZW/LacJ mice (258). In those mice, the canonical ATG start site is mutated to 
GTG, and as a result the translation is initiated later in the sequence. This leads to a tetherin 
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protein that lacks the N-terminal 12 amino acids (designated as NZW tetherin), and in particular 
the endosomal recycling motif, resulting in higher cell-surface expression and more potent 
inhibition of Friend retrovirus release compared to C57BL/6 (full length) tetherin in vitro. 
Furthermore, NZW tetherin expression correlates with a decrease of Friend retrovirus replication 
and pathogenesis in vivo. 
 Altogether, these observations demonstrate that tetherin is is a bona fide antiviral protein, 
which plays a major role in vivo by reducing retroviral replication and disease. 
 
 
1.7 Mechanisms of Evasion and Accessory Viral Proteins 
One striking contrast between Gammaretroviruses and HIV-1 is the relative simplicity of the 
MLV genome. MLV only encodes the proteins that will be assembled into the progeny virus 
particles, whereas HIV-1 encodes four additional, so-called ''accessory proteins''. These 
accessory proteins include Vpr, Nef, Vpu and Vif. The SIVsm lineage from which HIV-2 derives, 
shares the same array of accessory proteins with the exception of Vpu, but additionally encodes 
Vpx. Although these proteins are dispensable for HIV-1 replication in vitro in many cases, in 
vivo, they contribute, to varying degrees, to efficient virus spread and disease induction. Their 
importance was first illustrated by the fact that SIVmac lacking a functional nef gene replicated 
poorly and did not cause disease in adult macaque monkeys (259). Furthermore, humans 
infected with nef-defective HIV-1 exhibit a slow/nonprogressor phenotype (260, 261). It is 
becoming clear that these proteins perform essential functions to ensure viral survival in a host(-
ile) environment (reviewed in (45)). They act by modulating various cellular pathways, host 
protein expression levels and immune responses, in order to create a cellular environment 
favourable for viral persistence, replication, transmission, dissemination and immune evasion 
(Table 1.2). Vpu and Nef can be associated in the same group because they both have effects 
on host cell surface molecules whereas Vif, Vpr and Vpx modulate cytoplasmic and nuclear 
proteins. These accessory proteins are a perfect example to illustrate the high degree of 
interaction between the virus and its host.  
 In this section, we will address the biological effects of these viral proteins on the host cell, 
and how they adapted to counteract cellular barriers. Despite not being an accessory protein, 
the structural protein capsid will also be mentioned given its ability to escape cellular 
recognition. 
 
1.7.1 Vpr and Vpx  
While Vpr is highly conserved in primate lentiviruses, Vpx is only encoded by the HIV-
2/SIVsm/SIVmac lineage. Vpr and Vpx share a high degree of sequence homology suggesting 
that they probably arose through either a gene duplication or homologous recombination. Both 
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are required for pathogenesis in rhesus macaques (262-265), and are incorporated into viral 
particles.  
 Vpr is packaged into virions at high levels, via interaction with the p6 subunit of Gag (136), 
and localizes to the nucleus of infected cells where it is believed to cause direct cytopathic 
effects. Expression of Vpr in dividing cells can block progression of the cell cycle in the G2 
phase after most or all of the cellular chromatin has been replicated. HIV-1 infected people 
display more CD4+ T cells in G2 phase than healthy uninfected controls (266). In vitro analyses 
showed that this effect was dependent on the ability of Vpr to interact with the cullin4A-DDB1 
E3 ubiquitin ligase complex through the adaptor protein DCAF1 (also referred to as VprBP) 
(267-271). Cell-cycle progression could be restored when interaction between DCAF1 and Vpr 
was disrupted, or when expression of DCAF1 or DDB1 was inhibited by siRNA. DDB1 (DNA 
damage-binding protein1) is not only a component of the cullin4A E3 ligase but also mediates 
the repair of DNA lesions generated during the S phase. Presumably by forming 
DCAF1/cullin4A-DDB1 complexes, Vpr prevents DDB1 from performing its DNA-repair function 
leading to an accumulation of damaged DNA. This, then, triggers the activation of the DNA 
damage-sensing kinase ATR (ataxia telangiectasia and Rad3 related) leading to G2 arrest 
followed by apoptosis (272). Therefore, Vpr mimics intracellular conditions that are similar to 
those encountered after DNA stress/damage. The benefits for HIV in stopping cell cycle is not 
fully understood but studies revealed that HIV-1 transcription is enhanced under such 
conditions. The uracil DNA glycosylases UNG2 and SMUG, involved in DNA repair, have been 
found to be sensitive to Vpr-mediated proteasomal degradation via the cullin4A complex but 
none have been linked to Vpr-mediated G2 arrest. Clearly Vpr-induced G2 arrest requires the 
cullin4 ubiquitin ligase complex but the substrate targeted for ubiquitination has not been 
identified yet. Based on the discovery that Vpx could recruit the same cullin4A E3 ligase as Vpr 
to degrade SAMHD1 (173, 273), it was thought that SAMHD1 was the substrate targeted by 
Vpr. But this was not the case, at least for HIV-1 Vpr.  
 In addition to G2 arrest, HIV-1 Vpr also facilitates infection of macrophages. But the levels of 
HIV-1 infection remain low in comparison to infection with HIV-2 or SIVmac. Adding Vpx in trans 
in HIV-1 infected macrophages and dendritic cells significantly increased their susceptibility to 
HIV-1 infection (274, 275) suggesting that these cells expressed an antiviral factor that was 
antagonized by Vpx. SAMHD1 (sterile alpha motif and HD domain 1) was recently identified as 
the cellular factor responsible for the inhibition of HIV-1 infection of dendritic and myeloid cells. 
SAMHD1 was identified using tandem affinity chromatography purification coupled with mass 
spectrometry. The lack of a monocytic cell line model in which HIV-1 infection was restricted has 
made the identification of the Vpx’ s target difficult. The authors identified SAMHD1 in PMA-
differentiated THP1 monocytic cells (173). SAMHD1 was initially identified as the human 
ortholog of the mouse gene Mg11, which is induced by interferon treatment of macrophages 
and dendritic cells (276).  
 To counteract SAMHD1, Vpx, like the other accessory proteins, serves as an adaptor protein 
bridging its substrate with the cellular ubiquitin machinery. Vpx interacts with SAMHD1 and 
recruits the same E3 ubiquitin ligase complex as Vpr, the cullin4A-DDB1-DCAF1, to mediate 
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SAMHD1 ubiquitination and subsequent degradation via the proteasomal pathway (273, 277). 
Silencing of SAMHD1 in non-permissive cell lines alleviates HIV-1 restriction, and addition of 
SAMHD1 to cells in which HIV-1 normally could replicate rendered them resistant to infection 
unless Vpx was expressed.  
 In the absence of Vpx in trans, HIV-1 reverse transcription is blocked in myeloid cells. This 
observation appears to be a consequence of the hydrolase activity of SAMHD1. SAMHD1 has 
been found to be a potent dGTP-stimulated triphosphohydrolase that converts deoxynucleoside 
triphosphates to the constituent deoxynucleoside and inorganic triphosphate (278). The crystal 
structure of the catalytic core of SAMHD1 (from residues 120 to 626) reveals that the protein is 
dimeric and indicates a molecular basis for dGTP stimulation of catalytic activity against dNTPs. 
Presumably, SAMHD1, which is highly expressed in dendritic cells, restricts HIV-1 replication by 
hydrolysing the majority of cellular dNTPs, thus inhibiting reverse transcription and viral 
complementary DNA synthesis. Therefore, SAMHD1 might be involved in regulating the 
cytoplasmic nucleic acid metabolism. It is for this reason that SAMHD1 has been referred to as 
a negative regulator of the innate immune response to interferon stimulatory DNA. This function 
has also been attributed to the cellular DNase TREX1 that degrades cytoplasmic nucleic acids 
(172). In the absence of TREX1, the resulting accumulation of cytosolic HIV DNA triggers IFN 
release and auto-immune responses that inhibit HIV replication and spreading. It is surprising 
that SAMHD1 degradation is not conserved in HIV-1, but hypothetically the inability of HIV-1 Vpr 
to degrade SAMHD1 may represent an advantage in that it would otherwise elicit strong 
antiviral interferon-induced immune responses by dendritic cells (174).  
 The discovery of SAMHD1 has provided evidence that accounts for the different degrees of 
permissiveness of human cells to HIV-1 infection. SAMHD1 is highly expressed by monocytes 
and monocyte-derived DCs (MDDC), and less well expressed in monocyte-derived 
macrophages (MDM) and absent from HIV-1 sensitive T cell lines suggesting a direct 
correlation between SAMHD1 expression levels and permissiveness of the cell types to HIV-1 
infection. 
 The SAMHD1 gene is mutated in a subset of patients suffering from Aicardi-Goutières 
syndrome (AGS), an early-onset disease that resembles a congenital viral infection (279). This 
syndrome is characterized by familial encephalopathy with predominantly neurologic symptoms 
and increased production of interferon alpha in the brain (280). In accordance with the results 
above, CD14+ monocytes isolated from AGS patients lack endogenous SAMHD1 and can 
support HIV-1 replication while the same cell subset from healthy donors cannot (281). 
 Vpx is not expressed in all lineages of primate lentiviruses and in those devoid of Vpx, it is 
Vpr that degrades SAMHD1 (282, 283). Based on evolutionary analyses and Vpr/Vpx’ species-
activities against the different SAMHD1 proteins, the appearance of SAMHD1-antagonistic 
function is predicted to be the result of neo-functionalization of Vpr that preceded the acquisition 
of Vpx in primate lentiviruses. Many lentiviral lineages leading to HIV-1 never acquired this 
function and only conserved the predicted ancestral function of cell cycle arrest. This ancestral 
function, then, disappeared from Vpx. 
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1.7.2 Vif and APOBEC3G 
Viral infectivity factor (Vif) is a 192 amino acid protein that allows HIV-1 replication by targeting 
the cellular restriction factor APOBEC3G (A3G or CEM15) (284) and others including 
APOBEC3B, D, E, F, H of debatable importance (Figure 1.24). Vif-defective HIV-1 can replicate 
in some permissive cells such as Jurkat and SupT1 cells because they are A3G negative, but 
cannot replicate in other non-permissive cells such as macrophages and primary human T cells. 
In the absence of Vif expression in restrictive cell lines, HIV-1 viral particles package 
APOBEC3G molecules through interactions with Gag nucleocapsid NC and viral RNA (285). 
The mechanistic details allowing this incorporation have not been fully established, but once in 
the cytoplasm of the newly infected cell, A3G through its association with the RTC deaminates 
cytidine residues in nascent minus-strand viral cDNA into uridine residues (286-288). The direct 
consequence is the generation of guanosine-to-adenosine hypermutation of the viral plus strand 
sequence encoding for non-functional viral proteins. However, A3G's ability to edit viral DNA 
does not appear to be the only mechanism of restriction since A3G mutants that have lost their 
enzymatic-editing function are still able to inhibit viral infectivity (289). Importantly, in the 
presence of A3G the levels of cDNA accumulating during HIV-1 infection are also diminished. 
Based on this observation, it was initially thought that the recognition of uridine-containing DNA 
by host DNA repair enzymes could then trigger DNA degradation. However, this hypothesis was 
discounted because inhibition of uracil-DNA-glycosidase fails to enhance the DNA levels in the 
presence of A3G (290, 291). It was then proposed that A3G bound to viral RNA might sterically 
hinder the translocation of RT along the viral RNA template and thus inhibiting cDNA synthesis 
(292). 
 Vif enables HIV-1 to evade the antiviral activities of APOBEC3G by targeting it for 
proteasomal degradation (293, 294). Vif has been shown to interact with APOBEC3G and 
recruit the cullin5-elonginB/C-Rbx2 E3 ubiquitin ligase complex via its SOCS box (suppressor of 
cytokine signalling box) (295). This SOCS box contains an elongin C binding helix (the BC-box), 
a conserved HCCH Zn binding motif and a short Cullin Box. Recently, the transcription cofactor 
CBF-β has been identified as an additional component recruited by Vif to the E3 ligase complex 
and important to promote HIV-1 infection (296). In such configuration, ubiquitin molecules are 
transferred from an, as yet unknown, E2 ubiquitin-conjugating enzyme to APOBEC3G (poly-
ubiquitination), thus marking it for degradation via the 26S proteasome. Through the depletion 
of APOBEC3G enzymes from the cytoplasm of infected cells, Vif prevents their incorporation 
into viral particles. 
 The mode of action of Vif is species-specific in that HIV-1 Vif can only counteract human but 
not agm APOBEC3G (297), whereas SIVagm Vif is able to counteract agm APOBEC3G but not 
the human version. This species-specificity correlates with the ability of Vif to only bind and 
prevent encapsidation of the APOBEC3G from its corresponding host. A single mutation in 
human A3G found in agm A3G (D128K) is sufficient to confer resistance to HIV-1 Vif and 
sensitivity to SIVagm Vif (298).  
 In addition to APOBEC3G, APOBEC3F can also restrict the replication of Vif-deficient virus 
and is counteracted by Vif in a similar way to APOBEC3G (299). APOBEC3G and APOBEC3F 
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belong to the mammalian APOBEC (apolipoprotein B mRNA-editing enzyme catalytic 
polypeptide 1-like) family of cytidine deaminases, of which at least nine other members appear 
to be expressed in humans. As expected, these proteins are expressed in the natural targets of 
HIV-1 infection, T cells and macrophages. APOBEC3 genes are unique to mammals and are 
believed to play an important role in the innate host immune response illustrated by A3G’s 
activity against HIV-1 mentioned above. In the mouse genome, at the equivalent locus to A3G, 
is located Rfv3, a host resistance gene for Friend murine retrovirus. Not only HIV-1 is sensitive 
to restriction by APOBEC3 proteins, other types of viruses such as hepadnaviruses (hepatitis 












Figure 1.24: APOBEC3G/F inhibit HIV-1 infection and are antagonized by Vif. 
Vif-deleted HIV-1 particles from the producer cell (left side) are packaged with the cellular 
factors APOBEC3G/F and infect a target cell (right side). In the target cell, A3G/F associate with 
the reverse transcription complex and induce two effects: deamination of cytidine residues into 
uridine residues in minus reverse strand transcripts causing hypermutation of the viral DNA, and 
reduction of the levels of viral cDNA by physically interfering with the reverse transcription 
process. In the presence of Vif in the producer cell, A3G/F are degraded and cannot be 
incorporated into viral particles. Figure adapted from (300).	  
 
1.7.3 Nef and Cell Surface Receptors  
Nef is a myristoylated protein encoded by all primate lentiviruses that binds to the inner leaflet of 
cellular membranes. Many functions have been attributed to Nef for infectivity and pathogenicity 
due to its ability to modulate the expression of a large range of cell surface receptors and 
molecules in T cells and antigen-presenting cells (reviewed in (45)). Overall, the downregulation 
of Nef-targeted proteins leads to enhancement of infectivity, reduction of super-infection, 
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disruption of immunological responses and regulation of T cell activation, thus creating the 
perfect environment for viral replication and persistence. 
 The effect of Nef on viral pathogenicity can be illustrated by the fact that defective forms of 
nef were found in HIV-1 infected individuals termed long-term nonprogressors (261). 
Furthermore, while SIVmac is usually highly pathogenic, macaques inoculated with Nef-deleted 
SIVmac have extremely low viral loads, resulting in either no pathogenicity or a markedly long 
disease course (259).  
 All HIV/SIV Nef alleles can downregulate the levels of CD4 in infected cells. Nef binds to 
CD4 and recruits the clathrin adaptor AP-2, which leads to the formation of clathrin-coated pits 
(301, 302). Clathrin-coated vesicles containing CD4 are then endocytosed and sorted to the 
lysosomes via the ESCRT machinery for degradation. Thereby, Nef-mediated CD4 cell-surface 
downregulation prevents infected T cells from undergoing a second round of infection which 
might be deleterious for the cell viability and consequently for viral replication. The removal of 
CD4 from the cell surface might also stabilize the envelope proteins and facilitate their 
incorporation into nascent virions resulting in higher infectivity and replication of HIV-1 (303, 
304). By comparison, Vpu also causes a decrease of CD4 levels on the cell surface, but Vpu 
targets CD4 molecules earlier in the secretory pathway through interactions occurring in the 
endoplasmic reticulum.  
 The MHC class I molecules, HLA-A and HLA-B but not HLA-C, are also downmodulated by 
Nef. MHC class I molecules are expressed at the surface of most cells and can be loaded with 
viral antigens. Cytotoxic T cells (CTLs) can then recognize infected cells via a specific TCR that 
together with CD8 interact with the MHC class I molecule associated with the antigen peptide. 
This recognition elicits the lysis of the infected cell. Thus, Nef-mediated MHC class I 
downregulation enables infected cells to escape from adaptive immune responses (305). With 
regards to the mechanistic aspects, two pathways have been proposed. First, Nef binds to the 
cytoplasmic tail of MHC class I early in the secretory pathway, and recruits AP-1 complex to 
deliver its substrate to endosomes (306-308). Alternatively, Nef activates a signalling cascade 
leading to the endocytosis of MHC class I from the cell surface (309). Additionally, Nef 
suppresses MHC class II expression from the cell surface of professional APCs, thus impairing 
activation of naïve CD4+ T cells and subsequent T-helper cells-mediated immune responses 
(310-312).  
 Nef has also been shown to modulate infectivity of viral particles by facilitating viral core 
penetration of the cortical actin network during the initial phases of infection. By pseudotyping 
with VSV-G, the infectivity of Nef-deleted virus could be restored. Furthermore, recent studies 
showed that Nef interacts with dynamin 2, a GTPase that is required for clathrin-mediated 
endocytosis, to enhance infectivity of virions (313). Based on these observations, it was 
proposed that Nef through the recruitment of dynamin 2 might modify the composition of viral 
membranes to enhance their infectivity. 
 Nef also interacts with a serine/threonine kinase, member of the p21-activated kinase (PAK) 
family (314). Once Nef binds to PAK, the kinase is activated and this ultimately leads to 
inactivation of a pro-apoptotic Bad protein.  
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 Nef expression was also shown to increase DC-SIGN levels on the cell surface of dendritic 
cells (315). In the context of HIV-1 infection, cells expressing DC-SIGN are able to retain 
attached virions in an infectious state for several days and transmit them to T cells through a 
process called transinfection.  
 While Nef alleles from the great majority of primates lentiviruses, including HIV-2, 
downmodulate cell surface TCR-CD3 (316) and reduce TCR-induced NFAT activation, HIV-1 
Nef is devoid of this attribute and this difference has been proposed to govern the pathogenic 
outcome of lentiviral infections. However, this notion is debated since SIVmac causes disease 
in infected monkeys while being able to downregulate CD3 through its Nef protein. Natural SIV 
infections are usually not pathogenic for their primary host and this correlates with low levels of 
T cell activation and apoptosis. However, pathogenic HIV infections are associated with high 
levels of immune activation causing cell death (AICD). The ability of SIVs to downregulate TCR-
CD3 to limit T cell activation is intriguing since generally this process contributes to replenish 
the pool of infectable cells and stimulates virus replication. It is possible that by doing so, Nef 
might adjust T cell activation to an optimal level where viral replication is promoted and AICD 
avoided. 
 Finally, as mentioned previously, most of SIV Nefs target a conserved motif in tetherin 
cytoplasmic tail and bind the clathrin adaptor complex AP-2 to stimulate tetherin internalization 
from the cell-surface. This function is not conserved in HIV-1 Nef. 
 Recently, the NK cell activating ligand PVR was also found to be downregulated by HIV-1 
Nef (317). This contributes to the avoidance of recognition and lysis of infected cells by NK 
cells. 
  
     CELLULAR TARGETS OF HIV-1 VPU 
 






Co-factor Mechanism Biological effect / Benefit to Virus 
 
Vpr  
     HIV-1 
     HIV-2 










Unknown - G2 cell-cycle arrest --> HIV-1 transcription 
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- Prevent super-infection 
- Facilitate Env incorporation into nascent 
virions 
- Disruption of CD4-based immune responses 
 
Escape from CTLs recognition 
 
 
Reduce antigen presentation  
 
 
Avoid cytotoxic function of NK cells 
Avoid cytotoxic function of NK cells  
 
 
Promote transinfection between DCs and T 
cells 
 
Block responsiveness of infected T cell to 
activation -->  Avoid AICD  
 
 
Table 1.2: Four accessory proteins devoted to create the ideal cellular environment for 
viral replication. 
This table displays the host molecules and cellular pathways targeted by accessory proteins 
encoded by primate lentiviruses HIV and SIV. Restriction factors are indicated with an asterisk. 
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1.7.4 HIV-1 Capsid and TRIM5α 
Tripartite motif-containing protein 5 alpha (TRIM5α) was isolated as the cellular factor 
responsible for blocking HIV-1 infection in Old World Monkey (OWM) cells (318). TRIM5α is 
expressed in the cytoplasm and recognizes specific motifs within the incoming retroviral capsid 
proteins, thus providing species-specific retrovirus restriction at the stage of reverse 
transcription. TRIM5α blocks infection before the establishment of a provirus in the target cell. 
The human orthologue of TRIM5α, initially designated Ref1, cannot target HIV-1 CA but can 
mediate restriction of several strains of MLV (319-321).  
 TRIM5α comprises an N-terminal RBCC domain made up of RING (R), B-box (B), and 
coiled-coil (C) modules and a C-terminal B30.2 domain. The B30.2 domain mediates virus 
binding and determines antiviral specificity, whereas the RBCC domain is important for TRIM5α 
multimerization and appears responsible for recruiting the proteasome. 
 The molecular details by which TRIM5α blocks virus replication are not well understood. 
TRIM5α is auto-ubiquitinylated in a RING dependent way and rapidly turned over by the 
proteasome (Figure 1.25). Presumably, when incoming sensitive retroviral cores encounter 
ubiquitinated-TRIM5α, they also become recruited to the proteasome and destroyed before the 
reverse transcription process takes place. Proteasomal inhibitor treatment allows the virus to 
reverse transcribe, however, the infection is not rescued because reverse transcripts fail to 
integrate. This suggests that TRIM5α-virus complexes remain uninfectious even when protected 
from degradation. It is thought that the formation of such complexes disrupts the reconfiguration 
and uncoating steps necessary to ensure the transition of RTC into PIC and subsequent nuclear 
import. Therefore, TRIM5α mediates an early block in the HIV-1 replication cycle that appears to 
occur before and after reverse transcription. 
 Among New World primates, only owl monkeys exhibit post-entry restriction of HIV-1 (322). 
This block in owl monkeys results from the retrotransposition of cyclophilin A encoding 
sequence into TRIM5α gene giving rise to a TRIM5-CypA (TRIM-Cyp) fusion protein (323). A 
similar protein has also been identified in several species of macaques via a similar 
retrotransposition event. HIV-1 restriction by TRIMCyp is capsid-specific illustrated by the 
inability of TRIMCyp to block SIVmac infection. HIV-1 restriction in owl monkeys is completely 
abrogated when the interaction between HIV-1 CA and CypA is disrupted, either by mutations 
altering capsid or by treatment of targets cells with the cyclophilin-binding drug, cyclosporine 
(CsA). In HIV-restricted owl monkey cells, cyclophilin A helps TRIM5 restriction by facilitating its 
binding to the CA. But the role of CypA is not clear; because for instance in human cells CypA 
has the opposite effect, its binding with CA seems to inhibit restriction by TRIM5α and is 
required for maximal infectivity.  
 Importantly, the HIV-1 genome does not encode a protein whose the function is to target 
TRIM5α like it is the case with APOBEC3G, Tetherin and SAMHD1 through respectively the 
accessory proteins, Vif, Vpu and Vpx. Instead, sequence variations within the CA sequence 
combined with the recruitment of the cellular protein CypA appear to allow HIV-1 to escape from 
TRIM5α-mediated restriction. 
 
     CELLULAR TARGETS OF HIV-1 VPU 
 




























Figure 1.25: Model of TRIM5α-mediated post-entry restriction of HIV-1. 
A: By virtue of its RING domain, TRIM5α is auto-ubiquitinated and as a result becomes a 
substrate for the proteasome. Incoming viral capsids interact with ubiquitinated-TRIM5α and 
become also part of the complex targeted for proteasomal degradation. In that case TRIM5α 
induces a block before the reverse transcription occurs. B: In the absence of proteasomal 
degradation (inhibition by MG132), reverse transcripts can be generated but fail to integrate. 
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1.8 HIV-1 Vpu 
In 1988, two independent groups, led by William A. Haseltine and Malcolm A. Martin reported 
the identification of an additional gene encoded by the HIV-1 genome (325, 326). The open 
reading frame from which this protein is synthesized was originally designated U, and so they 
proposed to call the new gene vpu, for viral protein Unique. Importantly, antibodies against this 
novel protein were detected in the sera of people infected with HIV-1. This protein distinguished 
HIV-1 isolates from the other human and simian immunodeficiency viruses (HIV-2 and 
SIVmac/sm) that do not encode a similar protein. Later on, SIV strains encoding homologues of 
Vpu were identified (SIVcpz, SIVgsn, SIV mon, SIVmus, SIVden, SIVgor). Early after its 
discovery, studies revealed a key role of Vpu for efficient virus replication. A five-to-ten fold 
reduction in progeny virions was observed after the infection of T lymphocytes with a mutant 
virus bearing a frame-shift mutation into the vpu open reading frame. Subsequently, Vpu has 
been considerably studied to better understand its role in HIV-1 replication and pathogenesis.  
 
1.8.1 The Vpu protein of HIV-1: Structure and Characteristics 
Vpu is a 16-kDa type I integral membrane protein consisting of an N-terminal transmembrane 
anchor (residues 1-27) followed by a C-terminal hydrophilic region that protrudes into the 
cytoplasm (28-81) (Figure 1.26A) (327). The transmembrane segment adopts an alpha-helical 
secondary structure anchored in the membrane lipid bilayer with a tilt angle of 13 degrees (328, 
329) (330). In addition to its role in mediating interactions with Vpu's targets, the 
transmembrane domain serves as a signal peptide that remains uncleaved and is thought to 
interact with other Vpu molecules to form pentameric structures (327, 331). Based on structural 
similarity with the M2 protein from the influenza A virus, and on the fact that it induced Na+ and 
K+ flux in Xenopus Oocytes, it was thought that Vpu TM domain could form cation-selective ion 
channels (332). This was also confirmed by introduction of purified Vpu, expressed from 
Escherichia coli, in planar lipid bilayers (333). In both experiments, Vpu increased membrane 
conductance to sodium and potassium cations but not to anions. This was dependent on the TM 
domain since a scrambled TM sequence into full-length Vpu abrogated its capacity to increase 
membrane conductance in oocytes. But whether the ion channel activity is required for Vpu 
function is still under debate. In that regard, while substitution of the serine residue (S23) into 
alanine abrogates ion channel function, Vpu remains able to enhance virus release in the 
presence of tetherin (cf. Chapter 5). The cytoplasmic region is formed of two alpha helices 
(designated as αH-1 and αH-2) linked by a conserved DSGNES motif that includes a pair of 
serine residues (S52 and S56) phosphorylated by casein kinase II (334-337). The Vpu 
cytoplasmic tail contains a high proportion of charged residues which include a membrane 
proximal stretch of positively charged basic residues followed by a series of negatively charged 
acidic residues in the C-terminal part of the protein that confer an overall negative electrostatic 
charge to the molecule (Figure 1.26B) (338). In more detail, the membrane-spanning N-terminal 
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domain is connected to the cytoplasmic tail by a short positively charged linker that is predicted 
to interact with the negatively charged heads of the lipid surface. This small flexible arm is then 
followed by the helix 1 composed of an alternance of hydrophobic (uncharged residues), basic 
and acidic residues rendering the region amphipathic (Figure 1.26). Potentially, the hydrophobic 
side of the helix 1 would be buried in the lipid bilayer, exposing the hydrophilic (charged 
residues) side to the cytoplasm. The flexible portion interconnecting the two cytoplasmic alpha 
helices is likely to form a loop pointing away from the membrane due to the polar nature of the 
two highly conserved phosphorylated serine residues. However, these conformations are, at 
present, just models of the tertiary structure of Vpu based on highly purified segments of Vpu 
proteins. The configuration adopted by Vpu might be completely different in the context of an 
infected cell. In that regard, Vpu’s interactions with several host factors, notably CD4 or tetherin, 
might result in a profound modification of its tertiary structure, in particular, the orientation of the 
cytoplasmic helices. 
 Vpu is synthesized late in HIV-1 replication cycle, from a Rev-dependent bicistronic mRNA 
that also encodes the envelope glycoprotein (cf. section 1.4.4) (339). This allows Vpu and Env 
expression to be coordinated during HIV-1 infection. While Env incorporation into the viral 
particle is essential to generate infectious virus, Vpu protein is not incorporated into HIV-1 
virions and therefore performs its function within the infected cell. 
 Vpu proteins from subtype B strains, which is the version of Vpu most commonly studied 
since its identification, localize predominantly to internal cellular membranes, including the 
trans-Golgi network (TGN) and endosomes but only a minor localization at the plasma 
membrane has been detected (340, 341). Recent studies indicate that a fraction of Vpu was 
associated in raft-membrane (342), although the relevance of this for counteracting the particle 
release restriction imposed by tetherin is still unclear (343, 344). Vpus from HIV-1 Group M 
clade C and SIVcpz have been found to accumulate mainly at the cell surface (345, 346). 
Interestingly, this divergence in the Vpu cellular localization might be driven by putative 
trafficking signals in the cytoplasmic tail since these regions are not conserved among Vpu 
alleles from different HIV-1 subtypes. These putative localization motifs include a tyrosine 
(YxxΦ in which Φ refers to a hydrophobic residue) sorting motif in the hinge region that links the 
transmembrane domain to the cytosolic tail and an acidic/dileucine based ([D/E]xxxl[l/I/V]) signal 
in the second alpha helix (Figure 1.26B).   
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Figure 1.26: Schematic representations of Vpu.  
A: Secondary structure of Vpu. This model is based on NMR studies and modelling data 
performed from fragments of Vpu. To date the full-length protein has not been successfully 
crystallized. The Vpu transmembrane domain is tilted at 13° degrees. In this model, the first 
alpha helix is aligned with the lipid bilayer and the two phospho-serine residues protrude into 
the cytoplasm. The numbers in red indicate amino acid positions of the NL4.3 prototypical Vpu 
allele. B: Amino acid sequence of NL4.3 Vpu	  annotated with structural features described in 
panel A. Acidic residues negatively charged are indicated in red and basic residues positively 
charged are annotated in blue. The conserved β-TrCP binding motif in the cytoplasmic tail that 
contains the two phosphorylation sites (S52 and S56) is also indicated. 
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Figure 1.27: Wheel diagram of residues 37-51 from Vpu cytoplasmic tail showing the 
amphipathic nature of the first alpha helix.  
Negatively charged residues are depicted in green, positively charged residue in blue and 
hydrophobic residues in red. The hydrophobic residues form one side of the first alpha helix and 
are predicted to be submerged in the lipid bilayer, while the opposite side bearing the charged 
residues may be in contact with the phospholipid heads and facing the cytoplasm. Figure 
adapted from (338). 
 
 
 To date, four main functions have been associated with Vpu (Table 1.3) (reviewed in (347)). 
Firstly, Vpu induces a rapid degradation of newly synthesized CD4 molecules within the ER via 
a proteasomal pathway. Secondly, Vpu enhances HIV-1 particle release by counteracting 
tetherin. Vpu also inhibits the surface expression of the lipid antigen receptor, CD1d, in 
productively infected DCs to avoid recognition by the NKT cells (348). Finally, HIV-1 Vpu might 
ensure protection of infected cells from lysis by NK cells through the downmodulation of NTB-A 
(349) and PVR (317). Additionally, as an indirect consequence of Vpu interacting with β-TrCP, 
Vpu may interfere with essential cellular processes resulting in cell death via apoptosis (350).  
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Table 1.3: Activities of Vpu and their biological effects on HIV-1 replication.  
Vpu was also shown to induce CD4+ T cell death by apoptosis but this effect is not mentioned in 
this table because it is considered as being an indirect consequence of Vpu-binding to β-TrCP 
rather than a direct biological function of Vpu. 
 
1.8.2 Vpu, a multifunctional protein 
1.8.2.1 Vpu induces CD4 degradation 
Although HIV-1 penetrates the host cell by interacting with the CD4 surface receptor, the virus 
encodes two proteins out of fifteen, Nef and Vpu, which both target CD4 for degradation. Early 
after infection, expression of Nef accelerates the endocytosis of mature cell surface CD4 by a 
clathrin/AP-2 dependent pathway followed by delivery to the multivesicular bodies for 
subsequent degradation in lysosomes (301, 351). Unlike Nef, Vpu is translated at later stages of 
Function Mechanism Biological effect(s) 
CD4 degradation - Interaction through TM and 
cytoplasmic domains 
- Connects the E3 ubiquitin ligase SCF 
via recruitment of β-TrCP for 
proteasomal degradation (ERAD) 
- Prevention of super-infection 
- Release of Env precursor from the 
ER 
- Efficient virion release 
- Maintenance of infectivity 
- Avoid constant CD4+ T cell 
activation 
Tetherin inactivation - Prevents tetherin from being 
expressed on the cell surface  
- β-TrCP and ESCRT-dependent 
lysosomal degradation 
- Enhancement of virus release 
- Inhibition of tetherin-mediated 
NFκB signalling 
NTB-A downregulation 
from the cell surface 
- Inhibition of cell surface expression 
- No degradation 
- No enhancement of endocytosis   
- Interaction with Vpu TM domain 
required 
- Alteration of the cellular trafficking?  
- Protection of infected cells from 
NK-cell-mediated killing by 
hindering NK-cell degranulation 
PVR downregulation Not defined - Prevent NK cell-mediated lysis of 
infected cells 
CD1d downregulation - Suppress CD1d recycling from 
endosomal compartments to the PM 
- Retention into intracellular 
compartment 
- No degradation 
- No enhancement of endocytosis 
- Avoid recognition of APCs 
(monocytes, macrophages, DCs) by 
NKT cells  
                  
MHC Class I Not defined - Escape recognition of infected 
cells by CTLs 
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infection in a Rev-dependent manner, and targets newly synthesized CD4 in the ER for 
degradation by cytosolic proteasomes. The fact that two proteins are devoted to the same 
function suggests that suppression of CD4 expression must be important for the HIV-1 
infectious cycle. First, downregulation of CD4 from the cell surface of infected cells prevents 
further super-infections by new virions (352). Superinfected primary T cells show enhanced 
levels of apoptosis, so by reducing the levels of CD4 on the cell surface, Vpu may prevent 
premature cell death and expand the period of effective virus production. Vpu also prevents 
CD4 from interfering with the production of infectious virus particles (303, 353-356). CD4 can 
form complexes in the ER with newly synthesized Env precursor gp160, thus blocking the 
transport of Env towards the plasma membrane. But, in that scenario, Env proteins trapped in 
the endoplasmic reticulum would also result in the production of Env-deficient and non-
infectious virions. Therefore, Vpu intervenes to release trapped-Env proteins from gp160-CD4 
complexes and allow them to resume maturation, and trafficking towards the cell surface for 
their incorporation into nascent virions. Similarly, CD4 can also interact with Env glycoproteins 
at the site of viral assembly, at the plasma membrane, preventing them from being incorporated 
into progeny virions. Alternatively, CD4 can be incorporated into nascent virions along with Env 
but viral infectivity consequently would also be reduced. Altogether, these effects of Vpu on 
CD4 expression predispose the infected cell for optimal production of fully competent infectious 
virus particles.  
 The ability of Vpu to mediate the degradation of CD4 is linked to its capacity to physically 
interact with it. Mutagenesis studies have mapped the region from residues 414 to 419 
(LSEKKT) in the CD4 cytoplasmic domain, as crucial to allow Vpu binding and degradation 
(357-361). For Nef-targeting of CD4, the determinants in CD4 are distinct and involve a 
dileucine motif. The domains in Vpu required for CD4 binding are less defined but several 
studies tend to support that these binding determinants are likely to be present in the 
cytoplasmic region of Vpu. Firstly, a randomized Vpu TMD was still able to bind and induce CD4 
degradation as comparable levels than the wild type protein (362). Furthermore, Vpu and CD4 
cytoplasmic domains were found to interact in a yeast two-hybrid assay in the absence of their 
membrane anchor domains (363). In line with this, mutational analysis of the Vpu cytoplasmic 
tail revealed the importance of the first alpha helix for CD4 binding and degradation (364). A 
panel of mutations in the Vpu cytoplasmic region were generated to affect the integrity of the 
two alpha helices. It was found that both C-terminal alpha-helices were required for degradation 
of CD4, but only the first alpha helix located in the membrane-proximal region was required for 
mediating interaction with CD4. 
 Although the binding of Vpu to CD4 is necessary to induce CD4 downregulation, it is not 
sufficient. This is best evidenced by experiments using the Vpu mutant in which the two 
conserved phospho-serine residues at positions 52 and 56, within the region DSpGxxSp, are 
mutated into asparagines. This phosphorylation-defective mutant retained the capacity to 
interact with CD4 but cannot induce final depletion of CD4 molecules (365), (363), (366). This 
partial phenotype was attributed to the inability of phospho-defective Vpu mutant to bind the F-
box containing proteins β-TrCP1 and β-TrCP2. β-TrCP is one of the subunits of the multi-protein 
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E3 ubiquitin ligase complex, SCFβ-TrCP. In that complex, Vpu's phosphorylated serine residues 
bind to the C-terminal WD repeats of β-TrCP while the F-box domain mediates the connection 
with the other components of the E3 ubiquitin ligase complex (Skp1, Cullin-1) (367). 
Recruitment of this SCFβ-TrCP complex triggers the poly-ubiquitination of the CD4 cytosolic tail on 
lysines (368, 369) and serine/threonine residues (370), marking CD4 for degradation by the 
cytosolic proteasome (371), (372). Vpu itself appears to escape from ubiquitination and 
degradation. Therefore Vpu acts as an adaptor protein between its substrate, CD4, and the E3 
ubiquitin ligase complex.  
 While the first helix of Vpu seems to play a crucial role in mediating CD4 binding, the 
importance of the second alpha helix has yet to be determined. But it appears that some 
determinants in the second helix are required for CD4 degradation but not interaction. Deletion 
of the C-terminal 23 amino-acid residues or substitution of residues Val 64 to Met 70 impairs 
Vpu-mediated CD4 degradation without, yet, affecting CD4 binding (345, 364). Furthermore, an 
alanine scan of the entire second alpha helix revealed the requirement of two residues, Leu 63 
and Val 68 for CD4 downregulation by Vpu (373). Substitution of Leu 63 into alanine or valine 
residue did not affect binding to CD4 or β-TrCP suggesting that Vpu-mediated CD4 
downregulation might involve, in addition to CD4-interaction and β-TrCP recruitment, other 
processes. 
 Although most studies have focused on experiments demonstrating the role of Vpu and CD4 
cytosolic domains, the importance of the transmembrane domains for Vpu-mediated CD4 
downregulation cannot be excluded. This was illustrated in a recent study. Replacement of the 
vesicular stomatitis virus G glycoprotein (VSV-G) TMD for the CD4 TMD abolished Vpu-induced 
CD4 degradation (374). In the same study, a cluster of amino acids on the Vpu TMD (Val 20, 
Trp 22, Ser 23), centred on Trp 22, was identified as crucial for CD4 downregulation. Therefore 
the transmembrane domains of both CD4 and Vpu play important roles in the process of Vpu-
induced CD4 downregulation. However, the fact that a scrambled Vpu transmembrane domain 
is still able to interact and mediate CD4 degradation indicates that this interaction may not be 
dependent on the primary sequence of the Vpu transmembrane domain but rather on non-
specific interactions.  
 Vpu mediated CD4-ubiquitination in the ER suggests a subsequent degradation via the ER-
associated degradation (ERAD) machinery. ERAD generally ensures the removal of abnormal 
(misfolded or unassembled) proteins from the endoplasmic reticulum (375). ERAD targets are 
selected by a quality control system within the ER lumen and are ultimately destroyed by the 
cytoplasmic ubiquitin-proteasome system (UPS). The spatial separation between substrate 
selection and degradation in ERAD requires substrate transport from the ER to the cytoplasm 
by a process termed dislocation. ERAD substrates dislocated into the cytosol are then degraded 
by the 26S proteasome. Several lines of evidence distinguish the mechanism of Vpu-mediated 
CD4 degradation from the classical ERAD process (368). On one hand, the cytosolic E3 
ubiquitin ligase SCFβ-TrCP complex does not normally function in ERAD, but is responsible for the 
ubiquitination and degradation of cytoplasmic substrates such as IκBα and β-catenin. Instead, 
the ERAD pathway employs several membrane-bound ubiquitin ligases, including the HRD1-
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SEL1L complex, TEB4/MARCH-VI and the GP78-RMA1 complex. On the other hand, genetic 
analysis involving expression of CD4 and Vpu in a yeast system showed that CD4 degradation 
could persist even in the absence of key ERAD components such as Hrd1p, Hrd3p and Ubc7p, 
which are orthologous to the mammalian proteins HRD1, SEL1L and UBC7 respectively. These 
results suggest that the mechanism by which Vpu triggers CD4 degradation is fundamentally 
distinct from ERAD. This notion was tested by Magadan and colleagues, and interestingly they 
found additional components of the ERAD machinery required for Vpu-induced CD4 
degradation (370). They reported that siRNA depletion of the valosin-containing (VCP) protein 
AAA ATPase p97 and its associated co-factors UFD1L and NPL4 blocked CD4 degradation by 
Vpu. They showed that the VCP-UFD1L-NPL4 complex provided the machinery to extract CD4 
molecules from the ER into the cytosol; the UFD1L co-factor binds ubiquitinated CD4 through 
recognition of K48-linked polyubiquitin chains while the NPL4 subunit stabilizes the complex, 
and the valosin-containing (VCP) protein AAA ATPase p97 provides energy for the dislocation 
process through ATP binding and hydrolysis. Although VCP-UFD1L-NPL4 depletion abolished 
CD4 degradation, the bulk of CD4 molecules was still retained in the ER. They showed that this 
retention was dependent on interactions between Vpu and CD4 transmembrane domains but 
not on the cytoplasmic tail of CD4. 
 The data from Magadan and colleagues support a model in which Vpu would exert two 
temporally separable effects on CD4: ER retention followed by targeting to late stages of ERAD 
(Figure 1.28) (370). First, Vpu might retain CD4 in the ER compartment via transmembrane 
interactions, although this hypothesis is in contradiction with previous data showing that the 
majority of CD4 proteins, in an Env-deficient context, acquired an Endo-H resistance in the 
presence of Vpu suggesting trafficking through the Golgi apparatus. Then, the cytosolic domain 
of Vpu interacts with the cytoplasmic tail of CD4 and recruits the E3 ubiquitin ligase SCFβ-TrCP 
complex, which mediates the polyubiquitination of lysine and serine/threonine residues. 
Ubiquitination may further contribute to CD4 retention in the ER, and additionally marks CD4 for 
delivery to proteasomes. This last process involves the recruitment of the VCP-UFD1L-NPL4 
complex through recognition by UFD1L of K48-linked poly Ub chains on the CD4 cytosolic tail. 
The ATPase activity of VCP then drives dislocation of CD4 from the ER membrane into the 
cytosol for eventual degradation in proteasomes. Thus, Vpu appears to bypass the early stages 
of ERAD, including substrate recognition and ubiquitination by ERAD machinery components, 
but joins in the later stages, beginning with dislocation by the VCP-UFD1L-NPL4 complex (347).  
 In conclusion, the mechanism by which Vpu depletes the infected cells from CD4 expression 
at the cell surface involves a complex succession of events closely linked rendering the 
understanding difficult. In any case, Vpu-mediated CD4 degradation must be efficient and rapid 
since the half-life of CD4 drops from 6 hours to approximately 25 minutes in the presence of 
Vpu. Through this process, Vpu maintains viral infectivity during replication. 
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Figure 1.28: Model of Vpu-mediated CD4 degradation.  
The first step involves the retention of CD4 in the ER through TM domains interactions. 
Formation of Env/CD4 complexes could also contribute to this retention. The cytosolic domain 
of Vpu (likely to be mediated by the first alpha helix) then interacts with CD4 (region 414-
LSEKKT-419) and recruits the SCFβ-TrCP E3 Ub ligase complex, which mediates the addition 
of multiple moieties to lysine and serine/threonine residues in the cytosolic tail of CD4. 
Ubiquitination further contributes to CD4 retention in the ER, and additionally marks CD4 for 
delivery to proteasomes. This delivery involves recruitment of the p97(VCP)-UFD1L-NPL4 
complex through recognition by UFD1L of K48-linked poly-Ub chains on the CD4 cytosolic tail. 
Then, the ATPase activity of p97(VCP) drives dislocation of CD4 from the ER membrane to the 
cytosol for eventual degradation in proteasomes. Figure adapted from (347). 
 
1.8.2.2 Vpu inactivates tetherin's antiviral function  
Vpu counteracts tetherin to prevent it from trapping nascent retroviral particles at the cell 
surface, and as a result allows efficient cell-free virion release into the extracellular milieu. Since 
its discovery several groups have tried to understand the mechanism employed by Vpu to 
achieve complete inactivation of tetherin molecules. Vpu has been shown to exert several 
effects on tetherin: degradation, interaction, cell-surface downregulation, trafficking alteration 
and intracellular sequestration (reviewed in (192)). After four years of extensive publications on 
the molecular mechanism of Vpu-mediated tetherin antagonism, we now better understand how 
Vpu overcomes tetherin, and despite some question marks persisting in this area, we can begin 
to establish one unified model that encompasses all the phenotypes described so far. 
     CELLULAR TARGETS OF HIV-1 VPU 
 
- 89 - 
a) Vpu prevents tetherin from being expressed at the site of virus assembly 
The first striking effect of Vpu on tetherin appeared from the observation that tetherin 
expression at the plasma membrane was reduced in the presence of Vpu (187). Since HIV-1 
assembly, budding and release occur at the cell surface it was thought that by mediating 
tetherin downregulation from its site of action, Vpu could abolish the antiviral activity. But this 
notion was challenged when Vpu was shown to enhance HIV-1 virus release in the absence of 
tetherin cell surface downregulation (376). Indeed, in CEMx174 and H9 cells (T cell lines), virus 
replication was Vpu-dependent but cell-surface tetherin levels were not affected by Vpu 
expression. However, this phenotype has never been reproduced in any other studies (220, 
377, 378). 
 Tetherin is believed to restrict viral particle release by physically cross-linking the cell 
membrane and the virus membrane together (cf. section 1.6.4) (197). Consistent with this, 
tetherin is incorporated into virions (214, 215, 379). In the presence of Vpu, tetherin packaging 
into viral particles is reduced suggesting that Vpu might directly block tetherin incorporation into 
virions at the site of viral assembly. But this conclusion is cofounded by the fact that Vpu leads 
to a reduction of tetherin levels at the cell surface. Other studies have shown that Vpu 
association in membrane rafts was required for enhanced virus release (342). Since tetherin 
also localized to the lipid rafts at the plasma membrane through its GPI lipid anchor, it was 
proposed that Vpu displaced tetherin out of the raft domains to inactivate its antiviral function. 
But again this notion is not supported by more recent studies (343, 344). 
 Several studies have investigated the mechanism by which Vpu induces tetherin cell-surface 
downregulation and some determinants have been identified. Firstly, the cellular protein β-TrCP 
from the E3 ubiquitin ligase complex is required for optimal cell-surface downregulation of 
tetherin by Vpu (220). Indeed, Vpu-mediated tetherin cell surface downregulation is severely 
impaired when a dominant negative form of β-TrCP (ΔF-box β-TrCP) is expressed. ΔF-box β-
TrCP can mediate interactions with Vpu but cannot link it to the other components of the 
ubiquitin machinery, and this mutant also inhibits degradation of CD4 by Vpu. Similarly, Vpu-
mediated tetherin downregulation is affected when expression of β-TrCP-1 and β-TrCP-2 are 
simultaneously depleted by shRNA. Moreover, when the DSGxxS β-TrCP binding motif in Vpu 
is mutated, tetherin downregulation is also compromised. In accordance with the notion that 
tetherin downregulation is the mechanism by which Vpu counteracts tetherin, ΔF-box β-TrCP 
over-expression and mutation in the β-TrCP binding motif also affects the enhancement of virion 
release by Vpu. These data suggest that Vpu might recruit the ubiquitin ligase machinery via 
interaction with the cellular co-factor β-TrCP to downregulate tetherin from the cell surface and 
allow enhancement of particle release. However, in all cases where the recruitment of β-TrCP 
by Vpu was affected, the inhibition of tetherin restriction was not completely abolished, 
suggesting that another mechanism was also involved. In other words, despite the importance 
of β-TrCP for Vpu-mediated tetherin downregulation, it was unclear how much the recruitment 
of this co-factor by Vpu contributed to the antagonistic process. We now know that β-TrCP is 
essential for lysosomal degradation of tetherin and consequently for optimal cell-surface 
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downregulation. But it is the commitment into that degradative pathway which is thought to be 
the major cause of tetherin counteraction rather than the β-TrCP dependent degradation per se. 
 Tetherin is internalized from the plasma membrane and delivered back to the plasma 
membrane through a clathrin-dependent pathway that involves the sequential action of AP2 and 
AP1 adaptor complexes (206, 207). Early studies showed that the clathrin adaptor protein 
complex AP-2 was also found to be required for Vpu-mediating tetherin cell-surface 
downregulation (220). Similar effects were observed in cells transfected with the dominant 
negative mutant of dynamin 2, which inhibits the membrane scission of endocytic vesicles (218, 
380). Based on these observations, it was proposed that Vpu might stimulate/accelerate 
clathrin-dependent endocytosis of tetherin from the cell surface. But this was contradicted by 
reports showing that in fact the rate of internalization of tetherin was not enhanced by Vpu 
expression (377, 381, 382). Alternatively, since inhibition of endocytosis through AP-2 
knockdown or dominant-negative dynamin 2 (K44A), can also lead to a reduction of the pools of 
tetherin in recycling vesicles, it could not be excluded that Vpu might prevent endocytosed 
tetherin from recycling back to the plasma membrane. This scenario was ruled out by 
experiments showing that Vpu still actively counteracted and depleted cell-surface levels of a 
tetherin mutant, in which the residues Y6 and Y8 required for endocytosis were mutated (377). 
 We now know that cell-surface tetherin downregulation is a consequence of two additive 
effects of Vpu: Vpu first interacts with tetherin in the TGN by virtue of its transmembrane 
domain. Thereafter, Vpu/tetherin complexes are routed to late endosomes for subsequent 
degradation. Thus, AP2 being required for optimal tetherin cell-surface downregulation may be 
due to the fact that under condition where it is silenced, Vpu can only target newly synthesized 
tetherin molecules and not those being recycled. This is likely to be sufficient to overcome 
tetherin as suggested by a recent report showing that AP2 knockdown had no significant impact 
on Vpu-mediated tetherin antagonism (383). The partial cell-surface downregulation observed 
by β-TrCP depletion is likely to be a result of the non-commitment of tetherin molecules into the 
degradative pathway.  
 The next two paragraphs address in detail the two complementary effects of Vpu on tetherin 
that ultimately lead to an optimal reduction of tetherin levels on the plasma membrane. 
 
 
b) Vpu physically associates with tetherin 
Interactions between Vpu and tetherin were considered even before the direct evidence of 
physical interaction by co-immunoprecipitation studies. The first evidence was revealed by 
sequence analysis of tetherin showing that the protein had undergone strong positive selection 
in its TM domain during primate evolution (224). As commonly observed, these changes reflect 
the imprints resulting from pressures exerted by external agents such as viruses, suggesting 
that Vpu might have been one of those viral factors contributing to tetherin evolution. The 
evidence of interaction was revealed by studies showing that Vpu antagonized tetherin in a 
species-specific manner (223, 224). HIV-1 Vpu can only counteract closely related tetherin 
proteins from humans, chimpanzees and gorillas while other Vpus from SIVs infecting old world 
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monkeys can only overcome tetherin proteins from their corresponding host. Importantly this 
species-specificity is governed by the transmembrane domains of both proteins; exchange of 
human tetherin transmembrane domain by those from rhesus tetherin conferred resistance to 
Vpu. Likewise, a single mutation into human tetherin TMD by a residue found in monkey 
tetherin TMD could also confer resistance to HIV-1 Vpu. Later on, co-immunoprecipitation 
studies confirmed this species specificity by showing that Vpu and tetherin could interact with 
each other via their transmembrane domains (218, 377). In line with the genetic evidence, Vpu 
co-immunoprecipitates with human, but not monkey tetherin. Replacement of tetherin TMD by 
Tfr (transferrin receptor) TMD inhibited Vpu recognition, and chimeric Vpu proteins bearing CD4 
TMD were also unable to bind tetherin molecules. In accordance with this, early data 
demonstrated that when Vpu TMD was modified either by deleting segments, scrambling or 
multiple amino acid replacements, the enhancement of virus release by Vpu was severely 
compromised (362, 384, 385). The determinants in Vpu TMD required for interaction with 
tetherin have been mapped. Three residues, A14, A18 and W22 that form one face of the 
transmembrane domain have been found to be essential for tetherin interaction and antagonism 
(cf. Chapter 5) (221). This observation was then confirmed by NMR spectroscopy studies that 
showed the importance of the conserved AxxxAxxxAxxxW face of Vpu TMD helix (386). The C-
terminal region of tetherin TM domain helix was proposed to fit between the alanines on this 
interactive face of Vpu. In the tetherin TM domain, mutations on residues I34, L37 and L41 
affect its sensitivity for Vpu (222). These aspects will be further expanded in Chapter 5. 
 Vpu-mediated tetherin interaction is required for all the effects identified so far (377). 
Modifications that disrupt this interaction prevent Vpu from inducing tetherin downregulation, 
degradation and antagonism. Although interaction in the TGN is the most advantageous 
scenario for Vpu because it can then access both to newly synthesized and recycled tetherins, 
interaction occurring early in the secretory pathway cannot be excluded (cf. Chapter 6). 
 
 
c) Vpu induces tetherin degradation 
Vpu not only leads to a reduction of tetherin levels at the plasma membrane but also induces a 
decrease of intracellular pools of tetherin (218-220, 387, 388). Under Vpu expressing conditions 
the half-life of tetherin molecules is shortened by approximately two fold. 
 Two main cellular degradation pathways have been investigated. Early studies reported a 
role of the proteasomal pathway in tetherin degradation by Vpu (387, 388). Firstly, tetherin 
levels could be restored by treatment with the proteasomal inhibitor MG132, but this observation 
does not exclude a role for lysosomes since both degradation pathways can be ubiquitin-
dependent and long-term treatment with MG132 depletes pools of free ubiquitin. In support of 
tetherin degradation via the proteasome, the expression of a dominant negative form of 
ubiquitin (Ub-K48R) and the depletion of the ERAD component AAA-ATPase p97 partially 
inhibited Vpu-mediated tetherin degradation (388). However, this phenomenon was later shown 
to be an artefact of high levels of tetherin accumulating in the ER (381). Under conditions where 
tetherin is over-expressed, such as those existing in transient-transfection experiments, ERAD-
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dependent degradation of tetherin by Vpu was detected, but not in infected cells with 
physiological levels of both Vpu and tetherin.  
 Alternatively, Bafilomycin A1 and lysosomal protease inhibitors have also been found to 
rescue tetherin expression levels from the cell lysates suggesting the implication of the 
lysosomal pathway (218-220). This was confirmed by the observation that essential 
components of the ESCRT machinery were required for Vpu-mediated tetherin degradation and 
optimal cell-surface downregulation. Knockdown of Tsg101, and the ESCRT-0 component HRS, 
or expression of the dominant negative form of Vps4 blocked Vpu-mediated tetherin 
degradation (389). However, since Tsg101 and Vps4 are also required for HIV-1 budding, and 
HRS is important for HIV-1 production, their role for Vpu-mediated enhancement of viral particle 
release could not be tested. This issue has been resolved through the identification of the 
ESCRT-I component UBAP1 (390). UBAP1 is specifically required for ESCRT-dependent 
endosomal degradation, but not for viral assembly or cytokinesis. While UBAP1 knockdown 
rescued tetherin levels from Vpu-mediated degradation it did not affect enhancement of virus 
release suggesting that Vpu induced an ESCRT-dependent lysosomal degradation of tetherin, 
but this was dispensable for inactivating tetherin's antiviral activity. Finally, siRNA-mediated 
depletion of Rab7a, which inhibits the early to late endosomal maturation, induced a '' tetherin-
like '' phenotype on HIV-1 release in HeLa (391), suggesting that tetherin was likely targeted to 
the late endosomal compartment in the presence of Vpu. 
 β-TrCP, especially the β-TrCP-2 isoform, was also shown to be required for the degradation 
process (219, 220, 388) suggesting that Vpu might induce tetherin ubiquitination like it does to 
degrade CD4. In agreement with this, mutations on the potential ubiquitin-acceptors in tetherin 
cytoplasmic tail (K18 and K21) abolished Vpu-mediated mono-ubiquitination and degradation 
(210, 392). However, consistent with the notion that Vpu's ability to degrade tetherin is not 
strictly required for antagonism, the same study showed that tetherin mutants bearing those 
mutations were still sensitive to Vpu-mediated counteraction (cf. Chapter 4). β-TrCP-dependent 
ubiquitination on the cytoplasmic tail lysines was then confirmed by another group (393). 
Importantly, the authors also found that not only the lysines but also the serine/threonine motif 
(STS) was ubiquitinated in the presence of Vpu. In contrast to the lysines, this STS motif was 
essential for optimal tetherin cell-surface downregulation and antagonism by Vpu. These data 
indicate that the ubiquitination on lysine residues might be essential to engage the degradation 
machinery while ubiquitination on serine/threonine residues may participate more directly to the 
antagonistic process. Moreover, tetherin ubiquitination by Vpu may also be involved in diverting 
tetherin's natural cellular trafficking. 
 The Vpu S52,56A mutant provides another way to illustrate that Vpu-mediated tetherin 
degradation and inactivation are two separated effects. Vpu S52,56A cannot be phosphorylated 
by casein kinase II and as a consequence is unable to bind β-TrCP. For this reason, Vpu 
S52,56A does not lead to tetherin ubiquitination and degradation, however it still retains some 
levels of antagonism against tetherin. So once again, this suggests that the success of tetherin 
antagonism does not entirely rely on the ability of Vpu to mediate tetherin ubiquitin-ESCRT-
dependent lysosomal degradation but involves additional mechanisms. However, under 
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conditions where tetherin is highly expressed, the degradation process might be more 
important. This is evidenced by studies showing that, in macrophages, Vpu S52,56A replication 
is severely impaired while in T cells it could replicate almost as efficiently as the wild-type (254). 
It is unlikely that Vpu acts in a cell-type dependent manner but instead, its activity might vary 
from one cell type to another depending on the levels of tetherin expressed in these cells. In 
macrophages, which express high levels of tetherin (394), Vpu's ability to degrade tetherin 
might be determinant for efficient counteraction, while in T cells, low amount of tetherin 
molecules might be easily neutralized by Vpu without the need of complete destruction. 
 Taken together, these data suggest that tetherin is degraded, most likely, in lysosomal 
compartments by an ubiquitin/β-TrCP and ESCRT-dependent mechanism. But it is unclear how 
much this mechanism contributes to the full antagonism of tetherin. Vpu exerts a primary effect 
on tetherin that leads to its inactivation and subsequently to its degradation. But it cannot be 
excluded that in certain circumstances degradation might be dispensable (392). However, if 
Vpu's primary function is saturated and some levels of tetherin are restored at the plasma 
membrane, then tetherin degradation becomes essential. A description of this primary 
mechanism mediated by Vpu is provided in the next paragraph. 
 
 
d) Towards a unified model of Vpu-mediated tetherin antagonism 
As tetherin degradation is not strictly required for Vpu activity and Vpu does not stimulate 
clathrin-mediated tetherin endocytosis, it was thought that Vpu interfered with tetherin trafficking 
to the cell-surface as a means to antagonize it. To investigate this scenario, Dube and 
colleagues established an assay to quantify the amount of tetherin re-expressed at the cell 
surface resulting from protein intracellular trafficking (377, 382). For this assay, cells were first 
treated with pronase to remove all the proteins at the plasma membrane. They found that the 
kinetics of tetherin re-expression at the cell surface was significantly delayed in the presence of 
Vpu. This suggests that Vpu interferes with tetherin trafficking along the secretory and/or 
recycling pathways. Since a large fraction of Vpu co-localizes with residual tetherin at steady 
state in the TGN, it was proposed that Vpu prevented tetherin from reaching the plasma 
membrane by retaining/sequestrating tetherin molecules in the TGN (378). In line with this 
hypothesis, mutations of conserved residues R30 and K31 within the hinge region that affect 
accumulation of Vpu in the TGN and consequently the degree of co-localization with tetherin, 
correlated with an attenuation of HIV-1 release (341). But at this point it was unclear why 
tetherin molecules accumulated in the TGN in the presence of Vpu. This was clarified by a 
recent study from Kueck et al, in which they proposed that Vpu did not directly mediate the 
sequestration of tetherin in the TGN per se but rather interacted with tetherin to commit it into a 
cellular pathway that led to degradation (Figure 1.29) (383). Therefore, retained tetherin 
observed in the TGN under Vpu expression is likely to be the result of the accumulation of 
molecules queuing for their delivery into endosomal compartments. At steady state, only the 
pools of tetherin and Vpu that accumulate in the slowest cellular pathway are visualized and this 
gives the impression that Vpu mediates an active sequestration of tetherin. In the same study, 
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the authors showed that the EXXXLV motif in the second alpha helix of Vpu cytoplasmic tail 
was the sorting signal that regulated the targeting of tetherin into a cellular pathway away from 
the plasma membrane. The EXXXLV motif resembles an acidic dileucine sorting signal 
(D/E)XXXL(L/I/V). Importantly, Vpu EXXXLV mutant was defective for tetherin cell-surface 
downregulation, degradation and efficient antagonism, but not for tetherin interaction. The 
evidence suggested that this motif acted as a sorting/trafficking signal that governed the post-
binding routing of tetherin/Vpu complexes from the TGN and/or recycling vesicles to endosomal 
compartments, thus preventing the transit of tetherin molecules to the plasma membrane. 
However, the EXXXLV motif cannot be qualified as a bona fide sorting signal because the cargo 
adaptor that binds to it has not been identified. The fact that clathrin was required for Vpu-
mediated antagonism and that EXXXLV motif could be substituted by the AP-2 binding motif 
from HIV-1 Nef to restore full tetherin antagonism, suggested that this motif acted as a clathrin-
adaptor binding site. However, none of the clathrin-adaptor complexes tested in this study 
including AP1, AP2 and AP3 were found to be required for tetherin antagonism (383). In the 
same study, the authors showed that enhanced levels of tetherin expression required the ability 
of Vpu to mediate tetherin degradation. While in CD4+ T cells Vpu ELV mutant is almost as 
functional as the wild-type to promote virus release, upon IFN-α treatment HIV-1 bearing Vpu 
ELV becomes as defective as Vpu-deleted virus. 
 In summary, the emerging consensus is that Vpu interacts with tetherin molecules through 
transmembrane interactions in the TGN and/or recycling endosomes. In the presence of 
ubiquitinated tetherin, the trafficking signal in the second alpha helix of Vpu drives Vpu/tetherin 
complexes towards the endosomal pathway. Tetherin molecules are then sorted by components 
of the ESCRT machinery that delivers it to lysosomal compartments for degradation. At present 
it is unknown whether Vpu recruits the E3 ubiquitin ligase SCFβ-TrCP to ubiquitinate tetherin in 
the TGN or in the recycling compartments. Ubiquitination might also further contribute to retain 
tetherin in the TGN and/or recycling vesicles. Presumably, since β-TrCP or ESCRT disruptions 
rescue tetherin at the cell surface we can speculate that in the absence of degradation some 
tetherin molecules can reach the plasma membrane as a result of their accumulation in the 
TGN. For this reason, Vpu S52-56D mutant defective for tetherin degradation causes a stronger 
re-localization of the cellular pool of tetherin in the TGN than the Wt Vpu (377).  
 In summary, Vpu-mediated block of tetherin incorporation into assembling virions seems to 
be the resulting effect of a complex intracellular mechanism exerted on tetherin by Vpu. 
Diversion of the cellular trafficking of tetherin toward the cell surface and subsequent 
degradation account for the total absence of tetherin expressed at the cell surface and allows 
the nascent viral particles to be released without any obstacles. 
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Figure 1.29: Model of Vpu-mediated tetherin antagonism. 
Tetherin and Vpu are synthetized in the ER and then acquire maturation through trafficking into 
the Golgi apparatus. In the absence of Vpu, tetherin reaches the plasma membrane. The 
protein can then be endocytosed in clathrin-coated pits, transported to the TGN via recycling 
endosomes and probably recycles back to the cell surface. Tetherin endocytosis requires AP-2 
that binds the tyrosine-based motif in tetherin cytoplasmic tail and acts as an adaptor protein to 
recruit clathrin. Dynamin 2 is also required for tetherin internalization from the plasma 
membrane. By virtue of their transmembrane domains, Vpu and tetherin interact with each other 
in the TGN. Thereafter, Vpu/tetherin complexes are routed to late endosomes bypassing the 
plasma membrane. This trafficking is thought to be governed by a sorting signal in Vpu second 
alpha helix (ExxxLV) and is clathrin-dependent. Recruitment of the E3 ubiquitin ligase complex 
SCFβ-TrCP by Vpu induces tetherin ubiquitination on its cytoplasmic tail. Ubiquitinated-tagged 
tetherin molecules are then sorted by components of the ESCRT machinery to the late 
endosomes for subsequent degradation in the lysosomes. HRS, Tsg101, Vps4 and UBAP1 are 
all required for Vpu-mediated tetherin degradation. Interference with late endosomes formation 
by mutants of Rab7 impact Vpu's ability to degrade tetherin, while disruption of the recycling 
compartment by a dominant Rab11a mutant compromises Vpu-mediated virus release. 
Knockdowns of AP-1 and Vps26 that regulate transport of cargo proteins from the endosomes 
to the Golgi do not affect Vpu-mediated tetherin antagonism. The blue arrow indicates the 
natural cellular trafficking of tetherin in the absence of Vpu expression, while the brown arrow 
indicates the cellular trafficking imposed by Vpu on tetherin. The cellular components required 
for the indicated pathways are written in red. 
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1.8.2.3 Vpu downmodulates NTB-A and CD1d  
Natural killer (NK) cells constitute a major component of the innate immune system due to their 
ability to lyse virus-infected cells. They act as a first line in immune surveillance and defence 
against viruses before the establishment of antigen-specific adaptive immune responses 
(reviewed in (395)). NK cells mediate cell lysis through the release of cytoplasmic lytic granules 
such as perforins and granzymes into the target cell. This degranulation is triggered by 
interactions between NK cell surface receptors and their corresponding ligands on target cell. 
These receptor-ligand interactions are divided into three major categories depending on their 
effects on NK cell state: inhibiting, activating and co-activating. For instance, NKG2D is a potent 
NK-cell activation receptor (aNKR) able to recognize stress-induced molecules, such as ULBP-
1/2 as ligands expressed at the surface of target cells. Although engagement of aNKR (signal 1: 
activation state) is necessary for NK-cell-mediated cell lysis of infected cells, this process also 
requires the simultaneous activation of co-receptors (signal 2) to trigger degranulation. One 
such factor that regulates NK-cell cytolysis is the NK-T and B cell antigen (NTB-A) co-activator 
receptor. NTB-A is a member of the signalling lymphocytic activation molecule (SLAM) family of 
receptors, and is found on all blood-derived NK, T, and B cells. It is a type 1 transmembrane 
protein of the immunoglobulin superfamily that functions as a homotypic ligand-coactivation NK 
receptor pair. 
 Early studies indicated that NK cells were ineffective at killing primary HIV-1 infected T cells 
(396). Surprisingly, examination of the infected cell surface receptors revealed that virus 
infection leads to a decrease in surface expression of HLA-A and -B inhibitory ligands through 
the action of HIV-1 Nef (397) and an increase in activating ligands for NKG2D through the 
action of Vpr (398-400). The downregulation of inhibitory ligands combined with the 
upregulation of activating ligands should make HIV-1 infected cells ideal targets for NK cell-
mediated destruction. However, the ability of NK cells from even healthy uninfected individuals 
to destroy HIV-1 infected cells has been consistently characterized to be weak. For this reason 
it was thought that additional factors might be involved in regulating NK activity against HIV-1 
infected cells.  
 A recent study reported the ability of HIV-1 Vpu to interfere with NK-cell degranulation by 
downmodulating NTB-A at the cell surface of infected cells (349). As a consequence, CD4+ T 
cells infected with HIV-1 Vpu mutant elicited at least 50 per cent more NK cell degranulation 
than wild-type virus, resulting in an higher capacity to lyse HIV-infected cells. Thus Vpu 
dowmodulation of NTB-A protects the infected cell from lysis by NK cells (Figure 1.30). 
Interestingly, Vpu-targeting NTB-A involves distinct mechanisms to those used to downregulate 
CD4 and tetherin. Indeed, Vpu does not affect the intracellular levels of NTB-A and does not 
rely on the recruitment of β-TrCP to reduce cell surface NTB-A levels. Although Vpu does not 
accelerate NTB-A internalization as a means to deplete the coactivation NK receptor ligand 
from the cell surface, the viral protein interacts with NTB-A through its transmembrane domain 
and the Vpu TM region was found to be required for NTB-A downmodulation. Together, these 
results suggest that Vpu might interfere with NTB-A trafficking and/or recycling and as such 
sequester NTB-A in an intracellular compartment. So, Vpu mediating NTB-A downregulation 
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provides an explanation to account for the lack of killing of HIV-1 infected cells despite strong 
activation of NK cells. Similarly, Vpu also downmodulates another NK cell-activating ligand, 
PVR (317), however this appears to be in conjunction with Nef. More studies will need to be 
done to determine how the virus regulates the balance between activation and degranulation of 
NK cells.  
 Similar to NK cells, dendritic cells (DCs) also play an important role in viral infections as 
initiators of innate and adaptive immune responses. For instance, interaction between DCs and 
the innate-like CD1d-restricted natural killer T (NKT) cells results in the mutual activation of both 
cells and the subsequent initiation of cellular immune responses. Thus, NKT can rapidly secret 
T helper type 1 and 2 cytokines to activate and regulate a variety of other cell types, including 
DCs, NK cells, B cells and T cells. Recently, HIV-1 Vpu was found to inhibit the surface 
expression of CD1d in productively infected DCs (348). CD1d is a class I MHC-like membrane-
associated protein expressed by antigen-presenting cells (APCs) and is involved in presenting 
exogenous pathogen-derived lipid antigens to NKT cells. Thus, by interfering with the CD1d 
antigen presentation pathway, Vpu prevents infected DCs from activating CD1d-restricted NKT 
cells (Figure 1.30). Considering its importance in early innate immune responses and presence 
at major HIV-1 transmission sites (mucosal surfaces), targeting the CD1d mediated lipid-antigen 
presentation may be an additional strategy for HIV-1 to evade innate cellular immune 
responses. Again, Vpu does not affect the rate of CD1d endocytosis or induce rapid CD1d 
degradation. Instead, Vpu co-localizes and interacts with CD1d in early endosomal 
compartments suppressing CD1d from recycling back to the plasma membrane. Hence, 
keeping CD1d away from the antigen-loading compartment (late endosomes) in combination 
with reducing its surface expression might be an efficient way for HIV-1 to avoid activation of 
NKT cells by infected DCs.  
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Figure 1.30: Vpu modulates the innate immune responses through the downregulation of 
NTB-A and CD1d.  
Expression of HIV-1 Vpu in infected cells leads to cell-surface downregulation of CD1d and 
NTB-A (and also tetherin as described above). Reduction of CD1d cell-surface levels prevents 
presentation of lipid antigens to CD1d-restricted NKT cells, thereby avoiding their activation. 
Additionally, Vpu can also cause inhibition of cell surface expression of NTB-A to protect 
infected cells from NK-cell-mediated killing. Lysis of infected cell by NK cell requires both 
activation of NKG2D by its ligand ULBP1-2 and NTB-A to elicit degranulation (release of 
perforins and granzymes). On the overall, these effects of Vpu weaken the efficiency of the 
innate immune responses directed against HIV-1-infected cells. Figure adapted from (401). 
 
1.8.2.4 Vpu induces cell death by apoptosis 
As discussed above, one of the main pathologic characteristics in HIV-1 infected patients is the 
decrease of CD4+ T lymphocytes. Uninfected bystander CD4+ T cells die by apoptosis caused 
by aberrant T cell signalling, secretion of factors such as Tat, Nef, or Vpr or release from HIV-
infected cells of cellular apoptosis-inducing factors (TNF-α). In productively HIV-infected CD4+ T 
lymphocytes, viral replication can induce direct cytopathic effects leading to cell death by 
necrosis. In these cells, HIV-1 infection also causes through the action of Vpr, cell cycle arrest 
in G2/M phase leading to cell death by apoptosis. Although CD4+ T cells infected with a Vpr-
defective HIV-1 undergo less apoptosis than those infected with HIV-1 Wt, some annexin V 
positive cells can still be detected suggesting that another component of HIV-1 genome might 
contribute to the induction of apoptosis in infected cells (402).  
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 Vpu has been proposed to induce apoptosis in infected cells as a consequence of its 
interaction with β-TrCP (Figure 1.31) (350, 403). Mechanistically, Vpu is thought to induce 
apoptosis by competitively binding with high affinity to β-TrCP, and thus interfering with the 
cellular functions in which the F-box protein is normally involved, in particular the degradation of 
β-catenin and IκB, or ubiquitination of the tumor suppressor p53. Accumulation of unprocessed 
IκB molecules further prevents activation of NF-κB, which as a result cannot trigger the 
transcription of genes involved in cell proliferation, cytokine production or in the regulation of 
apoptosis. In particular, reduction of NF-κB activity leads to an inhibition of expression of anti-
apoptotic proteins such as the Bcl-2 family proteins (e.g. Bcl-x1 and A1/Bfl-1) or TNF-R complex 
proteins (e.g. TRAF1). TRAF1 plays an essential role in inhibiting caspase-8 activation but in 
Vpu-expressing cells the levels of TRAF1 are reduced and no longer sufficient to block the 
cytokine-induced activation of caspase-8. This results in the release of cytochrome c from the 
mitochondria, normally inhibited by the Bcl-2 family proteins, whose the expression is limiting in 
the presence of Vpu, and subsequent activation of caspase-3. Finally, active caspase-3 triggers 



















Figure 1.31: Model for Vpu-induced apoptosis through activation of the caspase pathway.  
Upon stimulation of cells by cytokines such as TNF-α, IκB is rapidly phosphorylated by an IκB-
specific kinase, resulting in a rapid degradation of IκB via a β-TrCP dependent pathway. Vpu by 
recruiting β-TrCP impedes on the proteasomal degradation of IκB resulting in the inhibition of 
NF-κB activation and subsequent NF-κB-dependent expression of anti-apoptotic Bcl-2 family 
proteins or TNF-R complex proteins (e.g. TRAF1). The steps inhibited by the action of Vpu are 
indicated with red arrows and steps activated by Vpu conditions are shown in green. Figure 
adapted from (338).  
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Chapter 2 Aim of Thesis 
 
Vpu contributes to render the cellular environment less hostile for HIV-1 replication. This is 
achieved through the downregulation of several host proteins. In that regard, the aim of this 
thesis is to contribute to the understanding of the mechanism by which Vpu targets those 
cellular proteins. This thesis includes four chapters of experimental data that aim to 
demonstrate: 
 1. The viral protein K5, through its ubiquitin ligase activity, overcomes the antiviral restriction 
of tetherin imposed on the release of Kaposi’s sarcoma-associated herpesvirus 
 2. The transmembrane domain of Vpu is an essential determinant for Vpu's ability to 
counteract tetherin 
 3. Intrinsic defects in Vpu from Group O HIV-1 account for its lack of tetherin antagonism 
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Chapter 3 Materials and Methods 
3.1 Working with DNA 
3.1.1 Amplification of DNA fragments by Polymerase Chain Reaction  
- Synthesis of single M-Vpu transmembrane domain point mutants by single PCR: 
All point mutations in the Vpu transmembrane domain were generated by site-directed 
mutagenesis PCR (QuickChange, Stratagene). The mammalian expression vector pCR3.1 
encoding a codon-optimized version of HIV-1 NL4.3 Vpu tagged at the C-terminus with a 
hemagglutinin epitope (-HA) was used as template to initiate the polymerase chain reaction. 
PCR reactions were carried out in a total volume of 50 µl containing between 15 and 30 ng of 
DNA template, 0.2 µM of each primers (reverse and forward), 200 µM of each dNTP (dATP, 
dCTP, dGTP and dTTP), 1-2 units of Phusion® High-Fidelity DNA Polymerase (New England 
Biolabs), and 10 µl of 5X Phusion HF reaction buffer. The PCR can be divided into three phases 
characterized by a succession of different temperatures (Table 3.1). Besides the initial 
denaturation step performed at 95°C for 30 seconds, the sample was then subjected to 16-18 
cycles with each cycle composed of a denaturation step at 95°C for 30 seconds during which 
the double strand DNA is separated into two single strands DNA, followed by an annealing step 
of 1 minute at 55°C which allows the primers to anneal to their complementary sequences and 
finally an elongation step performed at 68°C for 6 minutes (1 minute/kb of plasmid length). The 
forward and reverse oligonucleotide primers containing the desired point mutation were 
synthesized by MWG Eurofins, and each are complementary to opposite strands of the vector. 
The primers are between 25 and 45 bases in length with a melting temperature (Tm) of ≥78°C. 
The desired point mutation is located in the middle of the primer with approximately 10-15 
bases of correct sequence on either side. Finally, the primers were designed with a minimum 
GC content of 40% and terminate in one or more C or G bases. Incorporation of the 
oligonucleotide primers generates a mutated plasmid containing staggered nicks. 
 The Vpu mutant A14L-W22A was generated by QuickChange site-directed mutagenesis as 
above using pCR3.1-Vpu W22A as plasmid template for the PCR. 
 
- Synthesis of O-Vpu, chimeric genes and multiple point mutants by overlapping PCR: 
Codon-optimized Vpu group O genes derived from HIV-1 group O strains 9435, HJ001 and a 
consensus sequence assembled from 32 full-length O-Vpu sequences available in the HIV 
sequence database were synthesized by multiple overlapping PCRs. In that case no DNA 
template was required since the succession of primers mimics the entire O-Vpu sequence. Two 
PCR reactions were required; in the first reaction all primers were added to the PCR mix and 
only a few temperature cycles were performed (x 10 cycles) to generate a small amount of the 
desired O-Vpu gene. 1 µl of the product from the first PCR was then amplified by a second 
round of PCR for 30 cycles in the presence of only the terminal primers. Standard PCR settings 
were used for the overlapping PCRs (Table 3.1). 
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 The Vpu mutant A10,14,18L-W22A containing multiple mutations in its transmembrane 
domain was also synthesized by overlapping PCR using the same method than the one used to 
generate O-Vpu constructs. 
 Chimeric proteins bearing both sequences from O-Vpu and M-Vpu were also generated by 
overlapping PCR. In that scenario, M-Vpu and O-Vpu genes served as templates for two 
separated PCR reactions. The two resulting products were then mixed (1µl of each PCR 
products), used as templates and amplified after annealing with each other during the second 
PCR (x 30 cycles) in the presence of the corresponding primers. SNAT-1 and SNAT-2 
constructs with the their cytoplasmic tails swapped were generated using the same method. 
 All the Vpu and SNAT-1 mutants were generated with a Kozak consensus sequence located 
upstream of their start codon (GCCACC-ATG). SNAT-1 and SNAT-2 genes were amplified from 
cDNA of 293T cells with primers bearing the flanking cloning sites EcoRI and XhoI. 
	  
Step Time Temperature Cycles 
Initial Denaturation 30 seconds 94°C-95°C 1 x 
Denaturation 30 seconds 94°C-95°C  
 
30 x (standard conditions) 
16-18 x (QuickChange) 
Annealing 30 seconds (standard conditions) 
1 minute (QuickChange) 
55°C  
Extension 30 seconds * 
6 minutes 
72°C (standard conditions) 
68°C (QuickChange) 
Final extension 5-10 minutes * 72°C 1 x 
* 1 minute/kb of insert or plasmid length 
 
Table 3.1: Standard PCR thermal cycling conditions. 
 
3.1.2 Extraction and Purification of DNA fragments 
Amplified DNA resulting from the PCR was diluted in 10X DNA loading buffer (50% glycerol 
(v/v), 0.1 M EDTA, bromophenol blue (dye), in ddH2O), loaded into a 1.5% agarose gel and 
subjected to electrophoresis. Agarose gels were made by melting powdered agarose (w/v) 
(UltraPureTM Agarose, Invitrogen) in 1X Tris-acetate running buffer (1X TAE: 40 mM Tris-
acetate, 1 mM EDTA, 0.114% glacial acetic acid (v/v), pH 8.2-8.3), heated and supplemented at 
0.5 µg/ml with a solution of ethidium bromide (Sigma). Gels at a lower percentage of agarose 
(0.7-1%) were used for separation of DNA fragments > 3kb. Gels were run at between 60 and 
100 volts in 1X TAE buffer for approximately 1 hour, depending on the expected size of the 
bands. Band sizes were monitored by running the 2-log DNA ladder (range: 0.1-10.0 kb, New 
England Biolabs). DNA fragments were visualized on an ultra violet trans-illuminator using a 
CCD camera (BioRad). The DNA fragment band of interest (approximately 300 bp for Vpu and 
derived mutants; 1500 bp for SNAT-1) was excised from the gel, weighed and DNA was 
extracted and purified using QIAquick gel extraction kit protocol (QIAgen). 3 volumes of buffer 
QG were added to 1 volume of gel slice and incubated at 50°C for 10 minutes or more. After the 
gel slice has dissolved completely, one gel volume of isopropanol was added to the sample and 
mixed. The entire mix was then applied to the QIAquick column and centrifuged for 1 minute at 
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13,000 rpm in a top-bench centrifuge. The flow-through was discarded and 500 µl of buffer QG 
was added to the column to eliminate residual agarose gel and the sample was centrifuged for 1 
minute at 13,000 rpm. The flow-through was discarded and the column was washed with 750 µl 
of buffer PE, centrifuged for 1 minute at 13,000 rpm and then for an additional minute to ensure 
the complete removal of ethanol. The column was then placed into a clean 1.5 ml 
microcentrifuge tube and the DNA-bound was eluted by adding 20-50 µl of ddH2O. The column 
was left stand for 1 minute before being centrifuged for 1 minute at 13,000 rpm. The flow-
through contains purified DNA. 
 
 
3.1.3 DNA digestion by restriction endonucleases 
Gel purified DNA fragments of Vpu, tetherin, SNAT-1 and derived mutants were then digested 
by the restriction enzymes EcoRI and XhoI or NotI (New England Biolabs) to generate DNA 
inserts with sticky ends. The expression vectors pCR3.1 (transient expression vector) and 
pCMS28 (derivative of the retroviral vector pMigR1, cf. section 3.2.3) were also digested with 
the same endonucleases in order to be linearized. The enzymatic reactions were performed in a 
50 µl total volume. For plasmids digestion, 2 µg of DNA was digested with 10 units of each 
restriction enzyme (1 unit of enzyme is the quantity required to digest 1 µg of DNA), 5 µl of the 
appropriate 10X buffer, 5 µl of BSA 10X (5 µg) (if recommended) and the volume was 
completed to 50 µl with ddH2O. Gel purified DNA inserts were digested similarly but the volume 
of water for the digestion reaction was adjusted depending on the volume of ddH2O used for the 
elution step in the gel extraction protocol. DNA digestion by restriction endonucleases was also 
used for the screening of bacterial colonies from agar plates (cf. mini-prep).  
 For the QuickChange site-directed mutagenesis, the circular PCR product was digested with 
1 µl of DpnI endonuclease to allow cleavage of the methylated parental DNA template (target 
sequence: 5'-Gm6ATC-3') in order to select the newly synthesized plasmid containing the 
desired mutation.  
 All restriction digest reactions were incubated for 2-3 hours at 37°C. The digestion products 
were then loaded into an agarose gel and purified using the technique described above 
(QIAquick gel extraction kit). 
 To prevent re-circularization of cloning vectors especially linearized vectors containing non-
cohesive ends (pLHCX digested by HpaI), incubation with Antarctic Phosphatase (New England 
Biolabs) was performed for 30 minutes at 37°C to remove the 5´ phosphate groups from 
plasmid vector (dephosphorylation). The enzyme was then heat inactivated at 65°C for 10 
minutes before proceeding to the ligation reaction. Tetherin mutants (THN-K18R, THN-K21R, 
THN-K18,21R) were digested with PmeI enzyme from the pCR3.1 and subcloned into the HpaI-
digested pLHCX. 
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3.1.4 DNA Ligation  
Vpu or SNAT-1 DNA inserts and other derived constructs digested with EcoRI/XhoI or 
EcoRI/NotI enzymes were cloned into a pCR3.1-HA expression vector, pCMS28 or pCMS28-
GFP, previously linearized by digestion with the appropriate enzymes. Tetherin inserts were 
cloned into pLHCX vector. Ligation reactions were carried out in a total volume of 20 µl using 1 
µl of T4 DNA ligase (= 400 units) in the presence of 3 times more insert than vector (≈ 100 ng of 
vector), 2 µl of 10X T4 DNA ligase buffer (1X T4 DNA ligase buffer contains: 50 mM Tris-HCl 
(pH 7.5), 10 mM MgCl2, 10 mM dithiothreitol, 1 mM ATP, 25 µg/ml bovine serum albumin). 
Amount of insert was calculated with the following formula: 
X ng of insert = 3 * [ length of insert (bp) x mass of vector (ng) ] / length of vector (bp) 
 A negative control was also made containing no insert in the reaction mixture. The reaction 
was incubated at room temperature (20-25°C) for at least 1 hour before transformation into 
chemically competent bacteria. For blunt-end ligation, the reactions were carried out at 16°C 
and incubated overnight. 
 
 
3.1.5 Transformation of plasmid DNA into chemically competent bacteria  
50 µl of chemically competent DH5α E.coli were thawed on ice for a few minutes before being 
incubated with 5-50 ng of plasmid DNA or with 2-3 µl of ligation product or PCR product. After 
30 minutes incubation on ice, the cells were heat shocked at 42°C for 45 seconds. The bacteria 
were then allowed to recover on ice for 2 minutes before adding 100 µl of LB medium and 
incubated at 37°C for 30 minutes in a shaking incubator at 220 rpm. 150 µl of transformed cells 
were then plated onto LB-ampicillin (100 µg/ml) agar plates (LB-Agar Miller, Fisher) and 
incubated at 37°C or 30°C overnight. Retroviral vectors containing repetitive sequences were 
incubated at 30°C instead of 37°C to avoid genetic recombinations. Bacterial cells were grown 
in liquid phase Luria-Bertani Broth medium (LB) containing 1% tryptone (w/v), 0.5% yeast 
extract (w/v), and 1% NaCl (w/v) dissolved in ddH2O, supplemented with ampicillin (100 µg/ml) 
or on LB-Agar (37 g/1L ddH2O) poured into 10 cm sterile dishes for solid phase growth cultures. 
 Single colonies on agar plates were picked using a sterile tip, resuspended into 1-2 ml of 
LB/ampicillin medium and incubated at 37°C for a few hours or longer depending on the study. 
For the screening of colonies by PCR, cells were incubated until the medium became cloudy. 1 
µl of this culture was then used to perform the PCR. For the screening of colonies by enzymatic 
digestion the cultures were left overnight before performing the mini-prep DNA extraction. 
Starter cultures used to inoculate larger volume of LB medium (100 ml) for plasmid amplification 
(midi-prep) were also incubated overnight in a shaking incubator. 
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3.1.6 Plasmid DNA Amplification and Purification 
100 µl of a 2 ml starter culture grown overnight were inoculated in 100 ml of LB-Ampicillin 
medium and incubated overnight in a 250 ml flask at 37°C (or at 30°C for proviral plasmids) in a 
shaking incubator at 220 rpm. Bacterial cells were then harvested by centrifugation at 6000 x g 
for 15 minutes at 4°C. Plasmid DNA was extracted and purified using the QIAGEN plasmid midi 
kit (QIAGEN) whose the method is based on the principle of alkaline lysis. The bacterial pellet 
was resuspended in 4 ml of buffer P1 (50 mM Tris-Cl pH 8.0, 10 mM EDTA, 100 µg/ml RNase 
A). 4 ml of lysis buffer P2 (200 mM NaOH, 1% SDS (w/v)) were added to the sample, mixed and 
incubated at room temperature for 5 minutes. 4 ml of neutralization buffer P3 (3.0 M potassium 
acetate, pH 5.5) was added, mixed immediately and incubated on ice for 15 minutes. The 
sample was then centrifuged at 15,500 x g for 30 minutes at 4°C. The supernatant containing 
plasmid DNA was then applied to an equilibrated column (equilibrated by adding 4 ml of buffer 
QBT), and allowed to run through by gravity flow. The column was washed twice with 10 ml of 
buffer QC (1.0 M NaCl, 50 mM MOPS pH 7.0, 15% isopropanol (v/v)), and the DNA eluted with 
5 ml of buffer QF (1.25 M NaCl, 50 mM Tris-Cl pH 8.5, 15% isopropanol (v/v)). Eluted DNA was 
then precipitated by adding 3.5 ml of isopropanol and centrifuged for 30 minutes at 15,500 x g. 
After centrifugation the DNA pellet was transferred into a microcentrifuge tube, resuspended 
into 1 ml of 70% ethanol and centrifuged at 14,000 rpm for 10 minutes at 4°C in a top-bench 
centrifuge. The ethanol was discarded and the tube placed on a heating block at 50°C for a few 
minutes to dry the DNA pellet and remove the residual ethanol. Finally the DNA was redissolved 
in 100 µl of ddH2O. 
 Alternatively, plasmid DNA extraction was carried out from smaller cultures of 1-3 ml. The 
method is based on the same principle than the protocol mentioned above and only some 
buffers differ. Mini-preps were performed using the QIAprep Spin Miniprep kit (QIAGEN). The 
bacterial overnight culture was pelleted by centrifugation at 6000 rpm in a table-top 
microcentrifuge for 5 minutes at room temperature (15-25°C). The supernatant was then 
discarded and the pelleted bacterial cells were resuspended in 250 µl of buffer P1. Cells were 
lysed in 250 µl of buffer P2 and mixed by inverting the tube 4-6 times until the solution becomes 
clear. 350 µl of neutralization buffer N3 were added to the mixture and mixed immediately. The 
solution was then centrifuged for 10 minutes at 13,000 rpm and the resulting supernatant was 
applied to the QIAprep spin column and centrifuged for 1 minute at 13,000 rpm. The flow-
through was then discarded and the column washed by adding 500 µl of buffer PB before the 
addition of 750 µl of buffer PE. This step was followed by two successive centrifugations of 1 
minute each to completely remove the wash buffer. The column was then placed into a clean 
1.5 ml microcentrifuge tube. To elute the DNA, 20-50 µl of ddH2O were added to the center of 
the QIAprep spin column and the column was left stand for 1 minute before centrifugation.  
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3.1.7 Analysis and Sequencing of DNA  
DNA concentrations were determined using a Nanodrop ND-100 Spectrophotometer (Labtech 
International), with optical density measurements at 260 nm. This method is based on the fact 
that 1 OD260 unit corresponds to 50 µg/ml of double strand (ds) DNA. On the average the DNA 
plasmids midi preparations give 0.1 mg of purified DNA. The quality of the DNA sample is 
assessed by the OD260/OD280 ratio, which can be considered pure and relatively free from 
protein contamination for a ratio of 1.8. 1.5 µg of DNA preparations dissolved in 15 µl ddH2O 
were sent for sequencing to Eurofins MWG Operon. Vpu, tetherin and SNAT-1 constructs were 
sequenced by MWG via the T7 forward primer site in pCR3.1. 
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Gene Vector Cloning 
sites 
Resistance genes Tag Stable cell lines 
YFP pCR3.1  Ampicillin   
GFP pCR3.1  Ampicillin   








HA (position 463) 
 
HT1080 






HA (position 463) 
* 
HA (position 463) 
 
HT1080 






HA (position 463) 
* 
HA (position 463) 
 
HT1080 
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* 
HA (position 463) 
 
HT1080 
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O-Vpu Chimera	   pCR3.1	   EcoRI/XhoI	   Ampicillin	   HA (C-terminus)	   	  






HA (C-terminus) * 
HA (C-terminus)	  
 
293T / HeLa	  









293T / HeLa	  









293T / HeLa	  









293T / HeLa	  




















VSV-G	   pCMV	   	   Ampicillin	   	   	  
MLVgag-pol  	   Ampicillin 	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♭In tetherin sequence the HA tag is inserted at the amino acid position 463 with the numbering starting from the N-
terminus. The HA tag is localized between the extracellular coiled-coil domain and the GPI anchor. 
* Untagged versions of these proteins were also cloned (presence of a stop codon at the C-terminus) into the pCR3.1 
expression vector. 
** The pNL4.3delVpu was generated by replacing the ATG start codon of vpu ORF by a BamHI site (ggATccCAA) 
generating also one frame shift. 
 
 
Table 3.2: List of plasmid DNA constructs generated for transient expression of proteins, 
production of VLPs and associated stable cell lines synthesized. 
 
 
3.2 Working with Cells 
3.2.1 Cell Culture 
All adherent cells were maintained at 37°C/5% CO2 in Dulbecco's modified Eagle's medium 
(DMEM, Invitrogen) supplemented with 10% heat inactivated fetal bovine serum (v/v) (FBS, 
Invitrogen - inactivation for 30 minutes at 56°C) and gentamicin (0.02 mg/ml, Invitrogen) and cell 
density was monitored daily. For suspension cells such as Jurkat, RPMI 1640 medium 
(Invitrogen) was used as a culture medium instead of DMEM. All procedures were performed 
using sterile techniques in a laminar flow hood. HEK-293T cells, HeLa cells, HT1080 and Jurkat 
cells were obtained from the American Type Culture Collection (ATCC) and the HIV-1 reporter 
cell line HeLa-TZMbl was kindly provided by John Kappes through the NIH AIDS Reagents 
Repository Program (ARRP). HeLa cells modified to only express CD4 were provided by A. 
Akrigg through the National Institute of Biological Standards and Controls (NIBSC) Centre for 
AIDS Reagents. All cell lines were passaged at least every two days or more if needed for 
experimental purposes. Adherent cells were first washed with 3 ml of 1X phosphate buffered 
saline (1X PBS, Invitrogen) and dissociated from the tissue culture plate by addition of 2 ml of 
Trypsin (TrpLE Express + phenol red, Invitrogen) and then incubated for a few minutes at 37°C 
until the cells were detached. Cells were then resuspended into fresh pre-warmed DMEM.  
 HEK-293T cell line is a variant of HEK-293 cells that contains, in addition, the SV40 Large T-
antigen, that allows for episomal replication of transfected plasmids containing the SV40 origin 
of replication. Alternatively to HEK-293T cells (often designated as 293T), HeLa and HT1080 
were also used for this study (Table 3.3). HeLa cells are constitutively CXCR4 positive but do 
not express CD4 and CCR5. TZMbl cells are HeLa cells modified to express these lacking HIV-
1 entry receptors rendering them permissive to infection by HIV-1. These cells were further 
engineered to contain integrated reporter genes for firefly luciferase and Escherichia coli β-
galactosidase (lacZ) under the control of an HIV long-terminal repeat (LTR) promoter. In this 
configuration reporter gene expression is induced in trans by expression of the viral protein Tat 
soon after infection. β-galactosidase activity is quantified as relative luminescence units (RLU) 
and is directly proportional to the number of infectious virus particles present in the initial 
inoculum and by extension proportional to the number of virus particles.  
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 Stocks of frozen cells were kept in liquid nitrogen. Cells were pelleted by centrifugation at 
1,200 rpm for 5 minutes and resuspended into DMEM supplemented with 20% FBS (v/v) 
(Invitrogen) and 10% DMSO (v/v) (Sigma). The cells were cooled down at -80°C for a few days 
before being transferred to liquid nitrogen for long-term storage.  
	  
 
Table 3.3: List of cell lines used for this study. 
 
 
3.2.2 Transient transfection 
Cells were seeded a day prior to transfection. For indication, cells were plated at a density of 3-
4x105 in a well of a 6-well plate and at 105 cells per well of a 24-well plate. For each transfection 
sample, the appropriate amount of pCR3.1 vector encoding a given protein was diluted in 
DMEM without serum and mixed gently. Then, the transfection reagent was prepared in serum 
free medium and combined after 5 minutes incubation at room temperature with the diluted 
DNA. 293T cells were transfected with polyethylenimine (PEI solution prepared in ddH2O at 1 
mg/ml, 0.22 µm filtered and pH 7.0, Polysciences) whereas for HeLa cells, Lipofectamine 2000 
(2 mg/ml, Invitrogen) was used as a transfection reagent. In both cases, the transfection 
reagents facilitate entry of exogenous DNA into cell cytoplasm through endocytosis or 
membranes fusion. The solution was then mixed gently, incubated for 20 minutes at room 







Do not endogenously express tetherin 
Tetherin expression induced by IFN 
Absence of HIV-1 entry receptors 
HT1080 Fibrosarcoma DMEM 
Adherent cells 
 
Do not endogenously express tetherin 
 
Absence of HIV-1 entry receptors 
HeLa Cervical cancer  DMEM 
Adherent cells 
 
Endogenously express tetherin 
 
Absence of HIV-1 entry receptor CD4  
HeLa-TZMbl Cervical cancer DMEM 
Adherent cells 
 
Endogenously express tetherin 
 
Expression of HIV-1 entry receptors  
CD4 and CCR5 
 
β-galactosidase reporter gene under the 
control of HIV-1 promoter 






Endogenously express tetherin 
Expression of HIV-1 entry receptors 
CD4 and CXCR4 but not CCR5 
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temperature and added dropwise to the cells. Cells were then incubated for 48 hours prior to 
testing for protein expression, and medium was replaced 16 hours post-transfection. 
 
 
3.2.3 Generation of stable cell lines using retroviral vector transduction 
293T cells plated into a 6-well plate were transfected with expression vectors encoding MLV 
gag-pol proteins (1 µg), the VSV-G (0.2 µg) envelope protein and an MLV-based retroviral 
vector (1 µg), either the pCMS28 or the pLHCX. In this system, 293T cells serve as a packaging 
cell line. The retroviral vector pCMS28 is derived from pMigR1 and encodes a puromycin 
resistance gene. The resistance gene is linked via an internal ribosomal entry site (IRES) to the 
multi-cloning site, thereby coupling antibiotic selection to mRNA synthesis of the gene of 
interest. The multiple cloning site of this vector contains the restriction sites of the enzymes 
EcoRI, NotI and XhoI via which K5, Vpu and SNAT-1 genes were inserted. The pLHCX contains 
elements derived from Moloney murine leukemia virus and Moloney murine sarcoma virus. The 
5' viral LTR in this vector contains promoter/enhancer sequences that control expression of the 
hygromycin resistance gene for antibiotic selection in eukaryotic cells. In this construct, tetherin 
and the derived cytoplasmic tail tetherin mutants were cloned into the multiple cloning site 
immediately downstream of the human cytomegalovirus (CMV) promoter. Once in the cell, 
mRNA from the retroviral vectors is packaged via the packaging signal ψ into replication-
incompetent retroviral particles. This leads to the production of virus like particles (VLPs) 
containing the retroviral vector packaged into the structural proteins of MLV and bearing the 
VSV-G envelope protein at their surface. Importantly, for VLP production with pLHCX-THN, 100 
ng of pCR3.1-Vpu were added to inhibit restriction of particle release mediated by tetherin. 48 
hours post-transfection the virus like particles were harvested, 0.22 µm filtered and used to 
transduce 293T, HT1080 or HeLa cells. In most cases, spinoculation was used as a mean to 
increase delivery of virus particles into target cells (404). The spinoculation consists of 
centrifuging the plate for 2 hours at 3000 rpm at 20°C. By pseudotyping the VLPs with the VSV-
G envelope protein, these retroviral particles can infect and deliver the gene of interest into the 
host genome of a broad range of target cells. 48 hours later, transduced cells were split into a 
larger well format and placed under antibiotic selection (hygromycin at 100 µg/ml or puromycin 
at 1-2 µg/ml) and incubated at 37°C until all untransduced control cells had died. 
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3.2.4 Preparation of replication-competent HIV-1 virus stocks and Infection 
Semi-confluent HEK-293T cells on 6-well dishes were transfected with 2 µg of pNL4.3 or 
pNL4.3 (delVpu) and 0.2 µg of pCMV-VSV-G when necessary. This leads to the production of 
replication-competent HIV-1 virus particles that have both VSV-G and gp160 envelope proteins 
on their surface to allow infection of CD4 negative cells. Alternatively non-VSV-G pseudotyped 
HIV-1 virus stocks were also produced. 24 hours post-transfection, the medium was replaced 
and the cells were left in culture at 37°C for 24 more hours before being harvested. Then, 
supernatants containing viral particles were filtered 0.22 µm, aliquoted, stored at -80°C and 
subsequently titers determined on HeLa-TZMbl (cf. 3.3.1). Cells were infected with different 
multiplicities of infection (MOI) depending on the assay. For detection of tetherin or SNAT-1 
degradation mediated by Vpu, cells were infected with a MOI of 2. This multiplicity of infection 
ensures that approximately 90% of the cells were infected. To measure the production of virus 
particles released from a single round of infection through HeLa, 293T or HT1080 cells, MOIs of 
0.2-0.5-1 were used. MOIs lower than 0.2 were used to study virus replication (multiple cycles 
of infection) through the culture over time (MOI=0.1) in human primary CD4+ T cells. In that 
system, several rounds of replication are possible since these cells express all the HIV-1 entry 
receptors. For indication, a multiplicity of infection of 1 means that the amount of infectious virus 
particles (titrated on HeLa-TZMbl cells) added is the same than the amount of cells present in 
the culture, however the proportion of resulting infected cells is defined by the Poisson 
distribution indicated below: 
P(k)	  =	  e-­‐mmk/k!	  
In this equation, P(k) is the fraction of cells infected by k virus particles, and m is the MOI.	  
 
	  
3.2.5 HIV-1 virus release assay 
Subconfluent HEK-293T cells seeded at a density of 105 cells per well in a 24-well plate were 
transfected with 500 ng of HIV-1 proviral plasmid (pNL4.3, pNL4.3 delVpu) in combination with 
50 ng of pCR3.1-huTetherin and variable concentrations of pCR3.1-Vpu-HA or mutants thereof 
using PEI (5 µg/sample). The medium was replaced 16 hours after transfection, and viral 
supernatants and cell lysates were harvested 48 hours post-transfection. The infectivity of viral 
supernatants was determined by infecting HeLa-TZMbl and analyzing chemiluminescent β-
galactosidase activity 48 hours later (cf. section 3.3.1). Alternatively, to analyze physical particle 
release, 0.22 µm filtered supernatants were pelleted through a 20% sucrose-PBS cushion in a 
bench-top microcentrifuge at 14,000 x rpm for 90 minutes at 4°C, and pellets were resuspended 
in SDS-PAGE loading buffer. Virions and cell lysates were then subjected to SDS-PAGE and 
Western Blotting for HIV-1 p24-CA.  
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3.2.6 Gene expression knockdown by siRNA 
293T cells stably expressing SNAT-1/HA were seeded at a density of 1.5x105 cells per well in a 
12-well plate. After 3-4 hours, the first transfection was performed. Cells were transfected with 
Dharmafect transfection reagent (Dharmacon) with 100 pmoles of the corresponding siRNA 
(non-targeting control, UBAP1 or Tsg101 - QIAGEN) (Table 3.4) diluted in Optimem 
(Invitrogen). Medium was replaced 16 hours later. 48 hours post-transfection, 1/8 of the cells 
from one well of 12-well plate was reseeded into a 24-well plate and the second transfection 
was performed as before with 50 pmoles of siRNA oligo. 3-4 hours later, the cells were infected 






Table 3.4: Sequences of siRNA oligomers used to silence UBAP1 and Tsg101 
expressions in 293T SNAT-1/HA cells. 
 
 
3.2.7 Isolation of Peripheral Blood Mononuclear Cells (PBMC)  
Mononuclear cells (lymphocytes and monocytes) from human peripheral blood were isolated by 
a density gradient centrifugation method. Fresh blood taken from healthy donors was collected 
into heparin-coated tubes. The blood was then diluted by addition of an equal volume of 1X 
PBS (without Mg2+ and Ca2+). 30 ml of diluted blood was layered over 15 ml of Lymphoprep 
(Axis-Shield, sodium diatrizoate 9.1% (w/v); polysaccharide 5.7% (w/v)) in a 50 ml conical tube 
and centrifuged at room temperature (approximately 20°C) for 30 minutes at 1000 x g in a 
swinging-bucket rotor without brake. After centrifugation the mononuclear cells forming a 
distinct band (also called buffy coats) at the sample/medium interface were removed using a 
disposable Pasteur pipette without removing the upper layer. The harvested fraction was then 
diluted with a large volume of 1X PBS and the cells were pelleted by centrifugation for 10 
minutes at 300 x g. This washing step was repeated until the supernatant became completely 
clear. PBMCs count was determined using a haemocytometer. For indication, on average 2x106 
PBMCs should be isolated per ml of blood. 
 
 
3.2.8 Isolation and Purification of CD4+ T lymphocytes 
CD4+ T lymphocytes were isolated from PBMCs using Dynabeads Untouched human CD4 T 
cells kit (Invitrogen). This method allows the negative selection of CD4+ T cells by depletion of B 
Silenced-Gene Type Target sequence 
UBAP1 siRNA 5'-CTCGACTATCTCTTTGCACAT-3' 
Tsg101 siRNA 5'-CCUCCAGUCUUCUCUCGUC-3' 
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cells, NK cells, monocytes, platelets, dendritic cells, CD8+ T cells, granulocytes and erythrocytes 
from PBMCs leaving intact the wanted CD4+ T cells. Isolated CD4+ T cells are therefore bead- 
and antibody-free. PBMCs were resuspended in isolation buffer (Ca2+ and Mg2+ free 1X PBS 
supplemented with 2% FBS (v/v) and 2 mM EDTA). After addition of heat inactivated FBS, a 
mixture of mouse IgG antibodies against the non-CD4+ T cells was added to the sample and 
incubated for 20 minutes at 2-8°C. Cells were then washed with isolation buffer and pelleted by 
centrifugation at 300 x g for 8 minutes at 2-8°C. The supernatant was discarded and the cells 
were resuspended into fresh isolation buffer and incubated for 15 minutes at 18-25°C in the 
presence of pre-washed Depletion MyOne Dynabeads. This step allows the antibody-labelled 
cells to bind to the magnetic beads. The bead-bound cells were subsequently separated on a 
magnet for 1 minute and discarded. The supernatant contains the negatively isolated human 
CD4+ T cells. At this stage, a CD4+ T cells count was performed. For indication, 1/4 of PBMCs 
should be CD4+ T cells giving a total number of 2.5x107 CD4+ T cells in 50 ml blood. A fraction 
of isolated CD4+ T cells is conserved to check the purity. This fraction was stained with an anti-
CD4 antibody coupled to an APC fluorochrome before being analyzed by flow cytometry. 106 
CD4+ T cells were then plated into a well of a 24-well plate in a seeding volume of 1 ml pre-
warmed RPMI-1mM glutamine (supplemented with 10% heat inactivated dialyzed FBS (v/v), 
Invitrogen) in the presence of 25 µl of Dynabeads Human T-Activator CD3/CD28 (Invitrogen) in 
order to obtain a bead-to-cell ratio of 1:1. These beads mimic in vivo T cell activation from 
antigen-presenting cells by utilizing the two activators signals CD3 and CD28, bound to a three-
dimensional bead similar in size to the antigen-presenting cells. Cells were activated for 48 
hours with anti-CD3/anti-CD28 magnetics beads before HIV-1 infection. The beads were then 
removed and the cells were maintained in rhIL-2 (20 U/ml)(Roche). Alternatively, CD4+ T cells 
were stained with CellTrace Violet dye (Invitrogen) before addition of CD3/CD28 Dynabeads. 
 
 
3.2.9 Cell Proliferation 
CellTraceTM Violet Cell proliferation kit (Invitrogen) was used to label CD4+ T cells with a dye-
marker that allows monitoring of cell proliferation. This dye diffuses into cells where it is cleaved 
by intracellular esterases to yield a highly fluorescent compound. This compound covalently 
binds to intracellular amine and is inherited by daughter cells after cell division. Primary human 
CD4+ T lymphocytes were resuspended in a final concentration of 106 cells/ml in 1X PBS-5% 
dialyzed FBS. Cells were then mixed with a final CellTrace Violet concentration of 5 µM and 
incubated for 20 minutes at 37°C, protected from light. Any unbound dye was quenched by 
adding 5 times the original staining volume of RPMI-1mM glutamine to the cells. Cells were then 
incubated for 5 minutes at 4°C, pelleted via centrifugation and resuspended in fresh pre-
warmed RPMI-1mM glutamine at a final concentration of 106 cells/ml. Violet-labeled CD4+ T 
cells were then activated as above with CD3/CD28 Dynabeads (Invitrogen). A sample of violet-
labeled CD4+ T cells was maintained without CD3/CD28 stimulation in order to detect the 
generation 0. 
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3.3 Working with Viruses 
3.3.1 β-Galactosidase reporter assay: virus stock titration and virus release 
quantification 
- Absolute titration of virus stocks: 
HIV-1 virus stocks and those pseudotyped with VSV-G prepared as described in part 3.2.4 were 
titrated on HeLa-TZMbl cells. TZMbl cells were seeded at a density of 104 per well in a flat 
bottom 96-well plate (or 5x104 cells per well for a 48-well plate format) and infected 24 hours 
later with 25 µl input of serial dilutions from 10-1 to 10-6 of the initial virus stock. Two days post-
infection, cells were fixed with 0.5% glutaraldehyde/PBS for 15 minutes at room temperature, 
washed twice with 1X PBS and incubated with X-Gal substrate (solution at 1 mg/ml X-gal-
dimethylformamide in 5 mM K ferrocyanide, 5 mM K ferricyanide, 2 mM MgCl2, 0.02% NP40, 
0.01% Triton-X100 in 1X PBS) overnight at 37°C. Infected cells should turn blue as a result of 
the β-galactosidase activity induced by Tat expression. Blue colonies were then counted with a 
light microscope and the end point titer of virus (IU/ml) determined.  
 
 
- Relative titration for virus release: 
Alternatively, infected TZMbl cells were lyzed 48 hours post-infection in 50-100 µl of Tropix 
Galacto-Star Lysis Solution (100 mM potassium phosphate (pH 7.8), 0.2% Triton X-100, Applied 
Biosystems) for 10 minutes at room temperature. 10 µl of cell lysates were then transferred to a 
white luminescence microplate well and incubated for 10-15 minutes in the dark with 45 µl of 
Tropix Galacton-Star substrate diluted at 1:50 in Reaction Buffer Diluent (100 mM sodium 
phosphate (pH 7.5), 1 mM magnesium chloride, 5% Sapphire-II enhancer, Applied Biosystems). 
The light signal was then measured using a luminescence counter (Victor Light 1420-Perkin 
Elmer) and Wallac 1420 workstation software. In that system, HeLa-TZMbl cells serve as a HIV-
1 reporter cell line and allow to quantify the infectivity of viral supernatants, which in that case, 
reflects the absolute amount of virions. 
 
 
3.3.2 Intracellular p24 staining 
Infected primary human CD4+ T cells or Jurkat cells were fixed in 4% paraformaldehyde solution 
at 4°C for 10-20 minutes, washed 2 times in cold staining buffer (1X PBS, 2 mM EDTA, 2% FBS 
(v/v)) and stored at 4°C for up to 3-4 days in staining buffer before FACS analysis. Cells were 
then pelleted to remove the staining buffer and permeabilized for 15 minutes with BD 
Perm/Wash buffer (saponin and FBS diluted in ddH2O, BD Cytofix/Cytoperm 
fixation/permeabilization kit; BD Biosciences). Cells were then pelleted by centrifugation, 
resuspended in 50 µl of BD Perm/Wash buffer containing HIV-1 Gag antibody diluted at 1:100 
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(KC57 antibody conjugated to phycoerythrin (PE), Beckman-Coulter) (Table 3.5) and incubated 
at 4°C for 1 hour in the dark. The cells were then washed 2 times with BD Perm/Wash buffer 
and resuspended in staining buffer prior to flow cytometry analysis. Uninfected cells were also 
stained and used as negative controls to detect non-specific staining. 
 
 
3.3.3 HIV-1 replication in primary CD4+ T lymphocytes 
CD3/CD28-activated CD4+ T lymphocytes were infected with HIV-1 Wt or delVpu at a 
multiplicity of infection of 0.1 for 3-4 hours in 1 ml total volume of glutamine-free RPMI medium. 
10 ml of glutamine-free medium was then added to each sample (uninfected, HIV-1 Wt, HIV-1 
delVpu) and cells were pelleted by centrifugation for 2 minutes at 2000 rpm. The supernatant 
was then discarded and replaced by 10 ml fresh glutamine-free medium. This washing step was 
then repeated one more time to ensure complete removal of glutamine. Cell pellets were 
resuspended in the appropriate volume of glutamine-free medium to obtain a density of 5x105 
cells/ml. 200 µl of this solution (= 105 cells) were then distributed into a 96-well plate. The plate 
was then centrifuged for 2 minutes at 2000 rpm, supernatants from each well removed and 
replaced with RPMI medium supplemented with IL-2 (30 units/ml), heat inactivated, dialyzed 
and treated FBS (Invitrogen) and the appropriate glutamine dilution (dilution range from 0 mM to 
2 mM). Infected CD4+ T cells were then incubated at 37°C. Cells and viral supernatants were 
harvested at several time points post-infection. A time point 24 hours post-infection was always 
taken in order to get a common and synchronous amount of virus for each conditions tested. 
The cells were stored at 4°C for p24 intracellular staining (cf. section 3.3.2) and viral 
supernatants titrated on HeLa-TZMbl cells (cf. section 3.3.1). 
 
 
3.4 Working with Proteins 
3.4.1 Co-immunoprecipitations 
Subconfluent HEK-293T cells seeded at 3-4x105 per well in a 6-well plate were transfected with 
500-800 ng of Vpu expression vector (Vpu cloned into pCR3.1 or pCRV1), the appropriate Vpu 
mutant or pCR3.1-YFP, and 500-800 ng of pCR3.1-huTetherin or pCR3.1 SNAT-1/HA. At 48 
hours post-transfection, the medium was removed and the cells were resuspended into 1 ml of 
cold lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, complete protease inhibitors (Roche), 
and 1% digitonin (w/v) (Calbiochem)) and lysed for 30 minutes at 4°C on a rotational tumbler. 
The nuclei were then removed by centrifugation for 5 minutes at 10,000 x g and the supernatant 
was transferred into a new tube and pre-cleared for 30 minutes at 4°C on a rotator with 60 µl of 
pre-washed protein G-agarose beads (Invitrogen). The samples were then centrifuged for 5 
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minutes at 10,000 x g at 4°C and the supernatant transferred into a new tube. 80 µl of the 
cleared-supernatant serving as cell lysates control were taken and diluted in 2X SDS-PAGE 
loading buffer. The remaining supernatants (≈ 900 µl) were then incubated with 5 µg/ml mouse 
anti-HA antibody (Covance) for 2 hours at 4°C on a rotational tumbler before addition of 75 µl of 
fresh protein G-agarose. The samples were incubated for a further 3 hours at 4°C and then 
washed 4 times (4 cycles of centrifugation at 3500 x g of 1 minute at 4°C) in lysis buffer 
containing 0.1% digitonin (w/v). Finally, the last 100 µl were removed using a 26G needle and 
the beads resuspended in 100 µl of 2X SDS-PAGE loading buffer. 
 
 
3.4.2 Detection of ubiquitinated tetherin 
This assay was performed to detect ubiquitinated tetherin molecules in the presence of Vpu or 
K5 expression. HeLa cells seeded on 10cm plates were transiently transfected with a pCR3.1 
THN-HA expression vector (5 µg) in combination with pCR3.1 K5, Vpu or GFP (2 µg) 
expression vectors and in the presence or absence of a 6-His-tagged ubiquitin encoding 
plasmid (2 µg). 48 hours after transfection, cells were treated for 8 hours with BafA1 (100 nM, 
Sigma) to prevent further tetherin degradation. Cells were lysed in buffer A (6 M guanidine-HCl, 
0.1 M Na2HPO4/NaH2PO4, 10 mM imidazole and pH adjusted to 8.0 with NaOH), sonicated and 
ubiquitinated proteins were isolated by binding to 50 µl of Ni-NTA agarose beads (Invitrogen) for 
3 hours at room temperature on a rotator. The resin was then washed twice with buffer A 
followed by two washes with buffer A/TI (1 volume of buffer A + 3 volumes of buffer TI) and 
washed one more time with buffer TI (25 mM Tris.Cl, 20 mM imidazole, pH 6.8). Finally, the 
bound ubiquitinated proteins were eluted from the resin by adding 100 µl of 2X SDS-PAGE 
loading buffer supplemented with 100 mM imidazole. 
 
 
3.4.3 SDS-PAGE and Western blotting 
Protein samples resuspended in 2X SDS-PAGE reducing loading buffer (20% (v/v) glycerol, 4% 
(w/v) SDS, 100 mM Tris-HCl (pH 6.8), 200 mM β-mercaptoethanol, 0.2% (w/v) bromophenol 
blue) were denatured for 10 minutes at 100°C before being loaded into a Sodium Dodecyl 
Sulphate PolyAcrylamide Gel Electrophoresis (SDS-PAGE). The purpose of SDS-PAGE is to 
separate proteins according to their molecular size. Denaturating separating gels (10% gels 
contain: 25% (v/v) of acrylamide 40% solution (acrylamide:BIS-acrylamide-29:1, Fisher), 0.1% 
(w/v) SDS, 0.1% (v/v) TEMED (N,N,N’,N’-Tetramethyl-ethane-1,2-diamine, Sigma), 375 mM 
Tris-HCl (pH 8.8), 0.05% (w/v) ammonium persulphate in ddH2O) were cast using the Mini-
PROTEAN Tetra Cell electrophoresis system (Biorad). Gels of either 8% (proteins > 80 kDa) or 
10-12% (20kDa < proteins < 80kDa) were also used. The separating gel was then overlaid with 
1 ml of isopropanol and left for 30 minutes at room temperature until the gel was polymerized. 
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The isopropanol was then removed and the upper part of the gel washed several times with 
ddH2O and dried with paper before layering the top with the stacking gel (9.3% (v/v) of 
acrylamide 40% solution (acrylamide:BIS-acrylamide, 29:1, Fisher), 0.1% (w/v) SDS, 0.1% (v/v) 
TEMED, 125 mM Tris-HCl (pH 6.8), 0.05% (w/v) ammonium persulphate in ddH2O). Combs 
containing 15 spacers (0.75mm/well) were then inserted into the glass plates through the 
stacking gel and the solution was left at room temperature to allow it to polymerize. 10 µl of 
each protein sample was loaded per well. 5 µl of protein ladder (Prestained Protein Marker, 
broad range (7-175 kDa), New England Biolabs) solution was loaded in the first well of each gel. 
Gels were then placed into Biorad chambers into a tank filled with running buffer (0.1% (w/v) 
SDS, 25 mM Tris-Base, 200 mM glycine, pH 8.8). Gels were run at 80 volts for 15 minutes until 
the samples started to migrate through the separating gel, and then switched to 100 volts until 
the end of the run for approximately 1.5 hours.  
 Separated proteins were then transferred onto 0.45 µm nitrocellulose membrane (Hybond 
ECL nitrocellulose membrane, GE-Amersham Biosciences) in transfer buffer (20% ethanol (v/v), 
25 mM Tris-Base, 200 mM glycine) at 18 volts overnight or at 100 volts for 1 hour. The 
nitrocellulose membrane was incubated with blocking buffer (5% milk (w/v) (dried skimmed milk, 
Marvel) in 0.1% (v/v) PBS-Tween 20) on a shaker for 1-2 hours at room temperature or 
overnight at 4°C to saturate non-specific binding sites. Membranes were incubated with the 
appropriate primary antibody (Table 3.5) diluted in blocking solution, for approximately 1-2 
hours at room temperature, or overnight at 4°C. Membranes were then washed four times with 
washing buffer (0.1% (v/v) Tween 20 in 1X PBS) on the shaker for 5-10 minutes each time. 
Membranes were then incubated with the secondary antibody (Table 3.6) diluted into the milk 
solution, for 1 hour at room temperature. Depending on the nature of the detection method, 
membranes were incubated either with horseradish peroxidase (HRP) conjugated secondary 
antibodies for detection by enhanced chemiluminescence (ECL) method or with IRDye 800-700 
conjugated secondary antibodies for detection with LI-COR Odyssey Infrared Imaging System. 
The membranes were then washed four times on the shaker for 5-10 minutes each time. For 
ECL development, activity of HRP-conjugated antibodies was detected by incubation of the 
membrane with SuperSignal West Pico Chemiluminescent solutions in a 1:1 ratio 
(2ml/membrane, Thermo Scientific) for 5 minutes and the resulting chemiluminescence signal 
visualized using an ImageQuant LAS 4000 mini system consisting of a Luminescent Image 
Analyser and a F0.85 43 mm LAS high sensitivity lens (GE Healthcare). For LI-COR detection, 
membranes were rinsed in 1X PBS and scanned at high resolution (169-84 µm) using the LI-
COR Odyssey infrared imaging systems (LI-COR Biosciences).  
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Antibody Source Species Antigen Dilution Application 
α  TGN46 AbD Serotec Sheep Human TGN46 1:100 IF (TGN marker) 
α  Vpu NIH ARRP* Rabbit NL4.3 Vpu (amino acids 33-





α  p24 Beckman Coulter Mouse HIV-1 proteins 55,39,33 
&24kDa of core antigen 
1:50-1:100 FC  
(Gag intracellular 
staining) 
α  p24 
187 



















α  HA Rockland Rabbit HA epitope tag 1:1000 WB / IF 
α  BST-2 NIH ARRP* Rabbit Human BST-2 1:1000 WB 






Human BST-2 1:200 FC 
α  Hsp90 Santa Cruz Rabbit Human Hsp90 1:5000 WB 
α  PDI Invitrogen Mouse Protein disulfide isomerase 
(PDI) 
1:1000 IF  
(ER marker) 
α  CD63 Biolegend Mouse CD63 
(Hybridoma supernatant) 
1:10 IF  
(Late endosome 
marker) 
α  CD4-APC BD Biosciences Mouse Human CD4 receptor 1:100 FC 
α  SNAT-1 Santa Cruz Rabbit Amino acids 1-60 at the N-
terminus of SNAT-1 
1:1000 WB 
* NIH AIDS Research & Reference Reagent Program 
WB= Western Blot 
IF= Immunofluorescence 
FC= Flow Cytometry 
IP= Immunoprecipitation 
 





* NIH AIDS Research & Reference Reagent Program 
WB= Western Blot 
IF= Immunofluorescence 
FC= Flow Cytometry 
IP= Immunoprecipitation 
 
Table 3.6: List of secondary antibodies used in this study. 
Antibody Source Conjugation Dilution Application 
Goat α-Mouse Cell Signalling HRP 1:5000 WB - ECL 
Goat α-Rabbit Cell Signalling HRP 1:5000 WB - ECL 
Goat α-Mouse LI-COR Biosciences IRDye 680 1:5000 WB - LICOR 
Goat α-Rabbit LI-COR Biosciences IRDye 800 1:5000 WB - LICOR 
Donkey α-Mouse Molecular Probes - (Invitrogen) Alexa Fluor 488 
Alexa Fluor 647 







Goat α-Mouse Molecular Probes - (Invitrogen) Alexa Fluor 488 





Donkey α-Rabbit Molecular Probes - (Invitrogen) Alexa Fluor 680 
Alexa Fluor 488 







Goat α-Rabbit Molecular Probes - (Invitrogen) Alexa Fluor 594 1:500 IF 
Donkey α-Sheep Molecular Probes - (Invitrogen) Alexa Fluor 594 1:500 IF 
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3.4.4 Imaging: immunofluorescence and confocal microscopy 
Cells were plated on glass coverslips placed at the bottom of a well of a 24-well plate. To 
facilitate adhesion of 293T cells, the coverslips were pre-treated with poly-L-lysine (Sigma) for 
10 minutes and washed with DMEM. 24 hours later, the cells were transfected with 100 ng of 
Vpu-HA expression vector, Vpu TM domain mutants or SNAT-1/HA. Alternatively, 293T-SNAT-
1/HA and HT1080/THN-HA (+/- Vpu or K5) cells were plated on glass coverslips and infected 24 
hours later with HIV-1 Wt or HIV-1 delVpu or Vpu mutants at an MOI of 0.2-1. At 24 hours post-
transfection or 48 hours post-infection, the cells were fixed in 4% paraformaldehyde 
(formaldehyde 4% (v/v) in 1X PBS) for 15 minutes, washed in 1X PBS-10 mM glycine and 
permeabilized in 0.1% (v/v) Triton X-100 (in staining buffer: 1X PBS supplemented with 1% BSA 
(w/v)) for 15 minutes at room temperature. Cells were then washed with the staining buffer and 
incubated for 1 hour at room temperature with the primary antibody (Table 3.5) and agitated 
slowly on the shaker. Alternatively, cells were blocked for 0.5-1 hour in staining buffer before 
incubation with the primary antibody (for endoplasmic reticulum staining with PDI). The cells 
were washed 3 times in 1X PBS-1% BSA (w/v) and incubated at room temperature with the 
secondary antibody coupled to fluorophores in 1X PBS for 1 hour in the dark (Table 3.6). The 
cells were then washed 3 times with 1X PBS. The coverslips were then mounted on slides using 
ProLong Antifade (Molecular Probes, Invitrogen) containing DAPI (4',6- diamidino-2-
phenylindole) for visualization of the nucleus, dried at 50°C for 20-30 minutes or overnight in the 
dark and examined on a Leica DM-IRE2 confocal microscope (63.0x oil immersion lens). Cells 
on coverslips can be stored at 4°C protected from the light.  
 
 
3.4.5 Cell surface protein expression: Flow cytometry (FACS) 
HeLa cells in 6-well dishes were transfected with 400 ng pCR3.1-enhanced green fluorescent 
protein (eGFP) and 400 ng pCR3.1-Vpu-HA or TM mutant. Alternatively, HT1080/THN-HA (+/-
Vpu or K5) cells were treated with Bafilomycin A1 (100 nM), concanamycin A (100 nM) or 
MG132 (1 µg/ml) for 10-14 hours. 293T SNAT-1/HA cells seeded into a 24-well plate at a 
density of 105 cells per well were transduced with VLPs packaged with pCMS28 Vpu*-GFP 
vector whereas Jurkat cells were infected with vesicular stomatitis virus G (VSV-G)-
pseudotyped HIV-1 Wt and HIV-1 delVpu (and derived Vpu TM domain mutants) at a multiplicity 
of infection of 1. At 48 hours post-transfection/transduction/infection, the cells were harvested 
and stained either for surface endogenous tetherin or surface SNAT-1/HA. Once the medium 
was removed from the plate, the cells were detached and resuspended into 1X PBS 5-10 mM 
EDTA. The cells were then transferred into a tube and pelleted by centrifugation at 3500 rpm for 
1 minute at 4°C. During FACS staining, the cells were constantly kept at 4°C. The supernatant 
was then aspirated and the cells were incubated with the appropriate primary antibody (Table 
3.5) diluted in FACS buffer (1X PBS- 1% BSA (w/v), 0.1% sodium azide (w/v)) for 1 hour on ice. 
Cells were then washed 3 times in 1X PBS-1% BSA before addition of the secondary antibody 
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(Table 3.6) and incubated for 1 hour at 4°C. Cells were then washed 3 times in FACS buffer and 
the last wash was performed with cold 1X PBS. At this step, the cells can be fixed with 2% 
paraformaldehyde (v/v) and stored at 4°C in the dark. Tetherin and SNAT-1/HA expressions on 
GFP+ cells were then analyzed using a FACSCalibur flow cytometer (Becton Dickinson) and 
FlowJo software. 
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Chapter 4                                                                          
Restriction of Kaposi’s Sarcoma-associated Herpes Virus 
particle release by tetherin is antagonized by the RING-CH 
ubiquitin ligase K5 
 
The study presented in this chapter was published in collaboration with Claire Pardieu from 
Greg J. Towers's group as '' The RING-CH Ligase K5 Antagonizes Restriction of KSHV and 




4.1.1 K5, a viral immune modulator 
The human herpesvirus 8 (HHV-8) also known as Kaposi’s sarcoma-associated herpesvirus 
(KSHV) belongs to the Rhadinovirus genera (or γ-2) of the γ-herpesvirus subfamily and is one 
of the seven currently known human cancer viruses (oncovirus) (reviewed in (405)/chapter 72). 
As its name implies, KSHV is associated with the development of a type of cancer, Kaposi’s 
sarcoma, commonly occurring in AIDS patients. KSHV also causes B-cell neoplasms, 
multicentric castleman's disease and primary effusion lymphoma. KSHV is composed of a large 
double-stranded genomic DNA protected by two layers of viral proteins, a capsid and a matrix 
(or tegument), which are enclosed in a lipid envelope derived from the host cell membrane. 
KSHV entry occurs through macropinocytosis, a form of endocytosis for absorption of 
extracellular particles. Inside the infected cell, the viral life cycle proceeds through two distinct 
phases, either a latent or a lytic phase. During the latent phase, the expression of viral genes 
required for virus production and assembly is inhibited by the viral-latency-associated nuclear 
antigen (LANA) and only the viral DNA is replicated by the host cell machinery, whereas in the 
lytic phase these genes are activated to allow production of virus particles. Ultimately, 
thousands of virus particles can be made from a single cell, resulting in lysis of the infected cell. 
The primary viral protein responsible for the switch between latent and lytic replication is the 
ORF50 replication transactivation activator (RTA).  
 Inspired by studies which showed a downregulation of MHC class I molecules by mK3 from 
the murine ϒ-herpesvirus 68 (MHV68) infection of murine fibroblasts, the KSHV genome was 
screened for gene products inhibiting MHC class I expression (406). Interestingly, two genes, 
K3 and K5 (also known as MIR1 and MIR2, respectively) were identified as immunomodulators 
able to reduce MHC class I expression in human cells. Immunomodulators of pathogens 
frequently target multiple cellular proteins, thus preventing recognition by different immune cells. 
One pathway targeted by KSHV via K3 and K5 is the antigen presentation by major 
histocompatibility complex class I molecules (reviewed in (241)). By interfering with MHC class I 
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expression, KSHV becomes less detectable by cytotoxic T cells. Additional cell surface targets 
of K5 were then identified, particularly those involved in T cell and NK cell recognition of virally 
infected cells. In addition to MHC class I molecules, K5 targets the HFE protein (human 
hemochromatosis protein related to MHC class I molecules) (407) and also adhesion molecules 
(ICAM-1, PECAM, ALCAM and VE-cadherin) (408), co-stimulatory molecules (B7.2) (409), 
ligands for NKT cells (CDd1) (410), ligands for NK cells (MICA, MICB, AICL) (411), cytokine 
receptors (IFN- γR1) (412), cellular restriction factors (tetherin or BST-2) (191), the plasma 
membrane t-SNARE syntaxin-4 (191) and a member of the TGF-beta family (BMPRII) (413). 
Tetherin, ALCAM (CD166) and syntaxin-4 were identified by a novel quantitative membrane 
proteomics approach termed SILAC (Stable Isotope Labelling with Amino acids in Cell culture) 
(191). In this screen, BST-2 (tetherin) was scored as the most highly under-represented protein 
in K5-expressing HeLa cells.  
 K5 belongs to a family of viral- and cellular-membrane-spanning RING E3 ubiquitin ligases 
found in mammals. K5 consists of a cytoplasmic amino-terminal RING-CH domain followed by 
two membrane-traversing domains, resulting in a type III transmembrane topology (Figure 4.1) 
(414). The RING domain binds an ubiquitin-conjugating enzyme (E2) and catalyses the transfer 
of the ubiquitin on its substrates. While E2 provides the ubiquitin, E3 confers the specificity for 
the target. K5, probably, derives from host genes since mammals encode similar proteins, 
termed membrane-associated RING-CH (MARCH) proteins whose role, mainly described 
through studies on viral proteins, is to modulate the intracellular trafficking and turnover of 
transmembrane protein targets (241). K5 is most closely related to MARCH-VIII. MARCH 
ligases mediate the ubiquitination of lysine or cysteine residues in the cytoplasmic tail of target 
transmembrane proteins. For most substrates, ubiquitination occurs in a post-endoplasmic 
reticulum compartment and ubiquitinated proteins are endocytosed, sorted to multivesicular 
bodies (MVB) in a clathrin-dependent process and degraded in lysosomes (415, 416). ER-
associated proteasomal degradation (ERAD) has also been observed for some substrates of K5 
(CD31/PECAM) (417). Although K5 is less effective at downregulating MHC class I, it does 
have a broader substrate specificity than K3 that seems to be conferred by the transmembrane 
regions since substitution of these domains of K3 by K5 was able to transfer substrate 
specificity of the proteins. However, the rules for target selection have yet to be established.  
 Therefore, the E3 ubiquitin ligase K5, enables KSHV viral survival and replication by 
inhibiting the immune response through the downregulation of a panel of cellular proteins. In the 
next section we will specifically study the role of K5 in targeting tetherin. 
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Figure 4.1: Structural features of K5 protein. 
K5 is a membrane-anchored protein with two transmembrane domains. The RING-CH domain 
displayed at the N-terminus and the C-terminal region are cytoplasmic. The two transmembrane 
segments are linked via a short extracellular loop. 
 
4.1.2 KSHV particle release is sensitive to tetherin-mediated restriction in a K5 
dependent-manner 
 
Previous studies have shown the broad spectrum of enveloped viruses restricted by tetherin 
(204, 208-211, 213). K5 targeting tetherin, therefore, led us to speculate the existence of an 
antiviral activity of tetherin against KSHV. To demonstrate a potential inhibition of KSHV particle 
release by tetherin, our collaborators Pardieu et al. measured KSHV production in the presence 
of increasing amounts of exogenous human tetherin (cf. published papers). Interestingly, a 
linear decrease in release of KSHV infectious virus was observed when increasing amounts of 
the tetherin-expressing plasmids were transfected. Further experiments showed that RNAi-
depletion of K5 during lytic replication suppressed KSHV particle release in cells expressing 
constitutively tetherin. Therefore, K5 plays an important role in overcoming tetherin-mediated 
restriction of herpesvirus release. 
	  
4.2 Results: K5 is a potent tetherin antagonist 
Having established the role of K5 for efficient KSHV particle release in tetherin-expressing 
conditions, we investigated the cellular and molecular biology of the mechanism by which K5 
overcomes tetherin-mediated restriction. 
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4.2.1 K5 rescues Vpu-defective HIV-1 particles release from tetherin-mediated restriction 
For HIV-1 it has been well documented that Vpu counteracts tetherin activity to allow efficient 
viral particle release (186). We asked whether K5 expression could substitute for Vpu and 
promote the release of tetherin-restricted HIV-1 delVpu particles. Firstly, HeLa cells were 
transfected with a NL4.3 proviral construct or a Vpu-defective counterpart in combination with 
HA-tagged K5 or Vpu expression vectors (Figure 4.2A-B-C). The presence of Vpu serves as a 
control in this experiment to monitor efficient tetherin counteraction. K5 expression in trans 
rescued HIV-1 delVpu release to levels achieved by Vpu, as evidenced either by titration of HIV-
1 virions released into the supernatant onto the HIV-1 indicator cell line HeLa TZM-bl or 
measurement of HIV-1 p24 capsid protein in the supernatant by Western blot. Importantly, K5 
expression had no effect on the processing of the gag precursor, Pr55, to the mature p24 
capsid. 
 K5 acts as an E3 ubiquitin ligase to target several immune receptors (241). This function 
requires a functional RING-CH domain that recruits an E2-conjugating enzyme and catalyses 
the transfer of an ubiquitin moiety to its target protein (Figure 4.1). To test the importance of this 
ubiquitin ligase activity for K5 mediating tetherin counteraction, a RING deletion mutant of K5 
(K5delRING) was generated, and tested for its ability to counteract tetherin-mediated HIV-1 
delVpu restriction. Despite similar expression levels as K5 wild-type, K5delRING mutant failed 
to rescue the HIV-1 delVpu particle release from HeLa cells (Figure 4.2A-B-C). 
 Similar experiments were conducted in a tetherin-deficient cell line (HT1080) stably 
expressing an HA-tagged version of human tetherin (HT1080/THN-HA), and subsequently 
transduced with pCNCR retroviral vectors co-expressing DsRed and Vpu, or K5 or K5delRING 
(Figure 4.2D-E). 48 hours later, when more than 90% of the cells were DsRed positive, cells 
were infected with VSV-G pseudotyped HIV-1 Wt or HIV-1 delVpu at a multiplicity of infection of 
0.2 (cf. Chapter 3). As expected, in HT1080/THN-HA, 20 fold less viral particles were released 
by HIV-1 delVpu compared to HIV-1 Wt. Furthermore, expression of K5 and Vpu but not 
K5delRING could rescue HIV-1 delVpu particles release from HT1080/THN-HA cells. 
Measurement of Gag levels in supernatants and extracts of infected cells by Western blot 
indicated that the effects of tetherin, Vpu and K5 were on HIV-1 release and not Gag protein 
expression. 
 Taken together,	   these data demonstrate the functional homology that KSHV-encoded K5 
shares with HIV-1 Vpu in counteracting tetherin. 	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Figure 4.2: K5 rescues Vpu-defective HIV-1 particle release from tetherin-mediated 
restriction.  
A and B: HeLa cells were co-transfected with HIV-1 Wt or HIV-1 delVpu proviral plasmids in 
combination with empty vector, or expression vector encoding Vpu, HA-tagged K5 or K5 lacking 
the N-terminal RING domain. 48 hours post-transfection, cell lysates and pelleted supernatants 
were analysed for HIV-1 Gag proteins by Western blot using an anti-p24CA monoclonal 
antibody (A) or an anti-HA monoclonal (B). C: Viral supernatants were also used to infect HeLa-
TZM indicator cells and infectious viral release determined by relative β-galactosidase activity 
48 hours later. Results are the mean of 3 independent experiments and errors are standard 
error of the mean. D and E: HT1080 cells stably expressing human tetherin (HT1080/THN-HA) 
were transduced with CNCR retroviral vectors encoding both dsRED and either Vpu, K5 or 
K5(del RING) at doses sufficient to give > 90% transduction as determined by flow cytometry. 
Cells were then infected with HIV-1 Wt or HIV-1 delVpu pseudotyped with VSV-G at an MOI of 
0.2. Cell lysates and supernatants were processed as in (A) 48 hours later. Results are the 
mean of 3 independent experiments and errors are standard error of the mean. 
 
 
 K5 could not antagonize tetherin function in transiently-transfected 293T cells, even when 
tetherin expression was titrated to vary its expression level (Figure 4.3). Interestingly, 293T cells 
are also unable to support HIV-2 Env’s anti-tetherin activity (230), suggesting that this particular 
cell line might be poorly suited for characterization of some tetherin antagonists. We propose 
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Figure 4.3: Lack of K5 activity against tetherin in 293T cells.  
293T cells were co-transfected with HIV-1 Wt or HIV-1 delVpu proviral plasmids in combination 
with empty vector, or expression vector encoding Vpu, or K5 and increasing doses of tetherin 
plasmid. 48 hours post-transfection, infectivity of viral supernatants was titrated on HeLa-TZMbl 
cells as above. This result is a representative example of three independent experiments. 
 
 
4.2.2 K5 depletes cell-surface human tetherin but not Rhesus macaque tetherin  
Many studies have documented the ability of HIV-1 Vpu to reduce tetherin levels from the cell 
surface (187, 220, 376, 377). We therefore tested whether K5 could act in a similar way to 
counteract tetherin. HT1080/THN-HA cells were transduced with a retroviral vector encoding 
dsRED and either wild-type K5 or the RING-deleted K5 mutant (K5delRING). 48 hours post-
transduction, cells were harvested, stained for tetherin-HA and surface expression levels in 
dsRED positive population were quantified by flow cytometry (Figure 4.4). As expected, K5 but 
not K5delRING expression resulted in the loss of tetherin levels at the cell-surface (Figure 
4.4A). This result demonstrates that K5, like Vpu, mediates tetherin downregulation from the 
cell-surface and that this function requires a functional RING-CH domain. We then examined 
whether K5 could target another non-human primate orthologue of tetherin. Previous studies 
have shown that Vpu acts only against human, chimpanzee and Gorilla tetherins. Sensitivity of 
human tetherin can be abolished by mutation of a single amino acid in the transmembrane cap 
of human tetherin present in Old World monkeys (T45I) coupled with an in frame deletion of a 
GI pair at the N-terminus of the human tetherin TM domain (delGI) (224). In this assay we 
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tested whether K5 displayed such species-specificity in its mode of action. HT1080 cells stably 
expressing either the HIV-1 Vpu-resistant human tetherin (delGI,T45I) or Rhesus macaque 
tetherin, were transduced with a retroviral vector encoding K5 and assayed for expression of 
cell-surface tetherin levels. Interestingly, whilst K5 downregulates tetherin delGI-T45I, no 
appreciable reduction of cell-surface Rhesus macaque tetherin was detected after K5 
expression (Figure 4.4B). Together these data suggest that K5 also displays species-specificity 
in its antagonism of primate tetherins similarly to HIV-1 Vpu but the determinants of this 
specificity are distinct. Further studies will be required to determine the residues in tetherin that 





























Figure 4.4: K5 mediates cell-surface downregulation of tetherin.  
A: HT1080/THN-HA cells were transduced with retroviral vectors (pCNCR) encoding dsRED 
and either K5 or K5(del RING). 48 hours post-transduction, the cells were immunostained for 
surface tetherin using an anti-HA monoclonal antibody and an Alexa-488-conjugated goat-anti-
mouse secondary antibody. Surface expression of tetherin was then analyzed in the dsRED 
positive population by flow cytometry. Parental HT1080 cells were used as a control for 
background antibody binding and are represented by the red line. Tetherin levels in HT1080 
cells expressing tetherin alone are indicated by the purple line and levels of tetherin after K5 
expression is represented by the green line. The median fluorescence intensities in the top 
corner of each histogram are representative examples of three independent experiments. B: 
The same analyses were performed on HT1080 cells stably expressing the HA-tagged Vpu-
resistant human tetherin (delGI,T45I) and rhesus tetherin. Labelling is similar to panel A.  
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4.2.3 K5 induces endolysosomal degradation of tetherin 
As Vpu mediates tetherin degradation, we then examined the fate of tetherin after K5 
expression. HT1080/THN-HA cells were transduced to stably express K5 (HT1080/THN-HA K5) 
or Vpu (HT1080/THN-HA Vpu) and intracellular levels of tetherin were compared to levels in 
unmanipulated cells. Tetherin appears in Western blots as a heterogeneous smear of 
glycosylated species that varies between cell types (197, 376). After K5 and Vpu expression, 
tetherin levels in the modified cell lysates were decreased (to 4% of wild-type in the case of K5 
and to 31% of wild-type for Vpu), suggesting that, like Vpu, K5 induces tetherin degradation 
(Figure 4.5). We then addressed the nature of the process by which K5 achieves tetherin 
depletion. For this purpose we examined the role of lysosomal degradation using the vacuolar 
ATPase inhibitor bafilomycin A1 (Baf A1) or by inhibiting proteasomal degradation using 
MG132. We then measured steady state levels of tetherin in K5 expressing cells in parallel with 
Vpu expressing cells to compare the two mechanisms. HT1080/THN-HA, HT1080/THN-HA K5 
and HT1080/THN-HA Vpu were treated with Baf A1 or MG132 for 16 hours. Both Baf A1 and 
MG132 rescued tetherin levels in cells lysates from Vpu and K5 expression. Baf A1 treatment 
rescued not only mature tetherin species, but also lower molecular weight fragments 
presumably corresponding to partially degraded products of tetherin. This result suggests that 
K5 degrades tetherin via an endolysosomal process, similar to that by which it degrades Class I 
MHC. Furthermore, the rescue of tetherin degradation products in HT1080/THN-HA cells that 
do not express K5 or Vpu suggest that tetherin natural turnover involves the endosomal 
pathway. Treatment with bafilomycin A1 was more potent at rescuing tetherin levels than 
MG132. The fraction recovered after MG132 treatment in K5-expressing cells is likely due to 
depletion of free cytoplasmic ubiquitin interfering with the endolysosomal pathway rather than 
inhibition of the proteosome. In K5-expressing cells, MG132 treatment only rescues mature 
forms of tetherin suggesting that K5 mediating tetherin ubiquitination is upstream of lysosomal 
degradation. In contrast, in Vpu-expressing cells, MG132 appears much more efficient to 
restore tetherin levels than Baf A1 and again differential tetherin species were rescued by each 
inhibitor.  
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Figure 4.5: Effects of endosomal and proteasomal inhibitors on K5 inducing tetherin 
degradation.  
Western blots of cell lysates from HT1080/THN-HA cells stably expressing K5 or Vpu from 
retroviral vectors. Cells were treated for 16 hours with Baf A1 (100 nM), MG132 (1mg/ml) or 
DMSO as a control, lysed and separated by SDS-PAGE. THN-HA expression was detected by 
Western blotting using an anti-HA antibody. Percentage of mature tetherin levels, normalized to 
Hsp90 loading are displayed below each lane.  
 
 
 Since K5 induces tetherin downregulation from the cell-surface, we next examined the 
effects of K5 expression on tetherin subcellular localization. HT1080/THN-HA +/- K5 cells were 
immunostained via the HA tag and observed by confocal microscopy (Figure 4.6A). Tetherin 
localizes predominantly to the plasma membrane with a minor fraction of the intracellular 
localization coincident with the late endosome marker CD63. This observation is consistent with 
the notion of natural tetherin turnover in endolysosomal compartments. As expected, K5 
expression results in a loss of tetherin detectable at the cell-surface with the majority of residual 
tetherin relocalized into CD63+ intracellular compartments, implicating K5-induced endosomal 
degradation. This observation correlates with the sensitivity of tetherin degradation to Baf A1. In 
contrast, in Vpu expressing cells, tetherin was never observed in CD63+ endosomes, but 
instead localized predominantly to compartments that stain positive for the trans-golgi network 
marker TGN46 (Figure 4.6B). Of note, similar tetherin relocalization was observed after 
expression of the HIV-2 and SIVtan envelope glycoproteins, two other tetherin antagonists (230, 
231). While Vpu and K5 both induce tetherin to be relocalized in intracellular compartments, the 
trans-Golgi network or late endosomes, the mechanisms by which they achieve tetherin 
degradation imply distinct pathways. Thus, the subcellular localization of tetherin after K5 
expression suggests that K5 causes it to be delivered to late endosomes for degradation. 
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Figure 4.6: Subcellular localization of tetherin in K5 and Vpu-expressing cells.  
A: Representative examples of HT1080/THN-HA, HT1080/THN-HA K5 and HT1080/THN-HA 
Vpu cells immunostained for tetherin with a rabbit anti-HA antibody (red) and an antibody for the 
late endosomal marker CD63 (green). Nuclei were counterstained with DAPI (blue) and cells 
examined by confocal microscopy. B: HT1080/THN-HA Vpu cells stained for THN-HA (green) 
and the trans-Golgi marker TGN46 (red) were processed as above.  
 
 
4.2.4 K5-mediated tetherin degradation and cell-surface depletion requires lysine 18 
The fact that both K3 and K5 target lysine residues in MHC class I molecules cytoplasmic tail 
(241) led us to examine the importance of the two lysine residues, in positions 18 and 21 in the 
cytoplasmic domain of tetherin for K5 mediated antagonism. Lysine 18 and 21 were mutated 
alone or in combination to arginine residues and cloned into a retroviral vector (pLHCX). 
HT1080 stably expressing these tetherin mutants (HT1080/THN-HA K18R; HT1080/THN-HA 
K21R; HT1080/THN-HA K18,21R) were then transduced with a puromycin-selective retroviral 
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vector encoding K5 or Vpu. Resistant cells were selected in order to maintain a steady 
expression level of these viral proteins. HT1080/THN-HA Wt, K18R, K21R or K18,21R cells 
expressing K5 or the corresponding empty vector where seeded at a density of 4x105 and 
harvested one day later in SDS-PAGE loading buffer. Lysates were then blotted against the 
epitope HA for detection of intracellular levels of tetherin (Figure 4.7A). On the Western blot, 
tetherin appears as multiple bands, as described above. As expected, K5 expression reduced 
level of THN-HA Wt by 92%. Similar depletion of THN-HA K21R was detected in K5-expressing 
cells (90%) but levels of THN-HA K18R and THN-HA K18,21R were less affected by K5 
expression with only 41% and 32% of tetherin depletion achieved respectively. In this system, 
the tetherin lysine mutants are expressed at higher levels than the wild-type protein suggesting 
a potential involvement of these residues for the natural tetherin turnover. Whereas in the 
similar system Vpu could cause 74% of tetherin Wt degradation, only 44% and 12% of tetherin 
K18R and K21R degradation respectively, were achieved by Vpu (Figure 4.7B). When both 
















Figure 4.7: Lysine tetherin mutants are differentially affected by K5 and Vpu. 
A: Western blots of cell lysates from HT1080/THN-HA cells and isogenic pools stably 
expressing K5 from retroviral vectors. Cells were seeded at a density of 4x105, lysed 24 hours 
later in reducing loading buffer, separated by SDS-PAGE and subjected to Western blotting. 
THN-HA was detected by anti-HA antibody, with Hsp90 serving as a loading control and 
visualized using Licor fluorescently coupled 680 and 800 nm secondary antibodies. Percentage 
of tetherin degradation in K5 expressing cells was calculated by comparison to tetherin levels 
detected in K5 negative cells and normalized to Hsp90 loading and displayed below each lane. 
B: Same as in A but with HT1080/THN-HA stably expressing Vpu.  
 
 
 Consistent with the notion that K5 targets tetherin for its delivery to late endosomes, tetherin 
K21R but not tetherin mutants K18R and K18,21R resistant to K5-mediated degradation were 
redistributed to CD63+ compartments upon K5 expression (Figure 4.8). Tetherin mutants 
bearing the K18 mutation were found to be predominantly localized at the plasma membrane 
upon K5 expression. 
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Figure 4.8: K18 in the tetherin cytoplasmic tail is required for K5-mediated delivery to late 
endosomes. 
HT1080/THN-HA K18R, HT1080/THN-HA K21R and HT1080/THN-HA K18,21R expressing 
empty vector or K5 were co-stained for THN-HA (red) and CD63 (green). Cells were then 
observed by confocal microscopy. Images show representative examples of the subcellular 
localization of tetherin Wt or the indicated mutant observed in K5-expressing cells. 
 
 
 We then checked whether the inability of K5 to target the lysine 18 in the tetherin 
cytoplasmic tail to induce tetherin degradation was associated with a lack of THN-HA K18R cell-
surface downregulation. HT1080/THN-HA Wt, K18R, K21R or K18,21R cells expressing K5 or 
the corresponding empty vector were stained for cell-surface tetherin via the HA tag and levels 
of tetherin measured by flow cytometry (Figure 4.9). All tetherin mutants were expressed at the 
cell surface, but the lysine mutants were expressed at higher levels than the wild-type protein as 
previously observed from expression in cell lysates. Unlike THN K21R, cell-surface levels of 
THN K18R and THN K18,21R were mostly unaffected by K5 expression. 
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Figure 4.9: K18 in the tetherin cytoplasmic tail is required for K5-mediated cell surface 
downregulation. 
Flow cytometry analyses of HT1080 cells expressing wild type tetherin or the indicated mutant. 
Purple histograms represent THN-HA levels on unmanipulated cells, with the green overlay 
showing tetherin levels in the equivalent cells stably expressing K5. Red histograms represent 
the antibody isotype control. The median fluorescence intensities in the top corner of each 
histogram are representative examples of three independent experiments. 
 
 
4.2.5 Tetherin antagonism by K5 implies tetherin cell-surface downregulation and 
degradation 
We then asked whether in the absence of cell-surface downregulation and degradation, K5 
could still antagonize tetherin. HT1080/THN-HA Wt, K18R, K21R or K18,21R cells expressing 
K5, Vpu or the empty vector were infected with VSV-G pseudotyped HIV-1 wild-type or HIV-1 
delVpu at a multiplicity of infection of 0.2. Two days later, cells were harvested and the 
infectivity of the supernatants determined on HeLa-TZM cells (Figure 4.10A). As expected, both 
K5 and Vpu expression rescue HIV-1 delVpu particle release from wild-type tetherin expressing 
cells. But in the context of K18R mutation alone or in combination with K21, K5 but not Vpu 
failed to rescue wild-type virus production. HT1080/THN-HA K21R also restricted HIV-1 delVpu 
virus production similarly to the wild-type protein and expression of K5 or Vpu in trans could 
restore virus release. These data suggest again that the determinants that confer sensitivity to 
Vpu or K5 are governed by different residues in the tetherin sequence. To further investigate the 
implication of the lysine residues in Vpu sensitivity for tetherin targeting, 293T cells were 
transiently transfected with HIV-1 Wt or HIV-1 delVpu proviruses in the presence of increasing 
doses of tetherin wild-type (THN-Wt), THN K18R, THN K21R or THN K18,21R. Two days post-
transfection, viral supernatants were assayed for infectivity and cells lysates and pelleted virions 
analysed by Western blot for HIV-1 p24-CA and THN-HA expression (Figure 4.10B-C). As 
expected, in the presence of tetherin wild-type, HIV-1 delVpu particle release is strongly 
decreased. At high doses of tetherin wild-type, particle release of HIV-1 Wt tends toward levels 
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of HIV-1 delVpu virus production, presumably because of tetherin over-expression conditions 
saturating the ability of Vpu to overcome the cellular factor. Importantly, mutations on K18 and 
K21 residues, alone or combined, do not alter tetherin sensitivity to Vpu since the fold-ratio viral 
particle release between HIV-1 Wt and HIV-1 delVpu is similar to tetherin Wt for all tetherin 
mutants tested. These observations were confirmed by quantitative Western blot of pelleted 
virions released. Together these data suggest that K5 targets the lysine K18 but not K21 in the 
tetherin cytoplasmic tail to inactivate tetherin, but in the case of Vpu, those residues are 
dispensable to mediate tetherin antagonism. Similarly, Goffinet et al. also showed that steady-
state levels of THN K18,21A were completely refractory to Vpu-induced depletion, despite 
efficient Vpu-mediated release enhancement (392). Thus, K5-mediated disruption of tetherin 
function requires the ability to target the lysine K18 in the tetherin cytoplasmic tail for 




































Figure 4.10: K18 is required for tetherin antagonism by K5 but both cytoplasmic tail 
lysines are dispensable for Vpu-mediated antagonism. 
A: HT1080/THN-HA Wt, HT1080/THN-HA K18R, HT1080/THN-HA K21R, HT1080/THN-HA 
K18,21R or derivatives stably expressing K5 or Vpu were infected with wild type HIV-1 or HIV-1 
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delVpu VSV-G pseudotypes at an MOI of 0.2. 48 hours after infection, cell supernatants were 
harvested and the released infectivity determined on HeLa-TZM cells. Results are the mean of 
3 independent experiments and errors are standard error of the mean. B and C: The effect of 
tetherin lysine mutants on HIV-1 release in 293T cells. Cells were transiently transfected with 
wild type HIV-1 or HIV-1 delVpu proviruses with increasing doses of the indicated THN-HA 
mutant. 48 hours after transfection, viral supernatants were assayed for infectivity on HeLa-TZM 
cells (B) and cell lysates and pelleted virions analyzed by Western blot for HIV-1 p24 CA and 
THN-HA expression (C). 
	  
	  
 As shown above, the determinants required for K5 and Vpu-mediated tetherin degradation 
are distinct, with K18 and K21 being preferentially targeted by K5 and Vpu respectively. While 
for K5 the residues involved for tetherin antagonism correlate with those required for 
degradation, for Vpu these two processes might not be as strictly linked. This observation can 
be exemplified by the ability of the Vpu S52,56A mutant to counteract tetherin's function while 
being ineffective at mediating tetherin degradation. Vpu S52,56A was initially described as 
inefficient at recruiting the β-TrCP, a substrate adaptor for an SCF (Skp Cullin- F-box) E3 
ubiquitin ligase complex, to mediate CD4 degradation (cf. Chapter 1). Studies showed the 
requirement of β-TrCP1/2 for optimal downregulation and degradation of tetherin. Indeed, 
expression of dominant negative β-TrCP, or suppression of endogenous β-TrCP by RNA 
interference results in a significant decrease in tetherin degradation and downregulation. We 
tested the defect of Vpu S52,56A in mediating tetherin degradation by infecting HT1080/THN-
HA and 293T/THN-HA with VSV-G pseudotyped HIV-1 Wt, HIV-1 delVpu or HIV-1 Vpu S52,56A 
at a MOI of 2. 48 hours later, cells were lysed and samples Western blotted with anti-HA for 
detection of THN-HA expression levels (Figure 4.11A). While both HT1080/THN-HA and 
293T/THN-HA infected with HIV-1 Wt displayed a decrease of THN-HA expression in cell 
lysates, cells infected with HIV-1 Vpu S52,56A showed similar levels of tetherin expression as 
those infected with HIV-1 delVpu virus. Similarly, stable expression of Vpu S52,56A in 
HT1080/THN-HA did not impact upon intracellular level of THN-HA (Figure 4.11B). Together 
these data show that Vpu S52,56A fails to induce tetherin degradation. 
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Figure 4.11: Vpu S52,56A fails to degrade tetherin. 
A: HT1080 and 293T stably expressing THN-HA were infected with HIV-1 Wt, HIV-1 delVpu or 
HIV-1 Vpu S52,56A pseudotyped with VSV-G at an MOI of 2. 48 hours later, cell lysates were 
harvested and analysed on SDS-PAGE and THN-HA was detected using an anti-HA antibody. 
B: HT1080/THN-HA stably expressing Vpu Wt or Vpu S52,56A were Western-blotted for 
tetherin detection via the HA tag.  
 
 
 We then examined the anti-tetherin function of Vpu S52,56A in the absence of  tetherin 
degradation. 293T cells were transfected with HIV-1 NL4.3 Wt, HIV-1 NL4.3 delVpu or HIV-1 
NL4.3 Vpu S52,56A proviruses in the presence of increasing doses of a human tetherin 
expression vector. At 48 hours post-transfection, virus production was assessed by measuring 
infectivity of viral supernatants on HeLa-TZMbl sensitive cells (Figure 4.12A-top). As expected, 
production of HIV-1 delVpu virus was reduced in the presence of tetherin in a dose-dependent 
manner compared to HIV-1 Wt.  HIV-1 Vpu S52,56A virus particle release showed an 
intermediate phenotype but retained significant activity to antagonize tetherin. This partial 
activity of Vpu S52,56A mutant was not due to a lack of expression as indicated by the 
expression levels on Western blot (Figure 4.12A-bottom). Virus particle release was similarly 
affected in HT1080/THN-HA cells infected with HIV-1 Vpu S52,56A (Figure 4.12B). 
 We then tested whether Vpu S52,56A displayed similar activity against endogenous levels of 
tetherin. HeLa cells were infected with VSV-G pseudotyped HIV-1 Wt, HIV-1 delVpu or HIV-1 
Vpu S52,56A at a MOI of 0.2. After two days in culture, viral supernatants were harvested and 
virus production quantified as before (Figure 4.12C). We found that virus particle release of HIV-
1 Vpu S52,56A was only approximately two fold lower than HIV-1 Wt and significantly higher 
than release of the Vpu-defective virus. These data suggest that Vpu S52,56A is more sensitive 
to higher expression levels of tetherin. In HeLa cells, in which the expression level of 
endogenous tetherin is lower than in 293T transiently-transfected or in HT1080/THN-HA, Vpu 
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S52,56A antagonizes tetherin almost as efficiently as the wild-type Vpu suggesting that 
degradation is more important in cells expressing high tetherin levels. Altogether, these data 
show that Vpu S52,56A does not induce tetherin degradation, but retains partial function to 
antagonize tetherin in a tetherin-dose dependent manner. Thus, Vpu can antagonize virion 
tethering in the absence of tetherin degradation. In contrast to K5, Vpu's ability to degrade 
tetherin does not entirely account for the full disruption of tetherin antiviral function and might be 



























Figure 4.12: Vpu S52,56A fails to degrade tetherin but retains antagonism.  
A: 293T cells were co-transfected with HIV-1 Wt, HIV-1 Vpu S52,56A or HIV-1 delVpu proviral 
plasmids in combination with an increasing amount of tetherin. 48 hours post-transfection, 
pelleted supernatants were used to infect HeLa-TZM indicator cells and infectious viral release 
determined by relative β-galactosidase activity. Western blot of 293T transfected by proviral 
plasmids NL4.3 HIV-1 Vpu or HIV-1 Vpu2/6. Vpu was detected using anti-Vpu antibody (rabbit 
polyclonal). B: HT1080/THN-HA cells were infected with HIV-1 Wt, HIV-1 delVpu or HIV- 1 Vpu 
S52,56A pseudotyped with VSV-G at an MOI of 0.2. 48 hours post-infection, viral release was 
determined as above. C: Same as B but with HeLa cells.  
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4.2.6 K5-mediated tetherin delivery to late endosomes is ubiquitin-dependent 
Several lines of evidence suggest that K5 mediates ubiquitination of tetherin to deliver it to late 
endosomes. Firstly, the catalytic RING domain is required for removal of tetherin from the cell-
surface. Secondly, lysine residues, which often serve as ubiquitin-acceptors, on tetherin 
cytoplasmic tail are required for K5-mediated tetherin counteraction. Finally, K5 mediated-
tetherin degradation is sensitive to MG132 treatment, which is known to reduce the intracellular 
ubiquitin pool availability after prolonged exposure. We therefore examined the effects of 
proteasomal and endosomal inhibitors on cell-surface tetherin levels in K5 expressing cells. 
HT1080/THN-HA cells expressing either K5 or Vpu were stained for HA and levels of cell-
surface tetherin measured by flow cytometry after a 16 hours treatment with the indicated drug 
(Figure 4.13A). Interestingly, although endosomal inhibition with Baf A1 treatment rescued 
tetherin proteins in the cell extracts of K5 expressing cells neither Baf A1 or Concanamycin A 
could rescue tetherin levels at the cell surface. However, with MG132 a consistent fraction of 
tetherin was rescued at the cell surface (Figure 4.13A-B). Presumably, ubiquitination of tetherin 
(reduced by prolonged MG132 treatment) results in its removal from the cell surface followed by 
endosomal sorting. Inhibition of endosome acidification induces tetherin to accumulate in 
intermediate endosomal compartments without being degraded. In contrast, none of the 
inhibitors significantly rescued tetherin surface expression in Vpu-expressing cells indicating 
again the divergence between K5 and Vpu mediating tetherin degradation. These observations 
coupled with the previous data demonstrate that K5 induces an ubiquitin-dependent 
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Figure 4.13: Effects of proteasomal and endosomal inhibitors on cell-surface tetherin 
levels in cells expressing K5 or Vpu. 
A: HT1080/THN-HA, HT1080/THN-HA K5 and HT1080/THN-HA Vpu were surface stained for 
tetherin levels and analyzed by flow cytometry. Purple histograms represent tetherin levels on 
DMSO treated cells. Green overlays indicate tetherin levels after treatment with the indicated 
drug. The pink histogram overlays show the levels of tetherin on untreated HT1080/THN-HA 
from the upper row for comparison. The median fluorescence intensities in the top corner of 
each histogram are representative examples of three independent experiments. B: Confocal 
image of a representative HT1080/THN-HA K5 cell treated with MG132 and stained for THN-HA 
(red) and CD63 (green).  
 
 
4.2.7 Ubiquitination of tetherin cytoplasmic tail lysine residues by K5 
As lysine residues serve as targets for ubiquitination and the K18 mutant is resistant to K5-
mediated tetherin downregulation and delivery to late endosomes, we next asked whether K5 
could induce tetherin ubiquitination on its cytoplasmic lysine residues. HeLa cells were 
transiently transfected with a THN-HA Wt or THN-HA K18,21R expression vector in combination 
with a ubiquitin bearing a six-histidine tag (Figure 4.14). Cells were incubated for 48 hours and 
for the last 8 hours before harvest, cells were treated with Baf A1 to block tetherin degradation. 
Subsequently, ubiquitinated proteins were isolated by incubating whole cell lysates with nickel-
agarose beads. Cell lysates and pull-downs were analysed by Western blot for THN-HA 
detection. In the presence of either co-transfected K5 or Vpu, THN-HA molecules could be 
isolated from the transfected cells. The ubiquitinated tetherin predominantly formed a single 
species at a size suggestive of mono-ubiquitination. Comparatively, K5 mediates 
polyubiquitination of MHC class I molecules via mixed Lys-63 and Lys-11 linkages on a single 
lysine acceptor residue (241). Interestingly, no ubiquitinated tetherin molecules were 
precipitated when their cytoplasmic lysine residues had been mutated, after either K5 or Vpu 
transfection. This implies the direct role of K5 and Vpu in mediating ubiquitination of the tetherin 
cytoplasmic tail. In the case of K5, this suggests that ubiquitination of K18 antagonizes tetherin-
mediated restriction and directs it to endosomal compartments for lysosomal degradation. In 
contrast, the action of Vpu also leads to lysine ubiquitination but this process seems to be 
dispensable to antagonize tetherin’s function suggesting that Vpu mediating tetherin 
antagonism and ubiquitin-dependent degradation are two separable events.  
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Figure 4.14: Tetherin cytoplasmic tail lysine residues are ubiquitinated in the presence of 
K5 and Vpu. 
HeLa cells were transiently transfected with the indicated THN-HA expression vector in 
combination with K5, Vpu or GFP and in the presence or absence of 6His-tagged ubiquitin. 40 
hours after transfection, cells were treated for 8 hours with Baf A1 (100 nM) to prevent tetherin 
degradation. Cell lysates were then harvested and ubiquitinated proteins were isolated by 
binding to Ni-Nti-agarose. Cell lysates and pull-downs were analyzed by Western blot for THN-
HA using the HA antibody. 
 
 
4.2.8 Tetherin's dual tyrosine-based endocytic motif is dispensable for K5 activity 
Tetherin bears in its cytoplasmic tail a dual-tyrosine based endocytic motif, YxY. This motif 
binds to the clathrin adaptors AP1 and AP2 and has been reported to be important for tetherin 
endocytosis and recycling (cf. Chapter 1) (207). To test whether K5-mediated tetherin 
degradation required this endocytic motif, the two tyrosine residues in the cytoplasmic tail of 
tetherin (positions 6 and 8) were mutated into alanine. Corresponding HT1080 stably 
expressing those tyrosine mutants were generated (HT1080/THN-HA Y6,8A) and analysed by 
immunofluorescence microscopy for tetherin cellular localization (Figure 4.15A). As expected, 
this mutant tetherin was found almost exclusively at the plasma membrane. K5 expression was 
then introduced in these cells and tetherin levels analysed by flow cytometry and Western blot 
(Figure 4.15B-C). Expression of K5 leads to tetherin downregulation from the cell surface and 
degradation in cell lysates. Thus, tetherin trafficking rerouted by K5 to late endosomes is 
independent of its endocytic motif, implying that K5 overrides the normal trafficking machinery to 
modify the cellular fate of tetherin.  
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Figure 4.15: K5 mediated tetherin downregulation does not rely on the endocytic-based 
motif in tetherin cytoplasmic tail. 
A: HT1080/THN-HA Y6,8A were imaged by confocal microscopy for tetherin (red). The cells 
were then manipulated to express K5 and analyzed by flow cytometry for surface tetherin (B) 
and by Western blot for total cellular tetherin levels (C).  
 
 
4.2.9 K5 mediating tetherin cell-surface downregulation involves the ESCRT pathway  
Components of the endosomal-sorting complex for transport (ESCRT) machinery are required 
for K3 targeting MHC class I molecules (416). Specifically, depletion of the ESCRT component 
Tsg101 leads to the recycling of MHC Class I molecules back to the cell surface in K3 positive 
cells because they can no longer be directed to MVBs. To examine the role of the ESCRT 
pathway in K5-mediated tetherin degradation, we tested whether downregulation of tetherin 
from the cell surface was affected by expression of a dominant negative form of VPS4 
(dnVPS4). VPS4 is the essential AAA-ATPase that provides the energy for ESCRT disassembly 
and recycling during the final membrane scission event in the sorting of cell surface receptors 
for endosomal degradation. HeLa cells were co-transfected with a GFP-catalytically inactive 
form of VPS4 (E228Q) and a K5 or K5delRING expression vectors. Two days post-transfection, 
endogenous cell-surface tetherin levels in GFP positive cells were analysed by flow cytometry 
(Figure 4.16). Interestingly, the dominant negative form of VPS4 (dnVPS4) could restore cell-
surface tetherin from K5 expression. Co-expression of K5delRING and dnVPS4 had no effect 
on tetherin cell surface levels. These results suggest that components of the ESCRT machinery 
are required for efficient tetherin downregulation from the cell surface. K5 induces a VPS4 
dependent trafficking of tetherin to MVBs (late endosomes) for destruction. This mechanism is 
similar to that used by K3 to downregulate MHC class I molecules. 
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Figure 4.16: Cell-surface downregulation of tetherin by K5 is inhibited by dominant-
negative VPS4.  
A: HeLa cells were transfected with wild type K5 or K5(del RING) expression vectors in 
combination with either GFP or a dominant negative mutant of VPS4 fused to GFP (VPS4 
E228Q). 24 hours later, cells were stained for cell surface tetherin using anti-BST2 monoclonal 
antibody and a goat-anti-mouse Alexa633 secondary antibody. Flow cytometry dot plots are 
shown. B: The mean florescent intensities (MFI) of surface tetherin expression in GFP positive 
and GFP negative populations from the samples in panel A are plotted. 
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4.3 Discussion 
In this study we examined the molecular mechanism employed by K5 to overcome tetherin-
mediated KSHV restriction. We found that by inducing tetherin ubiquitination, K5 triggers its 
removal from the cell surface and delivers it to late endosomes for destruction and this is 
sufficient to fully disrupt tetherin antiviral function. This mechanism is similar to that used by K5 
to internalize MHC class I molecules from the cell surface for rapid degradation (241). 
 K5-mediated tetherin degradation is sensitive to endosomal inhibitors, and overnight MG132 
treatment can rescue tetherin levels at the cell surface. For most of its substrates identified so 
far, K5 induces endolysosomal degradation with the exception of the target PECAM that is 
degraded via the ERAD pathway. In this study we identified a key residue in the cytoplasmic tail 
of tetherin required for K5 to antagonize tetherin‘s antiviral activity. Mutation of lysine 18 impairs 
the ability of K5 to induce tetherin ubiquitination and subsequent endosomal sorting for final 
destruction in lysosomes. It is surprising that K5 can target this membrane-proximal lysine (K18) 
which is so close to the membrane that the positively charged residue might be predicted to be 
embedded within the phospholipid bilayer so as not to be available for ubiquitination. However, 
one idea is that the proximity of K5, itself a membrane protein, may help expose the acceptor 
lysine for targeting. Interestingly, studies about ubiquitin-acceptor sites revealed that K5 not only 
prefers membrane proximal targets, as opposed to the more distal targets favoured by K3, but 
that the juxtamembrane cytoplasmic portions of K5 themselves contribute to this target 
preference (418). 
 KSHV encodes a E3 ubiquitin ligase to manipulate the ubiquitin pathway to further its own 
replication (419). Exploiting the ubiquitin pathway provides KSHV with a powerful mechanism 
for disposing of inhibitory elements of the immune system such as restriction factors. Moreover, 
ubiquitination is a dynamic process and enables KSHV to react rapidly to a hostile environment. 
Ubiquitination of tetherin by K5 may occur at the plasma membrane triggering its internalization, 
as K5 and K3 do with MHC class I molecules, but no evidence has been established to rule out 
a potential ubiquitination of tetherin molecules en route to the plasma membrane. Since K5 
localizes predominantly to the endoplasmic reticulum at steady state (414, 417), it cannot be 
excluded that K5 might ubiquitin-tag tetherin early in the synthesis process, in the ER, for a 
degradation process initiated later in the secretory pathway. Comparatively, in the case of MHC 
class I, K3 and K5 can only ubiquitinate an EndoH resistant form of class I, suggesting targeting 
of MHC molecules in the late secretory pathway (post-ER). Alternatively, K5 might also traffic 
transiently to the TGN or the plasma membrane, or even act as a cargo loaded with its 
substrates until they reach the appropriate cellular compartment. This last scenario implies a 
retrieval signal in K5 sequence that would force the ubiquitin ligase to come back to the ER. 
More studies will need to be done to determine whether K5 stimulates tetherin internalization at 
the plasma membrane or reroutes tetherin to endosomes from the Golgi bypassing the cell 
surface.  
 We found that the RING domain was essential for K5 mediating tetherin antagonism since a 
RING deleted K5 protein lacked the ability to rescue HIV-1 delVpu particle release and was 
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defective for tetherin cell-surface downregulation. K5 is less effective at downregulating MHC 
class I molecules than K3, but has a broader substrate specificity. So far, this specificity has 
been mapped to the transmembrane regions but the determinants in the K5 sequence required 
for interaction with tetherin have yet to be determined. Without ruling out a direct interaction with 
tetherin, K5 could bind an adaptor protein, which would provide a platform for ubiquitination of 
several target proteins.  
 In this study we also demonstrated the importance of having an intact ESCRT pathway in 
K5-mediated cell-surface tetherin disposal. Indeed, compromising MVB formation using 
dnVPS4 resulted in a rescue of tetherin levels at the cell surface in K5 expressing cells. We also 
showed that K5 could fully substitute for Vpu in mediating the efficient release of HIV-1 particles 
from tetherin-expressing cells.  
 This study also showed the differences between the mechanisms by which K5 and Vpu 
disrupt tetherin's antiviral function. Both K5 and Vpu reduce tetherin expression from the cell 
surface and induce its degradation. In the case of K5, ubiquitination of tetherin triggers its 
delivery to late endosomes for destruction, and that is sufficient to overcome tetherin function 
and allow efficient virus particle release. For this reason, the molecular determinants required 
for K5 mediated-tetherin antagonism correlate with those involved in mediating tetherin 
ubiquitination and associated degradation or cell-surface downregulation. However, when 
tetherin degradation is prevented, either by mutating its cytoplasmic lysine residues or by 
mutating the phosphorylation site DSGNES, Vpu's ability to counteract tetherin is not completely 
abrogated. In line with this observation, Tokarev et al., subsequently showed that Vpu-
stimulated tetherin ubiquitination could be abolished when all potential ubiquitination sites in the 
cytoplasmic domain, including lysines, cysteines, serines and threonines were mutated (393). 
Only a serine-threonine-serine (STS) sequence was shown to be specifically important for cell-
surface tetherin downregulation and optimal relief of restricted virion release. These data 
suggest that degradation by itself does not account for the full anti-tetherin activity of Vpu. Since 
this study was published, several pieces of evidence showed that Vpu mediated tetherin 
degradation and antagonism were two separable events. This was best evidenced by silencing 
expression of an ESCRT-I component, UBAP1, required for tetherin depletion induced by Vpu 
but not for counteracting the antiviral activity (390). By re-routing the cellular trafficking of 
tetherin, Vpu prevents it from being expressed at the site of virus assembly. This is sufficient to 
overcome the antiviral activity and does not necessarily require the physical removal of tetherin 
(cf. Chapter 8). 
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Chapter 5                                                                          
Determinants of Tetherin antagonism in the transmembrane 
domain of HIV-1 Vpu 
 
The study presented in this chapter was published as '' Determinants of tetherin antagonism in 
the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein '' (221). 
 
5.1 Introduction 
As discussed in the introduction, despite encoding Vpu, SIVcpz and SIVgor viruses rely on their 
Nef protein to counteract chimpanzee and gorilla tetherins while their Vpus are limited to CD4 
degradation (226). However, in humans the situation is reversed with HIV-1 Vpu being a potent 
tetherin antagonist whereas Nef-targeting of tetherin was lost during primate evolution because 
of a deletion of five amino acids in tetherin cytoplasmic tail (225, 227). Selective pressure on 
SIVcpz resulted in the adaptation of Vpu to target the tetherin transmembrane domain and this 
was presumably an essential requirement for the virus zoonosis into the human host. Exchange 
of SIVcpz Vpu TM domain with those from HIV-1 Vpu can confer to SIVcpz Vpu antagonism 
against human tetherin (420), suggesting that the HIV-1 Vpu TM domain was the result of 
SIVcpz Vpu TM domain adaptation to human tetherin. For this reason, HIV-1 Vpu can only 
antagonize variants of tetherins from humans and chimpanzees but not those from old world 
monkeys. This situation can be reversed by reciprocal exchange of the transmembrane 
domains between human and monkey tetherins underscoring, once again, that the tetherin 
transmembrane domain was the region targeted by HIV-1 Vpu (224). Computational analysis of 
the tetherin TM domain predicted that some residues had been under positive selection. In line 
with the notion of co-evolution between host and pathogens, when those residues were 
replaced by their monkey homologues they could confer resistance to human tetherin against 
HIV-1 Vpu.  
 HIV-1 Vpu mediates interactions with tetherin through its transmembrane domain and this is 
a prerequisite to overcome tetherin's antiviral function (218, 377). Deletion of parts of the Vpu 
TM domain, scrambling or multiple amino acid replacements block Vpu-enhanced virus release 
(362, 384, 385). However, the determinants in the Vpu TM domain required for the interaction 
with tetherin have not been fully identified. In this study, we carried out mutagenesis of the HIV-
1 NL4.3 Vpu TM domain to show that a conserved face of the HIV-1 group M Vpu 
transmembrane helix is required for tetherin interaction and antagonism.  
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5.2 Results 
5.2.1 Screening of Vpu transmembrane domain for tetherin antagonism 
To better characterize the determinants of tetherin antagonism in the Vpu TM domain, we 
conducted scanning mutagenesis through this region (residues 5 to 28) of a codon-optimized 
HIV-1 NL4.3 Vpu bearing a C-terminal HA tag (Figure 5.1A). All non-alanine residues were 
mutated individually to alanines, while bulkier hydrophobic leucine residues replaced those that 
were alanines. These Vpu TM mutants were then screened for their ability to rescue Vpu-
defective HIV-1 from tetherin-mediated restriction. Human 293T cells, which lack endogenous 
tetherin expression, were transfected with HIV-1 NL4.3 delVpu proviruses in the presence of a 
fixed dose (50 ng) of a human tetherin expression vector and either a plasmid encoding HA-
tagged wild-type (Wt) Vpu or the TM domain mutants. At 48 hours post-transfection, cell lysates 
and viral supernatants were harvested and analyzed by Western blotting or titrated on HeLa-
TZM indicator cells (Figure 5.1B). As expected, in the presence of human tetherin, the release 
of infectious HIV-1 delVpu was reduced approximately 50-fold, as determined by the infectivity 
of harvested supernatants on HeLa-TZM indicator cells, and expression of wild-type Vpu in 
trans rescued the majority of this defect. Two mutants, the A14L and W22A mutants, were 
markedly defective in viral rescue compared to the control, with a third, the A18L mutant, 
displaying a minor defect. Interestingly, mutation of S23, which has been shown previously to 
completely abolish the ion channel activity of Vpu (421), or V13, I17, and V21, which would line 
the pore of a putative channel (329), conferred no defect in tetherin antagonism, suggesting that 




















Figure 5.1: Scanning mutagenesis of the HIV-1 NL4.3 Vpu TM domain and tetherin 
antagonism. 
A: A schematic representation of point mutations made in the TM domain of a codon-optimized 
HIV-1 NL4.3 Vpu protein. B: 293T cells were transiently transfected with 500 ng of HIV-1 
delVpu provirus, 50 ng of tetherin plasmid, and 25 ng of the indicated Vpu expression vector. 48 
hours after transfection, the resulting viral supernatants were assayed for infectivity on HeLa-
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TZM indicator cells by measuring β-galactosidase activity (top). Error bars are +/- standard error 
of the mean (SEM) for three independent experiments. 293T cell lysates from one replicate of 
the assay were subjected to SDS-PAGE, blotted for Vpu-HA, with the 90-kDa heat shock 
protein (Hsp90) serving as a loading control (bottom), and analyzed by a LiCor quantitative 
imager. Numbers below the lanes indicate the percentages of relative Vpu expression 
compared to that of the wild-type protein. 
 
 
 To characterize the functional mutants further, the A14L, A18L, and W22A mutants or two 
combined mutants, the A14L/W22A and A10L/A14L/A18L/W22A mutants, were re-screened 
against a fixed dose of tetherin, but with varying levels of Vpu expression, and virus release 
characterized by both infectious titer release and physical particle yield by quantitative Western 
blotting (Figure 5.2A-B). Despite equivalent expression levels of Vpu and HIV-1 Gag in producer 
cells, neither the A14L mutant nor the W22A mutant could fully rescue HIV-1 delVpu from 
tetherin, and both remained defective compared to the wild-type Vpu, even at the highest 
inputs. The A18L mutant was the least defective and regained most of its function at higher 
plasmid concentrations. Combining the A14L and W22A mutants into a single mutant, either in 
the context of the A14L/W22A or A10L/A14L/A18L/W22A mutant, rendered Vpu effectively 



















Figure 5.2: Vpu A14L and W22A are defective for tetherin antagonism. 
A: 293T cells transfected with 500 ng of HIV-1 Wt or HIV-1 delVpu and 50 ng of tetherin 
expression vectors with increasing doses of the indicated Vpu-HA mutant. The resulting 
infectivity was determined as described before, and error bars represent +/- SEM for three 
independent experiments. B: Cell lysates and pelleted virions from one replicate of that shown 
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in panel A were subjected to SDS-PAGE and LiCor Western blotting was performed for HIV-1 
p24-CA, Vpu-HA, and Hsp90 (top). The histogram (bottom) indicates supernatant virion yield 
(p24 band intensity) relative to the release of HIV-1 Wt in the absence of tetherin.  
 
 
 Finally, we engineered A14L and W22A mutants back into the HIV-1 NL4.3 genome to place 
them under wild-type viral Vpu expression conditions and tested virus release from 293T cells 
transfected with tetherin (Figure 5.3A-B). Consistent with expression of the mutants in trans, we 
found that the mutant carrying A14L alone and the combined mutant had a defect in release 
equivalent to a full Vpu deletion, whereas W22A retained a low level of tetherin antagonism. 
Thus, positions A14, W22, and, to a lesser extent, A18, appear to be key residues required for 




















Figure 5.3: The effect of A14 and W22 mutations in the context of full-length proviral 
clones. 
HIV-1 Wt, HIV-1 delVpu, HIV-1 Vpu A14L, HIV-1 Vpu W22A, and HIV-1 Vpu A14L-W22A 
proviral clones were transfected into 293T cells in the presence or absence of 50 ng of tetherin 
expression vector. Forty-eight hours later, the supernatants were assayed for infectivity on 
HeLa-TZM cells (A) and pelleted virions (B), and cell lysates were processed for Western 
blotting as described in the legend to Figure 5.2. Error bars are +/- standard error of the mean 
(SEM) for three independent experiments.  
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5.2.2 Mutants A14L and W22A fail to downregulate tetherin from the cell surface 
To further characterize the nature of the defect in the Vpu TM mutants, we first determined their 
effects on cell surface tetherin levels. Vpu expression leads to a downregulation of cell surface 
tetherin and subsequently a degradation step which itself is dispensable for Vpu activity under 
certain circumstances (187, 376, 387). Tetherin-positive HeLa cells were co-transfected with an 
empty vector control or Vpu expression vector in combination with a GFP marker plasmid. At 48 
hours post-transfection, the cells were harvested, stained for cell surface tetherin using a 
specific monoclonal antibody, and analyzed by flow cytometry (Figure 5.4). Tetherin was 
downregulated from the cell surface of GFP+ cells expressing Vpu, and as expected, this 
downregulation was reduced in the presence of the Vpu S52,56A mutant that does not interact 
with β-TRCP1/2 (187, 220, 387). Both the A14L and W22A mutants failed to fully downregulate 
tetherin, and either multiple mutant containing both A14L and W22A mutations was completely 





















Figure 5.4: Effects of Vpu TM mutations on cell surface levels of tetherin in HeLa cells. 
HeLa cells were transfected with a wild-type Vpu (Vpu Wt)-encoding vector or the indicated 
mutant and a GFP-expressing construct. Cell surface staining for endogenous tetherin was 
analyzed by flow cytometry 48 hours later. Histograms show the tetherin levels on GFP+ cells in 
empty vector control cells (black) or in Vpu mutant-expressing cells (gray) and are 
representative examples of three independent experiments. The median fluorescence 
intensities are indicated in the top corner of each histogram. The solid peak histogram 
represents the binding of the isotype control. 
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 To confirm this with a more physiologically relevant infected cell type, CD4+ Jurkat T cells 
were infected with VSV-G-pseudotyped wild-type HIV-1, HIV-1 delVpu, HIV-1 Vpu S52,56A, 
HIV-1 Vpu A14L, HIV-1 Vpu W22A, or HIV-1 A14L/W22A, and 48 hours later, cells were stained 
for surface tetherin and intracellular Gag (p24-CA) (Figure 5.5). As expected, Gag-positive cells 
in cultures infected with wild-type HIV-1, but not with HIV-1 delVpu or HIV-1 Vpu S52,56A, 
showed loss of tetherin expression at the cell surface. However, in line with our findings for 
transfected cells, Jurkat cells infected with viruses bearing an A14L mutation showed little cell 
surface tetherin reduction. The W22A mutant retained a residual ability to downregulate cell 
surface tetherin, again consistent with our previous observations. Thus, Vpu TM mutants that 
cannot antagonize tetherin function are concomitantly defective for cell surface tetherin 

























Figure 5.5: Effects of Vpu TM mutations on cell surface levels of tetherin in CD4+ Jurkat T 
cells. 
Jurkat cells were infected with the indicated VSV-G-pseudotyped viral stocks at an MOI of 0.2. 
Forty-eight hours later, cells were stained for surface tetherin expression and intracellular Gag 
and analyzed by flow cytometry. Gag-positive infected cells were gated (black square), and 
surface tetherin levels were compared. Numbers indicate median fluorescence intensities of 
surface tetherin on the infected cells. 
 
 
 We also tested our Vpu mutants for their ability to downregulate CD4. Although CD4 and 
Vpu have been shown to interact through cytoplasmic tail interactions, a role for the TM domain 
has been implicated by some (385), but not others (362). HeLa/CD4 cells were transfected as 
described above, and cell surface CD4 levels were measured 48 hours later (Figure 5.6). As 
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expected, Vpu expression led to a reduction in surface CD4 that again was blocked in the 
presence of an S52,56A mutant. Vpu A14L retained the ability to downregulate CD4, indicating 
that this mutant is specifically defective for tetherin antagonism. In contrast, and consistent with 
the work of Tiganos et al. (385), the Vpu W22A mutant and multiple mutants bearing this lesion 
were also defective for CD4 downregulation. This was further confirmed by work from 
Bonifacino's group showing that mutation of W22 did not prevent interaction of Vpu with CD4 
but enhanced the oligomerization state of Vpu and reduced CD4 polyubiquitination leading to 
accumulation of CD4 molecules in the ER membrane (374). These retained CD4 molecules 
were found to be unable to be dislocated from the ER to the cytosol for degradation via the 
proteosome. Thus, both tetherin and CD4 downmodulation require residues in the Vpu TM, but 




























Figure 5.6: W22 but not A14 is required for Vpu-mediated CD4 downregulation. 
HeLa/CD4 cells were transfected with a wild-type Vpu (Vpu Wt)-encoding vector or the 
indicated mutant and a GFP-expressing construct. Cell surface staining for endogenous CD4 
was analyzed by flow cytometry 48 hours later. Histograms show the CD4 levels on GFP+ cells 
in empty vector control cells (black) or in Vpu mutant-expressing cells (gray). The median 
fluorescence intensities indicated in the top corner of each histogram are representative 
examples of three independent experiments. The solid peak histogram represents the binding of 
the isotype control. 
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5.2.3 Defective Vpu TM mutants localize to the TGN 
While CD4 degradation occurs in the endoplasmic reticulum (ER), Vpu-mediated virus release 
is sensitive to brefeldin A (365), suggesting that tetherin antagonism takes place outside the 
ER. Vpu localizes to the TGN and endosomal compartments, and the ability to localize to the 
TGN has been shown to be important for tetherin antagonism (341). Indeed, mutations in the 
hinge region (R30A, K31A) (341) or in the second alpha helix (motif EXXXLV) (383) cytoplasmic 
tail of Vpu that impair its TGN localization are associated with reduced virus release. It has been 
proposed that the TGN was the cellular compartment from where Vpu/tetherin complexes were 
committed to the endosomal pathway for degradation. Vpu localization to the TGN allows it to 
access both to pre-existing tetherin recycling via the TGN and to newly synthesized tetherin 
trafficking through the Golgi en route from the ER to the cell-surface. Since the TM domain(s) of 
integral membrane proteins may be involved in subcellular localization (422), we next sought to 
rule out whether our Vpu TM mutants were aberrantly localized. HeLa cells transfected with 
Vpu-HA or TM mutants were grown on coverslips, fixed 24 hours later, immunostained for Vpu 
(anti-HA) and the TGN marker TGN46, and examined by confocal microscopy (Figure 5.7). As 
expected, wild-type Vpu-HA localizes predominantly to perinuclear and punctate structures, with 
much of the perinuclear signal overlapping with the TGN, consistent with previous studies. We 
found that all of our Vpu TM mutants localized similarly, with TGN accumulation visible in all 
cases. These data suggest that Vpu localization to the TGN is independent of the ability to 
counteract tetherin.  
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Vpu-A14L                TGN46                     overlay             
Vpu-W22A               TGN46                      overlay             
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Figure 5.7: Subcellular localization of Vpu TM mutants in HeLa cells. 
HeLa cells were transfected by either 100 ng Vpu Wt-HA or the indicated mutant. A total of 24 
hours later, the cells were fixed and stained for Vpu localization with anti-HA antibody (green) 
and a TGN marker (TGN46; red) and examined by confocal microscopy. Images are 
representative examples of Vpu-expressing cells.  
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Vpu                        Tetherin                 TGN46                   overlay                       
 We then examined Vpu and tetherin localization in infected HT1080 cells expressing tetherin 
bearing an extracellular HA tag (HT1080/THN-HA, cf. Chapter 4) (Figure 5.8). As expected, in 
these cells tetherin localizes to the plasma membrane as well as the TGN since both newly 
synthesized tetherin and that which recycles passes through the Golgi network en route to the 
PM (193, 207). We found that wild-type Vpu and residual tetherin colocalized in the TGN with a 
concomitant reduction in cell surface expression. In contrast, and consistent with the flow 
cytometry data presented in Figure 5.4 and Figure 5.5, cells infected with a virus bearing the 
A14L/W22A mutation showed no evidence of tetherin relocalization from the PM to the TGN. 
This indicates that the defect in tetherin antagonism for A14L and W22A mutants of Vpu is likely 
not due to gross subcellular mislocalization, and that Vpu localization to the TGN and Vpu-





























Figure 5.8: Subcellular localization of Vpu TM mutants in infected HT1080/THN-HA cells. 
HT1080/THN-HA cells were infected with HIV-1 Wt or HIV-1 Vpu A14L/W22A at an MOI of 0.2. 
Forty-eight hours later, the cells were fixed and stained for Vpu (green), TGN46 (red), and 
tetherin-HA (blue) and examined by confocal microscopy. Images are representative examples 
of uninfected and HIV-1 Vpu A14L-W22A infected HT1080/THN-HA cells. Image of HIV-1 Vpu 
Wt infected HT1080/THN-HA is representative of cells in which residual tetherin could still be 
detected. 
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5.2.4 Vpu/tetherin interaction requires residues A14 and W22 
We then assessed the ability of Vpu TM mutants to co-immunoprecipitate tetherin as an 
indicator of direct or indirect interaction between the proteins. 293T cells were transfected with a 
human tetherin expression vector and wild-type Vpu-HA or the TM mutant. 48 hours after 
transfection, cell lysates were immunoprecipitated with an anti-HA antibody. As shown in Figure 
5.9, when transiently over-expressed in 293T cells, tetherin appears predominantly as a single 
species, likely to be a precursor mannosylated form, at a low molecular weight while higher 
molecular species running as a smear are only detected with long-exposure conditions. These 
latest forms are likely to be mature glycosylated species of tetherin. In contrast, in stable 
HT1080/THN-HA only the smear of high molecular species is mainly observed (cf. Chapter 4). 
This difference may reflect the fact that under conditions of transient expression in 293T cells, 
maturation through addition of carbohydrates to tetherin occurs more slowly than translation 
(197). As shown in Figure 5.9, tetherin (both low and high molecular species) was efficiently co-
immunoprecipitated with wild-type Vpu, despite total cellular tetherin levels being lower in cell 
lysates due to Vpu-induced degradation (Figure 5.9, low-exposure lysate panel). The A14L and 
W22A mutants displayed little or no tetherin degradation and only poorly co-immunoprecipitated 
with the protein. Furthermore, combined mutants containing both A14L and W22A were further 
reduced in their ability to co-immunoprecipitate tetherin. Thus, the defect in tetherin antagonism 
in the A14L and W22A mutants correlates directly with their failure to interact with tetherin in co-
IPs. Coupled with the observation that these mutants localize identically to wild-type Vpu, the 
data strongly suggest that these positions in the Vpu TM domain are critical for the interaction 
with tetherin. Interestingly, the fact that we co-immunoprecipitated the lower-molecular-weight, 
immature form of tetherin with Vpu suggests that while Vpu exerts its effect on tetherin in a 
post-ER compartment, interaction may occur prior to further carbohydrate modification (cf. 
Chapter 6). 
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Figure 5.9: Vpu TM mutants are unable to co-immunoprecipitate tetherin. 
293T cells were transfected with the indicated plasmid Vpu vectors or the indicated mutant and 
with tetherin. YFP only or tetherin only served as negative controls. Forty-eight hours later, Vpu 
was immunoprecipitated (IP) via the HA tag from cell lysates and subjected to SDS-PAGE. 
Total lysates and immunoprecipitates were then Western blotted for tetherin and Vpu-HA. 




5.2.5 Defective Vpu TM mutants retain the ability to form multimers  
Oligomers of Vpu can be detected in infected cells (327, 331), although their functional 
significance for tetherin antagonism is not known. We then asked whether the ability of Vpu to 
form multimers was affected in the context of A14 and W22 residues mutated as a possible 
cause to account for a lack of interaction with tetherin. Western blots of post-nuclear lysates of 
Vpu-HA-transfected 293T cells run under non-reducing conditions without prior boiling displayed 
a higher-molecular-mass form of Vpu (approximately 80 kDa) in addition to a monomer (Figure 
5.10), consistent with previous observations (327). This species of Vpu was also detected for 
the Vpu A14L/W22A mutant at enhanced levels, suggesting these mutations did not abolish 
Vpu multimerization and might even contribute to stabilize oligomeric forms. In addition, this 
mutant also formed a larger (approximately 100- to 120-kDa) form. In line with this observation, 
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a report from the Bonifacino group suggested that W22 was not required for Vpu-Vpu 
interactions and even prevented assembly of Vpu complexes into inactive oligomeric form 





















Figure 5.10: Vpu A14L-W22A mutant can self-associate. 
293T cells transfected with HA-tagged Vpu or Vpu A14L/W22A were lysed in 1% digitonin after 
48 hours, subjected to non-reducing SDS-PAGE without prior boiling, and Western blotted with 
an anti-HA monoclonal Ab. Higher molecular mass forms of Vpu are indicated with a star. 
 
 
5.2.6 Oligomerization state of Vpu required for targeting tetherin 
It has not been established whether Vpu targets tetherin as a monomer or if the multimerization 
state of Vpu is required to generate a functional binding interface with the tetherin 
transmembrane domain. To address this point, we first asked whether the Vpu A14L,W22A 
mutant could also form complexes with Vpu Wt proteins. 293T cells were transfected with Vpu-
YFP and either Vpu-HA or Vpu A14L/W22A-HA. Under the same immunoprecipitation 
conditions, in which Vpu TM mutants failed to interact with tetherin (cf. Figure 5.9), we could 
show that wild-type Vpu tagged with YFP could co-immunoprecipitate with both Vpu-HA and 
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Figure 5.11: Vpu A14L-W22A mutant can multimerize with Vpu Wt. 
293T cells were transfected with Vpu-YFP and either Vpu-HA or Vpu A14L/W22A-HA. Forty-
eight hours later, cell lysates were immunoprecipitated with anti-HA Ab as described previously, 
and whole lysates and IP fractions Western blotted for Vpu-HA and Vpu-YFP with anti-HA and 
anti-GFP antibodies, respectively. 
 
 
 Based on the above observation, we reasoned that if tetherin antagonism was mediated by 
functional Vpu multimers, a Vpu A14L/W22A mutant might be a dominant-negative inhibitor of 
tetherin antagonism. However, titration of Vpu TM mutants into HIV-1 Wt viral release assays 
did not induce any enhanced sensitivity to tetherin, despite estimated mutant Vpu levels being 
10-fold over that expressed from the provirus (Figure 5.12A-B). Thus, while not ruling out that 
Vpu acts as a multimer to target tetherin, these data show that the ability of Vpu TM mutants to 
associate with wild-type Vpu does not compromise its function. However, it cannot be excluded 
that a small fraction of functional Vpu might be sufficient to antagonize tetherin in a virus release 
assay, thus masking the potential dominant negative effect of the Vpu TM domain mutant. 
Consistent with these data, NMR studies suggest a monomeric interaction of Vpu with tetherin 
(386). 
 Further investigations will need to be performed to determine the exact stoichiometry of Vpu 
relative to tetherin required to achieve its anti-tetherin activity. Similarly to what has been 
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proposed in the case of CD4, a stock of Vpu monomers might be held under inactive multimeric 
forms before being engaged with tetherin molecules. In such a scenario, mutations on residues 














Figure 5.12: Vpu A14L-W22A mutant does not act as dominant-negative inhibitor of 
tetherin antagonism. 
A: 293T cells were transfected with wild-type HIV-1 NL4.3 Wt proviral plasmid, 50 ng of tetherin, 
and the indicated amount of Vpu-HA or mutant, and infectious release was determined on 
HeLa-TZM cells 48 hours later. Dotted lines represent wild-type and Vpu-defective viral titers in 
the absence of any expression of Vpu in trans. B: Cell lysates of the 100-ng input described in 
the legend to panel A blotted with an anti-Vpu polyclonal Ab to allow simultaneous detection of 
the Vpu-HA expressed in trans and the wild-type Vpu expressed from the NL4.3 provirus. 
 
 
5.2.7 Residues A14, A18 and W22 form a face of the Vpu transmembrane helix 
A solid-state nuclear magnetic resonance (NMR) structure of the NL4.3 Vpu TM domain in lipid 
membranes has been determined previously (329, 423). The core TM domain (residues 8 to 25) 
forms a slightly kinked alpha helix tilted at approximately 13 degrees to the vertical. Residues 
A10, A14, A18, and W22 form one diagonal face of the helix (Figure 5.13). Because Vpu can 
form ion-permeable channels, this structure was further modeled to account for this, and the 
most favorable conformations that would allow channel function were predicted to be a tetramer 
or a pentamer (329). In this conformation, W22 is predicted to protrude outward from the 
pentamer and may give stability to the structure in the membrane. A14 and A18 are positioned 
at the interface with the adjacent monomers, and therefore, their replacement with bulkier 
leucine residues may impinge on this interaction and, although not sufficient to block Vpu 
multimerization, alter the conformation or stoichiometry of Vpu oligomers or segregate Vpu 
monomers into multimeric complexes. Alternatively, or in addition to contributing to interhelical 
contacts or stability, A14, A18, and W22 might also contribute to a conserved binding surface 
for interaction with another protein, potentially tetherin. 
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Figure 5.13: Residues A14, A18, and W22 form one face of the Vpu TM helix. 
Positions of A14, A18, and W22 (red) in the solid-state NMR structure of the NL4.3 Vpu TM 
domain determined in membranes and the modeled tetrameric and pentameric assemblies 
based on it, as determined by Park et al. (329). Images were generated in PyMol from the 
RSCB protein database entries 1PI7 (pentamer) and 1PI8 (tetramer). 
 
 
5.2.8 Residues A14, A18 and W22 are conserved in HIV-1 group M and N but not O 
We next looked at the conservation of the above TM positions in Vpu sequences deposited in 
the HIV Sequence Database (www.hiv.lanl.gov). Alignment of the TM domains of 1,197 group M 
Vpu sequences showed that the positions equivalent to A18 and W22 are highly conserved 
(Figure 5.14A). The majority of sequences also have the equivalent of position 14 as A, but in 
many cases this can be V. Interestingly, we found that a valine in position 14 was also 
functional to counteract tetherin (Figure 5.14B). Notably, we did not find an L at this position in 
naturally occurring group M sequences. The same was observed with the small number of 
group N Vpu sequences available; the equivalents of positions 14, 18, and 22 were A, A, and 
W, respectively. Interestingly, this was not the case for HIV-1 group O Vpu proteins, which have 
been shown to be defective in tetherin antagonism (226). Here the position 14 equivalent is 
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amino acid position












































almost always L, and the majority of sequences have an N at position 18. Again the W is 
invariant, which, since group O Vpu proteins retain CD4 degradation activity (226), is consistent 
with W22A mutants of NL4.3 Vpu being defective for both tetherin and CD4 downregulation. 
Thus, the residues we have identified as important for tetherin antagonism in HIV-1 NL4.3 Vpu 






















Figure 5.14: Residues A14, A18, and W22 are conserved in HIV-1 groups M and N, but not 
O. 
A: Logo plots of the TM domains of Vpu sequences drawn from the HIV Sequence Database 
(www.hiv.lanl.gov). Group M comprises 500 clade B, 200 clade C, 200 clade A, 200 clade D, 42 
clade F, 48 clade G, and 7 clade H TM sequences. Arrows indicate the equivalent positions of 
NL4.3 Vpu A14, A18, and W22 residues. B: 293T cells were transiently transfected with 500 ng 
of HIV-1 delVpu provirus, 50 ng of tetherin plasmid, and 25 ng of the indicated Vpu expression 
vector. 48 hours after transfection, the resulting viral supernatants were assayed for infectivity 
on HeLa-TZM indicator cells by measuring β-galactosidase activity. 
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5.3 Discussion 
In this chapter we have identified two residues, A14 and W22 in the Vpu transmembrane 
domain, that are important for Vpu's ability to overcome tetherin antiviral function. We found 
that, despite localizing to similar cellular compartments as the wild-type protein, Vpu constructs 
bearing these mutations were defective in mediating interactions with tetherin. As a result, these 
mutations also impaired the ability of Vpu to reduce cell-surface tetherin levels and by extension 
tetherin degradation. We then investigated whether the oligomerization state of Vpu was 
affected by these mutations. We found that Vpu A14L-W22A mutant was able to self-associate 
to form multimers and was also functional to bind to the wild-type Vpu. These results suggest 
that these mutations compromised interactions with tetherin by means other than interfering 
with the formation of Vpu multimers. It is unknown whether Vpu acts on tetherin as a monomer 
or whether it needs to form multimeric complexes to be able to target tetherin. The Vpu A14L-
W22A domain mutant binds the wild-type Vpu protein, we therefore reasoned that if Vpu acted 
as a multimer to target tetherin, Vpu TM domain mutant may have a dominant-negative effect 
on the HIV-1 Wt viral particle release. However, we found that HIV-1 Wt particle release was not 
affected by addition in trans of Vpu A14L-W22A despite expression levels of Vpu TMD mutant 
ten fold higher than Wt Vpu. These data tend to support a model in which monomeric form of 
Vpu binds to tetherin. More studies will need to be performed to determine the exact 
oligomerization state and the stoichiometry of Vpu required to target tetherin.  
 In this study we also addressed whether the residues required for tetherin counteraction 
corresponded to those required for CD4 degradation. Unlike W22, mutation on residue A14 did 
not impact on Vpu's ability to induce CD4 downregulation. Similarly, Vpu proteins from group O 
HIV-1, which are functional to target CD4, also have a tryptophan residue at the equivalent 
position but not an alanine in position 14. These results indicate that the determinants of Vpu-
mediated CD4 degradation are not only located in the cytoplasmic tail but the Vpu TM domain 
might also have an important role. This idea was further supported subsequently by a recent 
study from the Bonifacino group in which they investigated the determinants in Vpu and CD4 
TM domains required for CD4 downregulation (374). They found that the W22 was required to 
prevent assembly of Vpu into an inactive, oligomeric form, and to promote CD4 
polyubiquitination and subsequent degradation via the proteasome. While Vpu W22 did not 
prevent interaction with CD4, its mutation led to the accumulation of CD4 molecules in the ER 
membrane instead of being dislocated in to the cytosol. In the same study, the authors also 
identified two residues, Val20 and Ser23, in the Vpu TM domain that mediated retention of Vpu 
and, by extension, CD4 in the ER. In our screen, when those residues were replaced by alanine 
they were still functional to antagonize tetherin and promote virus release. Based on these data, 
it is possible that mutation of W22 might stabilize the multimeric structure of Vpu preventing 
monomers from being released to target tetherin. This hypothesis is in agreement with our data, 
as we showed that the high molecular weight forms of Vpu A14L-W22A were detected on a 
non-reducing Western blot at higher levels than those from Vpu Wt.  
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 Another important aspect of this study is the fact that the residue A14, identified to be 
important to mediate tetherin interaction, is highly conserved in all Vpus from HIV-1 group M 
and N that possess an anti-tetherin function, but not in Vpu proteins from group O HIV-1 or 
SIVcpz that are devoid of human tetherin antagonism (226). Interestingly, a recent study 
showed that anti-human tetherin activity could be conferred to SIVcpz Vpu by replacing parts of 
its TM domain by those from HIV-1 Vpu TM domain (420). Importantly, the residues identified in 
our study were present in the SIVcpz Vpu that gained function against human tetherin. These 
data indicate that adaptation of this region of Vpu TM domain, encompassing A14 and W22, 
might have been driven by the zoonosis of the virus into the human population. Predicted 
structures of the Vpu transmembrane domain based on solid-state NMR reveals that residues 
A14, A18 and W22 form one face of the helix, suggesting that they might be directly involved to 
generate a functional binding interface with tetherin (329). By mutating those positions in the 
transmembrane domain we may have affected the residues directly in contact with residues in 
tetherin transmembrane domain or disrupted the overall conformation of Vpu protein required to 
mediate tetherin interaction. In accordance with these data, subsequent NMR spectroscopy-
based models revealed that the conserved AxxxAxxxAxxxW helix face of Vpu TM domain 
directed the interaction with tetherin (386). Alanine residues in the Vpu TM domain are 
predicted to fit into ridges formed by large hydrophobic residues in the tetherin TM domain and 
W22 ensures the correct positioning of the Vpu helix within the bilayer for interaction with 
tetherin. Alternatively, these mutations might stabilize the formation of Vpu multimers rendering 
the Vpu monomers unable to target tetherin. Of note, binding of Vpu induced a chemical shift in 
the NMR spectrum for several tetherin TM domain residues including V30, I34, L37 and L41 
(386). Without dismissing the role of Vpu acting as ion-channel to promote virus release, we 
have not found residues that were both involved for ion channel activity and required for tetherin 





     CELLULAR TARGETS OF HIV-1 VPU 
 
- 164 - 
Chapter 6                                                                                 
Intrinsic defects of Group O HIV-1 Vpu in counteracting 
Tetherin 
 
The study detailed in this chapter was published as '' Separable determinants of subcellular 




6.1 HIV-1 Group O, imperfect adaptation of SIVcpz to humans? 
Chimpanzees from west central Africa infected with SIVcpz are believed to constitute the 
primary reservoir of HIV-1 pandemic (reviewed in (11)). This cross-species transmission must 
have happened at least four times, giving rise to HIV-1 group M (major), N (non-M and non-O), 
O (outlier) and P. HIV-1 group M (HIV-1 M) appears to be the most virulent form and is 
predominantly responsible for HIV-1 pandemic. HIV-1 group O is characterized by a high 
genetic divergence from HIV-1 group M and most cases of HIV-1 group O infection are detected 
in Cameroon, where the prevalence is estimated to be about 1% of all HIV infections (15). 
Cases of HIV-1 O infections have also been described in countries with previous colonial links 
to this region such as France. Later studies have reported the identification of HIV-1 group O-
like viruses in wild gorillas (425). It has been proposed that chimpanzees transmitted HIV-1 
group O-like viruses either to gorillas and humans independently, or to gorillas that then 
transmitted the virus to humans. While HIV-1 group O-infected individuals can progress to 
AIDS, the spread of this virus appears to be inefficient compared to group M. However, the 
reasons for the lower prevalence of group O remain unknown. Vpu proteins from group M (M-
Vpu) can both antagonize tetherin efficiently and mediate the degradation of CD4 (226). The 
ability of M-Vpu to target human tetherin is an adaptation that presumably occurred during the 
zoonosis of the virus to humans because SIVcpz Vpu is defective for this attribute. In contrast, 
the Vpu proteins from Group O HIV-1 are unable to target tetherin but still retain the ability to 
degrade CD4, whereas this situation is reversed in HIV-1 group N, with Vpu retaining some 
level of tetherin antagonism but losing activity against CD4. It has been speculated that Vpu 
adaptation to human tetherin may have therefore been important for the pandemic spread of 
HIV/AIDS (426). 
 In this study, we characterized the cell biological basis for the defects in the Vpu proteins 
from HIV-1 group O (O-Vpu) that impair their ability to antagonize tetherin.  
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6.2.1 Group O Vpu does not overcome tetherin's antiviral action 
HIV-1 group O Vpu has been shown to lack the ability to counteract human tetherin but can still 
induce CD4 degradation (226). To confirm this, a Vpu gene from HIV-1 group O strain 9435 was 
synthesized with a C-terminal HA tag and tested for its ability to block tetherin's antiviral 
function. 293T cells were co-transfected with a fixed dose of tetherin plasmid, increasing 
amounts of Vpu expression vectors, and a proviral plasmid of HIV-1 NL4.3 deleted for the Vpu 
gene (HIV-1 delVpu). At 48 hours post-transfection, cells were lysed and supernatants were 
analyzed by Western blotting for p24 and Vpu detection or titrated on HeLa-TZMbl indicator 
cells (Figure 6.1). As expected, a prototype M-Vpu (NL4.3) efficiently rescues virus production 
in the presence of tetherin. In contrast, O-Vpu of strain 9435 (O-Vpu 9435 Wt) was unable to 
rescue particle release from tetherin restriction, even at higher plasmid inputs, and was 
equivalent to an M-Vpu A14L-W22A TM mutant that we have shown previously to be defective 
for tetherin antagonism (221) (cf. Chapter 5). All proteins were expressed at comparable levels 
in cell lysates, and O-Vpu 9435 expression did not affect intracellular Gag protein synthesis 
(Figure 6.1B). Whereas M-Vpu runs on a Western blot as a single species, O-Vpu 9435 




















Figure 6.1: Defects in tetherin antagonism by O-Vpu 9435. 
A: 293T cells were transiently transfected with 500 ng of HIV-1 delVpu provirus, 50 ng of 
tetherin plasmid, and increasing doses of the indicated Vpu expression vector or the empty 
vector control (mock). At 48 hours post-transfection, the resulting viral supernatants were 
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assayed for infectivity on HeLa-TZMbl indicator cells by measuring β-galactosidase activity at 48 
hours post-infection. RLU, relative light units. Error bars are +/- standard error of the mean 
(SEM) for three independent experiments. B: Cell lysates and pelleted virions from cells 
transfected with 50 ng of Vpu plasmid were subjected to SDS-PAGE and blotted for Vpu-HA, 
p24-CA, and Hsp90 protein, which served as a loading control, and analyzed by a LiCor 
quantitative imager. Relative virus release was calculated as a percentage of the virion p24 
band intensity of the no-tetherin control.  
 
 
6.2.2 Lack of cell-surface tetherin downregulation by Group O Vpu 
M-Vpu overcomes human tetherin by inducing its removal from the cell surface and blocking its 
incorporation into nascent virions. To address whether O-Vpu fails to antagonize tetherin 
because it cannot induce its downregulation, tetherin-positive HeLa cells were co-transfected 
with an empty vector control or a Vpu expression vector in combination with a GFP marker 
plasmid. At 48 hours post-transfection, cells were harvested and stained for surface tetherin 
levels (Figure 6.2). As expected in GFP-positive cells, expression of M-Vpu Wt but not M-Vpu 
A14L-W22A leads to a decrease of tetherin levels at the cell surface. Expression of O-Vpu 9435 




















Figure 6.2: Defects in tetherin cell-surface downregulation by O-Vpu 9435. 
HeLa cells were co-transfected with 400 ng of GFP marker plasmid and the indicated Vpu 
expression vector. At 48 hours post-transfection, endogenous surface tetherin was 
immunostained and expression levels were quantified by flow cytometry. Histograms represent 
the tetherin levels on GFP-positive gated cells in empty vector control cells (black peak) or in 
Vpu-expressing cells (overlaid gray peak) and are representative examples of three 
independent experiments. Median fluorescence intensities of the overlaid histogram are 
indicated in the top right corner. The solid peak histogram represents the binding of the isotype 
control. 
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6.2.3 Group O Vpu fails to interact with tetherin 
M-Vpu mediates tetherin downregulation through interactions via their transmembrane domains. 
Mutations impairing this interaction render Vpu incapable of allowing co-immunoprecipitation of 
tetherin from cell lysates (221). We then assessed the ability of O-Vpu 9435 to interact with 
tetherin in this assay. 293T cells were co-transfected with tetherin and Vpu-HA expression 
vectors. Two days after transfection, cells were lysed and Vpu proteins were 
immunoprecipitated via the HA epitope and analyzed by Western blotting (Figure 6.3). As 
expected, tetherin co-immunoprecipitates with M-Vpu Wt and not with the transmembrane Vpu 
mutant (M-Vpu A14L-W22A). Similarly, tetherin also failed to co-immunoprecipitate with O-Vpu 


























Figure 6.3: Defects in tetherin binding by O-Vpu 9435. 
293T cells were transiently transfected with 500 ng of human tetherin-encoding plasmid and 
500 ng of the indicated Vpu-HA expression vector. After 2 days of incubation, Vpu was 
immunoprecipitated (IP) via the HA tag from cell lysates and subjected to SDS-PAGE. Total cell 
lysates and immunoprecipitates were then Western blotted for tetherin and Vpu-HA. Molecular 
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6.2.4 Group O Vpu retains the ability to downregulate CD4 
Although O-Vpu bears in its sequence the key features required for CD4 downregulation, which 
are the tryptophan residue in the TMD (W22) and the β-TRCP binding site in the cytoplasmic 
tail, we tested whether our O-Vpu construct could mediate CD4 downregulation from the cell 
surface. CD4-positive HeLa cells were co-transfected with an empty vector control or a Vpu 
expression vector in combination with a GFP marker plasmid. At 48 hours post-transfection, 
cells were harvested and stained for surface CD4 levels (Figure 6.4). As expected in GFP-
positive cells, expression of O-Vpu 9435 Wt leads to a decrease of CD4 levels at the cell 
surface. So, despite the defects in tetherin antagonism, this O-Vpu construct retained the ability 


















Figure 6.4: O-Vpu 9435 expression leads to a reduction of CD4 levels on the cell surface. 
HeLa/CD4 cells were co-transfected with 400 ng of GFP marker plasmid and O-Vpu 9435 Wt 
expression vector. At 48 hours post-transfection, endogenous surface CD4 was immunostained 
and expression levels were quantified by flow cytometry. Histograms represent the CD4 levels 
on GFP-positive gated cells in empty vector control cells (black peak) or in Vpu-expressing cells 
(overlaid gray peak) and are representative examples of three independent experiments. 
Median fluorescence intensities of the overlaid histogram are indicated. 
 
 
6.2.5 Group O Vpu localizes to ER-associated compartments 
Group M Vpu localization in the TGN has been shown to be important to suppress tetherin 
restriction activity, consistent with Vpu inducing sequestration of tetherin in the TGN and 
preventing its transit to the plasma membrane (341, 377). Here we addressed whether the O-
Vpu 9435 cellular localization accounts for its inability to block tetherin function. HeLa cells were 
transfected with a Vpu-HA-encoding vector. Twenty-four hours later, cells were fixed and 
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immunostained for Vpu-HA and either the ER marker, protein disulfide isomerase (PDI), or the 
trans-Golgi network marker, TGN46 (Figure 6.5). As expected, M-Vpu localized in perinuclear 
compartments that mainly overlay with TGN46-positive compartments but not with PDI. 
However, although a minor fraction of O-Vpu 9435 localizes in the TGN, the majority forms a 
reticular staining pattern that partially overlays with PDI-positive compartments, suggesting that, 
unlike M-Vpu, O-Vpu 9435 localizes to ER-associated compartments. Thus, the failure of O-Vpu 
9435 to antagonize tetherin correlates both with its inability to interact directly with tetherin and 


































Figure 6.5: O-Vpu 9435 localizes to the ER. 
HeLa cells were transfected by either 100 ng of M-Vpu Wt-HA or O-Vpu Wt-HA plasmid. 
Twenty-four hours later, the cells were fixed and stained for Vpu detection with anti-HA antibody 
(green), a TGN marker (TGN46; red), or an ER marker antibody (PDI; red) and examined by 
confocal microscopy. Images are representative examples of Vpu-expressing cells. 
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6.2.6 Retention of Vpu in the Endoplasmic Reticulum prevents tetherin antagonism 
We next investigated the functional consequences of restricting Vpu expression to the ER. Vpu-
induced virus release from CD4+ T cells is sensitive to brefeldin A (365), suggesting that Vpu 
function requires post-ER trafficking. However, broad inhibition of the secretory pathway will 
also affect tetherin trafficking, potentially confounding this conclusion. To circumvent this, we 
made an M-Vpu protein bearing an ER retention signal derived from the bovine foamy virus 
envelope protein (-KKDQ) at the C-terminus (427). As expected, M-Vpu KKDQ shows a reticular 
staining overlapping with PDI-positive compartments, indicative of an ER localization (Figure 
6.6A), with only a minor fraction of M-Vpu KKDQ proteins localizing with the TGN marker. M-
Vpu KKDQ displays weak activity against tetherin restriction, despite increasing doses of 
plasmid (Figure 6.6B), indicating that post-ER trafficking of Vpu is essential for tetherin 
antagonism. Similarly, transfection of tetherin-positive HeLa cells reveals that M-Vpu KKDQ fails 


























Figure 6.6: Retention of M-Vpu in the ER inhibits tetherin antagonism. 
A: HeLa cells were transfected by 100 ng of M-Vpu KKDQ-HA plasmid. Twenty-four hours later, 
the cells were fixed and stained for Vpu detection with anti-HA antibody (green), a TGN marker 
(TGN46; red), or an ER marker antibody (PDI; red) and the appropriate secondary antibodies 
and examined by confocal microscopy. Images are representative examples of Vpu-expressing 
     CELLULAR TARGETS OF HIV-1 VPU 
 
- 171 - 
cells. B: 293T cells were transiently transfected with 500 ng of HIV-1 delVpu provirus, 50 ng of 
tetherin-encoding plasmid, and increasing amounts of the indicated Vpu expression vector. 
Cells and supernatant-containing viral particles were harvested at 48 hours post-transfection. 
The resulting infectious virions in culture supernatants were titrated on HeLa-TZMbl indicator 
cells by measuring β-galactosidase activity at 48 hours post-infection. Vpu protein expression in 
cell lysates was analyzed by Western blotting using an anti-HA antibody. C: The indicated Vpu 
constructs were co-transfected in HeLa cells with a GFP-encoding vector, and surface tetherin 
levels were quantified by flow cytometry at 48 hours post-transfection. Histograms represent the 
tetherin levels on GFP-positive gated cells in empty vector control cells (black peak) or in Vpu-
expressing cells (overlaid gray peak) and are representative examples of three independent 
experiments. Median fluorescence intensities of the overlaid histogram are indicated in the top 
right corner. The solid peak histogram represents the binding of the isotype control. 
 
 
6.2.7 ER-retained Group M Vpu proteins can still interact with tetherin 
M-Vpu KKDQ mimics O-Vpu cellular localization thus providing a useful tool to determine 
whether the inability of O-Vpu to interact with tetherin is related to its ER-cellular localization. 
Interestingly, preventing M-Vpu from leaving the ER does not impair its ability to interact with 
tetherin in co-immunoprecipitates from transient transfections (Figure 6.7A). This was not due to 
tetherin-Vpu interactions occurring during the immunoprecipitation, as subsequent mixing of cell 
lysates from 293T cells transfected with either Vpu or tetherin individually failed to yield tetherin 
co-immunoprecipitating with Vpu-HA (Figure 6.7B). Besides, in accordance with data from the 
chapter 5, in the presence of M-Vpu Wt it is mainly the low molecular weight species of tetherin 
that is immunoprecipitated from this transient expression system but traces of a smear of higher 
molecular weight can also be detected. However, with M-Vpu KKDQ only the low molecular 
weight forms of tetherin were pulled down. These data therefore suggest that Vpu and tetherin 
may interact early in the secretory pathway, but only after exit from the ER is Vpu able to exert 
its inhibitory effect on tetherin activity. Furthermore, these results suggest that O-Vpu 9435 
localization in the endoplasmic reticulum may contribute to its deficiency in tetherin antagonism 
but does not account for its lack of tetherin interaction. 
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Figure 6.7: Retention of M-Vpu in the ER does not block interaction with tetherin. 
A: 293T cells were transiently transfected with 500 ng of human tetherin-encoding plasmid and 
500 ng of the indicated Vpu expression vector. After 2 days of incubation at 37°C, Vpu was 
immunoprecipitated via the HA tag from cell lysates and subjected to SDS-PAGE. Total cell 
lysates and immunoprecipitates were then Western blotted for tetherin and Vpu-HA detection. 
Molecular mass markers are indicated, and blots are a representative example of three 
independent experiments. B: Vpu and Tetherin do not interact in mixed cell lysates. 293T cells 
were transfected with either M-Vpu-HA or tetherin individually (samples A and B) or in 
combination (sample C). In sample A, the cells were removed from the plate and mixed prior to 
lysis, and in sample B the cells were lysed separately and post-nuclear supernatants mixed 
afterwards. Vpu-HA was immunoprecipitated from all three lysates as described before. 
Immunoprecipitates were then analyzed by Western blot using anti-HA and anti-tetherin 
antibodies, demonstrating that tetherin only co-immunoprecipitates with Vpu-HA from cells co-
transfected with both proteins. 
 
 
6.2.8 The defect in tetherin interaction maps to the transmembrane domain of Group O 
Vpu 
We then went on to assess the minimal changes needed in O-Vpu 9435 to allow it to 
antagonize human tetherin. O-Vpu 9435 and M-Vpu proteins are derived from distinct SIVcpz 
zoonoses and as such are very diverse at the amino acid level. However, they do have basic 
features known to be important for CD4 degradation (Figure 6.8A): first, the conserved W 
residue in the TM domain and, second, the dual serine motif phosphorylated by CKII that binds 
to β-TrCP. After the TM domain in Vpu is a putative hinge region followed by an amphipathic 
alpha helix (H1), which has been proposed to lie along the face of the membrane with the 
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nonpolar residues partially submerged and the charged residues interacting with the polar 
phospholipid heads (338). In contrast, in H1 of O-Vpu the TM-proximal part of the helix is 
extended by a run of alternating basic and acidic residues that breaks its amphipathicity. As we 
identified two distinct functional defects in the O-Vpu protein, we aimed first to map the region 
that was responsible for the lack of interaction with tetherin. Chimeric proteins, combining M-
Vpu TMD and O-Vpu CT or vice versa, were designed (Figure 6.8A) and tested for tetherin 
antagonism. We reasoned that if we found an O-Vpu chimera functional for tetherin 
counteraction they would be, by extension, able to mediate interaction with tetherin. 293T cells 
were co-transfected with a fixed amount of tetherin, Vpu, and the HIV-1 delVpu proviral plasmid. 
Forty-eight hours later, cells were analyzed by Western blotting and titrated on HeLa-TZMbl 
indicator cells (Figure 6.8B). Substitution of the two key residues from M-Vpu TMD, A14 and 
A18, essential for tetherin interaction (221), into O-Vpu TMD did not result in a functional O-Vpu 
mutant (O-Vpu B). Similarly, chimeras composed of O-Vpu TMD and M-Vpu CT (Vpu OTM-
MCT) were unable to enhance particle release in tetherin-expressing cells. The opposite mutant 
designed by adding the equivalent determinants of M-Vpu TMD into O-Vpu TMD (Vpu OBTM-
MCT) did not gain function to suppress tetherin restriction. However, two chimeras that were 
both composed of an intact M-Vpu TMD gained function against tetherin either in the context of 
the O-Vpu cytoplasmic tail (Vpu MTM-OCT) or with the M-Vpu first alpha helix (Vpu MTM-MH1-
OH2). However, as the lack of antagonism might be due to additional defects and not only the 
inability to interact, we also checked the ability of the Vpu mutants mentioned above for 
interacting with tetherin. As expected, Vpu MTM-OCT and Vpu MTM-MH1-OH2 were effective 
at co-immunoprecipitating tetherin molecules (Figure 6.8C). However, O-Vpu B, Vpu OTM-MCT, 
Vpu OBTM-MCT failed to pull-down tetherin from cell lysates. Therefore, only O-Vpu mutants 
bearing the transmembrane from M-Vpu were functional to mediate tetherin interaction. 
Altogether these data suggest O-Vpu's incapacity to bind tetherin seems to be an intrinsic 
defect of its transmembrane domain. 
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Figure 6.8: O-Vpu TMD accounts for the lack of tetherin interaction. 
A: Schematic representation of the Vpu topology and alignments comparing Vpu sequences 
from HIV-1 group M and group O or the indicated mutants. B: 293T cells were transfected with 
the HIV-1 delVpu provirus, a fixed dose of tetherin plasmid, and the indicated Vpu construct. 
After 2 days, viral supernatants were assayed on HeLa-TZMbl indicator cells and cells lysates 
were analyzed by Western blotting for Vpu-HA and Hsp90. Numbers below indicate the Vpu 
expression levels normalized with Hsp90 expression levels compared to the M-Vpu Wt protein 
expression. C: The indicated Vpu construct was co-expressed in 293T cells with 500 ng of 
human tetherin-encoding plasmid. At 48 hours post-transfection, cells were lysed and Vpu 
proteins were isolated via immunoprecipitation and subjected to SDS-PAGE. Both tetherin and 
Vpu-HA expressions were visualized on a Western blot using the appropriate antibodies. 
Western blots are representative examples of three independent co-IP experiments. 
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6.2.9 The defect in TGN localization maps to the first alpha helix of Group O Vpu 
We then investigated the region in the O-Vpu sequence that was responsible for its 
accumulation in the endoplasmic reticulum. We found that by adding the M-Vpu cytoplasmic tail 
into O-Vpu changed its ER-associated cellular localization to the TGN. Vpu OTM-MCT, Vpu 
OBTM-MCT displayed colocalization in HeLa-transfected cells with the TGN marker, TGN46 
(Figure 6.9). These data suggest that the cytoplasmic tail of O-Vpu is involved in the retention of 






















Figure 6.9: O-Vpu mutants bearing M-Vpu cytoplasmic tail localize to the TGN. 
HeLa cells were transfected by 100 ng of Vpu OTM-MCT or Vpu OBTM-MCT. Twenty-four 
hours later, the cells were fixed and stained for Vpu detection with anti-HA antibody (green) and 
a TGN marker (TGN46; red), the appropriate secondary antibodies and examined by confocal 
microscopy. Images are representative examples of Vpu-expressing cells. 
 
 
 We then checked whether the first or the second alpha helix of the M-Vpu cytoplasmic tail 
conferred TGN localization. Interestingly, although they both were able to mediate tetherin 
interaction, only Vpu MTM-MH1-OH2 but not Vpu MTM-OCT was associated with TGN46 
positive compartments suggesting that the O-Vpu first alpha helix was responsible for the 
cellular repartition in the ER (Figure 6.10A). Since these two mutants were both functional for 
tetherin antagonism despite distinct subcellular localization, we re-screened them against a 
fixed dose of tetherin but with various expression levels of Vpu (Figure 6.10B). Only Vpu MTM-
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MH1-OH2 gained function against tetherin restriction at lower plasmid inputs and at higher 
expression had activity almost to the levels of M-Vpu Wt. In contrast, Vpu MTM-OCT achieved 
only a low efficiency of tetherin antagonism, even at the highest plasmid concentrations. This 
data is consistent with the importance of Vpu association with the TGN for tetherin 
counteraction (341). Therefore, only Vpu proteins bearing an intact M-Vpu TMD in the context of 
the first alpha helix of M-Vpu cytoplasmic tail can overcome tetherin’s restriction. The 
simultaneous replacement of the tetherin interaction domain (TM) in the context of the first 
alpha helix (H1) of M-Vpu sequences that permit TGN localization is thus required for full 















Figure 6.10: Defects in O-Vpu can be rescued by replacement of the TM domain in the 
context of the M-Vpu first alpha helix. 
A: The indicated Vpu-HA chimeras (green) were transiently expressed in HeLa cells and co-
immunostained either with a TGN marker (TGN46; red) or with an ER marker (PDI; red). Images 
are representative examples of Vpu-expressing cells. B: 293T cells were transfected with the 
HIV-1 delVpu provirus, a fixed dose of tetherin plasmid, and various doses of the indicated Vpu 
mutants added in trans. After 2 days, viral supernatants were assayed on HeLa-TZMbl indicator 
cells and cells lysates from cells transfected 50 ng of Vpu plasmid were subjected to SDS-
PAGE and blotted for Vpu-HA and Hsp90.  
 
 
6.2.10 A single glutamic acid-to-lysine change in the cytoplasmic tail confers Group O 
Vpu localization to the TGN  
We next investigated the determinants in the H1 domain of O-Vpu that account for its 
localization to the ER. First, we assessed whether ER retention of our O-Vpu 9435 was 
representative of the known available sequences. To this end, we synthesized an HA-tagged 
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consensus O-Vpu (O-Vpu cons) from all the full-length sequences available in the HIV 
Sequence Database (http://www.hiv.lanl.gov) (n=32) and, additionally, the Vpu from the strain 
HJ001 (226). As expected, both proteins were defective for counteracting tetherin from 
transiently transfected 293T cells (Figure 6.11A) and failed to interact in co-
immunoprecipitations (Figure 6.11B), consistent with our previous observations. When we 
examined their subcellular localization, however, we observed that while O-Vpu consensus was 
again retained in the ER, HJ001 Vpu displayed a more prominent localization to the TGN 
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Figure 6.11: Anti-tetherin activities and subcellular localizations of a consensus O-Vpu 
and O-Vpu HJ001. 
A: Counteraction of tetherin-mediated restriction of HIV-1 delVpu from transfected 293T cells by 
the indicated O-Vpu-HA construct and corresponding Western blots of cell lysates and pelleted 
virions. Error bars are +/- standard error of the mean (SEM) for three independent experiments. 
B: Co-immunoprecipitation of O-Vpu-HA proteins with tetherin from transiently transfected 293T 
cells as described previously. C: Subcellular localization of the indicated O-Vpu-HA (green) in 
transfected HeLa cells co-stained either with a TGN marker (TGN46; red) or with an ER marker 
(PDI; red). Images are representative examples of Vpu-expressing cells.	  
 
 
 Alignment of the H1 domains of these proteins revealed that a major difference in HJ001 
was a membrane-proximal K residue at position 32 instead of an E in O-Vpu cons and 9435 
(Figure 6.12A). This lysine was present in only a minority of O-Vpu sequences, suggesting that 
the acidic residue is representative of HIV-1 group O. Interestingly, position 32 in O-Vpu is 
equivalent to K31 in M-Vpu, which is embedded within the putative membrane-proximal hinge 
YRKILR. Mutation of R30-K31 to alanines in HIV-1 NL4.3 Vpu was previously shown to lead to 
an endosomal localization and a concomitant decrease in anti-tetherin activity (341). To 
determine whether this residue also plays a role in O-Vpu localization, we replaced the hinge 
region with the equivalent part of M-Vpu in the context of the M-Vpu TM domain (MTM-RKILR-
OCT). In addition, we also made the E32K point mutation in O-Vpu 9435 and MTM-OCT. 
Examination of the localization of these Vpu proteins revealed that unlike the parental O-Vpu, 
MTM-RKILR-OCT, MTM-OCT E32K, and O-Vpu E32K all displayed localization to TGN46-
positive compartments (Figure 6.12B). These data suggest that a single point mutation in the 
first alpha helix of O-Vpu cytoplasmic tail is sufficient to abolish ER retention. 
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O-Vpu 9435          MHYKDLVIIIIISALLLVNVLIWMFNLRKYLEQKEQERREREIIERLRRIREIRDDSDYESNKEEEQEVMGLVHAHGFDNPMFEL 
O-Vpu HJ001         MHNKDLLIIIIVSALLLINVILWMFNLRTYLKQKRQDRREREVIERIRRIRQVREDSDYESNGEEEQEVMDLVHSHGFDNPMFEL 
O-Vpu Consensus     MHHRDLLTLIILSALLLINVILWNFILRKYLEQKKQDRREREILERLRRIREIRDDSDYESNGEEEQEVMDLVHSHGFDNPMFEL 

































Figure 6.12: An E32K point mutation confers TGN localization to O-Vpu. 
A: Alignment of the consensus O-Vpu, O-Vpu 9435, and O-Vpu HJ001 sequences (above) and 
expanded logoplot of the amino acid sequences of the first alpha helix of publicly available O-
Vpu sequences (n=32) (below). Position E32 is indicated (red arrow). B: Subcellular localization 
of the indicated O-Vpu-HA (green) in transfected HeLa cells co-stained with a TGN marker 
(TGN46; red). Images are representative examples of Vpu-expressing cells.	  
 
 
6.2.11 Minimal changes to render Group O Vpu a tetherin antagonist  
We established that O-Vpu was defective both for tetherin binding and also in its subcellular 
localization. These attributes are separable to the TM domain and the membrane-proximal 
hinge region of the first alpha helix of the cytoplasmic tail, respectively. We identified that O-Vpu 
binding to tetherin could be generated by replacing the entire TM domain from M-Vpu. As for 
the subcellular localization, substitution of the residue E32 in its first alpha helix by a lysine 
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could confer O-Vpu localization in the TGN. We then attempted to combine these modifications 
into a single O-Vpu mutant to see whether we could recapitulate tetherin antagonism in O-Vpu 
proteins. When transfected into 293T cells with tetherin, MTM-RKILR-OCT and MTM-OCT 
E32K both regained function equivalent to that of the MTM-MH1-OH2 chimera, indicating that 
this single amino acid change was sufficient to enhance tetherin antagonism (Figure 6.13). As 
expected, the E32K change on its own did not confer tetherin antagonism to O-Vpu due to its 
TM domain’s inability to interact with tetherin. Therefore, an E32K point mutation confers TGN 
localization and tetherin antagonism to O-Vpu bearing the group M TM domain. A single acidic 
residue present in the hinge region of the majority of O-Vpu sequences precludes the protein 
from leaving ER-associated compartments and is responsible for their poor activity against 
























Figure 6.13: An E32K point mutation confers tetherin antagonism to O-Vpu bearing M-
Vpu TM domain. 
293T cells were transfected with 500 ng of HIV-1 delVpu, 50 ng of tetherin, and various doses 
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6.3 Discussion  
The Vpu proteins of most group M viruses tested in a recent study can counteract human 
tetherin (226). By contrast, group O Vpu proteins are defective for this attribute, and in the few 
sequences from group N, Vpu counteraction of tetherin is variable. In this chapter, we have 
addressed the molecular and cell biological basis for the difference between M-Vpu and O-Vpu 
proteins. We have shown that O-Vpu is defective for tetherin antagonism for two reasons. First 
and most important, its TM domain lacks the capacity to interact with tetherin in co-
immunoprecipitations. However, the ability to bind tetherin is not sufficient to confer antagonism 
to O-Vpu. Secondly, O-Vpu appears to be retained in the ER and fails to localize to the TGN. 
This maps to the first alpha-helix of the cytoplasmic tail, specifically, a glutamic acid residue at 
position 32, found in the majority of O-Vpu sequences. Replacement of this region is also 
required for efficient tetherin antagonism and TGN localization. We showed previously that 
mutation of conserved residues A14, A18, and W22, which form one face of the M-Vpu TM 
domain, impairs tetherin interaction and antagonism (221). The A14 and A18 positions are 
conserved in M- and N-Vpu proteins but not in group O or SIVcpz Vpu proteins, suggesting that 
changes to this face of the TM domain helix may have been driven by adaptation of HIV-1 Vpu 
to human tetherin. In line with this observation, a recent study showed the importance of the 
conserved face AxxxAxxxAxxxW of Vpu TM domain for directing tetherin binding (386). 
However, replacement of these residues is not sufficient to confer tetherin interaction to O-Vpu. 
Moreover, in attempts to delineate the minimal requirements to render the O-Vpu TM domain 
capable of mediating tetherin antagonism in the context of MTM-MH1, no chimeric TM domain 
gained function. These results suggest that the functional binding interface of Vpu with tetherin 
is likely to be contextually dependent on the entire conformation of the TM domain.  
 The retention of O-Vpu in ER-associated compartments confers a defect to antagonism even 
when interaction with tetherin is mediated through a chimeric TM domain. This can be partially 
overcome by increased Vpu expression, which we interpret as being due to minor amounts of 
O-Vpu being observable in the TGN at high expression levels. Several years ago Schubert and 
Strebel demonstrated that brefeldin A inhibited Vpu-mediated HIV-1 release from infected CD4+ 
T cells (365), and the same laboratory has recently confirmed these data, in the light of the 
discovery of tetherin (381). However, because brefeldin A blocks the bulk flow of secretory 
proteins from the ER, including tetherin, we attempted to alleviate any potential confounding 
factors by appending a strong ER retention signal to M-Vpu. ER-retained M-Vpu was clearly 
defective for tetherin antagonism, but unlike O-Vpu, it was still able to interact with tetherin in 
co-immunoprecipitates, in contrast to a recent report (428). This suggests that while tetherin 
and Vpu can interact in the ER, antagonism of tetherin function requires trafficking of Vpu-
tetherin complexes into TGN compartments. Recent data from the Strebel group have further 
shown that under overexpression conditions, Vpu can induce ER-associated degradation of 
newly synthesized tetherin, but this does not happen in virus-infected cells (381). Thus, if Vpu 
and tetherin do interact prior to ER exit, the appending of the KKDQ motif leads to disruption of 
this interaction when the Vpu is retrieved from the cis-Golgi network. However, to definitively 
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show whether this is the case will require further fluorescence resonance energy transfer-based 
microscopy studies of Vpu-tetherin interactions in living cells. 
 The inability of O-Vpu to exit the ER maps to the membrane-proximal region of the first alpha 
helix of the cytoplasmic tail. The amphipathic nature of helix 1 is thought to allow it to lie partially 
buried along the face of the membrane with the basic residues in contact with the phospholipid 
heads (338). Between the TM domain and the first alpha helix is a putative hinge region, the 
basic residues of which in subtype B Vpu proteins have been implicated in endosome-to-TGN 
localization when mutated to hydrophobic residues (341). We found that replacement of the 
hinge region in O-Vpu 9435 with the corresponding RKILR of M-Vpu conferred both TGN 
localization and efficient tetherin antagonism when combined with the M-Vpu TM domain. This 
phenotype mapped to an acidic residue (E32) in the position equivalent to M-Vpu K31 that is 
conserved in the majority of O-Vpu proteins. Since the reverse mutation in M-Vpu did not lead 
to its ER retention (not shown), these data suggest to us that it is unlikely that this is a specific 
TGN-targeting motif itself. Rather, we suggest that the distribution of basic and acidic residues 
in the membrane-proximal region of the O-Vpu may influence the overall conformation of the 
cytoplasmic tail in relation to the membrane and that the retention of O-Vpu in ER-associated 
compartments may be related to such a structural change. It is interesting to note that O-Vpu 
9435 and chimeric molecules bearing its first alpha-helical region run as a doublet on SDS-
polyacrylamide gels, perhaps suggesting potential differences in conformation or 
phosphorylation. Since O-Vpu still downmodulates CD4, a process that requires interaction with 
the Vpu cytoplasmic tail and its phosphorylation, such putative conformational differences do 
not affect this ER-associated process. However, they do preclude tetherin antagonism without 
high overexpression. Interestingly, while the majority of O-Vpu proteins have an E at position 
32, a minority of sequences has K at this position and hence display increased TGN localization 
(exemplified by O-Vpu HJ001). The lack of a TMD-mediated interaction still precludes tetherin 
antagonism in this case. 
 In line with our findings, Petit et al, showed that both the transmembrane proximal domain 
and the TM domain of NL4.3 Vpu were essential for conferring anti-human tetherin activity to 
HIV-1 Group M Vpu (429). In this study they used different strains of O-Vpu (BCF06 and Ca9) 
and they could confer TGN localization to O-Vpu chimera bearing the TM domain from M-Vpu 
when residues I32 and L33 within the YXXφ motif of the M-Vpu proximal region were 
incorporated into O-Vpu BCF06. They hypothesized that one of the reason why O-Vpu BCF06 
and Ca9 were defective was due to their ability to disrupt the TGN compartment.  
 The Vpu protein of SIVcpz is able to downregulate CD4 but cannot target tetherin, 
presumably because this function became redundant when the ancestral virus acquired a 
tetherin-antagonizing Nef protein from the SIVrcm lineage (226). Unlike the result with the TM 
domain of O-Vpu, replacement of the TM domain of consensus SIVcpzUS Vpu with that of HIV-
1 M-Vpu is sufficient to confer tetherin antagonism (420). Groups M, N, O, and P represent four 
distinct zoonoses of SIVcpz strains to humans. Group O is also highly related to SIVgor, 
suggesting that both viruses have derived from the same SIVcpz strain relatively recently (less 
than 200 years) (430, 431). Whether group O was acquired directly from gorillas or whether 
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these are separate zoonoses of the same virus from chimpanzees is not clear. However, they 
were transmitted to humans, and in each case the zoonotic virus would have initially been 
unable to target human tetherin due to the loss of the Nef-targeting determinant in the human 
protein’s cytoplasmic tail (225-227). In the case of groups M and N, it is likely that the TM 
adaptation of the SIVcpz Vpu proteins was sufficient to adapt to tetherin antagonism, although 
N-Vpu proteins appear to have lost the ability to degrade CD4, the reason for which is unclear 
at present. HIV-1 group N Vpu might have acquired additional functions at the expense of the 
ability to target CD4. CD4 targeting is conserved in all other known HIV-1/SIV Vpu proteins, 
indicating that this is also an essential function and is maintained, despite Nef performing a 
similar role, further suggesting spatial and temporal differences for CD4 targeting. It is 
interesting to speculate that the competing pressure to maintain CD4 degradation in the more 
distantly related SIVcpz that gave rise to HIV-1 group O precluded its adaptation to human 
tetherin because of its ER retention. In SIVcpz infections in chimpanzees, the requirement of 
the protein to leave the ER efficiently may have been under less pressure to be maintained 
because SIVcpz Nef antagonized tetherin in this species and was lost. Of note, HIV-1 group O 
Nef proteins seem to have lost some of their Nef-associated anti-CPZ-tetherin activity following 
transmissions to humans. Alternatively, if group O was primarily derived from SIVgor, these 
differences in Vpu may be a reflection of the SIVcpz Vpu adaptation to new hosts in relatively 
quick succession. To understand this further, more detailed molecular and cellular 
characterization of SIV Vpu proteins is required. 
 It has recently become clear that primate lentiviruses are under evolutionary pressure to 
maintain an activity that counteracts tetherin. That O-Vpu and at least some N-Vpu proteins 
have no such activity has led to speculation that this Vpu function may account for the lack of 
efficient spread of groups N and O in humans compared to group M (426). Furthermore, 
evidence from HIV-2 in human and Nef-defective SIVmac-infected macaques suggests that 
when tetherin antagonism is compromised, viruses that restore the activity in their envelope 
glycoproteins can emerge (230, 231, 235). It should be borne in mind that group N and O 
viruses still retain the capacity to cause AIDS in infected individuals, and at present, it is not 
known whether the failure of O-Vpu to adapt to human tetherin has forced the acquisition of 
tetherin antagonism on the O-group Env. This is all the more plausible given that there is at 
least one documented case of an HIV-1 envelope glycoprotein with Vpu-like activity (432). But it 
cannot be excluded that tetherin antagonism in certain HIV-1 strains might not be absolutely 
required for disease progression, as suggested by recent studies showing that HIV-1 group P 
was unable to antagonize human tetherin by Vpu, Env or Nef (433).  
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Chapter 7                                                                               
Targeting of the glutamine transporter SNAT-1 by HIV-1 Vpu 
7.1 Introduction 
7.1.1 SNAT-1, a new cellular target of HIV-1 Vpu 
In the past few years the accessory proteins and their associated functions have been 
extensively studied to better understand their importance for HIV-1 replication. In some cases, 
these accessory proteins are not limited to one single cellular target. The panel of Vpu's targets 
is increasing. Well known to downregulate CD4 receptor from infected T cells, Vpu came again 
into full focus with the discovery of tetherin as a novel target. Since then, Vpu has been 
extensively studied and the panel of Vpu's cellular targets expanded considerably with a total of 
5 cellular proteins characterized so far (cf. Chapter 1). 
 For the purpose of finding new host proteins targeted by Vpu during HIV-1 infection, we have 
collaborated with Paul Lehner’s group in Cambridge. To address this project, we have 
examined the effects of Vpu expression on the plasma membrane proteomic profile of a derived 
CD4+ T-cell line (Jurkat). Protein abundance between cells stably expressing Vpu and control 
cells lacking Vpu expression was compared. Jurkat cells stably expressing the Vpu protein 
(Jurkat-Vpu) were generated by retroviral transduction using an MLV-based vector also 
conferring, once integrated into the host genome, resistance to puromycin. A control cell 
population (Jurkat-EV) was also made using the empty version of the vector used to express 
Vpu. The two cell populations mentioned above were subjected to SILAC (stable isotope 
labelling by amino acids in cell culture) analyses (Figure 7.1). This technique relies on the 
metabolic incorporation of light and heavy forms of specific amino acids. In our study, the Vpu 
positive cell line was grown in culture medium supplemented with isotopically labelled lysine 
and arginine resulting in the generation of ‘’heavy’’ proteins. In contrast, cells lacking Vpu 
expression were cultivated in normal medium, and incorporated consequently ‘’light’’ amino 
acids during protein synthesis. Then, cell extracts from both populations were treated in order to 
isolate plasma membrane proteins. The subsequent digestion of all membrane proteins with the 
serine protease, trypsin, generates a large panel of peptides, each of them corresponding to a 
unique protein. A unique protein can be identified by several peptides. The peptides are then 
separated and analysed by mass spectrometry (LC-MS: Liquid Chromatography and Mass 
Spectrometry). Pairs of identical heavy and light peptides can be differentiated via their mass 
difference and the height of the peak provides their corresponding abundance in the cell 
population. For instance, if the expression level of a given protein is not affected under Vpu 
expression the intensities of the light and heavy peaks will be equal. On the contrary, in 
conditions where Vpu induces changes in a protein’s abundance, the height of the heavy peak 
will become either lower (Vpu inducing downregulation) or higher (Vpu inducing upregulation) 
compared to the control cells. 
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Figure 7.1: Schematic representation of the SILAC Labelling and Purification Protocol.  
Experimental procedure used to identify plasma membrane proteins affected by Vpu 
expression. Method adapted from (434). 
 
 With this method, Paul Lehner’s group identified 814 unique membrane proteins. Among 
those proteins, 226 were not affected by Vpu expression (ratio light/heavy =1), 270 were 
upregulated (ratio light/heavy <1) and 318 proteins were expressed at lower levels in the 
presence of Vpu (ratio light/heavy >1) (Figure 7.2). More precisely, from 318 proteins 
downregulated by Vpu, only 13 were found to have a 2 fold or more expression difference. At 
the top of the list, as expected, tetherin was found to be the most downregulated protein under 
Vpu expression with a ratio of 12. The T cell glycoprotein, CD4 was also downregulated by 3.6 
fold. As an intermediate phenotype, the glutamine transporter SNAT-1 was downregulated 
approximately 10 fold (x9.9) in Vpu-expressing cells (Table 7.1).	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Figure 7.2: SILAC-based plasma membrane profiling of Vpu-expressing Jurkat cells. 
Single blue dots indicate the differential abundance of a given protein under Vpu expression. 
Proteins upregulated in Vpu-expressing cells (ratio > 0) are plotted on the right part of the 
graph. Blue dots displayed on the left part (ratio <0) represent the proteins downregulated in 
Vpu-expressing cells. Three important substrates of Vpu are highlighted on the graph: 1: 




Table 7.1: Selection of plasma membrane proteins displaying a 3-fold cut-off level of 
downregulation under Vpu expression in the SILAC screening. 
Candidates were identified by several unique peptides. Three additional Vpu substrates were 
identified but so far no functions have been associated with these proteins. 
 
 
 As a novel Vpu target, nothing is known about SNAT-1 in the context of HIV-1 infection. So 
far, as mentioned above, SNAT-1 (also known as SLC38A1) is a neutral amino acid transporter 
with high affinity for transport of glutamine. SNAT-1 plays an important role in the regulation of 
the glutamate/GABA-glutamine cycle in neurons (reviewed in (435)). Furthermore, SNAT-1, and 
its closest relative SNAT-2, have both been found to be upregulated upon T cell activation 
Protein Unique 
Peptides 
Ratio light/heavy Function 
Tetherin / BST-2 2 12 Antiviral restriction factor 
Viral sensor 
SNAT-1 (SLC38A1) 8 9.9 Amino acid transporter 
Glycerophosphodiester 
phosphodiesterase 2 
1 4.1 Enzyme that breaks 
phosphodiester bonds 
Transmembrane protein 63C 3 3.8 ? 
LMBR1 domain-containing protein 1 2 3.6 ? 
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concomitantly with increase in glutamine uptake (436). This project aims to investigate the 
physiological implications of SNAT-1 depletion by HIV-1 Vpu and the consequences of limited 
glutamine availability for HIV-1 replication in CD4+ T cells, as well as the mechanistic aspects of 
Vpu-mediated SNAT-1 degradation. 
 
 
7.1.2 SNAT-1, a glutamine transporter 
SNAT-1 (sodium-coupled neutral amino acid transporter 1) was identified by screening a rat 
cDNA library from glutamatergic neuronal cultures (437). The screening was performed using a 
mouse EST (expression sequence tag) that displayed high sequence identity with vesicular 
GABA/glycine transporters from the AAAP (amino acid/auxin permease) found in yeast, plants 
and C. elegans. Subsequently, a cDNA clone with an open reading frame of 1455 base pairs 
was amplified and originally designated as GlnT (glutamine transporter).  
 SNAT-1 belongs to the SLC38 family of solute carriers (SLC38A1) and was the first member 
of the system A family of neutral amino acid transporters to be cloned. The system A (SNAT-1, 
SNAT-2, SNAT-4) and system N (SNAT-3, SNAT-5) transporters of the SLC38 family each 
mediate sodium-dependent transport of small, aliphatic amino acids and exhibit marked 
inhibition at low extracellular pH (435). Comparatively, system N subtypes have narrow 
substrate profiles (glutamine, histidine and asparagine) whereas system A subtypes accept a 
broader range of amino acids including alanine, asparagine, cysteine, glutamine, glycine, 
methionine and serine. SNAT-1 has been found to be preferentially associated with the 
unidirectional co-transport of glutamine and sodium ions with a stoichiometry of 1:1 (438). 
Interestingly, in Xenopus oocytes expressing SNAT-1, Na+ binding is voltage-dependent and 
precedes the binding of amino acid and its simultaneous transport.  
 SNAT-1 is expressed in somata (cell bodies) and proximal dendrites of neurons (but not in 
the axon terminals) that use glutamine as a precursor for the synthesis of neurotransmitters 
such as glutamate and GABA (glutamatergic and GABAergic neurons) throughout the central 
nervous system (CNS) (Figure 7.3) (437, 438). In neurons, glutamine can be hydrolysed into 
glutamate by the mitochondrial enzyme phosphate-activated glutaminase (PAG). The converted 
glutamine can also serve as a direct precursor of GABA. Upon synaptic release, glutamate is 
then rapidly removed from the synaptic cleft by glutamate transporters that are located on 
surrounding astrocytes. There, the glutamine is synthesized back by conversion from glutamate 
catalysed by glutamine synthetase, an astrocyte specific enzyme. Then, the glutamine is 
exported from the astrocytes via SNAT-3 and possibly also SNAT-5, and then captured by 
SNAT-1 (and possibly also SNAT-2) for neuronal uptake. This mechanism explains the lack of 
SNAT-1 expression in astrocytes whereas SNAT-3 expression is largely confined to astrocytes. 
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Figure 7.3: Role of SNAT-1 in the glutamate-glutamine cycling between central astrocytes 
and neurons. 
An astrocyte is shown in contact with both the cell body and terminal of the neuron. SNAT1/2 
are localized both at the cell body and terminal; SNAT3/5 are only localized within the astrocyte. 
Figure adapted from (435). 
 
 
 At a tissue level, the predominant expression of SNAT-1 is detected in the brain, spinal cord, 
retina, placenta, heart and traces were found in lung, skeletal muscle, spleen and intestine 
(437). Present at high concentrations in the rat brain and spinal cord, SNAT-1 is not only 
expressed in glutamatergic (excitatory neurons) and GABAergic (inhibitory neurons) neurons 
but also in dopaminergic and cholinergic neurons (438). Importantly, SNAT-1 may also 
contribute to providing metabolic fuel via conversion of glutamine into α-ketoglutarate (Figure 
7.4) or in providing prerequisites (cysteine, glycine) for glutathione synthesis (439, 440). 
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Figure 7.4:  Glutaminolysis connects glutamine to the Krebs cycle. 
A: Overview of the citric acid cycle (Krebs cycle). Entry of glutamine into the cycle involves its 
conversion into α-ketoglutarate. B: Conversion of glutamine into α-ketoglutarate involves two 
reactions. First, the hydrolysis of the amino group of glutamine yielding glutamate and 
ammonium is catalyzed by the glutaminase enzyme. Then, glutamate can be converted into α-
ketoglutarate through 3 different catalyzing enzymes, glutamate dehydrogenase (GIDH) and 
glutamate pyruvate transaminase (GPT) or the glutamate oxaloacetate transaminase (GOT) 
that also require, in addition to glutamate, pyruvate and oxaloacetate, respectively.  
 
 
 SNAT-1 is a 485 amino-acid protein composed of eleven predicted hydrophobic membrane-
spanning segments (Figure 7.5), mainly localized in intracellular compartments including 
endosomes (435). Although SNAT-1 must perform its function at the cell surface, only a minor 
fraction is detected on the plasma membrane. No signal sequence is detected to drive 
membrane insertion in the N-terminal part of the protein suggesting that this part is likely 
retained in the cytoplasm leaving the short C-terminal part in the extracellular compartment. 
Predictive analyses based on the primary structure reveal potential motifs, such as N-linked 
glycosylation sites and phosphorylated-residues by protein kinase C. These analyses also 
propose a configuration where the large glycosylated loop between TMD V and VI and the C-
terminal part of the protein are extracellularly localized. 
  
A B 
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Figure 7.5:  Primary amino acid sequence and proposed structure of human SNAT-1. 
This spatial configuration is based on hydropathy analysis. The cytoplasm is shown above and 
the extracellular (or intraluminal) space below the membrane. Amino acid residues shared with 
the vesicular inhibitory amino acid transporter (VIAAT) are shown in yellow. Features such as 
potential sites for N-linked glycosylation (branches), acidic residues (-) and basic residues (+) 




7.2.1 SNAT-1 is degraded by HIV-1 Vpu  
To test whether Vpu induces SNAT-1 degradation in the cell system used in the SILAC study, 
Jurkat-Vpu cells were lysed and cell extracts run on Western blot to measure SNAT-1 
expression relative to the control cells (Jurkat-EV) (Figure 7.6A). Stable expression of Vpu 
results in a marked reduction of SNAT-1 expression levels in cell lysates suggesting that SNAT-
1 was not a false-positive candidate in the proteomics screen. SNAT-1 runs on a Western blot 
at a molecular weight of approximately between 50-80 kDa. HeLa cells stably expressing Vpu 
were generated (HeLa-Vpu) by retroviral transduction. HeLa cells were transfected with either 
siRNA against SNAT-1 or control siRNA, in parallel with HeLa-Vpu. Two days post-transfection, 
the cells were lysed and cell extracts analysed by Western blot (Figure 7.6B). Interestingly, Vpu 
expression led to the depletion of SNAT-1 to levels comparable with siRNA-mediated SNAT-1 
silencing. We then wanted to confirm whether we could still detect the effects of Vpu on SNAT-1 
in a system where Vpu was expressed at a more physiological level, in the context of virus 
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infection. Jurkat cells were infected with VSV-G pseudotyped HIV-1 Wt or HIV-1 delVpu at a 
multiplicity of infection of 2. 48 hours later, cells were lysed in loading buffer and protein 
samples blotted for SNAT-1 and β-actin, serving as a loading control (Figure 7.6C). Infection 





















Figure 7.6: Vpu induces degradation of endogenous SNAT-1. 
A: SNAT-1 degradation in Vpu-expressing Jurkat cells. B: SNAT-1 degradation in Vpu-
expressing HeLa cells. HeLa cells were transfected with SNAT-1 siRNA 48 hours before lysis. 
Endogenous SNAT-1 expression was then quantified by Western blot with anti-SNAT-1 
antibody. β-actin serves as loading control. C: SNAT-1 degradation in HIV-1 infected Jurkat 
cells. Cells were infected at a MOI of 2 with VSV-G pseudotyped HIV-1 Wt or delVpu and 
harvested 48 hours later. Stable cell lines from panels A, B and C were generated by Stuart 
Neil's lab and Western blots performed by our collaborators. 
 
 
 We then generated 293T cells stably expressing a C-terminally HA tag version of SNAT-1 
(293T SNAT-1/HA). As the HA tag is located on the extracellular part, expression of SNAT-1/HA 
on the cell surface can be measured by flow cytometry (Figure 7.7A). We then examined 
whether in this system expression of SNAT-1 at the cell surface was decreased in the presence 
of Vpu. 293T SNAT-1/HA cells were transduced with MLV-based vectors encoding Vpu or an 
empty control coupled to an IRES-eGFP gene. Two days post-transduction, cells were 
immunostained for HA and analysed by flow cytometry to quantify surface SNAT-1/HA 
expression levels (Figure 7.7B). Consistent with the depletion of SNAT-1 levels in cell lysates, 
GFP positive cells displayed a markedly reduced expression of SNAT-1 at the cell surface in the 
presence of Vpu Wt in comparison to cells transduced with the empty-GFP vector. Alternatively, 
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293T SNAT-1/HA were infected with VSV-G pseudotyped HIV-1 Wt or HIV-1 delVpu at 
multiplicity of infection of 2. Two days post-infection, cells were harvested and analysed by 
Western blot for anti-HA for SNAT-1 detection (Figure 7.7C). In 293T SNAT-1/HA cells infected 
with HIV-1Wt, SNAT-1 expression levels were 3 fold lower compared to uninfected cells, 
whereas cells infected with the version of HIV-1 lacking the Vpu gene, SNAT-1/HA levels were 
similar to levels expressed in uninfected cells. Therefore, the HA epitope added at the C-
terminus of SNAT-1 does not impair its sensitivity to Vpu. In this system SNAT-1 HA runs as a 
smear on a Western blot likely representing precursor and glycosylated forms. Altogether, these 


























Figure 7.7: Vpu induces degradation of exogenous SNAT-1. 
A: 293T SNAT-1/HA cells were immunostained with anti-HA antibody and levels of cell-surface 
SNAT-1/HA quantified by flow cytometry (grey histogram). The histogram with dashed line 
represents the binding of the isotype control. 293T were also stained with the anti-HA antibody 
and serve as background control (blue histogram). In SNAT-1 sequence the HA epitope is 
located at the short C-terminus extracellular part. B: 293T SNAT-1/HA cells were transduced 
with VLPs bearing Vpu Wt or the empty vector (EV). After two days in culture, cells were 
harvested and immunostained for surface SNAT-1 expression. Numbers indicate median 
fluorescence intensities of surface SNAT-1 in GFP+ gate (green square). C: SNAT-1 
degradation in infected 293T stably expressing SNAT-1/HA. Cells were infected at a MOI of 2 
with VSV-G pseudotyped HIV-1 Wt or delVpu and harvested 48 hours later. Exogenous SNAT-1 
expression was then quantified by Western blot with anti-HA antibody. The histograms 
represent the percentage of cell-surface SNAT-1/HA levels normalized to Hsp90. 
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 We then tested whether SNAT-1 interfered with tetherin-mediated reduction of virus particle 
release. 293T, 293T SNAT-1/HA, HeLa and HeLa SNAT-1/HA were infected with HIV-1 Wt or 
HIV-1 delVpu viruses at a MOI of 2, and incubated for two days. The supernatants were then 
harvested and titrated on HeLa-TZMbl indicator cells (Figure 7.8). In both tetherin-negative 
(293T and 293T SNAT-1/HA) and positive (HeLa and HeLa SNAT-1/HA) cell lines, over-


















Figure 7.8: Virus particle release in SNAT-1 expressing cells is still sensitive to Vpu-
mediated tetherin antagonism. 
293T, 293T SNAT-1/HA, HeLa and HeLa SNAT-1/HA were infected with VSV-G pseudotyped 
HIV-1 Wt or HIV-1 delVpu at an MOI of 2. 48 hours post-infection, viral supernatants were 
assayed for infectivity using HeLa-TZMbl reporter cells. Infectious virus release plotted on a log-
scale was determined by quantification of β-galactosidase activity in relative light units (RLU).  
 
 
7.2.2 Determinants of SNAT-1 downregulation in Vpu  
Vpu counteraction of tetherin requires the presence of intact key residues in the Vpu sequence. 
Mutations in the Vpu TMD domain impairing its ability to interact with tetherin, or modifications 
in its cytoplasmic tail altering its cellular trafficking, abolish the ability of Vpu to efficiently 
overcome tetherin-mediated restriction of virus particle release (221, 383). To identify whether 
residues in the transmembrane domain of Vpu were required to target SNAT-1, we tested the 
panel of Vpu TMD mutants (cf. alanine scan Vpu TMD mutants, chapter 5) for their capacity to 
downregulate SNAT-1 expression from the cell surface. 293T SNAT-1/HA cells were transduced 
with MLV-based vectors encoding Vpu Wt or Vpu TMD mutants coupled to an IRES-eGFP 
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gene. Two days post-transduction, cells were immunostained for HA and analysed by flow 
cytometry to quantify surface SNAT-1/HA expression levels (Figure 7.9). As expected, in GFP 
positive cells, the levels of cell-surface SNAT-1 were reduced in the presence of Vpu Wt. A five 
fold decrease in cell-surface levels of SNAT-1 is observed with Vpu-Wt compared to control 
cells transduced with the empty GFP vector. While Vpu I16A displayed a weaker ability to 
downregulate SNAT-1 expression than the wild type Vpu, the downregulation is completely 
abrogated by a Vpu construct bearing the W22A mutation. Additionally, we tested the 
importance of the two phosphorylated serine residues S52 and S56 in the conserved region of 
the Vpu cytoplasmic tail. Viral particles, bearing Vpu S52,56A changes transduced into 293T 
SNAT-1/HA cells failed to decrease SNAT-1 expression from the cell surface. Therefore, 
residue W22 and the dual serine motif S52,56 are required for Vpu-mediated SNAT-1 
downregulation. Comparatively, these determinants are similar to those involved in tetherin and 
CD4 targeting by Vpu suggesting potential similarities between the mechanisms; Vpu might 
induce a β-TrCP-dependent degradation of SNAT-1. To confirm these data, the defective Vpu 
mutants W22A and S52,56A were stably expressed in Jurkat cells via retroviral transduction. 
Cells were then processed for Western blotting to measure intracellular SNAT-1 expression 
levels (Figure 7.10A). As expected, Vpu Wt and Vpu A14L but not Vpu W22, Vpu A14L-W22A 
or Vpu S52,56A reduced SNAT-1 expression in cell extracts. The Vpu A14L mutant was 
introduced in this experiment in order to rule out that Vpu/tetherin interactions could influence 
Vpu-mediated SNAT-1 degradation. Similar results were observed in 293T SNAT-1/HA cells 
infected with viruses bearing Vpu mutations mentioned above (Figure 7.10B). VSV-G 
pseudotyped HIV-1 Vpu Wt, Vpu A14L viruses but not Vpu W22, Vpu A14L-W22A and Vpu 
S52,56A efficiently depleted SNAT-1 expression from 293T SNAT-1/HA infected cells (MOI= 2) 
despite equivalent Vpu expression levels. The profile of Gag on Western blot indicates that Vpu-
mediated SNAT-1 degradation does not affect the synthesis and further processing of structural 
viral proteins. These results provide useful tools to investigate further the molecular mechanism 
employed by Vpu to degrade SNAT-1. However, Vpu I16A introduced in the context of NL4.3 
proviral plasmid achieves similar depletion levels of SNAT-1 HA to Wt Vpu (Figure 7.10C). In an 
attempt to map the residues in Vpu sequence required for SNAT-1 downregulation, we have not 
yet identified mutations in Vpu that render Vpu selectively defective for SNAT-1 downregulation 
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Figure 7.9: The transmembrane residue W22 and the phosphorylation site S52, S56 in the 
cytoplasmic tail are required for Vpu-mediated SNAT-1 cell surface downregulation. 
Screening of the Vpu TMD residues for SNAT-1 downregulation in 293T SNAT-1/HA cells. 293T 
SNAT-1/HA cells were transduced with VLPs bearing Vpu Wt or the indicated Vpu mutant. After 
two days in culture, cells were harvested and immunostained for HA before flow cytometry 
analysis. Cell surface levels of SNAT-1/HA were measured in GFP positive cells (green gate, 
top panel). For each indicated Vpu mutant, the median fluorescence of SNAT-1/HA is 
normalized on the surface levels of SNAT-1/HA in Vpu-negative cells (bottom panel). The 
histograms display the average of the percentage of surface SNAT-1/HA levels obtained from 
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Figure 7.10: Mutations W22A and S52,56A abolish Vpu-mediated SNAT-1 degradation. 
A: Equivalent number of the indicated cell lines were harvested and blotted for endogenous 
SNAT-1 and β-actin as a loading control. Cell lines were prepared by myself and our 
collaborators performed Western blots. B: SNAT-1 degradation by Vpu TMD and 
phosphorylation mutants in HIV-1 infected 293T SNAT-1/HA cells. 293T SNAT-1/HA were 
infected with pseudotyped HIV-1 Wt or delVpu (MOI=2) and 48 hours later, cells were blotted for 
Hsp90, HA, Gag and Vpu. The histograms represent the percentage of total cellular SNAT-1/HA 
levels normalized to Hsp90. C: Ability of Vpu I16A to induce SNAT-1 degradation when 
expressed in the context of the proviral plasmid. Same experimental procedure as in B.  
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7.2.3 Vpu mediated SNAT-1 degradation is sensitive to lysosomal and proteasomal 
inhibitors 
Vpu induces SNAT-1 degradation but the nature of the degradation mechanism remains to be 
determined. To this end, 293T SNAT-1/HA cells were infected with VSV-G pseudotyped HIV-1 
Wt or HIV-1 delVpu and 36 hours later the cells were treated with different class of inhibitors or 
with DMSO as a control for untreated cells. Treatment with Bafilomycin A or Concanamycin A 
blocks the endolysosomal degradation through inhibition of vacuole-type H+-ATPase whereas 
MG132 inhibits directly the proteasome pathway. After 16 hours in the presence of the drugs, 
cells were harvested and blotted for SNAT-1/HA (Figure 7.11). Both Bafilomycin and 
concanamycin inhibitors rescued SNAT-1 expression levels in cells lysates from HIV-1 Wt 
infected cells suggesting that Vpu degrades SNAT-1 via an endolyzosomal process. A 
prolonged MG132 treatment also restored SNAT-1 expression suggesting a ubiquitin-
dependent mechanism mediated by Vpu. Thus, Vpu might use the ubiquitin-tag machinery to 
direct SNAT-1 for endosomal destruction. Since ubiquitinated-proteins targeted for degradation 
via the endolysomal pathway are recruited and sorted by components of the ESCRT machinery, 
we investigated the role of two ESCRT subunits, UBAP1 and Tsg101. Ubiquitin associated-
protein 1 (UBAP1) is a subunit of ESCRT-I that forms a complex by interacting with Tsg101, 
Vps28 and Vps37 and has been shown recently to be involved in the degradation of tetherin 
mediated by both K5 and Vpu (390). Tsg101 is a core ESCRT-I component required for all 
ESCRT functions. Depletion of cellular Tsg101 arrests HIV-1 budding at a late stage (140, 141). 
293T SNAT-1/HA cells were transfected once with siRNA against UBAP1 or Tsg101 and 
transfected again 48 hours later with the same siRNA oligos before being infected at a 
multiplicity of infection of 2 with pseudotyped HIV-1 Wt or HIV-1 delVpu virus particles. Two 
days post-infection, cells were harvested and subjected to SDS-PAGE and Western blotting to 
quantify SNAT-1/HA expression (Figure 7.12A). Vpu was found to achieve similar levels of 
degradation of SNAT-1 in UBAP1-depleted cells as in cells transfected with non-targeting 
siRNA oligos. Similar to UBAP1 depletion, silencing of Tsg101 also had no impact on the ability 
of Vpu to induce SNAT-1 degradation. As expected, Tsg101 knockdown also reduced UBAP1 
expression (Figure 7.12A), induced accumulation of Gag-p25 in cell lysates and decreased viral 
particle release by 10 fold compared to control cells (Figure 7.12B). Interestingly, in Tsg101-
depleted cells, SNAT-1 expression was decreased likely due to toxicity. These data suggest 
that Vpu-mediated SNAT-1 degradation is lysosomal and ubiquitin dependent but ESCRT 
independent, unless there are ESCRT functions that do not involve Tsg101. However, this is 
unlikely because it is known that Tsg101 is tightly regulated and when its expression is inhibited 
no ESCRT complexes can form because the others subunits become unstable (441). This likely 
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Figure 7.11: Effects of endolysosomal and proteasomal inhibitors on Vpu-mediated 
SNAT-1 degradation. 
293T SNAT-1/HA cells, initially transfected with VSV-G HIV-1 WT or HIV-1 delVpu viruses, were 
treated for 16 hours with Bafilomycin A1 (100nM), concanamycin A, MG132 (1µg/ml) or DMSO 
as a control, before being lysed and Western blotted for HA and Hsp90. The histograms 
represent the percentage of total cellular SNAT-1/HA levels normalized to Hsp90. 
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Figure 7.12: siRNA-mediated silencing of UBAP1 and Tsg101 do not impact Vpu-
mediated SNAT-1 degradation. 
A: 293T SNAT-1/HA cells were transfected twice (cf. chapter 2) with siRNA oligos against 
UBAP1, Tsg101 or control siRNA and infected with HIV-1 Wt or delVpu. A total of 48 hours later 
cells were lysed in loading buffer and processed for Western blotting. The total cellular SNAT-
1/HA levels normalized to Hsp90 are indicated. B: Viral supernatants from A were titrated on 




7.2.4 SNAT-1 sensitivity to Vpu is not determined by its cytoplasmic tail 
Vpu-mediated tetherin antagonism requires interaction of both proteins via their transmembrane 
domains. Recently, Vpu TM domain has also been shown to be essential to retain CD4 
molecules in the endoplasmic reticulum before their subsequent degradation via ERAD (370). 
We then examined the importance of the region formed of 11 membrane-traversing segments, 5 
intracellular loops, 5 extracellular loops and a short extracellular C-terminus, in the SNAT-1 
sequence for the ability of Vpu to degrade SNAT-1. Importantly, SNAT-2 (SLC38A2), another 
member of the SLC38 family of solute carrier acting also as an amino acid transporter, was not 
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found to be downregulated by Vpu in the SILAC screen, although it was identified. This 
characteristic provides a useful tool to map the determinants in SNAT-1 that confer its sensitivity 
to Vpu. SNAT-1 and SNAT-2 display the same predicted topology and share 52% of sequence 
homology facilitating the design of chimera SNAT-1/SNAT-2 proteins (Figure 7.13).  
 The cytoplasmic tails of SNAT-1 and SNAT-2 were swapped resulting in two chimeras 
(Figure 7.14A). SNAT 1-2 chimera is mainly identical to SNAT-2 but has the cytoplasmic tail of 
SNAT-1 whereas SNAT 2-1 chimera is the SNAT-1 protein with SNAT-2 cytoplasmic domain. 
293T cells stably expressing SNAT-2/HA, SNAT 1-2/HA and SNAT 2-1/HA were made and 
tested for Vpu-mediated degradation. The cells were infected with VSV-G pseudotyped HIV-1 
Wt or HIV-1delVpu viruses at a MOI of 2. 48 hours later, cells were lysed in loading buffer and 
processed by Western blot for anti-HA (Figure 7.14B). In contrast to 293T SNAT-1/HA, infection 
of 293T SNAT-2/HA cells with HIV-1Wt or HIV-1 delVpu does not affect SNAT-2 expression 
levels demonstrating that Vpu is unable to target SNAT-2 for degradation. Therefore, Vpu 
displays specificity in its ability to target SNAT-1. Comparison between SNAT-1 and SNAT-2 
reveals a high degree of sequence divergence (Figure 7.13). Similarly, expression levels of 
SNAT 1-2 is also not affected by Vpu expression indicating that the cytoplasmic tail of SNAT-1 
by itself does not confer sensitivity for Vpu. However, chimeric SNAT-1 bearing the SNAT-2 
cytoplasmic tail (SNAT 2-1) remained sensitive to Vpu-mediated depletion. These results 
suggest that Vpu-mediated SNAT-1 degradation requires essentially the region outside the 
cytoplasmic tail in SNAT-1 sequence. Presumably, Vpu is likely to mediate interactions within 
this region of SNAT-1, but this region not only encompasses transmembrane domains but also 
five loops facing the cytoplasm and five extracellular loops. It is possible that these loops 
function to maintain the overall conformation of SNAT-1, thus stabilizing the incorporation of 
SNAT-1 into the membrane lipid bilayer. Moreover, it cannot be excluded that the intracellular 














Figure 7.13: Alignment of protein sequences between SNAT-1 and SNAT-2. 
Comparison of SNAT-1 and SNAT-2 protein sequences. The conserved residues are shown in 
red. The alignment was performed using the alignment tool FFAS03.  
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Figure 7.14: SNAT-1 transmembrane region confers sensitivity to Vpu. 
A: Schematic representation of SNAT-1/SNAT-2 chimera. B: SNAT-1 cytoplasmic tail is not 
required for Vpu-mediated SNAT-1 degradation. 293T cells stably expressing the indicated 
SNAT chimera were infected with HIV-1 Wt or the Vpu-defective HIV-1 counterpart at a 
multiplicity of infection of 2. After two days of incubation, cells were lysed and proteins 
expression quantified by Western blot. The total cellular levels of SNAT*/HA are normalized to 
Hsp90 and displayed on histograms. 
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7.2.5 Vpu physically associates with SNAT-1 
We then assessed the ability of Vpu to immunoprecipitate SNAT-1 molecules as an indicator of 
potential direct or indirect interaction between the two proteins. 293T SNAT-1/HA were 
transiently transfected with a pCRV1 expression vector encoding Wt Vpu, Vpu A14L-W22A or 
Vpu S52,56A. Two days later, cells were lysed, HA-tagged proteins immunoprecipitated and 
Western blotted for Vpu expression (Figure 7.15). We found that Wt Vpu and Vpu S52,56A but 
not Vpu A14L-W22A were co-immunoprecipitated with SNAT-1/HA molecules. The Vpu A14L-
W22A mutant is likely to be defective for tetherin interactions because of the missing tryptophan 
residue, which was previously shown to be also required to reduce cell-surface levels of SNAT-
1. Since Vpu bearing the mutation S52,56A is defective for mediating SNAT-1 degradation but 
not for interaction, this suggests that SNAT-1 binding to Vpu is likely to be necessary but not 
sufficient to mediate SNAT-1 degradation. This observation is similar to the tetherin study where 
physical interaction and degradation are separable events, for which the determinants differ but 























Figure 7.15: Vpu interacting with SNAT-1 involves the residues W22 but not the 
phosphorylation motif. 
293T SNAT-1/HA were transfected with pCRV1 Vpu Wt, Vpu A14L-W22A or Vpu S52,56A. 48 
hours post-transfection, cells were lysed and proteins immunoprecipitated with an anti-HA 
antibody. Lysates and precipitates were subjected to SDS-PAGE and Western blotted for Vpu 
and SNAT-1/HA.  
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7.2.6 SNAT-1 and Vpu colocalize into intracellular compartments 
In the absence of Vpu expression, SNAT-1 localizes at the plasma membrane and in 
intracellular compartments that mainly overlay with TGN46 positive compartments suggesting a 
trans-golgi network localization (Figure 7.16A). But despite its localization in the TGN and at the 
plasma membrane a large proportion of SNAT-1 staining appears to be associated with small 
vesicles likely to be endosomes. Interestingly, it has been shown that after T cell stimulation 
there was an increase in surface expression of glutamine transporters (436) consistent with the 
idea that increased glutamine transport might be due to a combination of increased protein 
expression and relocation of transporters from intracellular stores to the cell surface. Since Vpu 
and SNAT-1 can co-immunoprecipitate, it is likely that these two proteins are expressed into 
similar subcellular compartments. HeLa cells were transiently transfected with a Vpu-Cherry 
encoding vector and a plasmid encoding SNAT-1/HA. 24 hours post-transfection, cells were 
fixed in 4% paraformaldehyde, immunostained for SNAT-1/HA and observed by confocal 
microscopy (Figure 7.16B). Vpu and SNAT-1 colocalize in intracellular compartments that 
resemble vesicles. Alternatively, 293T SNAT-1/HA were infected with HIV-1 Wt or HIV-1 delVpu 
and stained for SNAT-1 and Vpu detection (Figure 7.16C). In HIV-1 Wt infected cells SNAT-1 
expression is not detected at the cell surface in comparison to uninfected control cells. Similar 
to tetherin, for the majority of infected cells no residual traces of SNAT-1 expression were 
detected in intracellular compartments. Only in transiently-transfected cells, we could observe 


















Figure 7.16: Subcellular localization of SNAT-1/HA. 
A: SNAT-1/HA subcellular distribution in the absence of Vpu in HeLa cells. HeLa cells were 
transfected with 100 ng of pCR3.1 SNAT-1/HA expression vector alone or in combination with 
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100ng of a cherry fused Vpu construct. 24 hours later, the cells were fixed in 4% 
paraformaldehyde, immunostained with anti-HA antibody, anti-TGN46 (cellular marker of TGN) 
and fluorescence signals observed by confocal microscopy. Images are representative 
examples of SNAT-1 expressing cells. B: Cherry-fused Vpu and SNAT-1/HA colocalize in 
transfected HeLa cells. C: Depletion of SNAT-1 from the cell surface in infected 293T SNAT-
1/HA cells. 293T SNAT-1/HA cells were infected with HIV-1 Wt at a multiplicity of infection of 1 
and fixed 48 hours later. Cells were then stained for Vpu and SNAT-1 detection with 
respectively anti-HA antibody (green) anti-Vpu antibody (red) and examined by confocal 
microscope. Nuclei were counterstained with DAPI (blue). Images are representative examples 
of HIV-1 infected 293T SNAT-1/HA.	  
	  
	  
7.2.7 Effects of SNAT-1-depletion by HIV-1 Vpu in primary CD4+ T lymphocytes 
Glutamine is the most abundant amino acid in the plasma and is essential for various 
biochemical functions including protein synthesis, cellular energy, inter-organ transfer of 
nitrogen, amine group donor for nucleotide synthesis and other important cellular processes. 
Recently, its role during CD4+ T lymphocyte activation has been demonstrated (436). 
Recognition of antigen presented by MHC-II molecules on APCs by the TCR complex triggers a 
succession of reactions ultimately leading to the activation of the naïve T cell. This activation 
leads to the secretion of cytokines, clonal expansion of the naïve T cell concerned, and 
differentiation into a given type of T cell subset. All these processes require a high energetic 
demand and force the cellular machinery to increase its metabolic activity. In these conditions, 
nutrients such as glutamine are essential to provide the basic building blocks of protein 
synthesis and also serve as substrates for many other metabolic processes.  
 T cell activation is absolutely dependent on extracellular glutamine (436). Removal of 
glutamine from activated T cells (anti-CD3/CD28 stimulation) in culture consistently inhibits T 
cell proliferation, blocks secretion of IL-2 and IFN-γ. In that sense, T cell activation is coupled to 
an increase in glutamine uptake. A 5 to 10 fold induction of glutamine uptake in activated T cells 
is observed comparatively to unstimulated control cells. Concomitantly to glutamine uptake 
increase, T cell activation also induces expression of glutamine transporters such as SNAT-1 
and SNAT-2.  
 Given the importance of glutamine for T cell function (436, 442-444), glutamine utilization 
might be regulated by T Cell Receptor (TCR)-initiated signals. TCR activation triggers multiple 
signal transduction pathways, including the members of the mitogen-activated protein kinase 
(MAPK) family. ERK 1/2 (extracellular signal regulated kinase) belongs to this family and was 
shown to increase expression of amino acid transporters from the system A (445). Consistent 
with this, treatment of stimulated T cells with ERK inhibitors completely blocks the increased 
glutamine uptake. This suggests that ERK acts downstream of TCR complex signaling to 
control SNAT expression, transport activity and positively regulates glutamine uptake (436). The 
high demand on glutamine during T cell activation suggests that glutamine might not only be 
used for protein synthesis. Indeed, the activity of the enzyme glutaminase, that catalyzes the 
conversion of glutamine into glutamate, is enhanced during T cell activation. Activities of 
enzymes ensuring conversion of glutamate into α-ketoglutarate, which then, can serve as a 
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substrate to enter the Krebs cycle, are also upregulated by T cell activation (436). In 
accordance with these published data, our collaborators showed that at glutamine 
concentrations lower than 1mM the number of cell divisions was severely impaired (Figure 
7.17A). At a glutamine concentration of 1mM, T cells displayed high proliferative capacity; 
nevertheless glutamine concentrations higher than 1mM did not significantly enhance the 
proliferation. By comparison, the physiological concentration of glutamine in vivo is 
approximately 0.6 mM and in vitro, normal culture media are supplemented with 2-4 mM final 
glutamine concentration. Similar to Carr et al, our collaborators demonstrated that expression of 
the SNAT-1 transporter was induced in activated primary human CD4+ T cell but not in resting T 
cells (Figure 7.17B). SNAT-1 expression was detectable from 48 hours post-activation and was 
found to be maximal four days post-stimulation with anti-CD3/CD28. Although SNAT-1 
knockdown in immortalized cells, such as Jurkat, does not affect cell growth, in primary human 
CD4+ T cells, depletion of SNAT-1 expression by RNAi strongly inhibits T cell proliferation 
despite increasing input of extracellular glutamine provided in the culture medium (Figure 
7.17C-D). 
 These results suggest that Vpu might, by degrading the transporter SNAT-1, block T cell 
proliferation through limiting the glutamine availability in infected T cells. To test this hypothesis 
several aspects will need to be addressed. Does Vpu expression affect the proliferative capacity 
of infected CD4+ T cells? And in that situation is HIV-1 replication more productive? The next 
part aims to understand the physiological implications of Vpu targeting SNAT-1 for HIV-1 
replication. 
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Figure 7.17: CD4+ T cell proliferation is SNAT-1 and glutamine dependent. 
These experiments were performed by Paul Lehner's group. A: Dependence on glutamine of 
primary human CD4+ T cell proliferation. CD4+ T cells isolated from PBMCs were labelled with 
CFSE as a proliferation marker and stimulated with anti-CD3/CD28 beads and placed in culture 
medium containing the indicated glutamine concentration. 96 hours post-stimulation, cells were 
harvested and mean number of cell divisions quantified by flow cytometry. B: SNAT-1 
expression in activated primary human CD4+ T cells. CD4+ T cells were extracted as above and 
harvested at 24, 48, 72 and 96 hours post-stimulation. Endogenous SNAT-1 expression levels 
were then analysed by Western blot with anti-SNAT-1 antibody. C: Effects of SNAT-1 silencing 
on CD4+ T cell proliferation. As in A but CD4+ T lymphocytes were electroporated with siRNA 
control or siRNA against SNAT-1. The cells were grown in media supplemented with different 
glutamine concentrations and the mean number of cell generations enumerated 96 hours post-
isolation. D: SNAT-1 knockdown in primary human CD4+ T cells. CD4+ T cells from C were 
subjected to SDS-PAGE and Western blotted for SNAT-1. 
	  
	  
7.2.7.1 Effects of Vpu expression on primary CD4+ T cells proliferative capacity 
Since SNAT-1 knockdown and limiting glutamine concentrations impaired T cell proliferation, we 
investigated whether Vpu expression could also directly cause inhibition of T cell proliferation. 
Untouched primary human CD4+ T cells were isolated from PBMCs, labelled with CellTrace 
Violet dye as a proliferation tracer, stimulated with anti-CD3/CD28 antibodies coupled to 
magnetic beads and cultured in 1mM glutamine-RPMI medium (Figure 7.18A). Since SNAT-1 
expression was detectable from 48 hours post-activation, at that time cells were infected with 
VSV-G pseudotyped HIV-1 Wt or HIV-1 delVpu at a multiplicity of infection of 1. This timing 
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permits synchronized expression of Vpu and SNAT-1 (Figure 7.17B and Figure 7.18B). Over 
the following 3 days, cells were harvested every day, and proliferation (via Violet dye) versus 
intracellular p24 staining (as a marker of infection) were then monitored by flow cytometry for 
each time point (Figure 7.19). Importantly, because Vpr can induce a G2 cell-cycle arrest of 
HIV-infected T cells, we used a Vpr mutant (Vpr L64P) that cannot mediate binding with the 
damage-specific DNA binding protein DDB1 required for Vpr-induced cell-cycle arrest and 















Figure 7.18: Monitoring the proliferation of HIV-1 infected primary human CD4+ T 
lymphocytes. 
A: Schematic representation of the experimental procedure. Primary human CD4+ T 
lymphocytes were isolated from PBMCs using a negative selection kit, labelled with CellTrace 
Violet dye and stimulated with anti-CD3/CD28 beads. CD4+ T lymphocytes were then cultured 
for two days in medium containing 1mM concentration of glutamine before being infected with 
VSV-G pseudotyped HIV-1 Wt or delVpu. Cells were collected at 24, 48, 72 hours post-
infection, stored in staining buffer. All the cells were stained at the same time for intracellular 
p24 and proliferation was measured by flow cytometry. B: Time course of Vpu expression in 
HIV-1 infected primary CD4+ T cells. CD4+ T cells were purified and infected as above. At day 3, 
4, 5 and 6 post-CD3/CD28 stimulation, cells were harvested in SDS-PAGE loading buffer and 
Vpu expression detected by Western blot. 
 
 
 24 hours post-infection 30% of T cells were p24 positive for both Wt and Vpu-defective HIV-1 
and approximately 40% the following day. Uninfected cells from the uninfected sample 
accumulated 4 divisions with approximately 25% of cells in the third generation, 43% in the 
second generation and 26% in the first generation (Figure 7.19A). Only a few cells were 
detected in the fourth generation. In contrast, infected T cells gated on the p24 positive gate 
displayed a reduced proliferation capacity. A proportion of 10% HIV-1 Wt (Vpr L64P) infected 
cells were detected in the third generation whereas twice as many Vpu-defective HIV-1 (Vpr 
L64P-delVpu) infected cells were present in the same generation. A similar delay was observed 
at day 2 and day 3 post-infection in the presence of Vpu. Indeed, at day 2 post-infection, 31% of 
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p24 positive HIV-1 Vpr L64P infected cells were detected in the second generation and 5% in 
the third generation whereas 38% and 14% of p24 positive HIV-1 L64P delVpu infected cells 
accumulated respectively in the same divisions. This delay seems to result from the fact that 
more cells accumulated in the first generation when infected with a Vpu-encoding HIV-1 (50%) 
while only 38% of HIV-1 delVpu infected cells were measured in the first division. These results 
were then confirmed by an additional experiment performed from a different blood donor (Figure 
7.19B). A similar pattern of proliferation was found. In all cases the expression of Vpu induced a 
delay of T cell proliferation. Cells infected with Vpu-expressing HIV-1 always displayed 
accumulation of cells in the early generations resulting in less cells counted in the last 
generations whereas Vpu-defective HIV-1 infected T cells had the opposite proliferation profile. 
However, the delay observed might be due to the cytopathic effects of Vpu rather than its role in 
regulating T cell proliferation. Indeed, Vpu has been suggested to promote T cell apoptosis by 
interfering with NF-κB activation in a manner dependent on β-TRCP interaction (350). 
Preliminary data showed that SNAT-1 degradation might be β-TRCP dependent, it is therefore 
possible that Vpu targeting SNAT-1 might also contribute to apoptosis. It would be interesting to 
determine whether Vpu-mediated degradation of tetherin, CD4 or SNAT-1 participate 
differentially to apoptosis or if there are any competitive pressures between these three 
degradation pathways. 
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Figure 7.19: Proliferation profile of primary human CD4+ T cells under HIV-1 infection. 
A: Primary human CD4+ T cells were isolated and infected as above. Proliferation in p24 
positive cells was measured at 24 (day 1), 72 (day 2) and 96 hours (day 3) post-infection by 
flow cytometry using Violet dye as a cell division tracer. Each histograms display the proportion 
of p24 positive CD4+ T cells in the indicated cell division (generation). Generations are indicated 
in colors. B: Similar experiment as in A but with a different blood donor. In that experiment, the 
infection levels were higher than in A. 
 
 
7.2.7.2 Influence of glutamine levels on HIV-1 replication  
Based on the hypothesis that Vpu degrades SNAT-1 to modulate the intracellular glutamine 
levels, we then asked whether HIV-1 replication was enhanced in glutamine concentrations (< 
1mM) that were shown to limit T cell proliferation. To address this, we examined HIV-1 
replication in infected cells maintained in different glutamine concentrations (Figure 7.20A). 
Untouched human CD4+ T cells were isolated from peripheral blood mononuclear cells (PBMC), 
stimulated with anti-CD3/CD28 antibodies and maintained in culture medium supplemented with 
minimal glutamine concentration (1mM). Two days later, the cells were infected with VSV-G 
pseudotyped NL4.3 HIV-1 Wt or HIV-1 delVpu at an MOI of 0.1 to allow the virus to replicate 
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through the culture over-time via multiple cycles of infection. Three hours post-infection, cells 
were washed to eliminate viruses in suspension and excess of glutamine. The cells were then 
placed in media containing dialyzed serum and a dilution range of glutamine concentrations  (0-
0.2-0.5-1mM). Then, several time points were collected and at which the infectivity of viral 
supernatants was assayed on TZMbl cells (Figure 7.20B) and cells stained for intracellular p24 
(Figure 7.20C). Firstly, we found, based on the infectivity assay of viral supernatants, that virus 
production was maximal at 3 days post-infection for HIV-1 Wt in all concentrations of glutamine 
tested. Virus production of HIV-1 delVpu reaches its peak one day later compared to HIV-1 Wt, 
at day 4 post-infection, for all the conditions tested with the exception of cells maintained in 
1mM extracellular glutamine concentration for which the maximal virus production is almost 
reached at day 3. This observation does not validate our hypothesis, as we would expect to 
have a lower virus replication rate in high glutamine levels when Vpu is not expressed. 
Unsurprisingly, HIV-1 delVpu viral titers were 1 log lower than those of HIV-1 Wt due to tetherin-
mediated particle release retention. Importantly, no defect in HIV-1 replication was observed at 
subphysiological glutamine concentrations (0.2; 0.5mM) suggesting that limited cell proliferation 
is not detrimental for virus replication. In the absence of extracellular glutamine (0mM), the 
replication rate of HIV-1 Wt was much slower with virus production reaching its peak 7 days 
post-infection. Since a similar delay was observed in HIV-1 delVpu infected cells, those effects 
could not be attributed to Vpu. Presumably, this delay reflects the fact that in such conditions 
fewer virus-producer cells are being generated due to limited cell proliferation thus impairing 
virus replication but HIV-1 might still manage to replicate in glutamine-free medium by acquiring 
the nutrients via autophagy. Replication rate analysed by examining the percentage of cells that 
became p24 positive over time revealed a similar picture (Figure 7.20C). These observations 
were confirmed by an additional experiment involving a second donor and two different 
experimental setups (Figure 7.21). Therefore, HIV-1 does not replicate more efficiently in low 
glutamine concentrations, such concentrations that limit T cell proliferation. In addition, HIV-1 
delVpu virus production does not seem to be significantly affected by varying doses of 
extracellular glutamine. Importantly, even at sub-physiological glutamine concentration (0, 0.2, 
0.5 mM) HIV-1 replicates efficiently. The differential effects of glutamine on HIV-1 replication is 
likely due to the fact that in lower glutamine concentrations T cell proliferation is decreased and 
consequently fewer T cells are available for rounds of re-infection and viral production. Taken 
together these data suggest that HIV-1 replication is not positively modulated by Vpu through 
the regulation of glutamine levels.  
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Figure 7.20: Effects of extracellular glutamine levels on HIV-1 replication in primary 
human CD4+ T cells (DONOR A). 
A: Schematic representation of the experimental procedure. CD4+ T cells were negatively 
isolated from fresh PBMCs and stimulated with anti-CD3/CD28 activator Dynabeads and 
cultured with medium containing 1mM concentration of glutamine. Two days later, cells were 
infected as above (MOI=0.1), washed 3 times and placed in medium containing the indicated 
concentration of glutamine (0, 0.2, 0.5 or 1mM). Time points were collected at the indicated time 
post-infection. For each time point, both cell lysates and supernatants were harvested. Virus 
production was determined by measuring the infectivity of viral supernatants via quantification of 
β-galactosidase activity on HeLa-TZMbl reporter cell lines (B). Cells lysates were stored in 
staining buffer, stained with PE-conjugated anti-p24 and analysed by flow cytometry (C). The 
p24 positive gate was set up using uninfected cells. 
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Figure 7.21: Effects of extracellular glutamine levels on HIV-1 replication in primary 
human CD4+ T cells (DONOR B). 
Same experimental procedure than the figure above but with blood from a different donor. A: 
Profile of HIV-1 replication via titration of viral supernatants on TZMbl cells. In this experimental 
setup, at each time point cells were centrifuged, viral supernatants collected and the same cells 
were cultured by adding fresh medium containing the appropriate glutamine concentration. B: In 
this experimental setup, cells were not passaged several times by replacing harvested-
supernatant. These two experiments involve the same donor. Viral supernatants were assayed 
on HeLa-TZMbl indicator cells as described before. 
 
 
 We then examined whether the infectivity of viral particles produced was impaired in limiting 
glutamine levels, conditions that Vpu might create through the degradation of SNAT-1. Primary 
CD4+ T cells were isolated and infected as mentioned above, at a MOI of 2. 48 hours post-
infection, the viral supernatants were titrated on HeLa-TZMbl cells and cell lysates Western-
blotted for Gag (Figure 7.22). We found no differences between the amounts of particles 
released from infected cells maintained in limiting or high glutamine levels, and this, for both 
HIV-1 Wt and delVpu viruses. Gag was indifferently processed in 0.2, 0.5, 1mM or 0mM 
glutamine concentrations. Therefore, one single round of HIV-1 replication in CD4+ T 
lymphocytes does not provide evidence that Vpu influences HIV-1 replication by 
regulating/limiting glutamine access. 
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Figure 7.22: Limiting glutamine levels do not affect intracellular Gag processing and 
single round viral particle release. 
A: CD4+ T cells were extracted, infected (MOI=2) with the indicated VSV-G pseudotyped HIV-1 
and cultured with different doses of extracellular glutamine. Cells were lysed 48 post-infection in 
SDS-PAGE loading buffer and Western blotted for gag and Hsp90. B: Viral supernatants from A 
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7.3 Discussion 
In this study we have, in collaboration with Paul Lehner's lab, identified a new target of HIV-1 
Vpu by proteomics analysis. SNAT-1 was, after tetherin, the second most downregulated 
plasma membrane protein by Vpu expression in the SILAC assay. Beyond that aspect, this 
technique provides a picture of the signature printed by Vpu on its host cell and might be used 
to determine fingerprints of many other viral components. So far, viral proteins have been 
shown to target several major components of the immune system such as restriction factors, 
cell-surface immune receptors, pathogens sensors, in order to escape recognition by the 
immune system. In that sense, SNAT-1 is particularly interesting and challenging since this 
protein acts as a glutamine transporter and thus represents a major component of cell 
metabolism, but it is unlikely to be a direct effector of immune responses. Vpu targets a cellular 
protein, which is not directly harmful for HIV-1, but its depletion might provide a better cellular 
environment for HIV-1 replication. The physiological implications of SNAT-1-depletion by Vpu 
have yet to be determined. Since T cell proliferation was shown to be glutamine and SNAT-1-
dependent we thought that Vpu could interfere with the glutamine uptake pathway to inhibit T 
cell proliferation. Additional experiments will need to be done to confirm whether, as expected, 
glutamine uptake of T cells infected with HIV-1 Wt is decreased compared to T cells infected 
with Vpu-defective HIV-1. Preliminary data suggest that T cells infected with Vpu-defective HIV-
1 undergo more cell divisions than those infected with HIV-1 Wt.  
 In the attempt to elucidate the benefits for the virus to inhibit T cell proliferation, we have not 
found any evidence that Vpu could, through the regulation of intracellular glutamine levels, 
positively affect HIV-1 replication. HIV-1 replication displayed a similar pattern of replication 
under either low or high glutamine inputs. The virus growth curves of all the glutamine 
concentrations tested always peak at the same time. Therefore, HIV-1 can cope with 
subphysiological glutamine levels. In the absence of glutamine, the replication rate was delayed 
but ultimately the virus managed to achieve efficient virus production in a Vpu-independent 
manner. With our collaborators we are currently setting up an assay to silence SNAT-1 
expression in primary human CD4+ T cells in order to mimic Vpu's effects. It would be 
interesting to study in such conditions the profiles of HIV-1 replication and T cell proliferation. 
 It is tempting to speculate that Vpu interferes with T cell metabolism as a means to regulate 
their activity. By limiting glutamine access Vpu could inhibit T cell proliferation and dampen T 
cell activation. This scenario is intriguing since T cell activation is a process that generally 
stimulates virus replication, however this mechanism might, at a late stage of infection, allow the 
survival of infected cells and avoid activation-induced cell death (AICD). Through the action of 
Vpu, infected T cells might during HIV-1 infection return to a resting mode as latently infected 
cells. These cells may constitute an HIV-1 reservoir because they contain in their genome a 
transcriptionally silenced proviral genome, therefore remaining protected from immune 
detection. Vpu might play an important role in balancing the T cell activation state and HIV-1 
replication. This mechanism may also be linked to the mTOR pathway (mammalian target of 
rapamycin). Indeed, the mTOR-signaling pathway has also been shown to be involved in T cell 
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metabolism and function (reviewed in (446)). It is currently thought that T cell activation requires 
a two-signal model. Signal 1 is the recognition of the antigen by the TCR complex and signal 2 
is the co-stimulation mediated by the engagement of CD28. But in that configuration, there is 
nothing to inform the T cell to differentiate into a T helper (Th1), Th2 or Th17 cell, a regulatory 
cell or a memory cell. This instruction comes from the presence of environmental cues (amino 
acids, energy, growth factors, cytokines) integrated by the PI3-kinase family members, mTOR. 
In that context, mTOR acts as an environmental sensor able to interpret signals from the 
extracellular compartment to dictate the course of T cell differentiation and function upon 
antigen recognition. In the context of our study, mTOR might be a key component able to sense 
the availability of glutamine in the microenvironment and drive, in consequence, the T cell fate. 
The lack of intracellular glutamine generated by Vpu expression might be sensed by 
components of the mTOR pathway, leading to their inactivation. So in that configuration, Vpu 
would inhibit mTOR (''turn-off'') and direct the cell towards the appropriate cellular response, for 
instance autophagy. Moreover, it cannot be excluded that glutamine transporters such as 
SNAT-1 might also be perfect candidates for glutamine sensing. Indeed, such proteins detected 
at the cell surface would have access to both intracellular and extracellular stores of glutamine.  
 Alternatively, we will also investigate the effects of SNAT-1 depletion and limiting glutamine 
levels on pro-inflammatory responses from HIV-1 infected dendritic cells and macrophages. In 
those cells, by degrading SNAT-1, Vpu might interfere with the glutamine metabolism required 
for cytokine production such as interferons (436). In that case, depletion of SNAT-1 in HIV-1 
infected cells would be an additional immuno-evasion strategy.  
 We also examined the molecular mechanism by which Vpu achieves SNAT-1 degradation. 
We found that SNAT-1 was degraded in HIV-1 infected cells and depleted from the cell surface 
in a Vpu-dependent manner. We have identified some residues in Vpu sequence important to 
mediate SNAT-1 downregulation and degradation. The tryptophan residue W22 in Vpu 
transmembrane domain and the phosphorylation site in the cytoplasmic tail were found to be 
required for SNAT-1 degradation. Mutation on W22 impaired the ability of Vpu to interact with 
SNAT-1 in co-immunoprecipitation studies while Vpu S52,56A was still able to pull-down SNAT-
1 suggesting that Vpu-mediating SNAT-1 binding was not sufficient for its ultimate degradation. 
By analogy, these two determinants are also required for Vpu-mediating CD4 and tetherin 
degradation suggesting that Vpu achieves SNAT-1 depletion by a similar mechanism involving 
the E3 ubiquitin ligase SCFb-TRCP. Importantly, the recruitment of β-TRCP by Vpu was shown to 
indirectly inhibit the NF-κB activation pathway and cause apoptotic effects (cf. introduction) 
(350). Vpu targeting SNAT-1 could therefore be an additional cause of T cell apoptosis. Since 
degradation of tetherin, CD4 and potentially SNAT-1 are all dependent on β-TRCP interaction, it 
would be interesting to investigate whether there are competitive pressures to maintain the 
degradation of one substrate over another in the context of infected cell. Treatment with 
endolysosomal inhibitors and MG132 rescues SNAT-1 expression from Vpu-mediating 
degradation suggesting an ubiquitin-dependent endolysosomal degradation pathway. However, 
depletion of two ESCRT-I components TSg101 and UBAP1 did not impact Vpu's ability to 
degrade SNAT-1, potentially suggesting an ESCRT-independent mode of lysosomal 
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degradation. We also showed that the cytoplasmic tail of SNAT-1 did not confer sensitivity to 
Vpu-mediated interaction and degradation. The determinants in SNAT-1 transmembrane region 
including the intra/extra cellular loops will be mapped by examining chimeric proteins bearing a 
truncated region of the SNAT-1 TMD and sequences from species SNAT-1 orthologues. In 
addition, Vpu colocalized with SNAT-1 into intracellular compartments. 
 Another important aspect of this project aims to screen Vpus from different HIV-1 and SIV 
strains for their ability to degrade SNAT-1. We know that tetherin antagonism is largely 
conserved in all primate lentiviruses even though most of the SIVs overcome tetherin from their 
corresponding host via the action of Nef. Bearing this in mind, it would be interesting to 
determine whether SNAT-1 counteraction is also an essential barrier to overcome for 
lentiviruses. If this was the case, we would expect to detect residues under positive selection in 
the regions of SNAT-1 targeted by Vpu. Preliminary data from our collaborators indicate that 
Group O Vpu proteins have not acquired the capacity to target SNAT-1 but Vpus from SIVPtt 
that gave rise to pandemic HIV-1 showed the ability to downregulate SNAT-1 from the cell 
surface. SIV Nef's ability to downregulate CD3 and CD28 was linked to reduced activation-
induced death in SIV-infected monkeys (316), therefore, we could speculate that HIV-1 Vpu 
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Chapter 8 General Conclusion 
 
24 years since the isolation of Vpu, understanding its role in HIV-1 infection is still a challenge. 
Vpu must be important for HIV-1 replication and/or pathogenesis since macaques infected with 
a Vpu-defective chimeric SHIV variant was found to revert back to a functional vpu open 
reading frame during the course of infection. Through the targeting of several cellular 
membrane-associated proteins, Vpu allows HIV-1 to escape recognition by the innate immune 
system and creates the optimal host cell conditions for virus replication and spread. It is 
intriguing that Vpu can interact with such a broad range of diverse cellular targets sharing little 
sequence homology. One of the best examples to illustrate the role of Vpu in counteracting 
defences developed by the cellular machinery, is the antagonism of the restriction factor, 
tetherin. Studying the mechanism by which Vpu overcomes tetherin’s antiviral activity provides 
a powerful tool to understand the complex interactions between HIV-1 and its host. 
 In the chapter 3, we present evidence that Kaposi's sarcoma-associated herpesvirus (KSHV) 
has also evolved a countermeasure to alleviate tetherin-mediated restriction of virus particle 
release. KSHV encodes a ubiquitin ligase, K5 that mediates tetherin ubiquitination on its 
cytoplasmic tail lysines (210). This triggers tetherin removal from the cell-surface and its 
subsequent routing towards the endosomal compartments for degradation. In this study we 
compared the mechanisms of tetherin degradation between K5 and Vpu. While for K5, tetherin 
degradation is sufficient to overcome the antiviral function, we showed for Vpu that final 
destruction of tetherin did not account for the full antagonistic effect. This was evidenced by the 
tetherin lysine mutants that appeared to be resistant to degradation but were still sensitive to 
Vpu-mediated enhancement of virus release. The Vpu S52,56A mutant also illustrates that 
degradation of tetherin and its inactivation are two decoupled events. Indeed, this mutant fails to 
reduce intracellular levels of tetherin but displays some activity to enhance virus particle 
release. Based on recent studies, we now better understand this duality (383). All the data tend 
towards a model in which Vpu prevents tetherin from being expressed at the sites of virus 
budding to allow optimal virus release. But this is not strictly linked to Vpu's ability to mediate 
degradation per se but rather to its capacity to engage tetherin into a degradative pathway from 
which it cannot reach the cell-surface. Because residual tetherin colocalizes with Vpu in the 
trans-Golgi network, it was therefore initially thought that Vpu, by interacting with tetherin, 
mediated its sequestration in the TGN. We now think that this is likely to be pools of 
tetherin/Vpu complexes that accumulate in the TGN before being routed to the endosomal 
pathway. Presumably, in fixed cells, mainly the Vpu/tetherin complexes that accumulate in the 
slowest cellular pathway are visualized. Those complexes found in the TGN are likely queuing 
for delivery into the endosomal pathway. Their subsequent trafficking into endosomes is 
clathrin-dependent and has been proposed to be governed by a motif in the second alpha helix 
of Vpu cytoplasmic tail (ExxxLV). Therefore, K5 mediates tetherin downregulation from the cell 
surface whereas Vpu blocks transit to the surface (378, 382). In both cases, K5 and Vpu block 
tetherin incorporation into membranes of budding virions by reducing the levels of tetherin on 
the cell surface. 
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 Several studies have investigated the nature of this degradation mechanism. Components of 
the ESCRT machinery were found to be required for Vpu-mediated tetherin degradation. 
Phosphorylation of Vpu on two conserved residues allows Vpu to bind the SCF-β-TrCP1/2 E3 
ubiquitin ligase that ubiquitinates the tetherin cytoplasmic tail on multiple residues. In this 
regard, the residues targeted by Vpu for ubiquitination are still unclear. Not only the lysines but 
also a motif of serine/threonine/serine residues appear to be required for Vpu-mediated 
ubiquitination, and in some instance they may contribute to the antagonistic process. 
Ubiquitination of tetherin by Vpu triggers the recruitment of ESCRT subunits that then, sort 
tetherin molecules to the lysosomes for degradation.  
 The basis of the mechanism by which Vpu counteracts tetherin is linked to its capacity to 
interact via its transmembrane with tetherin. In chapter 4, by mutational analyses of HIV-1 
Group M Vpu transmembrane domain, we have identified three amino acid residues that form 
one face of the transmembrane region of Vpu essential for tetherin interaction and antagonism. 
This face of Vpu transmembrane domain was also found to be important for mediating 
interaction with tetherin in a recent study. The data suggest that adaptation of this face of Vpu 
TMD might have been a prerequisite for virus zoonosis into the human host. This face includes 
a sequence of three alanines and a tryptophan spaced at four residue intervals within the Vpu 
TMD helix. It is thought that hydrophobic residues in the C-terminal region of the tetherin 
transmembrane domain might fit into the grooves formed by the alanines in the Vpu TMD. In 
that configuration, the tryptophan is thought to stabilize the overall structure of the Vpu TMD 
domain embedded into the lipid bilayer. These residues might also be involved in regulating the 
oligomerization state of Vpu. But more studies will need to be done to determine, first the driving 
force for multimerization and secondly whether Vpu acts on tetherin as a monomer or if higher 
order Vpu structures are required to neutralize tetherin's function. 
 Although M-Vpu and O-Vpu derive from an SIVcpz precursor, Vpu from group O HIV-1 has 
not acquired an anti-tetherin function. In chapter 5, we studied the molecular biology of HIV-1 
group O Vpu to understand the reasons that render this protein unable to counteract human 
tetherin. O-Vpu is defective both for tetherin binding and TGN-associated subcellular 
localization. These defects map to the transmembrane and the region in the membrane 
proximal of O-Vpu cytoplasmic, respectively. Only O-Vpu chimera bearing these determinants 
displayed activity against tetherin. Since tetherin antagonism is conserved in all primate 
lentiviruses tested so far, in HIV-1 group O the anti-tetherin function might be supported by 
another viral component. As suggested by the study with Group P HIV-1, it cannot be excluded 
that some lentiviruses have not acquired such a function. Whether this reflects the lack of 
efficient spread into the human population as compared to the Group M, is unknown. 
 In addition to inducing CD4 and tetherin degradation, recently published studies revealed a 
role for Vpu in downregulating immuno-modulatory surface molecules such as CD1d, NTB-A 
and PVR possibly to avoid antigen-recognition by the immune system. Other cellular proteins 
might also be targeted by Vpu. Chapter 6 presents evidence that the glutamine transporter 
SNAT-1 is an additional cellular substrate of HIV-1 Vpu. While we do not yet understand the 
physiological implications of SNAT-1 depletion for viral replication, we have shown that CD4+ T 
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cells infected with Vpu-defective HIV-1 proliferate more than wild-type infected cells. The 
magnitude of the phenotype is, however, weak and more experiments are required to confirm 
our hypothesis. Alternatively, SNAT-1 might be essential during viral infection to actively 
participate in the production of pro-inflammatory cytokines. It would be interesting to investigate 
whether in Vpu expression conditions such immune responses are attenuated. 
 Therefore, Vpu promotes HIV-1 replication at different stages; first, during virus assembly, 
Vpu allows the production of infectious virions. Then, as these nascent virions are budding 
through the host cell surface, the absence of tetherin allows them to be released into the 
extracellular milieu. Finally, downregulation of activator ligands prevents the infected cell from 
being recognized by immune cells, and thus viral replication can persist. Therefore, Vpu plays a 
pivotal role in the progression of HIV-1 infection; abrogation of this protein's functions is then a 
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Abstract
Tetherin (CD317/BST2) is an interferon-induced membrane protein that inhibits the release of diverse enveloped viral
particles. Several mammalian viruses have evolved countermeasures that inactivate tetherin, with the prototype being the
HIV-1 Vpu protein. Here we show that the human herpesvirus Kaposi’s sarcoma-associated herpesvirus (KSHV) is sensitive to
tetherin restriction and its activity is counteracted by the KSHV encoded RING-CH E3 ubiquitin ligase K5. Tetherin expression
in KSHV-infected cells inhibits viral particle release, as does depletion of K5 protein using RNA interference. K5 induces a
species-specific downregulation of human tetherin from the cell surface followed by its endosomal degradation. We show
that K5 targets a single lysine (K18) in the cytoplasmic tail of tetherin for ubiquitination, leading to relocalization of tetherin
to CD63-positive endosomal compartments. Tetherin degradation is dependent on ESCRT-mediated endosomal sorting, but
does not require a tyrosine-based sorting signal in the tetherin cytoplasmic tail. Importantly, we also show that the ability of
K5 to substitute for Vpu in HIV-1 release is entirely dependent on K18 and the RING-CH domain of K5. By contrast, while Vpu
induces ubiquitination of tetherin cytoplasmic tail lysine residues, mutation of these positions has no effect on its
antagonism of tetherin function, and residual tetherin is associated with the trans-Golgi network (TGN) in Vpu-expressing
cells. Taken together our results demonstrate that K5 is a mechanistically distinct viral countermeasure to tetherin-mediated
restriction, and that herpesvirus particle release is sensitive to this mode of antiviral inhibition.
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Introduction
The inhibitory effect of type 1 interferons (type 1 IFN) on the
replication of mammalian viruses has been documented for over
50 years. However the effecter mechanisms that interfere with
virus replication have not been well characterized. While many
IFN response genes are known, few definitive antiviral functions
have been ascribed to them. Amongst the best characterized are
PKR/2959oligoadenylate synthetase, MxA and ISG15, all of
which have broad activity against a variety of mammalian RNA
viruses [1]. Recently the identification of retroviral restriction
factors including members of the APOBEC3 family of cytidine
deaminases, as well as TRIM5 and other members of the tripartite
motif protein family, has highlighted innate intracellular defense
mechanisms as key determinants of tropism for human and
primate immunodeficiency viruses [2,3]. Moreover, these antiviral
activities have driven the acquisition of viral countermeasures [2,4]
and thus interferon-inducible restriction factors are now thought to
represent an important arm of the antiviral innate immune system
[3].
Tetherin, (BST2/CD317) has recently been shown to inhibit
the release of HIV-1 particles that are defective for the accessory
protein Vpu [5,6]. In the absence of Vpu expression, nascent
HIV-1 particles assemble at the plasma membrane but remain
tethered to the surface of tetherin expressing cells via a protease-
sensitive linkage. Tethered virions are then endocytosed leading to
their accumulation in late endosomes [5,7,8]. Tetherin colocaliza-
tion with restricted viral particles on cell surfaces and in
endosomes is well documented [5,6,9]. Strikingly, it is tetherin’s
unusual topology that is thought to be directly responsible for its
mode of action [10]. Tetherin is a dimeric type-II membrane
protein consisting of an N-terminal cytoplasmic tail, an extracel-
lular domain with a putative coiled coil, and a C-terminal GPI
anchor which is required for its antiviral function [5,11]. It forms
dimers which are thought to cross-link viral and cellular
membranes during viral budding [10]. Tetherin appears to have
no direct association with any viral structural proteins and is
therefore able to restrict a range of unrelated viruses including
retroviruses, filoviruses and arenaviruses [9,12,13]. It is expressed
on mature B cells and plasmacytoid dendritic cells, but can be
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induced in many cell types by type-I interferon (IFN)
[8,14,15,16,17]. Sequence analysis of orthologues of tetherin from
primates indicates high levels of positive selection during their
evolution suggesting selective pressure from pathogenic viral
infections [18,19]. Together, these observations suggest that
tetherin may be an important antiviral defense against enveloped
virus replication, necessitating the acquisition of viral counter-
measures to antagonize its activity.
Interestingly, other potential viral countermeasures to tetherin
may exist. Kaposi’s sarcoma-associated herpesvirus (KSHV), also
known as Human herpesvirus 8 (HHV8), encodes two immuno-
modulatory membrane associated RING-CH (MARCH) E3
ubiquitin ligases named K3 and K5 [20]. K5 has been shown to
mediate the down-regulation of a variety of cell surface markers
including MHC class I, PE-CAM-1, CD80/CD86, ICAM-1,
IFNc receptor and NKG2D [21,22,23,24,25,26,27]. In a recent
proteomics screen Bartee and colleagues used a methodology
called stable isotope labeling of amino acids in cultured cells
(SILAC) to identify proteins that are removed from the plasma
membrane on K5 expression. One of the novel K5 targets found
was tetherin (BST2) [28]. Here we have tested the hypothesis that
tetherin restricts assembly/release of KSHV particles and that an
important function of K5 is to overcome this process.
Results
KSHV particle release is sensitive to tetherin-mediated
restriction
Tetherin has the capacity to restrict the release of diverse
enveloped viruses including filoviruses and arenaviruses [9,12,13].
Given the capacity of the KSHV protein K5 to reduce cell surface
expression of tetherin [28] we tested whether KSHV could be
restricted by the expression of increasing amounts of exogenous
human tetherin. We reasoned that the complex envelopment
strategy of herpesviruses [29] and the tropism of KSHV for
tetherin-positive mature B cells made this virus potentially sensitive
to restriction by tetherin. To test this we generated a HeLa cell line
harboring latent recombinant rKSHV.219 episomes under
puromycin selection which encode eGFP driven by the human
EF-1a promoter and DsRed driven by the KSHV PAN promoter
that responds to the KSHV immediate early protein RTA [30].
Transfection of these cells with an RTA encoding plasmid (pCMV
RTA) induces KSHV transcription, lytic replication and the
release of KSHV particles, the efficiency of which can be assessed
by measurement of RFP expression. The amount of virus released
48h post-RTA induction can be measured by quantitative PCR
(Q-PCR) detecting DNAse-I protected genomes in the supernatant
or by titration of infectious virus onto 293T cells and enumeration
of GFP expressing cells by flow cytometry.
We first determined whether transfecting a plasmid expressing
tetherin together with pCMV-RTA would impact on the amount of
infectious virions released into the supernatant. Figure 1A clearly
demonstrates a linear decrease in release of KSHV infectious virus
when increasing amounts of the tetherin-expressing plasmid are
transfected with a constant amount of pCMV-RTA. Similarly, Q-
PCR performed on DNAse-I resistant genomes showed a greater
than 10-fold decrease in total virions released for the highest dose of
tetherin-expressing plasmid used (Figure 1B). To control for
transfection efficiency, cells were recovered after virus collection
and cell lysates subjected to western blotting (Figure 1C). As expected,
increasing amounts of tetherin were detected as increasing amounts
of tetherin-expressing plasmid was transfected. Importantly, equal
RTA expression was found in all samples confirming that RTA levels
were not impacted by tetherin expression. To further rule out an
effect of tetherin expression on KSHV reactivation we also measured
lytic viral RNA production by quantitative RT-PCR. Ct values for
ORF37 were normalized to those obtained for cellular GAPDH.
Figure 1D shows very similar ORF37/GAPDH ratios for each
condition.Whilst unlikely, it is also possible that exogenous expression
of increasing amounts of tetherin might lower genomic replication,
thus leading to a reduced amount of virions and/or DNase-I resistant
genomes in the supernatant. To rule this out we measured
intracellular episomes in DNA extracts by Q-PCR. Figure 1E clearly
demonstrates that episome copy number was similar across all
conditions and could not account for reduced viral production.
Reduction of K5 expression using K5 specific shRNA
reduces KSHV release
We then tested whether K5 expression was required for efficient
KSHV release from r219-HeLa cells. We reasoned that if K5 is a
KSHV antagonist for tetherin then reducing its expression by
RNA interference (RNAi) should inhibit KSHV release. Three
shRNA hairpins were designed and expressed in 293T cells
together with a HA-tagged K5 protein. Reduction of K5
expression by the hairpins was assessed by recovering the cells
48 hours after transfection and subjecting the lysates to western
blot (Figure 2A). Blots probed with the anti-HA antibody were
stripped and re-probed for alpha tubulin to control for equal
loading (Figure 2A). All three hairpins reduced K5 expression with
hairpin 3 (sh-K5iii) being the most potent. We then expressed the
hairpins in r219-HeLa cells using lentiviral vectors [31]. 72 hours
later the cells were re-seeded and transfected with RTA to induce
KSHV lytic replication. Release of infectious KSHV was
measured by titration of supernatants on 293T as before
(Figure 2B). We found that expression of specific anti-K5 shRNA
reduced KSHV titer in the supernatant whereas expression of an
empty shRNA vector did not (Figure 2B). The number of DNAse-I
resistant KSHV genomes in the supernatant was also reduced by
all three shRNA vectors, as shown by taqman Q-PCR (Figure 2C).
Messenger RNA for the late gene ORF37 was measured by
quantitative RT-PCR in each sample and values were corrected
Author Summary
To replicate efficiently in their hosts, viruses must avoid
antiviral cellular defenses that comprise part of the innate
immune system. Tetherin, an antiviral membrane protein
that inhibits the release of several enveloped viruses from
infected cells, is antagonized by the HIV-1 Vpu protein. The
K5 protein of the human pathogen Kaposi’s sarcoma-
associated herpesvirus (KSHV) modulates the cell surface
levels of several host proteins including tetherin. We show
that KSHV release is sensitive to tetherin, and that K5
expression is required for efficient virus production in
tetherin-expressing cells. K5 is also capable of rescuing
Vpu-defective HIV-1 virus release from tetherin. K5
expression induces a down-regulation of cell-surface
tetherin levels and degradation in late endosomes, which
depends on a single lysine residue in the tetherin
cytoplasmic tail. Finally, we show that the ESCRT pathway,
which promotes the trafficking of cell surface receptors for
degradation, is required for K5-mediated tetherin removal
from the plasma membrane. Thus, we demonstrate that
herpesviruses are sensitive to the antiviral effects of
tetherin and that KSHV has evolved a mechanism for its
destruction. These findings extend the list of viruses
sensitive to tetherin, suggesting that tetherin counter-
measures are widespread defense mechanisms amongst
enveloped viruses.
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Figure 1. Over-expression of human tetherin restricts KSHV particle release. HeLa KSHV cells were transfected with an expression vector
encoding the KSHV early transcriptional activator RTA and increasing doses of pCR3.1 encoding human tetherin. Plasmid dose was kept constant
using pcDNA3.1. 48 hours after transfection supernatants were harvested, filtered and used to infect 293T cells (A) and infectious virus titer
determined by GFP expression in the target cells by flow cytometry. Values are presented as infectious units/ml. (B) Parallel supernatants were
treated for 2 hours with DNase-I and viral genomic DNA isolated and supernatant genome copy number enumerated by quantitative Taqman PCR
specific for ORF37. Values are presented as copies/ml. (C) Western blot analysis for RTA protein (top panel) performed on r219-HeLa cells after virus
collection indicates that RTA expression levels were equivalent in each sample. Blots were stripped and detection of tetherin using an anti-HA
antibody performed (middle panel) shows increasing tetherin levels across samples, as expected. Alpha tubulin was detected concomitantly to RTA
to demonstrate equal loading (bottom panel). (D) KSHV reactivation was equivalent in all samples as evidenced by measurement of ORF37 mRNA
levels by quantitative Taqman PCR and after normalization to GAPDH levels. (E) KSHV genome levels remained constant in all samples as evidenced
by equivalent numbers of intracellular KSHV episomes per nanogram of total cellular DNA. Results are the mean of 2 independent experiments and
errors are standard error of the mean.
doi:10.1371/journal.ppat.1000843.g001
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for cellular GAPDH mRNA levels. This demonstrated that
hairpin expression did not significantly inhibit KSHV reactivation
(Figure 2D). In fact hairpin 2 appeared to stimulate ORF37
expression in one experiment leading to the large error bar.
However, this experiment shows that inhibition of reactivation
cannot account for the loss of KSHV in the supernatant. To
further rule out an effect of hairpin expression on genomic
replication we also measured intracellular KSHV episomes by
DNA Q-PCR for ORF37 (Figure 2E) This control confirmed that
the number of KSHV episomes in the cells did not account for the
K5 hairpin induced defect in KSHV release and supports the
notion that K5 antagonizes tetherin.
These results suggest that K5 is required for efficient KSHV
particle release in a cell line that constitutively expresses tetherin
and that expressing increasing amounts of exogenous tetherin
further inhibits KSHV release. Together our data suggest that
tetherin has antiviral activity against KSHV and that K5 has an
important role in overcoming tetherin-mediated restriction.
K5 can substitute for Vpu in rescuing HIV-1 particle
release from tetherin-mediated restriction
Having established a role for K5 in counteracting tetherin
during KSHV release we then tested whether K5 expression could
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Figure 2. RNAi-depletion of K5 during lytic replication suppresses KSHV particle release. (A) Three shRNA hairpins were designed to
target K5 and co-expressed with K5-HA in 293T cells. The efficiency of reduction of K5 expression was assessed 48 hours later by western blot of total
cell lysates detecting the HA tag. Stripped blots were re-probed for alpha tubulin to demonstrate equal loading. (B & C) r219-HeLa cells were
transduced by lentiviral vectors encoding K5 shRNAs at an MOI of 5, reseeded 72 hours later and transfected with RTA expression plasmid the
following day. Supernatants were harvested 48 hours post-RTA transfection and KSHV titer expressed as infectious unit/ml (B) and DNase-I resistant
genome copies/ml (C) were determined as in Figure 1. At the time of harvest (48 hours post RTA transfection), ORF37 and GAPDH mRNA were
measured in the cell lysates by Taqman Q-RT-PCR to assess effect of the hairpins on KSHV reactivation and ORF37 expression (D). At the time of
harvest, cells were also kept to assess the effect of the hairpins on genome replication. Cellular DNA was extracted and KSHV episomes measured by
QPCR for ORF37 (E). Results are expressed as KSHV genomes per nanogram of total cellular DNA. Results are the mean of 2 independent experiments
and errors are standard error of the mean.
doi:10.1371/journal.ppat.1000843.g002
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Vpu and rescue the release of tetherin restricted HIV-1(delVpu)
particles [5]. We transfected HeLa cells with the HIV-1 molecular
clone NL4.3, or a Vpu-defective counterpart, together with
expression vectors for HA-tagged K5 or Vpu. As predicted, K5
expression potently rescued HIV-1(delVpu) release to levels
achieved by Vpu expression (Figure 3A). This was evidenced
both by measurement of HIV-1 p24 capsid protein released into
the supernatant by western blots as well as by titration of infectious
HIV-1 virus released into the supernatant on sensitive indicator
cells (Figure 3A, B and C). Importantly K5 expression had no
effect on wild-type HIV-1 particle release or on HIV-1 structural
protein expression. These data demonstrate that K5 is a functional
homolog of HIV-1 Vpu and that KSHV encodes a tetherin
countermeasure.
The fact that K5 has been demonstrated to be a RING
dependent E3 ligase for ubiquitin [20] suggested that the RING-
CH domain is important for its function. We therefore made a
RING deletion mutant of K5 (K5delRING) and tested its ability to
counteract tetherin restriction in an HIV-1 release assay as above.
Despite similar expression levels of the mutant and wild type K5
proteins (Figure 3B), the RING-defective K5 was unable to rescue
HIV-1(del Vpu) release from HeLa cells (Figure 3A and C). To
confirm that K5 can antagonize tetherin function we repeated the
experiment but in a tetherin-deficient cell line (HT1080) [5] stably
expressing a tetherin protein in which an HA-tag had been
inserted into the ectodomain at amino acid position 154 [9]. HT/
THN-HA cells were then transduced with retroviral vectors co-
expressing DsRed and Vpu, or K5 or K5delRING at doses
sufficient to give .90% DsRED-positive cells as demonstrated by
flow cytometry 48 hours later. The cells were then re-seeded and
infected with VSV-G pseudotyped HIV-1(wt) or HIV-1(del Vpu)
at a multiplicity of infection of 0.2. Since HT1080 cells are devoid
of CD4, VSV-G pseudotyping allows the measurement of a single
round of viral replication. Similar to the experiment in HeLa cells,
HT/THN-HA released HIV-1(del Vpu) particles approximately
20 fold less efficiently than they released wild type virus.
Furthermore, expression of either K5 or Vpu, but not K5delR-
ING, could rescue the tetherin mediated defect in virus release
(Figure 3D and E). Measurement of gag levels in supernatants and
extracts of infected cells by western blot indicated that the effects of
Figure 3. K5 rescues Vpu-defective HIV-1 particle release from tetherin mediated restriction. (A, B and C) HeLa cells were co-transfected
with HIV-1wt or HIV-1(del Vpu) proviral plasmids in combination with empty vector, or expression vector encoding Vpu, HA-tagged K5 or K5 lacking
the N-terminal RING domain. 48h post-transfection cell lysates and pelleted supernatants were analysed for HIV-1 Gag proteins by western blot using
an anti-p24CA monoclonal antibody (A) or an anti-HA monoclonal (B). Viral supernatants were also used to infect HeLa-TZM indicator cells and
infectious viral release determined by relative beta-galactosidase activity 48h later (C). (D and E) HT1080 cells stably expressing human tetherin
(HT1080/THN-HA) were transduced with retroviral vectors encoding both dsRED and either Vpu, K5 or K5(del RING) at doses sufficient to give .90%
transduction as determined by flow cytometry. Cells were then infected with HIV-1wt or HIV-1(del Vpu) pseudotyped with VSV-G at an MOI of 0.2. Cell
lysates and supernatants were processed as in (A) 48h later.
doi:10.1371/journal.ppat.1000843.g003
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tetherin, Vpu and K5 were on HIV-1 release and not gag protein
expression. Intriguingly, K5 could not antagonize tetherin
function in transiently-transfected 293T cells, even when tetherin
expression was titrated to vary its expression level (Figure S1). We
propose that 293T cells lack a co-factor essential for K5’s
antagonism of tetherin, but not for Vpu function. Interestingly,
293T cells are also unable to support HIV-2 Env’s anti-tetherin
activity [32], suggesting that this particular cell line might be
poorly suited for characterization of some tetherin antagonists.
Species-specific down-regulation of cell surface tetherin
by K5
Vpu has been shown to remove tetherin from the cell surface after
transfection [6] and in HIV-1-infected cells [32]. We therefore
tested whether K5 expression had the same effect on surface
tetherin levels in HT/THN-HA cells by expressing K5 via retroviral
transduction. Both K5 (Figure 4A) and HIV-1 Vpu (Figure S2)
expression led to a marked reduction of tetherin from the cell
surface. Importantly, the K5delRING protein was inactive in this
assay as predicted by data in Figure 3. HIV-1 Vpu-mediated
tetherin antagonism displays distinct species specificity for primate
tetherin genes with non-human primate orthologues being largely
insensitive to HIV-1 Vpu [18,19,33]. Sensitivity to HIV-1 Vpu
maps to the tetherin transmembrane domain and mutation of the T
residue at position 45 to the I present in Rhesus macaques (T45I)
coupled with an in frame deletion of a GI pair at the N-terminus of
the human tetherin protein’s TM (delGI-T45I) results in a human
tetherin that is completely resistant to HIV-1 Vpu [18] (Figure S2).
We therefore examined whether K5 also displays similar species–
specific effects (Figure 4B). Unlike HIV-1 Vpu, K5 was able to
down-regulate the THN(delGI-T45I) mutant human tetherin.
However, K5 was unable to down-regulate the rhesus macaque
tetherin protein. Thus K5 also displays species-specificity in its
antagonism of primate tetherins but the determinants of this
specificity are distinct from those of HIV-1 Vpu.
We then examined whether K5 could also down regulate
human tetherin from the surface of a B cell line carrying KSHV
(Figures 4C and D). Body-cavity-based lymphoma (BCBL) 1 cells
were transduced with a lentiviral vector encoding K5 or with an
empty vector and surface tetherin expression assessed by flow
cytometry analysis, using a specific antibody against human
tetherin. K5 expression led to a reduction of cell surface tetherin as
compared to the levels on cells treated with the empty vector or
levels detected on un-transduced cells (Figure 4C). The mean of
mean fluorescence intensity (MFI) values for 3 representative
experiments are also shown (Figure 4D).
K5 induces ubiquitin-dependent endolysozomal
degradation of tetherin
We next examined the fate of tetherin in K5-expressing cells.
HT/THN-HA cells were transduced to stably express K5 or Vpu
and intracellular levels of tetherin were compared to levels in
unmanipulated cells. Tetherin appears in western blots as a
heterogeneous smear of glycosylated species that varies between
cell types [10,17]. After K5 and Vpu expression, tetherin levels in
the modified cell lysates were decreased (to 4% of wildtype in the
case of K5 and to 31% of wildtype for Vpu), suggesting that, like
Vpu, K5 induces tetherin degradation (Figure 5A). At present it is
unclear whether Vpu induces tetherin degradation via a proteaso-
mal-dependent [19,34,35] or lysozomal pathway [36,37]. This is
further complicated by the fact that endolysozomal degradative
pathways are often also dependent on ubiquitin, and thus
proteasomal inhibition can inhibit them through depletion of free
cytoplasmic ubiquitin levels. We addressed the K5 mechanism of
action by examining the role of lysozomal degradation using the
vacuolar ATPase inhibitor bafilomycin A1 or by inhibiting
proteasomal degradation using MG132. We then measured steady
state levels of tetherin in K5 or Vpu expressing cells. A 16h
treatment with BafA1 or MG132 substantially rescued tetherin
levels from both Vpu and K5 expression. BafA1 treatment rescued
not only mature tetherin species, but also lower molecular weight
fragments that are likely to be partially degraded tetherin molecules.
This suggested that K5 degrades tetherin via an endolysozomal
process, similar to that by which it degrades Class I MHC [38]. The
rescue of tetherin degradation products in HT/THN-HA cells that
do not express HIV-1 Vpu or K5 suggested that endosomal
processing of tetherin contributes to its natural turnover. In contrast,
whilst MG132 treatment also rescued partially tetherin levels in
HT/THN-HA-K5 cells, mature species were predominant. In
Vpu-expressing cells MG132 appeared more potent for tetherin
rescue than BafA1, and again differential tetherin species were
rescued by each inhibitor. Together, these data suggest that while
tetherin degradation by K5 and Vpu are sensitive to both classes of
inhibitor, the stages of degradation that are affected are different.
Next we determined whether we could observe differences in
the cellular localization of tetherin induced by K5 or Vpu. In HT/
THN-HA cells, tetherin localized predominantly to the plasma
membrane with a small amount of the intracellular localizations
coincident with the late endosomal marker CD63 (Figure 5B) This
is consistent with the notion of natural tetherin turnover in
endolysozomal compartments. In K5 expressing cells, while
tetherin levels are markedly reduced, remaining tetherin was
much more often found associated with CD63+ late endosomes
than in controls (Figure 5B), implicating K5-induced endosomal
degradation. In contrast, in Vpu-expressing cells, tetherin was
never observed in CD63+ endosomes, but instead localized
predominantly to compartments that stain positive for the
Trans-Golgi marker TGN46 (Figure 5B and C). This localization
is similar to that observed after expression of the HIV-2 and
SIVtan envelope glycoproteins [32,39]. Thus, the subcellular
localization of tetherin after K5 expression suggests that K5 causes
it to be delivered to late endosomes for degradation. Importantly,
this distinguishes K5 and Vpu-induced tetherin antagonism and
implies distinct mechanisms.
Since the RING domain of K5 is required for tetherin down-
regulation from the cell surface, and degradation is sensitive to the
drug MG132, which also causes ubiquitin depletion, we
hypothesized that K5 mediated ubiquitination might drive
tetherin delivery to late endosomes. We therefore examined
whether proteasomal or lysozomal inhibition could rescue cell-
surface tetherin levels (Figure 5D). We found that whilst
endosomal inhibition with BafA1 treatment rescued tetherin
protein in the cell extracts of K5 expressing cells (Figure 5A)
neither BafA1 or concanamycin A could rescue tetherin levels at
the cell surface (Figure 5D). However, consistent with a role for
ubiquitination in the delivery of tetherin for endosomal degrada-
tion, MG132 treatment of tetherin-expressing cells did substan-
tially rescue tetherin levels at the surface of K5-expressing cells
(Figure 5D and E). In contrast, none of the inhibitors significantly
rescued tetherin surface expression in Vpu-expressing cells. These
observations demonstrate that K5-induces an endosomal degra-
dation of tetherin and suggest that an ubiquitin dependent process
is required for its delivery into this pathway. Conversely, HIV-1
Vpu causes tetherin degradation by a distinct mechanism that is
associated with its localization to the TGN (Figure 5B–C).
Next we asked whether the double-tyrosine based endocytic
motif in the tetherin cytoplasmic tail was required for K5-
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Figure 4. K5 mediates cell-surface down-regulation tetherin. (A) HT1080/THN-HA cells were transduced with retroviral vectors encoding
dsRED and either K5 or K5(del RING). 48h post-transduction the cells were immunostained for surface tetherin using an anti-HA monoclonal antibody
and an Alexa-488-conjugated goat-anti-mouse secondary antibody. Surface expression of tetherin was then analyzed in the dsRED positive
population by flow cytometry. Parental HT1080 cells were used as a control for background antibody binding and are represented by the red line.
Tetherin levels in HT1080 cells expressing tetherin alone are indicated by the purple line and levels of tetherin after K5 expression is represented by
the green line. (B) The same analyses were performed on HT1080 cells expressing the HA-tagged Vpu-resistant human tetherin (delGI,T45I) and
rhesus tetherin. Labeling is similar to panel A. (C) BCBL1 were transduced with a lentiviral vector expressing K5 (red line), an empty vector (black line),
or left untreated (grey peak), and cell surface expression of tetherin detected by flow cytometry 48 hours later as described above. (D) Mean
fluorescence intensity (MFI) values from (C) are also shown.
doi:10.1371/journal.ppat.1000843.g004
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Figure 5. Effects of proteasomal and endosomal inhibitors on tetherin levels and localization in cells expressing K5 and Vpu. (A)
Western blots of cell lysates from HT/THN-HA cells and isogenic pools stably expressing K5 or Vpu from retroviral vectors. Cells were treated for 16h
with BafA1 (100nM), MG132 (1mg/ml) or DMSO as a control, lysed and separated by SDS-PAGE. THN-HA was detected by anti-HA polyclonal antibody,
with Hsp90 serving as a loading control and visualized using Licor fluorescently coupled 650 and 800 nm secondary antibodies. Percent mature
tetherin levels, normalized to Hsp90 loading are displayed below each lane. (B) Representative examples of HT/THN, HT/THN-HA K5 and HT/THN-HA
Vpu cells immunostained for tetherin with a rabbit anti-HA antibody (red) and an antibody for the late endosomal marker CD63 (green). Nuclei were
counterstained with DAPI (blue) and cells examined by confocal microscopy. (C) HT/THN-HA Vpu cells stained for THN-HA (green) and the trans-Golgi
marker TGN46 (red) were processed as above. (D) Cells from A were surface stained for tetherin levels and analyzed by flow cytometry. Purple
histograms represent tetherin levels on DMSO treated cells. Green overlays indicate tetherin levels after treatment with the indicated drug. The pink
histogram overlays show the levels of tetherin on untreated HT/THN-HA from the upper row for comparison. (E) Confocal image of a representative
HT/THN-HA K5 cell treated with MG132 and stained for THN-Ha (red) and CD63 (green). (F) HT/THN-HA Y6,8A were imaged by confocal microscopy
for tetherin (red). The cells were then manipulated to express K5 and analyzed by flow cytometry for surface tetherin and by western blot for total
cellular tetherin levels.
doi:10.1371/journal.ppat.1000843.g005
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mediated degradation. This motif binds the clathrin adaptors AP1
and AP2 and has been reported to be important for tetherin
endocytosis and recycling [40]. HT1080 cells expressing THN-HA
Y6,8A were generated and tetherin localization determined by
immunofluorescence microscopy. As expected this mutant tetherin
was found almost exclusively at the plasma membrane (Figure 5F).
Interestingly, expression of K5 in these cells still led to significant
tetherin down-regulation and degradation (Figure 5F) as demon-
strated by flow cytometry and western blot. Thus tetherin
trafficking to late endosomes induced by K5 is independent of
its endocytic motif, suggesting that K5 targets tetherin for
degradation via a pathway that is independent from its normal
subcellular trafficking.
Delivery to late endosomes and antagonism of antiviral
activity by K5 is dependent on a single lysine residue in
the tetherin cytoplasmic tail
K5 targeting of class I MHC molecules depends on membrane
proximal lysine residues in their cytoplasmic tails [20]. Tetherin
also has two membrane proximal lysines, K18 and K21. To seek a
role for these residues we mutated them to arginine, singly or in
combination, in THN/HA and stably expressed these mutant
tetherins in HT1080 cells. We then stained the cell surface tetherin
via the HA tag and measured cell surface tetherin levels by flow
cytometry (Figure 6A). All tetherins were expressed at the cell
surface, but the lysine mutants were expressed at enhanced levels
as compared to the wild-type protein. This suggested that these
two lysines might be involved in natural tetherin turnover. When
K5 was expressed in the mutant tetherin cell lines, tetherin down-
regulation was almost completely prevented for proteins bearing a
K18R substitution. In contrast, K21R mutation had no effect on
K5-induced cell surface down-regulation. Furthermore, K21R but
not K18R or K18,21R mutants were consistently redistributed to
CD63+ compartments upon K5 expression (Figure 6B). We then
further examined whether K5 retained the ability to disrupt
tetherin function in the absence of cell-surface tetherin down-
regulation, as has been suggested for Vpu [17]. HT/THN-HA
and HT/THN-HA K18R cells expressing either K5 or Vpu were
infected with HIV-1wt and HIV-1(delVpu) VSV-G pseudotyped
Figure 6. K18 in the tetherin cytoplasmic tail is required for K5-mediated cell surface down-regulation and delivery to endosomes. (A)
Flow cytometry analyses of HT1080 cells expressing wild type tetherin or the indicated mutant. Purple histograms represent THN-HA levels on
unmanipulated cells, with the green overlay showing tetherin levels in the equivalent cells stably expressing K5. Red histograms represent the antibody
isotype control. (B) Representative examples the cells from (A) were stained for THN-HA (red) and CD63 (green) and examined by confocal microscopy.
doi:10.1371/journal.ppat.1000843.g006
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viruses at an MOI of 0.2. Supernatants were collected 48h later
and infectious virus output was measured on HeLa-TZM cells.
THN-HA K18R expressing cells restricted Vpu-defective HIV-1
release similarly to the wild type protein, however expression of
K5 failed to rescue the release of HIV-1(delVpu) from HT/THN-
HA-K18R cells (Figure 7A). By contrast Vpu-mediated antago-
nism of tetherin was unaffected by mutation of K18 in HT1080
cells (Figure 7A) or indeed either of the lysine residues in 293T
cells (Figure 7B). Thus, removal of tetherin from the cell surface
and delivery to late endosomes is required for K5-mediated
antagonism of its antiviral action and this is dependent on the
lysine at position 18. Measurement of gag levels in cell extracts and
supernatants by western blot demonstrated that tetherin expres-
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Figure 7. K18 is required for tetherin antagonism by K5 but both cytoplasmic tail lysines are dispensable for Vpu-mediated
antagonism. (A) HT/THN-HA and HT/THN-HA(K18R) or derivatives stably expressing K5 or Vpu were infected with wild type HIV-1 or HIV-1(delVpu)
VSV-G pseudotypes at an MOI of 0.2. 48h after infection cell supernatants were harvested and the released infectivity determined on HeLa-TZM cells.
(B and C) The effect of tetherin lysine mutants on HIV-1 release in 293T cells. Cells were transiently transfected with wild type HIV-1 or HIV-1(delVpu)
proviruses with increasing doses of the indicated THN-HA mutant. 48h after transfection viral supernatants were assayed for infectivity on HeLa-TZM
cells (B) and cell lysates and pelleted virions analyzed by western blot for HIV-1 p24 CA and THN-HA expression (C).
doi:10.1371/journal.ppat.1000843.g007
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of tetherin levels ensured that tetherin was expressed as expected
(Figure 7C).
Since lysine residues serve as targets for ubiquitination we
next sought evidence for tetherin ubiquitination in the presence
of K5. HeLa cells were transfected with THN-HA or THN-HA
K18, 21R in the presence of an ubiquitin bearing a 6-histidine
tag. The cells were treated for 8h with BafA1 to block tetherin
degradation and ubiquitinated proteins were isolated by
incubating whole cell lysates with nickel-agarose beads. In the
presence of either co-transfected K5 or Vpu, THN-HA
molecules could be isolated from the transfected cells
(Figure 8). The tetherin predominantly formed a single species
at a size suggestive of mono-ubiquitination. Interestingly, we
failed to pull down ubiquitinated tetherin molecules when their
cytoplasmic lysine residues had been mutated, after either K5 or
Vpu transfection. This implies that the action of both K5 and
Vpu leads to ubiquitination of the tetherin cytoplasmic tail. In
the case of K5, this suggests that ubiquitination of K18
antagonizes tetherin-mediated restriction and directs it to
endosomal compartments for degradation. Intriguingly, mutat-
ing the lysine residues does not make tetherin insensitive to Vpu
suggesting that tetherin becomes ubiquitinated as a consequence
of tetherin antagonism by HIV-1 Vpu but that this ubiquitina-
tion is not required for the antagonistic process.
K5-mediated down-regulation of tetherin is sensitive to
inhibition of the ESCRT pathway
There are several ubiquitin-dependent mechanisms by which
K5 might achieve tetherin degradation. For example, ubiquitina-
tion of tetherin’s cytoplasmic tail could stimulate its internalization
and mediate classical recruitment of the ESCRT pathway through
engagement of TSG101, as has been shown for K3 targeting of
MHC I [41]. This would lead to the budding of tetherin
containing vesicles into the lumen of multivesicular bodies for
degradation in lysozomes [42]. To examine the role of the ESCRT
pathway in K5-mediated tetherin degradation, we tested whether
K5-mediated loss of tetherin from the cell surface was sensitive to
expression of a dominant negative form of VPS4. VPS4 is the
essential AAA-ATPase that provides the energy for ESCRT
disassembly and recycling during the final membrane scission
event in the sorting of cell surface receptors for endosomal
degradation [43]. Co-transfection of HeLa cells with GFP-
dnVPS4(E228Q) [44] substantially rescued cell surface tetherin
levels from K5 as assessed by flow-cytometry (Figure 9A and B).
Expression of K5delRING has no effect on THN cell surface
expression, concordant with Figure 4, and neither does the
dominant negative VPS4 protein when expressed with the tetherin
RING mutant. Together with the demonstration that K5 leads to
tetherin ubiquitination and degradation, these observations
strongly suggest that K5 induces a VPS4 and ubiquitination-
dependent trafficking of tetherin from the cell surface to late
endosomes for destruction. Importantly, this mechanism is similar
to that used by K3 to down-regulate Class I MHC molecules
[38,41].
Discussion
Tetherin has emerged as a potent inhibitor of enveloped virus
release [5,6,9,12,13]. Recent evidence has demonstrated that
tetherin dimers act as a physical linkage between the membranes
of the infected cell and nascent virions [10]. This mechanism lends
itself well to a general non-specific antiviral inhibition that restricts
virus release and thereby interferes with viral spread to new target
cells. It also suggests that mammalian viruses may not be able to
easily mutate to avoid tetherin because tetherin does not directly
interact with any viral structural proteins. Sensitive viruses must
therefore evolve specific ways of counteracting it. In the case of
primate lentiviruses, several tetherin antagonists have now been
identified. The Vpu accessory protein antagonizes tetherin in
HIV-1 infected cells [5,6], whereas in a variety of SIVs that do not
encode a Vpu gene, the Nef protein can overcome the tetherin
orthologues from their host species [33,45]. Interestingly, HIV-2
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Figure 8. Tetherin cytoplasmic tail lysine residues are ubiquitinated in the presence of K5 and Vpu. HeLa cells were transiently
transfected with the indicated THN-HA expression vector in combination with K5, Vpu or GFP and in the presence or absence of 6His-tagged
ubiquitin. 48h after transfection, cells were treated for 8 hours with BafA1 (100nM) to prevent tetherin degradation. Cell lysates were then harvested
and ubiquitinated proteins were isolated by binding to Ni-Nti-agarose. Cell lysates and pull-downs were analyzed by western blot for THN-HA
detecting the HA tag.
doi:10.1371/journal.ppat.1000843.g008
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antagonize tetherin with their envelope glycoproteins. Outside the
Retroviridae, the ebolavirus glycoprotein has anti-tetherin activity
[13] and here we propose that human herpesvirus KSHV
antagonizes tetherin with K5.
While this study was in revision, a study from Mansouri and
colleagues showed that tetherin could be degraded by K5 in an
ubiquitin-dependent manner [46]. Our data demonstrate that K5
can fully substitute for Vpu in mediating the efficient release of
HIV-1 particles from tetherin-expressing cells. This requires the
K5 RING domain and leads to a cell-surface down-regulation of
tetherin followed by its degradation in endosomal compartments.
Down-regulation of tetherin by K5 and its targeting to
endosomes requires the membrane proximal lysine residue K18
in the cytoplasmic tail, and this process is sensitive to inhibition of
the proteasome with MG132. Since K5-induced ubiquitination of
tetherin is dependent on its cytoplasmic tail lysines, the effects of
proteasomal inhibition are likely to be due to depletion of
cytoplasmic ubiquitin levels, rather than blocking proteasomal
degradation of tetherin. Furthermore, K5-mediated tetherin
degradation requires a functional ESCRT pathway as shown
by the rescue of surface tetherin levels after expression of a















































K5(delRING)                        K5
GFP       dnVPS4         GFP        dnVPS4
Figure 9. Cell-surface down-regulation of tetherin by K5 is inhibited by dominant-negative VPS4. (A) HeLa cells were transfected with
wild type K5 or K5(del RING) expression vectors in combination with either GFP or a dominant negative mutant of VPS4 fused to GFP (VPS4 E228Q).
24h later cells were stained for cell surface tetherin using anti-BST2 monoclonal antibody and a goat-anti-mouse Alexa633 secondary antibody. Flow
cytometry dot plots are shown. (B) The mean florescent intensities (MFI) of surface tetherin expression in GFP positive and GFP negative populations
from the samples in panel A are plotted.
doi:10.1371/journal.ppat.1000843.g009
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K5 targets tetherin by inducing an ubiquitin-dependent sorting of
tetherin to multivesicular bodies where it is destroyed in a
lysozomal compartment, a similar mechanism to that of K3-
mediated degradation of Class I MHC molecules [41]. K3 targets
MHCI for ESCRT-dependent sorting and destruction via
addition of a single ubiquitin moiety to the molecule’s
cytoplasmic tail through recruitment of the E2 enzymes UbcH5B
and/or C [38]. Lysine-63 poly-ubiquitination is then induced
through the subsequent recruitment of Ubc13 [38]. While we
cannot rule out that K5 induces poly-ubiquitination of tetherin,
we were only able to observe species consistent with mono-
ubiquitination. Thus, while K5 induces ESCRT-dependent
tetherin degradation, the precise molecular details of the
endosomal targeting may differ between K3 and K5 targets.
Whether endocytosis of tetherin is stimulated by K5, or whether
it is routed to endosomes from the Golgi, bypassing the cell
surface remains an interesting question. Our observation that
surface down-regulation of tetherin is independent of its tyrosine-
based endocytic-sorting signal [40] suggests the latter. Since K5
localizes mainly to the ER [47], tetherin ubiquitination could
happen very early after synthesis leading to endosomal routing
independently of the cell surface. Similarly, Mansouri and
colleagues suggested that in K5-expressing cells, little tetherin
reaches the PM, based on surface biotinylation experiments [46].
However, neither of these results is unambiguous, especially if cell
surface turnover is fast. Further studies of the molecular details of
K5 mechanism are required to fully dissect its effects on tetherin
trafficking.
An important aspect of our study is the comparative analysis of
the mechanisms by which Vpu and K5 achieve tetherin
antagonism. Both proteins lead to cell surface down-regulation
and degradation of tetherin but the mechanism of Vpu remains
unclear. Several studies have shown that tetherin degradation is
blocked by proteasomal inhibition [19,34,35], whereas others
suggest endosomal degradation [36,37]. It is clear that whilst Vpu-
mutants that cannot interact with bTRCP2 cannot mediate
tetherin degradation [36,37], they can nonetheless antagonize
tetherin and rescue viral release [17]. Thus, the SCF-Skp1-cullin 1
ubiquitin ligase complex and perhaps an ER-associated degrada-
tive pathway are implicated in tetherin degradation and this
process presumably follows tetherin antagonism at the cell surface
[35,36]. Tetherin down-regulation and degradation might there-
fore not be as strictly linked during Vpu-mediated antagonism as it
is during K5 mediated antagonism of tetherin. Furthermore,
proteasomal inhibition appeared to be more potent than
endosomal inhibition in rescuing cellular levels of tetherin in
Vpu-expressing cells. Unlike K5, we saw no evidence of tetherin
redistribution to endosomes in response to Vpu. Rather, residual
tetherin can be seen in the TGN, consistent with a recent study
suggesting that Vpu localization to the TGN is important for
tetherin antagonism [48]. Similarly, proteasomal inhibition does
not restore tetherin to the surface of Vpu-expressing cells, and
neither does dominant negative VPS4 (not shown). Also consistent
with these observations, is our observation that Vpu can induce
ubiquitination of tetherin cytoplasmic tail lysine residues, but these
are dispensable for Vpu sensitivity. Thus their ubiquitination
appears to be a consequence of tetherin antagonism rather than
the absolute requirement for K18 demonstrated for K5 sensitivity.
In this respect, we suggest tetherin antagonism by Vpu precedes,
and may not be dependent on, degradation, but rather results in
the sequestration of tetherin away from budding virions,
preventing incorporation. Thus there are more parallels with the
mechanism by which HIV-2 and SIVtan envelopes antagonize
tetherin through sequestration in TGN-associated compartments
[32,39]. K5’s apparent inability to antagonize tetherin in 293T
cells, cells that support Vpu’s antagonism of tetherin, suggests that
Vpu and K5 may require different cellular cofactors. Clearly,
further comparative mechanistic studies will allow us to dissect the
differences and similarities in the mode of action of these two very
different proteins.
We, and others [46], have also shown that productive KSHV
release is restricted by tetherin expression and knockdown of K5
expression imparted a block to virus release. Furthermore,
tetherin expression is reduced on B cells after K5 expression.
Importantly, this indicates that herpesvirus particle assembly is
sensitive to the antiviral effects of tetherin. The mechanism of
herpesvirus assembly and envelopment is complex and contro-
versial, most studies have focused on herpes simplex virus type 1
(HSV-1). Immature HSV-1 capsids may bud through nuclear
membrane, re-entering the cytoplasm, and then bud again into
secretory vesicles [29] via an ESCRT dependent process [49].
Our data suggest that in the case of KSHV, at least one budding
stage is through a membrane accessible to tetherin. Tetherin is
highly expressed in terminally differentiated B cells and plasma
cells, important cellular targets for KSHV [50]. B cell to plasma
cell differentiation activates KSHV lytic replication through the
activation of XBP-1 and the unfolded protein response [51].
Therefore the virus undergoes productive replication in cells
that express high levels of tetherin. This cellular tropism may
have provided the selective pressure for K5 evolution to target
tetherin. K5 has the ability to modulate the expression of a
variety of cell surface molecules involved in immuno-recognition
(MHC and NK receptors) and cell adhesion, suggesting
targeting of tetherin is part of a wider immuno-evasion strategy
by KSHV [52]. Is tetherin antagonism found in other
mammalian herpesviruses? B cell expression of tetherin would
certainly suggest that this might be the case for Epstein Barr
Virus (EBV). Removal of MHC and related molecules is
certainly a common feature of several human herpesvirus
immune evasion strategies [52,53,54], and it is likely that if
other herpesviruses are sensitive to tetherin-mediated restric-
tion, proteins with analogous function to K5 might also target
tetherin. MARCH ligase homologues are also found in a variety
of poxviruses [20], which also have highly complex envelopment
strategies [55].
Aside from the cytoplasmic tail lysine residue K18, we do not
yet fully understand the determinants of sensitivity for tetherin’s
antagonism by K5. Data presented herein show that while K5,
like Vpu [18,19], cannot target tetherin from Rhesus macaques,
the TM domain positions that determine the difference in Vpu-
sensitivity do not confer resistance to K5. Tetherin has been
under high levels of positive selection during mammalian
evolution, particularly in the cytoplasmic tail and TM domain,
areas of the protein likely to be topologically accessible to viral
antagonists [18,19]. Several residues in the TM domain are
responsible for the species-specific activity of Vpu. However,
positive selection in other parts of tetherin may be due to selective
pressure exerted by distinct viral countermeasures. We speculate
that some mammalian herpesviruses, which show strong co-
evolution with their hosts, may have contributed to this
evolutionary pressure. Tetherin may therefore represent an
extremely interesting case study in the evolution of an antiviral
gene under regular assault by unrelated viral pathogens, as has
been suggested for PKR [56].
In conclusion, here we have demonstrated that tetherin is
capable of restricting a human herpesvirus and show that in the
case of KSHV, the virus has co-opted an immuno-modulatory
ubiquitin ligase to target this antiviral effector.
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Materials and Methods
Plasmids, cells and antibodies
All adherent cells were maintained in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% fetal calf serum
and antibiotics. BCBL-1 cells were maintained in Roswell Park
Memorial Institute (RPMI) medium supplemented with 10% FCS
and antibiotics. HeLa, 293T and HT1080 cells were obtained
from the ATCC. The HIV-1 indicator cell line, HeLa-TZM, that
expresses HIV-1 receptors and an integrated HIV-1-LTR
controlling expression of a beta-galactosidase reporter gene were
kindly provided by John Kappes and Xiaoyun Wu via the NIH
AIDS reagents program. HT1080/THN-HA is a clonal cell line
expressing human tetherin with an internal HA tag inserted at
nucleotide position 463 [18] expressed from an integrated MLV
proviral vector, pLHCX (Clontech). Mutants of tetherin were
constructed by standard methods and expressed from pCR3.1 and
pLHCX. Vpu, K5 and a K5 mutant lacking amino acids 1–62
encompassing the RING domain (K5delRING) were amplified by
PCR and inserted into pCR3.1 with C-terminal HA and mCherry
fusion tags and the retroviral vectors pCxCR, which also encodes
dsRED express as a marker gene, and pCMS28, a pMigR1
derivative encoding puromycin under control of an Internal
Ribosome Entry Site (IRES). The molecular clones of HIV-1
NL4.3 and the Vpu-defective counterpart have been described
previously [7]. Anti-HA monoclonal antibody HA1.11 was
obtained from Covance, rabbit anti-HA polyclonal was obtained
from Rockland and anti-BST2 monoclonal antibody was obtained
from Abnova. Secondary Alexa Fluor 488, 594 and 633 antibodies
for flow cytometry and microscopy were obtained from Molecular
Probes. For quantitative western blotting, Licor 680 and 800nm
secondary abs were used and blots scanned using a Licor scanner.
Production of KSHV
HeLa cells infected with KSHV were made by infecting HeLa
with rKSHV.219 a recombinant KSHV virus encoding RFP, GFP
and puromycin resistance, a gift from Jeff Vieira [30]. Cells were
selected and kept under puromycin selection. To induce
rKSHV.219 into the lytic cycle, r219-Hela cells were seeded at
3.105 cells/well onto 6-well plates and transfected with 1.5 mg of
an expression factor for RTA (pCMV-RTA) (a gift from Adrian
Whitehouse) using Fugene-6. RFP expression was visible a day
after transfection. The transfection mix was removed and replaced
with 2 ml of fresh medium. Virus was recovered another 24 hours
later, i.e. 48 hours after transfection, and filtered through 0.45 mM
device (Millipore) to remove any cellular debris. Infectious virus
was measured by titration of supernatants onto 293T cells and
total virus by QPCR on DNAse-I resistant genomes. To assay for
KSHV release in the presence of tetherin, r219-Hela cells were
transfected with pCMV-RTA and increasing doses of tetherin
expression vector pCR3.1-THN [5]. Plasmid dose was kept
constant using empty vector (pCDNA3.1). To assay for KSHV
release under conditions where K5 expression is reduced, r219-
Hela cells were seeded at 105 cells per well in 6-well plates
24 hours prior to transduction with the lentiviral vectors encoding
the K5 specific hairpins, or the empty vector, at a multiplicity of
infection (MOI) of 5. 72 hours post-transduction, cells were
counted, re-seeded into 6-well plates and transfected with RTA
encoding plasmid as above.
Quantitation of KSHV infectious particles by titration
onto 293T
293T cells were seeded at 105 cells/well in 12-well plates
24 hours prior to titration. For each viral collection 250 ml (a sixth)
of the final volume of filtered virus was added to fresh medium to a
final volume of 1 ml and used to infect 293T cells. Titrations were
performed in duplicate using polybrene (4mg/ml). 12-well plates
were subjected to spinoculation at 500 g for 1 hour at RT before
being returned to the incubator. Cells were analyzed by flow
cytometry 48 hours post-inoculation.
Quantitation of KSHV genomes by Taqman PCR against
KSHV early gene ORF37
KSHV genomes were quantified by extracting total DNA
(QIAamp, QIAGEN) from DNAse-I treated supernatant (70
units/ml for 2 hours, RQ1 Promega, UK) with 40mg of salmon
sperm DNA as a carrier (Sigma, Poole UK). 5mg of purified DNA
was subjected to quantitative Taqman PCR for KSHV early gene
ORF37 as described [57]. Absolute copy number was determined
with reference to a standard curve derived by QPCR against serial
dilutions of an ORF37 amplicon encoding plasmid, a gift from
David Bibby and Duncan Clark, as described [58].
Quantification of mRNA levels for the late gene ORF37 in
r219-HeLa cell lysates by Q-RT-PCR
Total mRNA was extracted from r219-HeLa cells after virus
collection, 48 hours post-RTA transfection (RNeasy, QIAGEN).
cDNA syntheses were performed on 4 ml of the RNA (SuperScript
II Reverse Transcriptase, Invitrogen) according to manufacturer’s
instructions. cDNAs were treated with 2 units of RNAse H
(Invitrogen) for 20 minutes at 37uC before being used in taqman Q-
PCR reactions for ORF37 and GAPDH. GAPDH primers were
GAPDH forward primer, 59-GGCTGAGAACGGGAAGCTT-39;
GAPDH reverse primer, 59-AGGGATCTCGCTCCTGGAA-39;
GAPDH probe, 59-FAM-TCATCAATGGAAATCCCATCACC-
A-TAMRA-39. Absolute copy number was determined with
reference to a standard curve derived by QPCR against serial
dilutions of a GAPDH amplicon encoding plasmid. QPCR for
ORF37 was performed as described above.
Quantification of the number of episomes per nanogram
of total DNA in r219-HeLa cells
Cellular DNA was extracted from r219-HeLa cells after virus
collection, 48 hours post-RTA transfection (QIAamp, QIAGEN)
and QPCR for ORF37 performed, as described above, on cellular
associated episomes. Copy numbers were normalized to quantities
of DNA used for each reaction.
Production of retroviral vectors and infectious HIV-1
(VSV-G pseudotypes)
Semi-confluent 293T cells on 6-well dishes were transfected
with 1mg of vector plasmid, 1mg of pMLVgag-pol or p8.91
(HIV-1 gag-pol, tat and rev expression vector) and 0.2mg
pCMV-VSVG. For full length replication competent HIV-1
(VSV-G) pseudotypes, 293T cells were transfected with 2mg of
pNL4.3 or pNL4.3(del Vpu) and 0.2mg of VSV-G. This leads
to production of replication competent HIV-1 that has both
VSV-G and HIV-1 gp160 envelope proteins on its surface.
Virus and vector stocks were harvested 48h post-transfection.
Those encoding florescent markers were titrated on HT1080
cells and analyzed by flow cytometry; lentiviral vectors
encoding shRNA hairpins were titered by Q-PCR on 293T
cells with primers specific for the HIV-1 LTR; and the
endpoint titer of full length HIV-1 pseudotypes was deter-
mined on HeLa-TZM cells by staining infected foci with X-Gal
48h post-infection.
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HIV-1 release assays
Subconfluent HeLa cells were transfected with 500ng of HIV-1
proviral plasmid and 100ng of pCR3.1-Vpu or pCR3.1-K5-HA/
K5delRING-HA using lipofectamine 2000 (Invitrogen). Viral
supernatants and cell lysates were harvested 48h later. Superna-
tant virions were filtered and pelleted at 30000g through 20%
sucrose/PBS cushion for 90 minutes. Lysates and virions were
then separated by SDS-PAGE and HIV-1 Gag proteins detected
using an anti-p24 monoclonal antibody CA183 (provided by B
Chesboro through the NIH AIDS Reagents repository). In
parallel, harvested supernatants were titered onto HeLa-TZM
indicator cells and 48 hours later beta-gal activity was determined
in cell lysates using a Tropix Beta-galactosidase activity kit
(Molecular Probes). For assays involving stable HT1080/THN-
HA cell lines, 105 cells were plated per well in a 12 well plate and
infected with 26104 infectious units (MOI 0.2) of HIV-1 (VSV-G)
or HIV-1(del Vpu)(VSV-G) viral stocks. 48h later cell lysates and
viral supernatants were treated as above.
Flow cytometry and confocal microscopy
Cell surface staining for tetherin and THN-HA was performed
using the appropriate antibodies by standard methods and
analyzed on a FACS-Calibur (Becton-Dickinson). Cells for
microscopy were grown on glass coverslips and transfected or
treated with BafA1 (100nM), concanamycin A (100nM) or MG132
(1mg/ml) (Sigma, UK) for 10h. The cells were then fixed in 4%
paraformaldehyde, permeabilized with 0.1% Triton-6100 and
stained with the required primary and secondary antibody. Cells
were then examined using a Zeiss confocal microscope.
Tetherin ubiquitination assay
HeLa cells seeded on 10cm plates were transiently transfected
with the indicated THN-HA expression vector (5ug) in combina-
tion with K5, Vpu or GFP (2mg) expression vectors and in the
presence or absence of a 6-His-tagged ubiquitin encoding plasmid
(2mg). 48h after transfection, cells were treated for 8h with BafA1
(Sigma) to prevent further tetherin degradation. Cells were lysed in
5M guanidinium hydrochloride, sonicated and ubiquitinated
proteins were isolated by binding to 50ml of Ni2+ Nti-agarose
(Invitrogen) for 3h at room temperature. The beads were eluted
with 100mM imidazole. Lysates and pull-downs were then
analyzed by western blot for THN-HA.
Supporting Information
Figure S1 K5 does not antagonize tetherin-mediated restriction
of HIV-1(del Vpu) in 293T cells. 293T cells were transfected with
wild type HIV-1 or HIV-1(del Vpu) proviral plasmids in
combination with either Vpu or K5 expression vectors and
increasing doses of pCR3.1 THN-HA. 48h later supernatant
infectivity was determined on HeLa-TZM cells and is shown
plotted against tetherin input.
Found at: doi:10.1371/journal.ppat.1000843.s001 (0.26 MB EPS)
Figure S2 Vpu mediates the surface down-regulation of THN-
HA but not THN-HA(delGI-T45I) or Rh-THN-HA in HT1080
cells. Surface expression levels of stably transduced HT1080 cells
expressing THN-HA, THN-HA(delGI-T45I) or Rh-THN-HA
and Vpu were measured by flow cytometry. The red line
represents staining in unmodified HT1080 cells, the purple
histogram represents tetherin expression levels in tetherin
expressing cells and the green line represents tetherin levels after
HIV-1 Vpu expression.
Found at: doi:10.1371/journal.ppat.1000843.s002 (0.29 MB EPS)
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Tetherin (BST2/CD317) potently restricts the particle release of human immunodeficiency virus type 1
(HIV-1) mutants defective in the accessory gene vpu. Vpu antagonizes tetherin activity and induces its cell
surface downregulation and degradation in a manner dependent on the transmembrane (TM) domains of both
proteins. We have carried out extensive mutagenesis of the HIV-1 NL4.3 Vpu TM domain to identify three
amino acid positions, A14, W22, and, to a lesser extent, A18, that are required for tetherin antagonism. Despite
the mutants localizing indistinguishably from the wild-type (wt) protein and maintaining the ability to
multimerize, mutation of these positions rendered Vpu incapable of coimmunoprecipitating tetherin or me-
diating its cell surface downregulation. Interestingly, these amino acid positions are predicted to form one face
of the Vpu transmembrane alpha helix and therefore potentially contribute to an interacting surface with the
transmembrane domain of tetherin either directly or by modulating the conformation of Vpu oligomers. While
the equivalent of W22 is invariant in HIV-1/SIVcpz Vpu proteins, the positions of A14 and A18 are highly
conserved among Vpu alleles from HIV-1 groups M and N, but not those from group O or SIVcpz that lack
human tetherin (huTetherin)-antagonizing activity, suggesting that they may have contributed to the adaption
of HIV-1 to human tetherin.
Tetherin (CD317/BST2) is an interferon-induced type II
membrane glycoprotein of unusual topology (4, 25, 44) that
potently restricts the release of diverse mammalian enveloped
viral particles from infected cells (24, 33, 42, 45, 49, 52, 63).
The protein consists of a short 21-amino-acid cytoplasmic tail,
a transmembrane (TM) domain, a predominantly helical ex-
tracellular domain containing three cysteine residues that me-
diate tetherin dimerization (1, 44, 48) and an extended parallel
coiled-coil (18), and a C-terminal glycophosphatidylinositol
anchor that links it back to the cellular membrane (25). These
structural features are key to the mode of tetherin activity (48).
Tetherin is localized to the plasma membrane (PM) and con-
stitutively recycles through intracellular compartments (25,
50). It is incorporated into budding virions and acts as a phys-
ical tether, cross-linking the virion and cellular membranes,
thereby preventing virus particle release from the host cell (11,
15, 16, 48). Strong evidence suggests that the dual membrane
anchor of tetherin allows it to form parallel dimers with one
terminal in the virion membrane and the other in the cell (48).
The result of this is that mature viral particles are retained on
cell surfaces by protease-sensitive linkages that contain teth-
erin, and virions can then be endocytosed and accumulate in
endosomal compartments (41, 42, 48). This relatively nonspe-
cific inhibition of virus release does not require that tetherin
interact directly with any virally encoded structural protein;
thus, several mammalian viruses have evolved to encode pro-
teins that specifically inactivate tetherin function (5), the pro-
totype being the human immunodeficiency virus type 1
(HIV-1) accessory protein Vpu (42, 63).
Tetherin antagonism is a highly conserved attribute among
primate immunodeficiency viruses (14, 23, 27, 53, 68), implying
that modulating tetherin activity is essential for these viruses in
vivo. While the Vpu protein overcomes tetherin-mediated re-
striction of HIV-1, simian immunodeficiency viruses (SIVs)
and HIV-2 that lack a vpu gene counteract tetherin through
their Nef protein (23, 68) or envelope glycoproteins (14, 23,
27). Primate tetherin antagonism by both Vpu and Nef is
species specific (13, 23, 36, 68). HIV-1 Vpu can counteract only
human, gorilla, and chimpanzee tetherins, whereas SIV Nef
proteins can target multiple primate tetherins but not the hu-
man protein (23, 36, 53, 67, 68). This specificity maps to resi-
dues in tetherin’s TM domain for Vpu (13, 36, 51) and a
cytoplasmic tail motif for Nef (23, 28, 68). It has been sug-
gested that both the cytoplasmic tail (28, 36) and the TM
domain (13, 36) have been subjected to high positive selection
during primate evolution. To add more complexity, SIVcpz,
the direct precursor of HIV-1, is a recombinant virus derived
from SIVs that encoded either a Vpu or a Nef with tetherin-
antagonizing activity (54). The SIVcpz Nef targeting of chim-
panzee tetherin was maintained, while the Vpu activity was
apparently lost (53). Since the Nef target sequence in the
cytoplasmic tail of human tetherin (huTetherin) has been de-
leted, the Vpu protein appears to have readapted to tetherin
antagonism in HIV-1, leading to speculation that Vpu-medi-
ated antagonism of tetherin may have been a prerequisite for
efficient human-to-human transmission (28, 53, 67).
Vpu is a 16-kDa membrane protein consisting of an N-
terminal TM domain and a C-terminal cytoplasmic tail made
up of two amphipathic alpha helices separated by a conserved
casein kinase II phosphorylation motif that mediates binding
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to TRCP1 and -2 (reviewed in reference 61). Vpu forms
multimers in infected cells (30), with the TM domains forming
a cation-permeable channel (10, 57), although the functional
relevance of this for counteracting tetherin is unclear at
present. In addition to antagonizing tetherin, a conserved func-
tion of most HIV-1/SIV Vpu proteins is to induce TRCP-
dependent ER-associated degradation of CD4 (3, 35, 38, 55,
65) to facilitate HIV-1 envelope maturation (66). In contrast,
Vpu antagonizes tetherin in a post-ER compartment (58). Vpu
localizes predominantly to the trans-Golgi network (TGN) and
recycling endosomes (8, 64). In response to Vpu, tetherin is
downregulated from the cell surface (63). Several reports also
demonstrate that Vpu induces tetherin degradation dependent
on the recruitment of a TRCP2-SCF-Cullin1 ubiquitin ligase
complex (6, 12, 22, 32, 39). While tetherin degradation is ubiq-
uitin dependent, it is unclear whether it occurs in lysosomes (6,
22, 39) or proteasomally following an ERAD-like process (12,
13, 32). Furthermore, evidence suggests that degradation and,
to some extent, cell surface downregulation of tetherin are
dispensable events in tetherin antagonism by Vpu (40). Vpu
localization to the TGN correlates with its ability to overcome
tetherin (8), and recent studies demonstrate that tetherin also
accumulates in the TGN in response to both Vpu and the
envelope glycoproteins of HIV-2 and SIVtan (7, 14, 17, 27, 45).
The TM domain of Vpu is essential for its antitetherin activity,
and early studies demonstrated that deletion of parts of the
TM (47), scrambling (56), or multiple amino acid replacements
(62) blocked Vpu-enhanced virus release. Vpu coimmunopre-
cipitates with human, but not monkey, tetherin, suggesting that
direct interaction between the two proteins is essential for
antagonism (7, 22). However, the determinants in the Vpu TM
domain required for this interaction have not been identified
fully. In this study, we carried out extensive mutagenesis of the
HIV-1 NL4.3 Vpu TM domain to show that a conserved face
of the HIV-1 group M Vpu transmembrane helix is required
for tetherin interaction and antagonism.
MATERIALS AND METHODS
Cells and plasmids. All cells were maintained at 37°C/5% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM) (Invitrogen, United Kingdom) supple-
mented with 10% fetal calf serum (FCS) and gentamicin. HEK293T cells and
HeLa cells were obtained from the American Tissue Culture Collection (ATCC),
and the HIV-1 reporter cell line HeLa-TZMbl was kindly provided by John
Kappes through the NIH AIDS Reagents Repository Program (ARRP); HeLa/
CD4 cells were provided by A. Akrigg through the National Institute of Biolog-
ical Standards and Controls (NIBSC) Centre for AIDS Reagents (Potters Bar,
United Kingdom). Human HT1080 cells stably expressing human tetherin tagged
extracellularly with an HA epitope have been described previously (45). The
HIV-1 molecular clone plasmid pNL4.3 was obtained from the NIH ARRP, and
the Vpu-defective counterpart has been described previously (41). pCR3.1 en-
coding codon-optimized HIV-1 NL4.3 Vpu tagged at the C terminus with a
hemagglutinin (HA) epitope was derived from pVphu (43) (kindly provided by
K. Strebel through the NIH ARRP). All transmembrane domain mutants of Vpu
(Fig. 1A) were generated by QuikChange site-directed mutagenesis PCR by
standard methods using the Phusion-II polymerase (New England Biolabs), and
sequences were confirmed. pCR3.1 expression vectors encoding tagged or un-
tagged human tetherins have been described elsewhere (24, 36, 42).
Virus release assays. Subconfluent HEK293T cells were transfected with 500
ng of proviral plasmid in combination with 50 ng of pCR3.1-huTetherin and
variable concentrations of pCR3.1-Vpu-HA or mutants thereof using polyethyl-
eneimine (1 mg/ml; Polysciences). The medium was replaced 16 h after trans-
fection, and viral supernatants and cell lysates were harvested 48 h posttransfection.
The infectivity of viral supernatants was determined by infecting HeLa-TZMbl
and analyzing chemiluminescent beta-galactosidase activity 48 h later using
Tropix beta-galactosidase reagent (Applied Biosystems). To analyze physical
particle release, filtered supernatants were pelleted through a 20% sucrose-PBS
cushion in a bench-top microcentrifuge at 20,000  g for 90 min at 4°C, and
pellets were resuspended in SDS-PAGE loading buffer. Virion and cell lysates
were then subjected to SDS-PAGE and Western blotting for HIV-1 p24-CA
using the monoclonal antibody (MAb) 187 (kindly provided by B. Chesebro
through the NIH ARRP), Vpu-HA using mouse anti-HA monoclonal Ab (Co-
vance), Hsp90 (rabbit polyclonal; Santa Cruz Biotechnologies), or Vpu (rabbit
polyclonal; kindly provided by K. Strebel through the NIH ARRP [30]) and
visualized by LiCor apparatus using secondary antibodies conjugated to fluoro-
phores (IRDye 800 goat anti-rabbit and IRDye 680 goat anti-mouse antibodies).
Flow cytometry. Subconfluent HeLa cells in 6-well dishes were transfected with
400 ng pCR3.1-enhanced green fluorescent protein (eGFP) and 400 ng pCR3.1-
Vpu-HA or TM mutant. At 48 h posttransfection, the cells were harvested and
stained for surface tetherin using a specific anti-BST2 monoclonal IgG2a anti-
body (Abnova) and goat anti-mouse IgG2a Alexa633-conjugated secondary an-
tibody (Molecular Probes, Invitrogen, United Kingdom). Tetherin expression on
GFP cells was then analyzed using a FACSCalibur flow cytometer (Becton
Dickinson) and FlowJo software. Alternatively Jurkat cells were infected with
vesicular stomatitis virus G (VSV-G)-pseudotyped HIV-1 at a multiplicity of
infection (MOI) of 0.2. Forty-eight hours later, cells were stained for surface
tetherin expression as described above, fixed and permeabilized for 20 min
(Cytofix/Cytoperm fixation/permeabilization kit; BD Biosciences), and stained
for intracellular HIV-1 Gag using the KC57 antibody conjugated to phyco-
erythrin (PE) (Beckman-Coulter).
Immunofluorescence microscopy. HeLa cells plated on glass coverslips were
transfected with 100 ng of Vpu-HA expression vector or TM domain mutants. At
24 h posttransfection, the cells were fixed in 4% paraformaldehyde, permeabil-
ized in 0.1% Triton X-100, and immunostained using a mouse anti-HA mono-
clonal antibody (Covance) and sheep anti-human TGN46 (Serotec) followed by
the appropriate donkey secondary antibodies coupled to Alexa 488 and 594
fluorophores (Molecular Probes, Invitrogen, United Kingdom). The coverslips
were then mounted on slides using ProLong Antifade containing DAPI (4,6-
diamidino-2-phenylindole) (Molecular Probes, Invitrogen, United Kingdom)
and examined on a Leica DM-IRE2 confocal microscope. Similarly, HT1080-
tetherin-HA cells were plated on coverslips and infected with VSV-G-
pseudotyped HIV-1 NL4.3 or Vpu mutant at an MOI of 0.2. Forty-eight hours
later, the cells were fixed and stained with Vpu-, HA-, and TGN46-specific
antibodies with the appropriate donkey secondary antibodies linked to Alexa
488, 647, and 594 dyes, respectively.
Immunoprecipitation. Subconfluent HEK293T cells were transfected with 500
ng of Vpu-HA, the appropriate TM mutant or pCR3.1-YFP, and 500 ng of
pCR3.1-huTetherin or pCR3.1-Vpu-YFP. At 48 h posttransfection, the cells
were lysed on ice for 30 min on ice in buffer containing 50 mM Tris-HCl (pH 7.4),
150 mM NaCl, complete protease inhibitors (Roche), and 1% digitonin (Cal-
biochem). After removal of the nuclei, the resulting supernatants were pre-
cleared for 30 min at 4°C with 60 l of protein G-agarose (Invitrogen). The
supernatants were then incubated with 5 g/ml mouse anti-HA (Covance) for 2 h
at 4°C before addition of 50 l of fresh protein G-agarose for a further 3 h. The
beads were then washed 4 times in lysis buffer containing 0.1% digitonin and
resuspended in SDS-PAGE loading buffer. Cell lysates and immunoprecipitates
were then Western blotted for Vpu using mouse anti-HA and for tetherin using
rabbit anti-BST2 (40) (kindly provided by K. Strebel through the NIH ARRP).
RESULTS
Identification and characterization of point mutations in
the Vpu transmembrane domain that inhibit tetherin antago-
nism. The TM domain of Vpu is an absolute requirement for
enhancing virus particle release (56). Recent studies have dem-
onstrated that Vpu and tetherin coimmunoprecipitate with
each other in a species-specific manner, strongly suggesting a
direct interaction (7). To better characterize the determinants
of tetherin antagonism in the Vpu TM domain, we conducted
scanning mutagenesis through this region (residues 5 to 28) of
a codon-optimized HIV-1 NL4.3 Vpu bearing a C-terminal
HA tag (Fig. 1A). All nonalanine residues were mutated indi-
vidually to alanines, while bulkier hydrophobic leucine resi-
dues replaced those that were alanines. These Vpu TM
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mutants were then screened for their ability to rescue Vpu-
defective HIV-1 from tetherin-mediated restriction. Human
293T cells, which lack endogenous tetherin expression, were
transfected with HIV-1 NL4.3 delVpu proviruses in the pres-
ence of a fixed dose of a human tetherin expression vector and
either a plasmid encoding HA-tagged wild-type (wt) Vpu or
the TM domain mutants. At 48 h posttransfection, cell lysates
and viral supernatants were harvested and analyzed by West-
FIG. 1. Scanning mutagenesis of the HIV-1 NL4.3 Vpu TM domain and tetherin antagonism. (A) A schematic representation of point
mutations made in the TM domain of a codon-optimized HIV-1 NL4.3 Vpu protein. (B) 293T cells were transiently transfected with 500 ng of
HIV-1 delVpu provirus, 50 ng of tetherin plasmid, and 25 ng of the indicated Vpu expression vector. At 48 h after transfection, the resulting viral
supernatants were assayed for infectivity on HeLa-TZM indicator cells by measuring beta-galactosidase activity (top). Error bars are  standard
error of the mean (SEM) for three independent experiments. 293T cell lysates from one replicate of the assay were subjected to SDS-PAGE,
blotted for Vpu-HA, with the 90-kDa heat shock protein (Hsp90) serving as a loading control (bottom), and analyzed by a LiCor quantitative
imager. Numbers below the lanes indicate the percentages of relative Vpu expression compared to that of the wild-type protein. (C) 293T cells
transfected with 500 ng of HIV-1 wt or HIV-1 delVpu and 50 ng of tetherin expression vectors with increasing doses of the indicated Vpu-HA
mutant. The resulting infectivity was determined as described in the legend to panel B, and error bars represent  SEM for three independent
experiments. (D) Cell lysates and pelleted virions from one replicate of that shown in panel C were subjected to SDS-PAGE and LiCor Western
blotting was performed for HIV-1 p24-CA, Vpu-HA, and Hsp90 (top). The histogram (bottom) indicates supernatant virion yield (p24 band
intensity) relative to the release of HIV-1 wt in the absence of tetherin. RLU, relative light unit; YFP, yellow fluorescent protein; THN, tetherin.
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ern blotting or titrated on HeLa-TZM indicator cells (Fig. 1B).
As expected, in the presence of human tetherin, the release of
infectious HIV-1 delVpu was reduced approximately 50-fold,
as determined by the infectivity of harvested supernatants on
HeLa-TZM indicator cells, and expression of wild-type Vpu in
trans rescued the majority of this defect. Two mutants, the
A14L and W22A mutants, were markedly defective in viral
rescue compared to the control, with a third, the A18L mutant,
displaying a minor defect. Furthermore, several mutants (the
V9A, V25A, and I27A mutants) also displayed slight (approx-
imately 2-fold) defects compared to the wild type, but this
appeared due to expression levels of the proteins rather than a
functional defect per se. Interestingly mutation of S23, which
has been shown previously to completely abolish the ion chan-
nel activity of Vpu (37), or V13, I17, and V21, which would line
the pore of a putative channel (46), conferred no defect in
tetherin antagonism, suggesting that formation of an ion con-
ducting pore may not be required to relieve the restriction.
To characterize the functional mutants further, the A14L,
A18L, and W22A mutants or two combined mutants, the
A14L/W22A and A10L/A14L/A18L/W22A mutants, were re-
screened against a fixed dose of tetherin, but with various levels
of Vpu expression and virus release characterized by both
infectious titer release and physical particle yield by quantita-
tive Western blotting (Fig. 1C and D). Despite equivalent
expression levels of Vpu and HIV-1 Gag in producer cells,
neither the A14L mutant nor the W22A mutant could fully
rescue HIV-1 delVpu from tetherin, and both remained de-
fective compared to the wild-type Vpu, even at the highest
inputs. The A18L mutant was the least defective and regained
most of its function at higher plasmid inputs. Combining the
A14L and W22A mutants into a single mutant, either in the
context of the A14L/W22A or A10L/A14L/A18L/W22A mu-
tant, rendered Vpu effectively unable to counteract tetherin at
any level of expression.
Finally we engineered A14L and W22A mutants back into
the HIV-1 NL4.3 genome to place them under wild-type Vpu
expression conditions and tested virus release from 293T cells
transfected with tetherin (Fig. 2A and B). Consistent with
expression of the mutants in trans, we found that the mutant
carrying A14L alone and the combined mutant had a defect in
release equivalent to a full Vpu deletion, whereas W22A re-
tained a low level of tetherin antagonism. Thus, positions A14,
W22, and, to a lesser extent, A18, appear to be key residues
required for tetherin antagonism in the Vpu TM domain.
The A14 and W22 mutants fail to downregulate tetherin
from the cell surface. To further characterize the nature of the
Vpu TM mutants, we first determined their effects on cell
surface tetherin levels. Vpu expression leads to a downregula-
tion of cell surface tetherin and subsequently a degradation
step which itself may be dispensable for Vpu activity (12, 40,
63). Tetherin-positive HeLa cells were cotransfected with an
FIG. 2. The effect of A14 and W22 mutations in the context of full-length proviral clones. HIV-1 wt, HIV-1 delVpu, HIV-1 Vpu A14L, HIV-1
Vpu W22A, and HIV-1 Vpu A14L/W22A proviral clones were transfected into 293T cells in the presence or absence of 50 ng of tetherin expression
vector. Forty-eight hours later, the supernatants were assayed for infectivity on HeLa-TZM cells (A) and pelleted virions (B), and cell lysates were
processed for Western blotting as described in the legend to Fig. 1.
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empty vector control or Vpu expression vector in combination
with a GFP marker plasmid. At 48 h posttransfection, the cells
were harvested, stained for cell surface tetherin using a specific
monoclonal antibody, and analyzed by flow cytometry (Fig.
3A). Tetherin was downregulated from the cell surface of
GFP cells expressing Vpu, and as expected, downregulation
was reduced in the presence of a Vpu mutant that does not
interact with TRCP1/2 and Vpu S52 56A (12, 39, 63). Both
the A14L and W22A mutants failed to fully downregulate
tetherin, and either multiple mutant containing both A14L and
W22A mutations was completely defective for downregulation.
To confirm this with relevant infected cells, CD4 Jurkat T
cells were infected with VSV-G-pseudotyped wild-type HIV-1,
HIV-1 delVpu, HIV-1 Vpu2/6, HIV-1 Vpu A14L, HIV-1 Vpu
W22A, or HIV-1 A14L/W22A, and 48 h later cells were
stained for surface tetherin and intracellular Gag (Fig. 3B). As
expected, Gag-positive cells in cultures infected with wild-type
HIV-1, but not with HIV-1 delVpu or HIV-1 Vpu2/6, showed
loss of tetherin expression at the cell surface. However, in line
with our findings for transfected cells, Jurkat cells infected with
viruses bearing an A14L mutation showed little cell surface
tetherin reduction. The W22A mutant retained a residual abil-
ity to downregulate cell surface tetherin, again in line with our
above observations. Thus, Vpu TM mutants that cannot an-
tagonize tetherin function are concomitantly defective for cell
surface tetherin downregulation and, by extension, degrada-
tion.
We also tested our Vpu mutants for their ability to down-
regulate CD4. Although CD4 and Vpu have been shown to
interact through cytoplasmic tail interactions, a role for the
TM domain has been implicated by some (62), but not others
(56). HeLa/CD4 cells were transfected as described above, and
cell surface CD4 levels were measured 48 h later (Fig. 3B). As
expected, Vpu expression led to a reduction in surface CD4
that again was blocked in the presence of an S52 56A mutant.
Vpu A14L retained the ability to downregulate CD4, indicat-
ing that this mutant is specifically defective for tetherin antag-
onism. In contrast, and consistent with the work of Tiganos et
al. (62), the Vpu W22A mutant and multiple mutants bearing
this lesion were also defective for CD4 downregulation. Thus,
both tetherin and CD4 downmodulation require residues in
the Vpu TM, but these determinants only partially overlap.
Defective Vpu TM mutants localize to the TGN. While CD4
degradation occurs in the endoplasmic reticulum (ER), Vpu-
mediated virus release is sensitive to brefeldin A (58), suggest-
ing that tetherin antagonism takes place outside the ER. Vpu
localizes to the TGN and endosomal compartments, and the
ability to localize to the TGN has been shown to be important
for tetherin antagonism (8). Moreover, tetherin itself recycles
via the TGN (25, 50), and recent data for both Vpu and
HIV-2/SIV envelopes suggest that sequestration of tetherin in
the TGN is associated with antagonism (7, 14, 17, 27). Since
the TM domain(s) of integral membrane proteins may be in-
volved in subcellular localization (59), we next sought to rule
out whether our Vpu TM mutants were aberrantly localized.
HeLa cells transfected with Vpu-HA or TM mutants were
grown on coverslips, fixed 24 h later, immunostained for Vpu
(anti-HA) and the TGN marker TGN46, and examined by
confocal microscopy. As expected, wild-type Vpu-HA localizes
predominantly to perinuclear and punctate structures, with
much of the perinuclear signal overlapping with the TGN (Fig.
4A), consistent with previous studies. We found that all of our
Vpu TM mutants localized similarly, with TGN accumulation
visible in all cases. These data suggest that Vpu localization to
the TGN is independent of the ability to counteract tetherin,
and similarly, Vpu localizes to TGN46 compartments in teth-
erin-negative cells (data not shown). We then examined Vpu
and tetherin localization in infected HT1080 cells expressing
tetherin bearing an extracellular HA tag (HT1080/tetherin-
HA) (Fig. 4B). As expected, in these cells tetherin localizes to
the plasma membrane (PM) as well as the TGN since both
newly synthesized tetherin and that which recycles passes
through the Golgi network en route to the PM (25, 50). Con-
sistent with reports of TGN accumulation of tetherin in HIV-
1-infected cells (7), we found that wild-type Vpu and tetherin
colocalized in the TGN with a concomitant reduction in cell
surface expression. In contrast, and consistent with the flow
cytometry data presented in Fig. 3, cells infected with a virus
bearing the A14L/W22A mutation showed no evidence of teth-
erin relocalization from the PM to the TGN. This indicates
that the defect in tetherin antagonism for A14L and W22A
mutants of Vpu is likely not due to gross subcellular mislocal-
ization and that Vpu localization to the TGN and Vpu-induced
accumulation of tetherin in TGN46-positive compartments are
independent events.
Tetherin poorly coimmunoprecipitates with Vpu TM mu-
tants. We then assessed the ability of Vpu TM mutants to
coimmunoprecipitate tetherin as an indicator of direct inter-
action between the proteins. 293T cells were transfected with a
human tetherin expression vector and wild-type Vpu-HA or
the TM mutant. At 48 h after transfection, cell lysates were
immunoprecipitated with an anti-HA antibody. As shown in
Fig. 5A, tetherin (both precursor mannosylated and mature
complex glycosylated forms) was efficiently coimmunoprecipi-
tated with wild-type Vpu, despite total cellular tetherin levels
being lower in cell lysates due to Vpu-induced degradation
(Fig. 5A, low-exposure lysate panel). The A14L and W22A
mutants displayed little or no tetherin degradation and only
poorly coimmunoprecipitated the protein. Furthermore, com-
bined mutants containing both A14L and W22A were further
FIG. 3. Effects of Vpu TM mutations on cell surface levels of tetherin and CD4. (A) HeLa cells were transfected with a wild-type Vpu (Vpu
Wt)-encoding vector or the indicated mutant and a GFP-expressing construct. Cell surface staining for endogenous tetherin was analyzed by flow
cytometry 48 h later. Histograms show the tetherin levels on GFP cells in empty vector control cells (black) or Vpu/Vpu mutant-expressing cells
(gray). The median fluorescent intensities indicated in the top corner of each histogram are representative examples of 3 independent experiments.
(B) Jurkat cells were infected with the indicated VSV-G-pseudotyped viral stocks at an MOI of 0.2. Forty-eight hours later, cells were stained for
surface tetherin expression and intracellular Gag and analyzed by flow cytometry. Gag-positive infected cells were gated (black square), and surface
tetherin levels were compared. Numbers indicate median fluorescence intensities of surface tetherin on the infected cells. (C) As shown in panel
A, but the effects of Vpu-wt or Vpu-TM mutants on surface CD4 were examined in transfected HeLa/CD4 cells.
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reduced in their ability to coimmunoprecipitate tetherin. Thus,
the defect in tetherin antagonism in the A14L and W22A
mutants correlates directly with their failure to interact with
tetherin. Coupled with the observation that these mutants lo-
calize identically to wild-type Vpu, these data strongly suggest
that these positions in the Vpu TM domain are critical for the
interaction with tetherin. Interestingly, the fact that we coim-
munoprecipitated the lower-molecular-weight, immature form
of tetherin with Vpu may suggest that while Vpu exerts its
effect on tetherin in a post-ER compartment, interaction may
occur prior to further carbohydrate modification.
Oligomers of Vpu can be detected in infected cells (21, 30),
FIG. 4. Subcellular localization and multimerization of Vpu TM mutants. (A) HeLa cells were transfected by either 100 ng Vpu wt-HA or the
indicated mutant. A total of 24 h later, the cells were fixed and stained for Vpu localization with anti-HA antibody (green) and a TGN marker
(TGN46; red) and examined by confocal microscopy. (B) HT1080/THN-HA cells were infected with HIV-1 wt or HIV-1 Vpu A14L/W22A at an
MOI of 0.2. Forty-eight hours later, the cells were fixed and stained for Vpu (green), TGN46 (red), and tetherin-HA (blue) and examined by
confocal microscopy.
FIG. 5. Vpu TM mutants are unable to coimmunoprecipitate tetherin but maintain the ability to multimerize with wild-type Vpu. (A) 293T cells were
transfected with the indicated plasmid Vpu vectors or the indicated mutant and with tetherin. YFP only or tetherin only served as negative controls.
Forty-eight hours later, Vpu was immunoprecipitated (IP) via the HA tag from cell lysates and subjected to SDS-PAGE. Total lysates and immuno-
precipitates were then Western blotted for tetherin and Vpu-HA. Molecular mass markers are indicated, and blots are a representative example of three
independent experiments. (B) 293T cells transfected with HA-tagged Vpu or Vpu A14L/W22A were lysed in 1% digitonin after 48 h, subjected to
nonreducing SDS-PAGE without prior boiling, and Western blotted with an anti-HA monoclonal Ab. (C) 293T cells were transfected with Vpu-YFP and
either Vpu-HA or Vpu A14L/W22A-HA. Forty-eight hours later, cell lysates were immunoprecipitated with anti-HA Abs as described in the legend to
Fig. 5A, and whole lysates and IP fractions Western blotted for Vpu-HA and Vpu-YFP with anti-HA and anti-GFP antibodies, respectively. (D) 293T
cells were transfected with wild-type HIV-1 NL4.3 proviral plasmid, 50 ng of tetherin, and the indicated amount of Vpu-HA or mutant, and infectious
release was determined on HeLa-TZM cells 48 h later. Dotted lines represent wild-type and Vpu-defective viral titers in the absence of any expression
of Vpu in trans. (E) Cell lysates of the 100-ng input described in the legend to panel D blotted with an anti-Vpu polyclonal Ab to allow simultaneous
detection of the Vpu-HA expressed in trans and the wild-type Vpu expressed from the NL4.3 provirus.
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although their functional significance for tetherin antagonism
is not known. We next asked whether we could detect Vpu
mutants in multimeric forms in transfected cells. Western blots
of postnuclear lysates of Vpu-HA-transfected 293T cells run
under nonreducing conditions without prior boiling displayed a
higher-molecular-mass form of Vpu (approximately 80 kDa) in
addition to a monomer (Fig. 5B), consistent with previous
observations (30). This species of Vpu was also detected for
the Vpu A14L/W22A mutant, suggesting that our TM mutants
did not abolish Vpu multimerization. In addition, this mutant
also formed a larger (approximately 100- to 120-kDa) form.
Furthermore, under the same immunoprecipitation conditions
in which Vpu TM mutants failed to interact with tetherin, we
could show that wild-type Vpu tagged with GFP could coim-
munoprecipitate with both Vpu-HA and Vpu A14L/
W22A-HA (Fig. 5C). Therefore, the defect in tetherin antag-
onism by our TM mutants was not due to an inability of the
proteins to self-associate, although whether the nature or sta-
bility of these mutant oligomers is different or whether other
cellular factors contribute to them is unknown. To characterize
this further, we reasoned that if tetherin antagonism was me-
diated by functional Vpu multimers, Vpu A14L/W22A mu-
tants might be dominant-negative inhibitors of tetherin antag-
onism. However, titration of Vpu TM mutants into HIV-1 wt
viral release assays did not induce any enhanced sensitivity to
tetherin, despite estimated mutant Vpu levels 10-fold over that
expressed from the provirus (Fig. 5D and E). Thus, while not
ruling out that Vpu acts as a multimer to target tetherin, these
data show that the ability of Vpu-TM mutants to associate with
wild-type Vpu does not compromise its function.
A14, A18, and W22 form a face of the TM helix that is
conserved in group M and N, but not O, Vpu proteins. We next
looked at the conservation of the above TM positions in Vpu
sequences deposited in the HIV Sequence Database (www.hiv
.lanl.gov) (Fig. 6A). Aligning the TM domains of 1,197 group
M Vpu sequences shows that the positions equivalent to A18
and W22 are highly conserved. The majority of sequences also
have the equivalent of position 14 as A, but in many cases this
can be V. Notably we did not find an L at this position in
naturally occurring group M sequences. The same was ob-
FIG. 6. Residues A14, A18, and W22 form one face of the TM helix and are conserved in HIV-1 groups M and N, but not O. (A) Logo plots
of the TM domains of Vpu sequences drawn from the HIV Sequence Database (www.hiv.lanl.gov). Group M comprises 500 clade B, 200 clade
C, 200 clade A, 200 clade D, 42 clade F, 48 clade G, and 7 clade H TM sequences. Arrows indicate the equivalent positions of NL4.3 Vpu A14,
A18, and W22 residues. (B) Positions of A14, A18, and W22 (red) in the solid-state NMR structure of the NL4.3 Vpu TM domain determined
in membranes and the modeled tetrameric and pentameric assemblies based on it, as determined by Park et al. (46). Images were generated in
PyMol from the RSCB protein database entries 1PI7 (pentamer) and 1PI8 (tetramer).
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served with the small number of group N Vpu sequences avail-
able; the equivalents of positions 14, 18, and 22 were A, A, and
W, respectively. Interestingly, this was not the case for HIV-1
group O Vpu proteins, which have recently been shown to be
defective in tetherin antagonism (53). Here the position 14
equivalent is almost always L, and the majority of sequences
have an N at position 18. Again the W is invariant, which, since
group O Vpu proteins retain CD4 degradation activity (53), is
consistent with W22A mutants of NL4.3 Vpu being defective
for both tetherin and CD4 downregulation. Thus, the residues
we have identified as important for tetherin antagonism in
HIV-1 NL4.3 Vpu are conserved in viruses that can antagonize
human tetherin, but not in those that cannot.
The solid-state nuclear magnetic resonance (NMR) struc-
ture of the NL4.3 Vpu TM domain in lipid membranes has
been determined previously (34, 46). The core TM domain
(residues 8 to 25) forms a slightly kinked alpha helix tilted at
approximately 13 degrees to the vertical. Residues A10, A14,
A18, and W22 form one diagonal face of the helix (Fig. 6B).
Because Vpu can form ion-permeable channels, this structure
was further modeled to account for this, and the most favor-
able conformations that would allow channel function were
predicted to be a tetramer or a pentamer (46) (Fig. 6B). In this
conformation, W22 is predicted to protrude outward from the
pentamer and may give stability to the structure in the mem-
brane. A14 and A18 are positioned at the interface with the
adjacent monomers, and therefore, their replacement with
bulkier leucine residues may impinge on this interaction and,
although not sufficient to block Vpu multimerization, alter the
conformation or stoichiometry of Vpu oligomers. Alterna-
tively, or in addition to contributing to interhelical contacts or
stability, A14, A18, and W22 might also contribute to a con-
served binding surface for interaction with another protein,
potentially tetherin.
DISCUSSION
The mechanism by which Vpu antagonizes tetherin activity
is unclear at present. While Vpu expression leads to either
endosomal or proteasomal degradation of tetherin (6, 12, 13,
22, 32, 39), the ultimate destruction of tetherin appears dis-
pensable (7, 40). Moreover, tetherin accumulation in the TGN
in response to Vpu suggests that removal of tetherin from the
cell surface is a result of Vpu inhibiting tetherin recycling/
transport to the plasma membrane, and Vpu localization to the
TGN, mediated by determinants in its cytoplasmic tail, corre-
lates with this activity (7, 8). Furthermore, in CD4 T cells,
removal of tetherin itself from the cell surface may not be
strictly required to block its antiviral activity (40). In this study
we have characterized transmembrane domain mutants of
HIV-1 NL4.3 Vpu that cannot antagonize tetherin-mediated
restriction of virion release, with major defects associated with
changes at positions A14 and W22. Vpu TM mutants defective
for tetherin antagonism are concomitantly defective for teth-
erin downregulation from the cell surface and, by extension,
degradation. This directly correlates with the inability of these
mutants to interact with tetherin in coimmunoprecipitations.
Since these residues are conserved in group M and N Vpu
proteins and their mutation does not grossly affect Vpu local-
ization to the TGN or prevent Vpu from interacting with itself,
we propose that A14, W22, and, to a lesser extent, A18 con-
tribute to the interaction between tetherin and Vpu. In the
absence of this interaction, antagonism of the antiviral activity
of tetherin, its cell surface downregulation, and its ultimate
degradation are all impaired.
While it cannot be ruled out that a cellular cofactor mediates
Vpu-tetherin interactions, the genetic evidence for direct bind-
ing between their TM domains is strong. First, the species
specificity of HIV-1 NL4.3 Vpu maps to positively selected
residues in the tetherin TM domain, suggesting that viral coun-
termeasures that target the tetherin TM may have acted as a
selective pressure on tetherin evolution (13, 36). In particular,
a GI deletion toward the N terminus (cytoplasmic) and a T45I
change at the C terminus (extracellular) of the tetherin TM
account for the sensitivity of human, but not macaque, tetherin
to NL4.3 Vpu, although additional residues can contribute to
Vpu sensitivity (36). Moreover, the Vpu proteins from other
HIV-1 group M strains have a more expanded tropism for
other primate tetherins (53). However, in the case of HIV-1
NL4.3, this species specificity correlates with the lack of coim-
munoprecipitation with insensitive primate tetherin variants
(7). Second, a recent study demonstrated fluorescence reso-
nance energy transfer (FRET) between Vpu and human teth-
erin that was dependent on the Vpu TM domain (2). Finally,
deletion mutations within the Vpu TM that encompass W22 or
the complete scrambling of its sequence have long been known
to inhibit Vpu-mediated virus release (47, 56, 62). Our data
build on these observations, implicating specific Vpu TM res-
idues in the interaction with tetherin that do not affect TGN
localization or block self-association.
Modeling of the Vpu TM structure has historically been
done on the basis that it forms a multimeric cation-permeable
channel in cellular membranes (10, 57). Since scrambling the
TM domain blocks both ion channel activity and efficient virus
release, it was thought that these activities were related (10,
57). Indeed, amiloride-based drugs that block Vpu channel
function have been shown to display antiviral activity against
HIV-1 in (tetherin-positive) macrophages (9), and other stud-
ies report that chimeric Vpu proteins bearing the TM domain
of the influenza A virus proton channel M2 were functional for
virus release and sensitive to rimantadine (19, 20). However,
since we found that mutation of S23, known to be required for
channel activity (60) and the potential target for amilorides
(26), had no effect on tetherin inactivation in our assays, there
appears to be a discrepancy in directly correlating cation trans-
port and virus release (tetherin antagonism). The role of ion
transport in Vpu function is therefore unclear, but given the
multifunctional nature of HIV-1 accessory proteins (31), it is
possible that the ion channel activity is related to a yet-to-be-
defined role of Vpu in HIV-1 replication.
We do not know the stoichiometry of the Vpu-tetherin in-
teraction or indeed whether Vpu multimerization is required
for its antagonism. Oligomers of Vpu can be detected in in-
fected cells (30). NMR structures of the Vpu TM have been
used to predict the conformation of Vpu multimers; however,
as discussed above, these have revolved around its ion channel
activity. More recent data suggest that there might be an equi-
librium of Vpu monomers and different multimeric forms (29),
while another FRET-based study provided evidence that Vpu-
Vpu interactions could be detected in Golgi-related structures
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but not in the ER (21), suggesting that Vpu multimerization
may occur differentially in subcellular compartments. Based on
the NMR structural model of a Vpu pentamer shown in Fig. 6
(46), an A14L mutation might disrupt interhelical interactions
in Vpu multimers and a W22A mutant might lose the stability
imparted by the tryptophan side chain. However, neither mu-
tation disrupts the ability of Vpu to interact with itself nor
alters its subcellular distribution, although they may lead to
additional multimeric forms at steady state (Fig. 5B). Further-
more, V13A and I16A mutants, which in the predicted mul-
timers would be associated with A14 on the adjacent helix, lack
significant defects in tetherin antagonism. A14 and W22 might
also contribute to a direct tetherin-interacting surface formed
upon Vpu multimerization. However, one piece of data from
our study is not consistent with Vpu targeting tetherin as a
functional multimer. Despite overexpressing Vpu mutants in
excess, we were unable to observe any dominant-negative ac-
tivity of A14L and W22A mutants against wild-type HIV-1
virion release in the presence of tetherin, as might be expected
if A14L/W22A mutations were disrupting the integrity or con-
formation of functional Vpu multimers. While not itself dem-
onstrating that Vpu acts on tetherin as a monomer, this ob-
servation shows that despite being unable to mediate tetherin
interaction, the ability of the A14L/W22A mutant to multi-
merize with the wild-type protein does not block its inactiva-
tion of tetherin. Alternatively, if Vpu did act on tetherin as a
monomer, the fact that A14, A18, and W22 form a face of the
TM helix might be indicative of the residues forming a binding
surface. If so, they could directly interact with residues in the
tetherin TM domain known to be required for sensitivity to
Vpu. Further in-depth structure/function analyses are required
to distinguish between these possibilities. Such studies will be
essential for the design of any potential Vpu inhibitors.
The ability to counteract tetherin is conserved among pri-
mate lentiviruses, indicating that this attribute is essential for
replication/transmission of these viruses in vivo (14, 23, 27, 42,
53, 68). Recent studies have suggested that the ability of HIV-1
Vpu to counteract human tetherin is a “reacquisition” of an
ancestral Vpu function in the SIVgsn/SIVmon/SIVmus lineage
that was lost in SIVcpz presumably due to redundancy with the
tetherin antagonism function of Nef (53). The selective pres-
sures that lead to the specific deletion of the SIV Nef target
sequence (G/DDIWK) in the cytoplasmic tail of human teth-
erin are unclear (23, 28, 68), although prehistoric human ex-
posure to Nef-like proteins from pathogenic viruses is a pos-
sible explanation. Regardless, the spread of SIVcpz to humans
to become HIV-1 presented the virus with a problem; the
tetherin countermeasure was ineffective (54). Recent data
from the Emerman group have demonstrated that swapping
the majority of the TM domain of HIV-1 Vpu, including the
residues identified herein, renders SIVcpz Vpu active against
human tetherin (28). The differences between the HIV-1 Vpu
and SIVcpz Vpu TM domains indicate that multiple changes
occurred during the adaption of HIV-1 Vpu to humans. Inter-
estingly, in terms of acquiring tetherin antagonism and main-
taining CD4 downregulation, there is evidence that this was
fully achieved only by HIV-1 group M, derived from the
SIVcpz zoonosis that gave rise to the HIV/AIDS pandemic
(53). Data from the small number of group N Vpu proteins
available suggest that tetherin antagonism has developed to
some extent here too, although these proteins now do not
target CD4. HIV-1 group O Vpu proteins, by contrast, are
devoid of tetherin antagonistic activity, while remaining capa-
ble of targeting CD4 (53). We note with interest that the
conservation of an A and, to a lesser extent a V, at the equiv-
alent to position 14 in the Vpu TM is found only in Vpu
proteins from groups M and N, whereas in group O it is
invariably L and is often acidic in SIVcpz. In our hands, an
A14L mutation was selectively defective for tetherin and had
no effect on CD4 downregulation. In contrast, the W residue is
invariant in all HIV-1/SIVcpz Vpu TMs, consistent with its role
in both tetherin antagonism and CD4 degradation. Position 18,
which when mutated to a leucine has a lesser effect on tetherin
antagonism in NL4.3 Vpu, is also highly conserved in groups M
and N but in group O is most often a polar residue (N or S).
Thus, the residues identified in our screen are associated with
Vpu proteins that can antagonize tetherin, but not those that
cannot. Whether these residues are sufficient to confer tetherin
antagonism to group O Vpu or whether they are necessary only
in the context of other differences in the TM domains, as
suggested by the data of Lim et al. (28), remains to be deter-
mined. As shown in Fig. 6A, several other positions in the
group M Vpu TMs are highly conserved, particularly surround-
ing A14 and W22, and when mutated individually, they had
little or no effect on tetherin antagonism in our transfection
assays but may have subtle context-dependent roles. Addi-
tional features of the cytoplasmic tail that modulate Vpu lo-
calization to the TGN also play a role in tetherin antagonism
(8), and it is at present unknown whether these are functional
in group O Vpu proteins.
In summary, we have identified conserved determinants in
the HIV-1 Vpu TM domain that contribute to tetherin inter-
action and antagonism. Further studies will determine the
structural implications of these mutations on tetherin binding
and the role of Vpu multimerization in the process and poten-
tially allow the design of antiviral candidates to disrupt Vpu-
tetherin interactions.
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Separable Determinants of Subcellular Localization and Interaction
Account for the Inability of Group O HIV-1 Vpu To
Counteract Tetherin
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Tetherin (BST-2/CD317) is thought to restrict retroviral particle release by cross-linking nascent viral and
cellular membranes. Unlike the Vpu proteins encoded by human immunodeficiency virus type 1 (HIV-1) group
M strains (M-Vpu), those from the nonpandemic HIV-1 group O (O-Vpu) are not able to counteract tetherin
activity. Here, we characterized the basis of this defect in O-Vpu. O-Vpu differs from M-Vpu in that it fails to
interact with tetherin and downregulate it from the cell surface. Unlike M-Vpu, O-Vpu localizes to the
endoplasmic reticulum (ER) rather than the trans-Golgi network (TGN). Interestingly M-Vpu bearing an ER
retention signal at the C terminus localizes similarly to O-Vpu. While it still interacts with tetherin, it fails to
promote virus release, suggesting that O-Vpu deficiency correlates with its cellular distribution in the endo-
plasmic reticulum as well as its failure to bind tetherin. O-Vpu–M-Vpu chimeras were designed to identify the
minimal changes required to restore tetherin antagonism. While several chimeric proteins bearing residues of
the M-Vpu transmembrane domain into the O-Vpu transmembrane domain recovered tetherin binding in
coimmunoprecipitation studies, efficient antagonism required an additional glutamic acid-to-lysine change in
the membrane-proximal hinge region of the O-Vpu cytoplasmic tail that was sufficient to abolish ER retention
and permit TGN localization.
Tetherin is a recently identified antiviral factor that inter-
feres with the late stages of the human immunodeficiency virus
type 1 (HIV-1) replication cycle by preventing the release of
nascent viral particles from infected cells (38, 59). It is an
interferon-induced type II membrane glycoprotein (3, 25, 40)
composed of a short cytoplasmic tail (CT), a transmembrane
domain (TMD), and an extracellular domain mainly consisting
of a coiled-coil region (19, 47, 56, 64), followed by a putative
glycophosphatidylinositol (GPI) lipid anchor at the C terminus
embedded in cholesterol-rich microdomains at the cellular
membrane (25). Tetherin localizes to the plasma membrane
(PM) and multiple membrane compartments, including the
trans-Golgi network (TGN), and recycles via the clathrin-adap-
tor complex (AP-1 and AP-2) endocytosis machinery (25, 43).
The protein’s function essentially relies on its unusual struc-
tural topology, underscored by the ability to create a com-
pletely artificial tetherin-like protein from unrelated protein
subunits with similar restriction activity (42). Tetherin is
thought to inhibit virus release by being incorporated into
nascent virions and directly cross-linking the viral and the
cellular membranes (11, 16, 42), leading to the accumulation of
fully mature virions at the plasma membrane, followed by
internalization and subsequent lysosomal degradation (37, 38).
Interestingly, since tetherin does not directly interact with any
virally encoded structural protein, it can block a broad spec-
trum of mammalian enveloped viruses, including retroviruses,
Ebola virus, Marburg virus, Lassa fever virus, and Kaposi’s
sarcoma-associated herpesvirus (KSHV; human herpesvirus 8)
(22, 23, 30, 41, 44). Concomitantly, many of these viruses have
evolved countermeasures that target tetherin function (5). The
prototype of these antagonists is the HIV-1 accessory protein
Vpu (38, 59).
Vpu is a 16-kDa phosphoprotein consisting of an N-terminal
transmembrane domain and a cytoplasmic tail that forms two
alpha helices linked by a conserved DGSNES motif that can be
phosphorylated by casein kinase II (55). The interaction of this
motif with -TrCP1 and -2 is required to mediate endoplasmic
reticulum (ER)-associated degradation of CD4 (2, 31, 48, 63).
The Vpu TM domain is thought to oligomerize to form pen-
tameric cation channels (10, 28, 50) and localizes predomi-
nantly to internal membrane structures, including the TGN
and endosomes (9, 61). Vpu is not incorporated into HIV-1
particles and therefore must perform its functions within the
infected cells. Vpu induces tetherin to be downregulated from
the cell surface (59) and degraded (6, 13, 20, 29, 34), although
whether this degradation is an absolute requirement to over-
come tetherin restriction is still unclear (35). The large fraction
of Vpu colocalization with tetherin in the TGN suggests that
newly synthesized or recycled tetherin from the cell surface
might be sequestered in the TGN (8), similarly to what has
been observed with HIV-2 Env (17, 26). Consistent with this,
TGN localization of Vpu correlates with antitetherin function
(9). Tetherin and Vpu interact with each other via their trans-
membrane domains (8, 20, 24, 62). Some of the determinants
required for the interaction have recently been mapped and
form single faces of both proteins’ respective TM domains. In
the tetherin TM domain, mutations on residues I34, L37, and
L41 affect its sensitivity for Vpu (24). In the viral protein,
residues A14, W22, and, to a lesser extent, A18 that form one
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face of the Vpu TMD are required for tetherin interaction and
antagonism (62).
The HIV-1 Vpu protein is able to counteract only human,
chimpanzee, and gorilla tetherins. This species specificity re-
sides in the aforementioned TM domain interactions, and sev-
eral of the determinants in the tetherin TM domain have been
subjected to positive selection during primate evolution (14,
33). In simian immunodeficiency virus (SIV) cpz, the direct
precursor of HIV-1, the Nef protein rather than Vpu antago-
nizes chimpanzee tetherin, and the ability of Vpu to target
human tetherin is an adaptation that presumably occurred
during the zoonosis of this virus to humans (21, 33, 45, 65, 66).
To add further to this complexity, only Vpu proteins from
HIV-1 group M, the viruses predominantly responsible for the
HIV-1 pandemic, can both antagonize tetherin efficiently and
degrade CD4. In HIV-1 group O, Vpu proteins are unable to
target tetherin but still retain the ability to degrade CD4,
whereas this situation is reversed in HIV-1 group N, with Vpu
retaining some level of tetherin antagonism but losing activity
against CD4 (45). HIV-1 group O infections are limited mainly
to Cameroon. While HIV-1 group O-infected individuals can
progress to AIDS, the spread of this virus appears to be inef-
ficient compared to group M (32). It has recently been specu-
lated that Vpu adaptation to human tetherin may have there-
fore been important for the pandemic spread of HIV/AIDS
(46).
In this study, we characterized the cell biological basis for
the defects in the Vpu proteins from HIV-1 group O (O-Vpu)
that impair its ability to antagonize tetherin. We found that
O-Vpu is defective both for tetherin binding and also in its
subcellular localization to the TGN. These attributes are sep-
arable to the TM domain and the membrane-proximal hinge
region of the first alpha helix of the cytoplasmic tail, respec-
tively. Simultaneous replacement of these domains in O-Vpu
with those from Vpu proteins encoded by HIV-1 group M
strains (M-Vpu) are required to reconstitute tetherin antago-
nism.
MATERIALS AND METHODS
Cells and plasmids. All cells were maintained at 37°C with 5% CO2 in Dul-
becco’s modified Eagle’s medium (DMEM; Invitrogen, United Kingdom) sup-
plemented with 10% fetal calf serum (FCS) and gentamicin. HEK293T (293T)
cells and HeLa cells were obtained from the American Type Culture Collection
(ATCC), and the HIV-1 reporter cell line HeLa-TZMbl was kindly provided by
John Kappes through the NIH AIDS Reagents Repository Program (ARRP).
HeLa/CD4 cells were provided by A. Akrigg through the National Institute of
Biological Standards and Controls (NIBSC) Centre for AIDS Reagents (Potters
Bar, United Kingdom). The HIV-1 molecular clone plasmid pNL4.3 was ob-
tained from the NIH ARRP, and the Vpu-defective counterpart has been de-
scribed previously (37). pCR3.1, encoding a codon-optimized HIV-1 NL4.3 Vpu
tagged at the C terminus with an HA epitope (pCR3.1-Vpu-HA), mentioned in
this study as M-Vpu Wt, was derived from pVphu (kindly provided by K. Strebel
through the NIH ARRP) (39). Codon-optimized Vpu group O (O-Vpu) genes
derived from HIV-1 group O strains 9435 and HJ001 as well as a consensus
sequence assembled from 32 full-length O-Vpu sequences available in the HIV
Sequence Database (http://www.hiv.lanl.gov) were synthesized by multiple over-
lapping PCRs and cloned into the expression vector pCR3.1. O-Vpu mutants and
chimeras were generated by QuikChange site-directed mutagenesis and overlap-
ping PCR, respectively, by standard methods using Phusion II polymerase (New
England BioLabs). All the sequences were confirmed.
Virus release assays. Subconfluent HEK293T cells were transfected with 500
ng of proviral plasmid in combination with 50 ng of pCR3.1 human tetherin and
variable concentrations of pCR3.1-Vpu-HA or mutants thereof using polyethyl-
enimine (1 mg/ml; Polysciences). The medium was replaced 16 h after transfec-
tion, and viral supernatants and cell lysates were harvested at 48 h posttransfec-
tion and analyzed for infectivity using HeLa-TZMbl indicator cells and particle
production by Western blotting and as described previously (62).
Flow cytometry. Subconfluent HeLa cells in 6-well dishes were transfected with
400 ng pCR3.1 encoding enhanced green fluorescent protein (pCR3.1-EGFP)
and 400 ng pCR3.1-Vpu-HA. At 48 h posttransfection, the cells were harvested
and stained for surface tetherin using a specific anti-BST2 monoclonal IgG2a
antibody (Abnova) and a goat anti-mouse IgG2a-allphycocyanin Alexa 633 con-
jugated as a secondary antibody (Molecular Probes, Invitrogen, United King-
dom). Tetherin expression in green fluorescent protein (GFP)-positive cells was
then analyzed using a FACSCalibur flow cytometer (Becton Dickinson) and
FlowJo software.
Immunofluorescence microscopy. HeLa cells plated on glass coverslips were
transfected with 100 ng of Vpu-HA expression vector. At 24 h posttransfection,
the cells were fixed in 4% paraformaldehyde, permeabilized in 0.1% Triton
X-100, and immunostained using mouse or rabbit anti-HA antibodies (Covance),
a sheep anti-human TGN46 (Serotec), and a mouse anti-protein disulfide
isomerase (anti-PDI; Molecular Probes, Invitrogen), followed by the appropriate
donkey secondary antibodies coupled to Alexa 488 and 594 fluorophores (Mo-
lecular Probes, Invitrogen, United Kingdom). The coverslips were then mounted
on slides using ProLong antifade reagent containing 4,6-diamidino-2-phenyl-
indole (Molecular Probes, Invitrogen, United Kingdom) and examined on a
Leica DM-IRE2 confocal microscope.
Immunoprecipitation. Coimmunoprecipitation of tetherin with Vpu-HA from
transfected HEK293T cells was performed as described previously (62). Cell
lysates and immunoprecipitates were Western blotted for Vpu using mouse
anti-HA and tetherin using rabbit anti-BST2 (kindly provided by K. Strebel
through the NIH ARRP).
RESULTS
O-Vpu 9435 fails to interact with tetherin or mediate its cell
surface downregulation and localizes to ER-associated com-
partments. HIV-1 group O Vpu has been shown to lack the
ability to counteract human tetherin but can still induce CD4
degradation (45). To confirm this, a Vpu gene from HIV-1
group O strain 9435 was synthesized with a C-terminal HA tag
and tested for its ability to block tetherin antiviral function.
293T cells were cotransfected with a fixed dose of tetherin
plasmid, increasing amounts of Vpu expression vectors, and a
proviral plasmid of HIV-1 NL4.3 deleted for the Vpu gene
[HIV-1(Vpu)]. At 48 h posttransfection, cells were lysed and
supernatants were analyzed by Western blotting for p24 and
Vpu detection or titrated on HeLa-TZMbl indicator cells (Fig.
1A). As expected, a prototype M-Vpu (NL4.3) efficiently res-
cues virus production in the presence of tetherin. In contrast,
O-Vpu of strain 9435 (O-Vpu 9435) was unable to rescue
particle release from tetherin restriction, even at higher plas-
mid inputs, and was equivalent to an M-Vpu A14L-W22A TM
mutant that we have shown previously to be defective for
tetherin antagonism (62). All proteins were expressed at com-
parable levels, and O-Vpu 9435 expression did not affect in-
tracellular Gag protein synthesis (Fig. 1A). Whereas M-Vpu
runs on a Western blot as a single species, O-Vpu 9435 appears
as a doublet. M-Vpu overcomes human tetherin by mediating
its removal from the cell surface and blocking its incorporation
into nascent virions. To address whether O-Vpu fails to antag-
onize tetherin because it cannot induce its downregulation,
tetherin-positive HeLa cells were cotransfected with an empty
vector control or a Vpu expression vector in combination with
a GFP marker plasmid. At 48 h posttransfection, cells were
harvested and stained for surface tetherin levels (Fig. 1B). As
expected in GFP-positive cells, expression of M-Vpu Wt but
not M-Vpu A14L-W22A leads to a decrease of tetherin levels
at the cell surface. Expression of O-Vpu 9435 had little effect
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FIG. 1. Defects in tetherin antagonism, binding, and downregulation by O-Vpu 9435. (A) 293T cells were transiently transfected with 500 ng of
HIV-1(Vpu) provirus, 50 ng of tetherin plasmid, and increasing doses of the indicated Vpu expression vector. At 48 h posttransfection, the resulting
viral supernatants were assayed for infectivity on HeLa-TZMbl indicator cells by measuring beta-galactosidase activity at 48 h postinfection. Cell lysates
and pelleted virions from cells transfected with 50 ng of Vpu plasmid were subjected to SDS-PAGE and blotted for Vpu-HA, p24-CA, and Hsp90 protein,
which served as a loading control, and analyzed by a LiCor quantitative imager. Relative virus release was calculated as a percentage of the virion p24
band intensity of the no-tetherin control. RLU, relative light units. (B) HeLa cells were cotransfected with 400 ng of GFP marker plasmid and the
indicated Vpu expression vector. At 48 h posttransfection, endogenous surface tetherin was immunostained and expression levels were quantified by flow
cytometry. Histograms represent the tetherin levels on GFP-positive gated cells in empty vector control cells (black peak) or in Vpu-expressing cells
(overlaid gray peak). Median fluorescence intensities of the overlaid histogram are indicated in the top right corner. (C) 293T cells were transiently
transfected with 500 ng of human tetherin-encoding plasmid and 500 ng of the indicated Vpu expression vector. After 2 days of incubation at 37°C, Vpu
was immunoprecipitated (IP) via the HA tag from cell lysates and subjected to SDS-PAGE. Total cell lysates and immunoprecipitates were then Western
blotted for tetherin and Vpu-HA. Molecular mass markers are indicated, and blots are a representative example of three independent experiments.
(D) As in panel B, but the effects of O-Vpu on surface CD4 were examined in transfected HeLa/CD4 cells.
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on surface tetherin levels. Finally, Vpu mediates tetherin
downregulation through interaction via their transmembrane
domains. Mutations impairing this interaction render the viral
protein incapable of allowing coimmunoprecipitation of teth-
erin from cell lysates (62). We then assessed the ability of
O-Vpu 9435 to interact with tetherin in this assay. 293T cells
were cotransfected with tetherin and Vpu-HA expression vec-
tors. Two days after transfection, cells were lysed and Vpu
proteins were immunoprecipitated via the HA epitope and
analyzed by Western blotting (Fig. 1C). As expected, tetherin
coimmunoprecipitates with M-Vpu Wt and not with the trans-
membrane Vpu mutant (M-Vpu A14L-W22A). Similarly, teth-
erin also failed to coimmunoprecipitate with O-Vpu 9435, sug-
gesting the lack of a direct interaction between the tetherin
TMD and O-Vpu TMD. Finally, despite these defects in teth-
erin antagonism, as expected, this O-Vpu construct retained
the ability to induce CD4 downregulation (Fig. 1D).
Vpu localization in the TGN has been shown to be impor-
tant to suppress tetherin restriction activity, consistent with
Vpu inducing sequestration of tetherin in the TGN (8, 9). Here
we addressed whether the O-Vpu 9435 cellular localization
accounts for its inability to block tetherin function. HeLa cells
were transfected with a Vpu-HA-encoding vector. Twenty-four
hours later cells were fixed and immunostained for Vpu-HA
and either the ER marker, protein disulfide isomerase (PDI),
or the trans-Golgi network marker, TGN46 (Fig. 2). As ex-
pected, M-Vpu localized in perinuclear compartments that
mainly overlay with TGN46-positive compartments but not
with PDI. However, although a minor fraction of O-Vpu pro-
tein 9435 localizes in the TGN, the majority forms a reticular
staining pattern that partially overlays with PDI-positive com-
partments, suggesting that, unlike M-Vpu, O-Vpu 9435 local-
izes to ER-associated compartments. Thus, the failure of O-
Vpu 9435 to antagonize tetherin correlates both with its
inability to interact directly with tetherin and with its lack of
accumulation in the TGN.
Retention of M-Vpu in the endoplasmic reticulum prevents
tetherin antagonism but does not block their interaction. We
next investigated the functional consequences of restricting
Vpu expression to the ER. Vpu-induced virus release in T cells
is sensitive to brefeldin A (51), suggesting that Vpu function
requires post-ER trafficking. However, the broad inhibition of
the secretory pathway will also affect tetherin trafficking, po-
tentially confounding this conclusion. To circumvent this, we
made a M-Vpu protein bearing an ER retention signal derived
from the bovine foamy virus envelope protein (-KKDQ) at the
C terminus (12). As expected, M-Vpu KKDQ shows a reticular
staining overlapping with PDI-positive compartments, indica-
tive of an ER localization (Fig. 3A), with only a minor fraction
of M-Vpu KKDQ proteins localizing with the TGN marker.
M-Vpu KKDQ displays weak activity against tetherin restric-
tion, despite increasing doses of plasmid (Fig. 3B), indicating
that post-ER trafficking of Vpu is essential for tetherin antag-
onism. Similarly, transfection of tetherin-positive HeLa cells
reveals that M-Vpu KKDQ fails to downregulate tetherin from
the plasma membrane (Fig. 3C). However, preventing M-Vpu
from leaving the ER does not impair its ability to interact with
tetherin in coimmunoprecipitates from transient transfections
(Fig. 3D). This was not due to tetherin-Vpu interactions oc-
curring during the immunoprecipitation, as subsequent mixing
of cell lysates from 293T cells transfected with either Vpu or
tetherin individually failed to yield tetherin coimmunoprecipi-
tating with Vpu-HA (see supplemental Fig. 1 [http://www.kcl
.ac.uk/schools/medicine/research/diiid/depts/infectious/groups
/neil/]). These data therefore suggest that Vpu and tetherin
may interact early in the secretory pathway, but only after exit
from the ER is Vpu able to exert its inhibitory effect on teth-
erin activity. Furthermore, these results suggest that O-Vpu
9435 localization in the endoplasmic reticulum may contribute
to its deficiency in tetherin antagonism but does not account
for its lack of tetherin interaction.
Defects in tetherin interaction and TGN localization map to
the TM domain and first alpha helix of O-Vpu, respectively.
We then went on to assess the minimal changes needed in
O-Vpu 9435 to allow it to antagonize human tetherin. O-Vpu
9435 and M-Vpu proteins derive from distinct SIVcpz zoo-
noses and as such are very diverse at the amino acid level.
However, they do have basic features known to be important
for CD4 degradation (7) (Fig. 4A): first, the conserved W
residue in the TM domain (58, 62) and, second, the dual serine
motif phosphorylated by CKII that binds to -TrCP (7). After
the TM domain in Vpu is a putative hinge region followed by
an amphipathic alpha helix (H1) which has been proposed to
lie along the face of the membrane with the nonpolar residues
partially submerged and the charged residues interacting with
the polar phospholipid heads (4). In contrast, in H1 of O-Vpu













FIG. 2. O-Vpu 9435 localizes to the ER. HeLa cells were trans-
fected by either 100 ng of M-Vpu Wt-HA or O-Vpu Wt-HA plasmid.
Twenty-four hours later, the cells were fixed and stained for Vpu
detection with anti-HA antibody (green), a TGN marker (TGN46;
red), or an ER marker antibody (PDI; red) and examined by confocal
microscopy.
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alternating basic and acidic residues that breaks its amphipath-
icity. Chimeric proteins, combining M-Vpu TMD and O-Vpu
CT or vice versa, were designed (Fig. 4A). 293T cells were
cotransfected with a fixed amount of tetherin, Vpu, and the
HIV-1(Vpu) proviral plasmid. Forty-eight hours later cells
were analyzed by Western blotting and titrated on HeLa-
TZMbl indicator cells (Fig. 4B). Substitution of the two key
residues from M-Vpu TMD, A14 and A18, essential for teth-
erin interaction (62), into O-Vpu TMD did not result in a
functional O-Vpu mutant (O-Vpu B), demonstrating that
these residues are not sufficient to confer tetherin antagonism.
Although they localized to the TGN (data not shown), chime-
ras composed of O-Vpu TMD and M-Vpu CT were unable to
enhance particle release in tetherin-expressing cells. The same
mutant designed by adding the equivalent determinants of
M-Vpu TMD into O-Vpu TMD (Vpu OBTM-MCT) did not
FIG. 3. Retention of M-Vpu in the ER inhibits tetherin antagonism but does not block interaction. (A) HeLa cells were transfected by 100 ng
of M-Vpu KKDQ-HA plasmid. Twenty-four hours later, the cells were fixed and stained for Vpu detection with anti-HA antibody (green), a TGN
marker (TGN46; red), or an ER marker antibody (PDI; red) and the appropriate secondary antibodies and examined by confocal microscopy.
(B) 293T cells were transiently transfected with 500 ng of HIV-1(Vpu) provirus, 50 ng of tetherin-encoding plasmid, and increasing amounts of
the indicated Vpu expression vector. Cells and supernatant-containing viral particles were harvested at 48 h posttransfection. The resulting
infectious virions in culture supernatants were titrated on HeLa-TZMbl indicator cells by measuring beta-galactosidase activity at 48 h postin-
fection. Vpu protein expression in cell lysates was analyzed by Western blotting using an anti-HA antibody. (C) The indicated Vpu constructs were
cotransfected in HeLa cells with a GFP-encoding vector, and surface tetherin levels were quantified by flow cytometry at 48 h posttransfection.
(D) 293T cells were transiently transfected with 500 ng of human tetherin-encoding plasmid and 500 ng of the indicated Vpu expression vector.
After 2 days of incubation at 37°C, Vpu was immunoprecipitated via the HA tag from cell lysates and subjected to SDS-PAGE. Total cell lysates
and immunoprecipitates were then Western blotted for tetherin and Vpu-HA detection. Molecular mass markers are indicated, and blots are a
representative example of three independent experiments.
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gain function to suppress tetherin restriction. However, two
chimeras that were both composed of an intact M-Vpu TMD
gained function against tetherin either in the context of the
O-Vpu cytoplasmic tail (Vpu MTM-OCT) or with the M-Vpu
first alpha helix (Vpu MTM-MH1-OH2). To characterize
these proteins further, Vpu MTM-OCT and Vpu MTM-MH1-
OH2 mutants were rescreened against a fixed dose of tetherin
but with various expression levels of Vpu. Despite both chi-
meras being effective at coimmunoprecipitating tetherin (Fig.
4C), only Vpu MTM-MH1-OH2 gained function against teth-
erin restriction at lower plasmid inputs (Fig. 4D) and at higher
expression had activity almost to the levels of M-Vpu Wt. In
contrast Vpu MTM-OCT achieved only a low efficiency of
tetherin antagonism, even at the highest plasmid inputs. Con-
sistent with the importance of Vpu association with the TGN
for tetherin antagonism (9), Vpu MTM-MH1-OH2 but not
Vpu MTM-OCT localized predominantly to the TGN rather
than the ER (Fig. 4E). Together these data suggest that amino
acid differences in the first alpha helix between O-Vpu 9435
and M-Vpu retain the former in ER-like compartments. Thus,
the simultaneous replacement of the tetherin interaction do-
main (TM) in the context of the first alpha helix of M-Vpu
sequences that permit TGN localization is required for full
antagonism of tetherin.
A single glutamic acid-to-lysine change in the putative hinge
region of O-Vpu proteins confers localization to the TGN. We
next investigated the determinants in the H1 domain of O-Vpu
that account for its localization to the ER. First, we assessed
whether ER retention of our O-Vpu 9435 was representative
of the known available sequences. To this end, we synthesized
an HA-tagged consensus O-Vpu (O-Vpu cons) from all the
full-length sequences available in the HIV Sequence Database
(http://www.hiv.lanl.gov) (n  32) and, additionally, the Vpu
from strain HJ001 (45). As expected, both proteins were de-
fective for counteracting tetherin from transiently transfected
293T cells (Fig. 5A) and failed to interact in coimmunopre-
cipitations (Fig. 5B), consistent with our previous observations.
When we examined the subcellular localization, however, we
observed that while Vpu-O cons was again retained in the ER,
HJ001 Vpu displayed more prominent localization to the TGN
(Fig. 5C). Alignment of the H1 domains of these proteins
revealed that a major difference in HJ001 was a membrane-
proximal K residue at position 32 instead of an E in Vpu-O
cons and 9435 (Fig. 6A). This lysine was present in only a
minority of O-Vpu sequences, suggesting that the acidic resi-
due is representative of HIV-1 group O (Fig. 6A). Interest-
ingly, position 32 in O-Vpu is equivalent to K31 in M-Vpu,
which is embedded within the putative membrane-proximal
hinge YRKILR. Mutation of R30-K31 to alanines in HIV-1
NL4.3 Vpu was previously shown to lead to an endosomal
localization and a concomitant decrease in antitetherin activity
(9). To determine whether this residue also plays a role in
O-Vpu localization, we replaced the hinge region with the
equivalent part of M-Vpu in the context of the M-Vpu TM
domain (MTM-RKILR-OCT). In addition, we also made the
E32K point mutation in O-Vpu 9435 and MTM-OCT. When
transfected into 293T cells with tetherin, MTM-RKILR-OCT
and MTM-OCT E32K both regained function equivalent to
that of the MTM-MH1-OH2 chimera, indicating that this sin-
gle amino acid change was sufficient to enhance tetherin an-
tagonism (Fig. 6B). As expected, the E32K change on its own
did not confer tetherin antagonism to O-Vpu due to its TM
domain’s inability to interact with tetherin (data not shown).
Examination of the localization of these Vpu proteins revealed
that unlike the parental O-Vpu, MTM-RKILR-OCT, MTM-
OCT E32K, and O-Vpu E32K all displayed localization to
TGN46-positive compartments (Fig. 6C). In contrast, the re-
ciprocal mutation, K31E, in the context of M-Vpu was not
sufficient to restrict the protein’s localization to ER-associated
compartments (data not shown). Thus, a single acidic residue
present in the hinge region of the majority of O-Vpu sequences
precludes the protein from leaving ER-associated compart-
ments and is responsible for their poor activity against human
tetherin even when TM-mediated interaction is restored.
DISCUSSION
The ability to counteract tetherin is a conserved attribute of
primate lentiviruses, although the viral protein that performs
this function varies (46). While tetherin antagonism is associ-
ated with the Vpu proteins of the SIVgsn/mon/mus lineage,
their descendant, SIVcpz Vpu, lacks this activity, probably due
to redundancy with a Nef protein acquired via recombination
from a SIVrcm-related virus (45). Adaptation of HIV-1 Vpu to
human tetherin is therefore associated with the genetic
changes that accompanied the zoonosis of SIVcpz to humans,
which has happened at least four times in the last century,
giving rise to groups M, N, O, and P (18). The Vpu proteins of
most group M viruses tested can counteract tetherin (45). In
contrast, group O Vpu proteins are defective for this attribute,
and in the few sequences from group N, Vpu counteraction of
tetherin is variable (45). In this study, we have addressed the
molecular and cell biological basis for the difference between
M-Vpu and O-Vpu proteins. We have shown that O-Vpu is
defective for tetherin antagonism for two reasons. First and
most important, its TM domain lacks the capacity to interact
FIG. 4. Defects in O-Vpu can be rescued by replacement of the TM domain in the context of the M-Vpu first alpha helix. (A) Schematic
representation of the Vpu topology and alignments comparing Vpu sequences from HIV-1 group M and group O or the indicated mutants.
(B) 293T cells were transfected with the HIV-1(Vpu) provirus, a fixed dose of tetherin plasmid, and the indicated Vpu construct. After 2 days,
viral supernatants were assayed on HeLa-TZMbl indicator cells and cells lysates were analyzed by Western blotting for Vpu-HA and Hsp90.
Numbers below indicate the Vpu expression levels normalized with Hsp90 expression levels compared to the M-Vpu Wt protein expression.
(C) The indicated Vpu constructs were coexpressed in 293T cells with 500 ng of human tetherin-encoding plasmid. At 48 h posttransfection, cells
were lysed and Vpu proteins were isolated via immunoprecipitation and subjected to SDS-PAGE. Both tetherin and Vpu-HA expressions were
visualized on a Western blot using the appropriate antibodies. (D) Same as in panel B but with various doses of the indicated Vpu mutants added
in trans. (E) The indicated Vpu-HA chimeras (green) were transiently expressed in HeLa cells and coimmunostained either with a TGN marker
(TGN46; red) or with an ER marker (PDI; red).
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with tetherin in coimmunoprecipitations. However, the ability
to bind tetherin is not sufficient to confer antagonism to O-
Vpu. O-Vpu appears to be retained in the ER and fails to
localize to the TGN. This maps to the first alpha helix of the
cytoplasmic tail, specifically, a glutamic acid residue at position
32, found in the majority of O-Vpu sequences. Replacement of
this region is also required for efficient tetherin antagonism.
Second, we further show that ER retention of M-Vpu fails to
antagonize tetherin, despite maintaining the ability to interact
with tetherin.
FIG. 5. Antitetherin activities and subcellular localizations of a consensus O-Vpu and O-Vpu HJ001. (A) Counteraction of tetherin-mediated
restriction of HIV-1(Vpu) from transfected 293T cells by the indicated O-Vpu-HA construct and corresponding Western blots of cell lysates and
pelleted virions as described in the legend to Fig. 1. (B) Coimmunoprecipitation of O-Vpu-HA proteins with tetherin from transiently transfected
293T cells as described in the text. (C) Subcellular localization of the indicated O-Vpu-HA (green) in transfected HeLa cells costained either with
a TGN marker (TGN46; red) or with an ER marker (PDI; red).
9744 VIGAN AND NEIL J. VIROL.
We showed previously that mutation of conserved residues
A14, A18, and W22, which form one face of the M-Vpu TM
domain, impairs tetherin interaction and antagonism (62). The
A14 and A18 positions are conserved in M- and N-Vpu pro-
teins but not in group O or SIVcpz Vpu proteins, suggesting
that changes to this face of the TM domain helix may have
been driven by adaptation of HIV-1 Vpu to human tetherin.
The O-Vpu TM domain failed to interact with human tetherin
in coimmunoprecipitations; however, replacement of these res-
idues is not sufficient to confer tetherin interaction to O-Vpu.
Moreover, in attempts to delineate the minimal requirements
to render the O-Vpu TM domain capable of mediating teth-
erin antagonism in the context of MTM-MH1, no chimeric TM
domain gained function (data not shown). These results sug-
gest that the functional binding interface of Vpu with tetherin
is likely to be contextually dependent on the entire conforma-
tion of the TM domain.
The retention of O-Vpu in ER-associated compartments
FIG. 6. An E32K point mutation confers TGN localization and tetherin antagonism to O-Vpu bearing the group M TM domain. (A) Alignment
of the consensus O-Vpu, O-Vpu 9435, and O-Vpu HJ001 sequences (above) and expanded logoplot of the amino acid sequences of the first alpha
helix of publicly available O-Vpu sequences (n  32) (below). Position E32 is indicated (red arrow). (B) 293T cells were transfected with 500 ng
of HIV-1(Vpu), 50 ng of tetherin, and various doses of the indicated Vpu-HA construct and processed as described in the legend to Fig. 4.
(C) Subcellular localization of the indicated O-Vpu-HA (green) in transfected HeLa cells costained with a TGN marker (TGN46; red).
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confers a defect to antagonism even when interaction with
tetherin is mediated through a chimeric TM domain. This can
be partially overcome by increased Vpu expression, which we
interpret as being due to minor amounts of O-Vpu being
observable in the TGN at high expression levels. Several years
ago Schubert and Strebel demonstrated that brefeldin A in-
hibited Vpu-mediated HIV-1 release from infected T cells
(51), and the same laboratory has recently confirmed these
data, in the light of the discovery of tetherin (1). However,
because brefeldin A blocks the bulk flow of secretory proteins
from the ER, including tetherin, we attempted to alleviate any
potential confounding factors by appending a strong ER re-
tention signal to M-Vpu. ER-retained M-Vpu was clearly de-
fective for tetherin antagonism, but unlike O-Vpu, it was still
able to interact with tetherin in coimmunoprecipitates, in con-
trast to a recent report (54). This suggests that while tetherin
and Vpu can interact in the ER, antagonism of tetherin func-
tion requires trafficking of Vpu-tetherin complexes into TGN
compartments. Recent data from the Strebel group have fur-
ther shown that under overexpression conditions, Vpu can
induce ER-associated degradation of newly synthesized teth-
erin, but this does not happen in virus-infected cells (1). Thus,
if Vpu and tetherin do interact prior to ER exit, the appending
of the -KKDQ motif leads to disruption of this interaction
when the Vpu is retrieved from the cis-Golgi network. How-
ever, to definitively show whether this is the case will require
further fluorescence resonance energy transfer-based micros-
copy studies of Vpu-tetherin interactions in living cells.
The inability of O-Vpu to exit the ER maps to the mem-
brane-proximal region of the first alpha helix of the cytoplas-
mic tail. The amphipathic nature of helix 1 is thought to allow
it to lie partially buried along the face of the membrane with
the basic residues in contact with the phospholipid heads (4).
Between the TM domain and the first alpha helix is a putative
hinge region, the basic residues of which in subtype B Vpu
proteins have been implicated in endosome-to-TGN localiza-
tion when mutated to hydrophobic residues (9). We found that
replacement of the hinge region in O-Vpu 9435 with the cor-
responding RKILR of M-Vpu conferred both TGN localiza-
tion and efficient tetherin antagonism when combined with the
M-Vpu TM domain. This phenotype mapped to an acidic res-
idue (E32) in the position equivalent to M-Vpu K31 that is
conserved in the majority of O-Vpu proteins. Since the reverse
mutation in M-Vpu did not lead to its ER retention, these data
suggest to us that it is unlikely that this is a specific TGN-
targeting motif itself. Rather, we suggest that the distribution
of basic and acidic residues in the membrane-proximal region
of the O-Vpu may influence the overall conformation of the
cytoplasmic tail in relation to the membrane and that the
retention of O-Vpu in ER-associated compartments may be
related to such a structural change. It is interesting to note that
O-Vpu 9435 and chimeric molecules bearing its first alpha-
helical region run as a doublet on SDS-polyacrylamide gels,
perhaps suggesting potential differences in conformation or
phosphorylation. Since O-Vpu still downmodulates CD4, a
process that requires interaction with the Vpu cytoplasmic tail
and its phosphorylation, such putative conformational differ-
ences do not affect this ER-associated process. However, they
do preclude tetherin antagonism without high overexpression.
Interestingly, while the majority of O-Vpu proteins have an E
at position 32, a minority of sequences has K at this position
and hence display increased TGN localization (exemplified by
O-Vpu HJ001). The lack of a TMD-mediated interaction still
precludes tetherin antagonism in this case.
The Vpu protein of SIVcpz is able to downregulate CD4 but
cannot target tetherin, presumably because this function be-
came redundant when the ancestral virus acquired a tetherin-
antagonizing Nef protein from the SIVrcm lineage (45). Un-
like the result with the TM domain of O-Vpu, replacement of
the TM domain of consensus SIVcpzUS Vpu with that of
HIV-1 M-Vpu is sufficient to confer tetherin antagonism (27).
Groups M, N, O, and P represent four distinct zoonoses of
SIVcpz strains to humans. Group O is also highly related to
SIVgor, suggesting that both viruses have derived from the
same SIVcpz strain relatively recently (less than 200 years) (57,
60). Whether group O was acquired directly from gorillas or
whether these are separate zoonoses of the same virus from
chimpanzees is not clear. However, they were transmitted to
humans, and in each case the zoonotic virus would have ini-
tially been unable to target human tetherin due to the loss of
the Nef-targeting determinant in the human protein’s cytoplas-
mic tail (21, 45, 66). In the case of groups M and N, it is likely
that the TM adaptation of the SIVcpz Vpu proteins was suf-
ficient to adapt to tetherin antagonism, although N-Vpu pro-
teins appear to have lost the ability to degrade CD4, the reason
for which is unclear at present (45). CD4 targeting is conserved
in all other known HIV-1/SIV Vpu proteins, indicating that
this is also an essential function and is maintained, despite Nef
performing a similar role, further suggesting spatial and tem-
poral differences for CD4 targeting. It is interesting to specu-
late that the competing pressure to maintain CD4 degradation
in the more distantly related SIVcpz that gave rise to HIV-1
group O precluded its adaptation to human tetherin because of
its ER retention. In SIVcpz infections in chimpanzees, the
requirement of the protein to leave the ER efficiently may have
been under less pressure to be maintained because SIVcpz Nef
antagonized tetherin in this species and was lost. Alternatively,
if group O was primarily derived from SIVgor, these differ-
ences in Vpu may be a reflection of the SIVcpz Vpu process of
adaptation to new hosts in relatively quick succession. To un-
derstand this further, more detailed molecular and cellular
characterization of SIV Vpu proteins is required. Further-
more, Vpu, like Nef, may have other targets, in addition to
CD4 and tetherin. Recent studies have implicated a role for
Vpu in downregulating CD1d and NTB-A to avoid killing of
infected cells by NK T cells and NK cells, respectively (36, 53).
Therefore, the adaptation of any SIV Vpu in a new species is
liable to be subject to further pressure to maintain functions
against these and other yet-to-be-identified immunomodula-
tory targets.
It has recently become clear that primate lentiviruses are
under evolutionary pressure to maintain an activity that coun-
teracts tetherin. That O-Vpu and at least some N-Vpu proteins
have no such activity has led to speculation that this Vpu
function may account for the lack of efficient spread of groups
N and O in humans compared to group M (46). Furthermore,
evidence from HIV-2 in human and Nef-defective SIVmac-
infected macaques suggests that when tetherin antagonism is
compromised, viruses that restore the activity in their envelope
glycoproteins can emerge (15, 26, 52). It should be borne in
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mind that group N and O viruses still retain the capacity to
cause AIDS in infected individuals, and at present, it is not
known whether the failure of O-Vpu to adapt to human teth-
erin has forced the acquisition of tetherin antagonism on the
O-group Env. This is all the more plausible given that there is
at least one documented case of an HIV-1 envelope glycopro-
tein with Vpu-like activity (49).
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